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Abstract 
 
This study was designed to identify the processes which underlie pain in symptomatic diverticular 
disease (SDD). Our hypothesis was that  a spectrum of both peripheral and central pathologies were 
involved, with those that had a more peripheral problem having abdominal symptoms only while 
those with multiple symptoms throughout the body, having an altered central pain processing. The 
first study examining the brain response to cutaneous pain using functional magnetic resonance 
imaging (fMRI) has supported this hypothesis. Although a statistically significant difference in 
sensory pain threshold was not demonstrated between the groups, fMRI imaging has shown greater 
emotional processing during pain and reduced anticipatory inhibitory responses in the high 
somatising symptomatic diverticular disease (HSDD) groups. However this is not as clear cut as we 
had anticipated which may be due to subject selection and demonstrate a spectrum of mixed 
peripheral and central changes as well as those with only peripheral or central components.  
 
In the second part we performed a randomized placebo controlled study of mesalazine 3gm versus 
placebo. Mesalazine significantly reduced expression of many genes associated with inflammation 
in SDD patients. A reduction in the median number of hours of pain per week was seen. The study 
was not designed to allow intention to treat analysis but has shown promising results which will 
need to be consolidated with future large scale studies. 
 
Both these studies support a tailored approach to SDD patient treatment based on the underlying 
pain process which can be both central and peripheral.  The Patient health questionnaire 12 
(PHQ12) may be one simple measure of doing this, but again needs to be confirmed with further 
larger studies.   
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Chapter 1: Introduction 
 
1.1 Definition and Incidence 
Colonic diverticulosis is the most common structural abnormality of the colon, yet our 
understanding of it is rudimentary. It affects 5% of people in their 5th decade and up to 66% of the 
elderly population in the United Kingdom. It is responsible for substantial morbidity with 68,000 
hospital admissions recorded per year in the UK and it contributes to about 2,000 deaths. 
 
The definitions of diverticulosis and diverticular disease were established by the European 
Association for Endoscopic Surgery consensus development meeting in 19991: 
 
³&RORQLF diverticular disease is a condition seen mostly in the sigmoid region. It is characterized 
structurally by mucosal herniation through the colonic wall, generally accompanied by muscular 
thickening, elastosis of the taenia coli, and mucosal folding. This condition may be asymptomatic 
(diverticulosis RU DVVRFLDWHG ZLWK ³V\PSWRPV´ WHUPHG diverticular disease, which may be 
complicated or uncomplicated. The term diverticulitis is used to indicate superadded inflammation 
involving the bowel wall. Other pathologic complications include perforation, fistula, obstruction, 
DQGEOHHGLQJ´ 
 
Studies using national databases of hospital admissions suggest its incidence and/or complications 
are increasing2-4. A recent study from the United States reported a 26% increase in admission for 
acute diverticulitis between 1998 and 2005. The rise in admission rates were greatest in younger 
patients e.g. 45-64years and 18-44 years2. In the 2004 National Hospital Discharge Survey in the 
United States America (USA), diverticular disease was responsible for 312,000 admissions and 1.5 
million days of hospital care5 at a cost of 2.6 billion US dollars per year6. This makes diverticular 
disease the 5th most costly gastrointestinal condition in the USA after gastro-oesophageal reflux 
disease, gallbladder disease, colorectal cancer and peptic ulcer disease6. The changing burden and 
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complications of disease, changing management and subsequent cost is likely to increase further as 
western populations age4, 7, 8.  
 
1.2 Aetiology of development and symptoms 
The mechanism by which diverticula develop is still not understood. A link with reduced dietary 
fibre KDVEHHQLGHQWLILHGVLQFHWKH¶V9-11. However the exact mechanism by which the mucosa 
herniates through the muscular wall of the colon, at the weak points where the blood vessels 
penetrate, to create the characteristic false diverticulum is still elusive. Several theories have been 
postulated, including: 
 
1.2.1 Increased intra-luminal pressure  
%DVHGRQWKHSULQFLSOHRI/DSODFH¶V/DZGHFUHDVHGstool bulk leads to a reduced colonic diameter 
and requires greater wall tension to transmit the stool along the colon. The increased wall thickness 
in DD has been used to support this theory12. 
 
1.2.2 Segmentation 
Excessive segmentation and uncoordinated contraction between the segments causes the raised 
intra-luminal pressure. Several motility studies have suggested that high pressure activity in the 
colon is more common in symptomatic DD patients and can be correlated with symptoms13. 
Electrophysiological activity has been reported to change with elevated activity in early and silent 
or low levels of activity in advanced DD cases14. When colonic muscle from DD patients is 
electrically and neurochemically stimulated, altered contraction and relaxation properties have been 
shown compared to controls15. However, the methodologies used between the studies vary and how 
well such models using resected muscle translate to clinical features is uncertain as the surgical 
manipulation and anaesthetic drugs used during surgery may well alter neuromuscular excitability. 
The alteration of the luminal contents of the gut, with bowel preparation, small numbers and poor 
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patient selection, different anatomical sites of measurement and limited duration of the studies also 
affect the ability to draw conclusions or extrapolate findings to the general population13. It has been 
suggested that the cause for bowel segmentation and altered colonic motility may be linked to age-
related loss of nerves from the gastrointestinal tract16. However, conflicting results have been 
reported in the number of nerve fibres, ganglia and interstitial cells of Cajal in DD patients. 
Although animal models and histological studies in humans suggest decreased nerve density with 
age15, there is no evidence to link this directly with the development of diverticula.  
 
1.2.3 Altered collagen and elastin deposition 
Increased risk of diverticula has been linked to several connective tissue disorders such as Elhers-
Danlos17-19 and Marfans20. Muscle wall thickening in DD is not due to hypertrophy of the 
longitudinal and circular muscle, but caused by deposition of elastin and collagen between the 
muscle fibres. Scarring from diverticulitis also changes the ratio of type I and III collagen21. 
Increased expression of matrix metalloproteinases (MMPs) and tissue inhibitors to matrix 
metalloproteinases (TIMPs) has been linked to disease severity21 22 23. However, altered collagen 
and enzyme levels can also occur with inflammation and could be a complication rather than a 
cause of DD.  
 
1.2.4 Genetics 
A family history has been implicated by some groups. Recent studies using  linked twin database 
and hospital records to show high concordance between monozygous twins, suggesting genetic 
link24. However no gene linkage studies have so far been performed and are long overdue as these 
would be likely to throw light on disease mechanisms and encourage new lines of research.  
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1.3 Risk factors for developing diverticular disease  
Diverticular disease can lead to a multitude of complications and has been classified into 
complicated and uncomplicated disease accordingly (see figure 1.1).  
 
Figure 1.1 Complications of Diverticulosis and Diverticular disease25-27  
 
 
In western countries it is most commonly found in the descending and sigmoid colon. Most 
research has concentrated on the 1-2% of the individuals with complicated disease, who often 
require hospital treatment. Research in this area has mainly focused on the epidemiology of these 
conditions or possible surgical treatments. However, for the vast majority of patients with 
uncomplicated diverticula, the condition is asymptomatic (ADD) and only a minority have 
recurrent episodes of chronic pain (SDD).  
 
Little is known about the risk factors for developing symptomatic uncomplicated diverticular 
disease (SDD). In a study of patients diagnosed with diverticulosis on barium enema, a third of 
patients reported recurrent episodes of pain in the left iliac fossa lasting 1 or more hours and 
occurring on 3 or more days per month26. The study suggested that a previous episode of 
inflammation, such as diverticulitis (RR 3.9), or psychological conditions can predispose people 
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with diverticular to develop chronic pain symptoms. The proportion of patients reporting pain was 
maintained over the 7 years between studies, demonstrating the prolonged morbidity, reduced 
quality of life and cost associated with this condition 28 29. 
 
Other risk factors for diverticular complications have been implicated from epidemiological 
studies, but there are no prospective studies so whether these are causative. These include: Low 
levels of physical activity, high BMI 30, 31 32, and smoking 33. Other suspected risk factors for 
diverticulitis include eating nuts, corn and pop-corn, but their association with complications has 
recently been questionned34. NSAIDs, hypertension, hyperuricemia, steroids, use of calcium-
channel blockers and anti-coagulants and patients with three concomitant metabolic diseases, 
including arteriosclerotic diseases, have increased the risk of diverticular bleeding35 36. A genetic 
component is also suspected from epidemiological work37. However it is not known if these also 
increase the risk of SDD.   
 
It has been suggested that chronic pain in diverticular disease may in fact be a form of irritable 
bowel syndrome (IBS).  Although there are many similarities between the conditions there are also 
several key differences as shown in figure 1.2  
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Figure 1.2 Similarities and differences between SDD and IBS  
 
 
There are several arguments against IBS and SDD being the same condition including:  
(i) The ROME criteria state that IBS is a diagnosis of exclusion occurring in a 
structurally normal bowel.  
(ii) Most patients with DD are much older than classical IBS patients, who are most 
frequently diagnosed in their 20s or 30s.  
(iii) '' SDWLHQWV¶ V\PSWRPV GR QRW Forrespond to the precise ROME criteria, such as 
altered bowel habit corresponding with the pain, or relief with defecation.  
 
For example, a questionnaire study from the USA has suggested an association between Rome II 
defined diarrhea predominant IBS and colonic diverticular disease38, but only 5.6 - 14.2% of 
VXEMHFWV PHW WKH 5RPH , FULWHULD IRU WKLV GLDJQRVLV LQ +XPHV HW DO¶V VWXG\26. There is also no 
evidence that a prior history of IBS leads to the development of diverticula or chronic pain with 
diverticular disease. Thus although superficially the two conditions are similar and owing to their 
frequent occurrence may overlap, there are important differences which will be explored in the 
following text. 
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1.4 Pathophysiology of chronic pain in uncomplicated symptomatic diverticular disease 
To understand how chronic pain may develop in diverticular disease it is first important to 
understand the normal pain pathways from the gut. 
1.4.1 Anatomy of normal pain pathways 
The pain pathways from the viscera and skin are similar and involve the cutaneous or enteric 
nervous system, afferent nerve fibres, spinal tracts and a variety of regions within the brain. These 
will be discussed in turn.  
 
(i) The enteric nervous system 
The nerve supply to the bowel is complex and poorly understood. Within the bowel, there are two 
plexus, the myenteric $XHUEDFK¶V)39 and submucosal 0HLVVHQHU¶V)40. The submucosal plexus can 
be further subdivided into the internal (true 0HLVVHQHU¶V) and external 6FKDEDGDVFK¶V) 41-44 (Figure 
1.3).  
 
Figure 1.3 Enteric nervous system of the bowel. 
 
These interconnect extensively and provide sensation, through stretch and chemical receptors, and 
can control secretion of mucus and motility.  
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(ii) Afferent Fibres 
Sensory information from the descending colon, sigmoid and rectum are relayed to the central 
nervous system by the sacral/pelvic and splanchnic afferent nerves. These innervations have 
endings which terminate in all layers of the bowel and can communicate extensively with the 
enteric nervous system, which makes identification of nociceptor transduction and modulation 
difficult45 (reviewed in Knowles and Aziz46). These afferent fibres can be classified further by46-50 
(see table 1.1);  
 (1) Trophic requirements (e.g. NGF, TrkA receptors, GDNF, BDGF),  
(2) Expression of neuro-chemical signaling and channels (e.g. Substance P, VIP, NOS, CGRP, 
ATP channels, TRP family, Sodium or potassium channels) and  
(3) Activity characteristics. 
 
Table 1.1 Nerve afferent type and characteristics in visceral pain transmission. 
(Based on review by Knowles and Aziz46) 
Name Properties Activation 
Tonic Wide Dynamic Range Low threshold receptors which increase 
firing activity linearly with increasing 
bowel wall stretch. 
High Threshold Respond to noxious 
stimuli 
Low firing activity at rest but increased 
ILULQJUDWHDWµSDLQIXO¶ERZHOZDOOWHQVLRQV 
Silent  Modified by inflammation Not active unless exposed to mediators of 
inflammation.  
Mesenteric and serosal Respond to distortion of 
mesentery and serosa 
Activated by high wall tensions involving 
the serosa or mesentery. 
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(iii) Dorsal Horn and Spinal Cord 
Spinal afferents from the bowel synapse with dorsal root ganglia within the dorsal horn. This is 
also the site where somatic (cutaneous) afferents synapse and is often referred to as viscero-somatic 
convergence. Visceral afferents make up approximately 7-10% of afferents to the spinal cord. In 
animal models, where afferent nerve synapses have been studied in most detail, the visceral 
afferents synapse most commonly in laminae I, II, V and X of the spinal cord. However, unlike 
somatic afferents, visceral afferents on entering the spinal cord send projections up and down the 
spinal cord, synapsing at multiple levels, resulting in diffuse overlapping of spinal segments and 
poor localization of visceral pain. Visceral afferents are also thought to send projections to 
autonomic ganglia, which can influence local reflexes and blood flow to the bowel (Reviewed in 
Knowles and Aziz46, See Figure 1.4 and 1.5)  
 
Figure 1.4 Diagram of Pain Pathways between the gastrointestinal tract and the brain 
 
 
 
 26 
Figure 1.5 Overview of Pain Pathways (Based of review by Knowles and Aziz46 and Mayer and 
Tillisch51). 
 
 
Key: ACC, anterior cingulate cortex (includes dorsal, rostal and midCC areas); AMYG, amygdala; 
ANS, autonomic nervous system; ENS, enteric nervous system; HpTH, hypothalamus; INS, insula 
(includes ant., mid. and post. areas); LC, locus coeruleus; PAG, periaqueductal gray; PFC, pre 
frontal cortex (includes dorsolateral and orbitofrontal areas); RVM, rostroventral medulla; S1&2, 
primary and secondary somatosensory cortices; Thal, thalamus;  
 
(iv) Spinal Tracts 
After synapsing, nociceptive information is transmitted by second order afferents to the brain. 
These neurons travel in several spinal tracts; anterolateral tracts e.g. spinothalamic, 
spinohypothalamic, spinomesencephalic, spinoreticular and dorsal columns52. It is thought the 
latter three spino-tracts are mainly involved in unconscious reflexes and autonomic responses. The 
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spinothalamic tract is thought to project to the thalamus where it is relayed to other areas involved 
in conscious pain perception and processing, such as the primary and secondary somatosensory 
cortices (S1 and S2), the insula (INS), the anterior cingulate cortex (ACC) and frontal cortices. 
Most of the information related to pain transmission in the dorsal columns comes from animal 
studies and its role in human pain is not fully understood. However it is thought that instead of 
transversing the spinal cord to run of the contralateral side, pain information is also transmitted by 
the ipsilateral dorsal columns to the contralateral ventral posterolateral nucleus of the thalamus46, 53. 
(See Figure 1.4 and 1.5) 
 
(v) The Brain 
The primary response to visceral and somatic pain is complex and not fully understood. Two 
pathways have been identified; the lateral sensory-discriminative and medial emotional or affective 
pathways. Cortical regions include the anterior cingulate cortex (ACC), posterior, mid and anterior 
INS, PFC, S1 and S2. Subcortical regions involve the PAG, HpTHal, AMYG, Hippocampus, and 
cerebellum (Figure 1.6).  
 
There are extensive connections between the ACC and INS, with co-activation occurring in most 
studies of emotion processing54. Both receive lamina spinothalamic projections and are connected 
to the parabrachial and periaqueductal gray (PAG), part of the descending nociceptive inhibitory 
control (DNIC) network, and the PFC54, producing a fronto-limbic regulatory network55-58.  
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Figure 1.6 Simplified diagram of some of the key brain regions involved in the modulation and 
perception of painful perception (modified from Lee and Tracey 201059) 
 
Orange areas: affective areas of pain processing. Blue: somatosensory areas of pain processing, 
Green: regions of higher emotional control, Purple: areas important in descending inhibitory 
and/or facilitatory controls. Grey: other keys areas with less defined role 
Key: ACC, anterior cingulate cortex; AMYG, amygdala; INS, insula (includes ant  and post. 
areas); MCC, mid cingulate cortex;  DL-PFC, dorsal lateral prefrontal cortex, VL-PFC, 
ventrolateral prefrontal cortex; VM-PFC, ventromedial prefrontal cortex; OFC, orbitofrontal 
cortex; PAG, periaqueductal gray; PCC, posterior cingulate cortex; PFC, pre frontal cortex 
(includes dorsolateral and orbitofrontal areas); RVM, rostroventral medulla; S1&2, primary and 
secondary somatosensory cortices; Thal, thalamus;  
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The INS is thought to integrate sensory and motor information from the viscera with the attentional 
and emotional centres. These involve the limbic system including the ACC and amygdala (AMYG) 
54, 60
. The insula plays an important role in risk perception, attention and anticipation54, 58, 61.  The 
pINS is also important, receiving  input from the spinal thalamocortical pathway and being 
somatotopically organized to a range of stimuli62-65, but not imagined or remembered pain66, 67. 
 
The PFC is complex and involves several centres in pain processing and modulation55, 57. The right 
lateral PFC is important in this process as it performs cognitive reappraisal of stimuli and inhibits 
limbic activity. The ventrolateral PFC also assists this process. It has been shown to be active in 
analgesia states (arising from the belief that pain can be controlled) and interacts with the nucleus 
accumbens to inhibit the activity of the AMYG68-70. Another part of the PFC, the ventromedial 
PFC, is involved with the fear of pain, although in some cases it can exacerbate anxiety and pain 
experience71, 72. 
 
Brain responses to visceral stimulation in healthy subjects has been reviewed recently by Mayer et 
al73. The review focused on visceral studies, which included papers on oesophageal, gastric, 
colonic and rectal stimulation using a variety of techniques. It identified consistently activated 
brain regions in all these studies. These included the posterior (pINS) and anterior (aINS) insula 
and the anterior cingulated cortex (ACC). Other regions with high consistency in reported 
activation included the primary somatosensory cortex (S1), regions within the Pre-frontal cortex 
(PFC) and thalamus (Thal). Direct anatomical connections between brain areas activated during 
rectal distension in healthy women (INS, ACC, THAL, S1, S2 and the PFC) have recently been 
observed using diffusion tensor imaging (DTI) 74.   
 
It also should be noted that most studies look at brief episodes of acute pain. Owen et al75 have 
addressed this issue by using arterial spin labeling (ASL) techniques to look at pain processing in a 
tonic muscular pain model in healthy volunteers. The 10 slices acquired covered from the thalamus 
to the somatosensory cortices only and did not include the cerebellum or the brainstem. Pain in the 
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first 5 minutes was associated with increased blood flow to the INS, bilateral putamen and the 
inferior frontal gyrus (IFG), the anterior MCC, Perigenual ACC, bilateral thalamus and contra-
lateral SII. However, bilateral insula and thalamus activity was prominent in prolonged pain, while 
the anterior mid-CC rapidly returned the baseline, suggesting a preferential decrease in emotional 
pain processing.  
 
Pain processing can also be modulated by several factors73, 76-79 which are shown in figure 1.7. 
These are possible processes that can be altered in disease states and will be discussed later in the 
introduction.  
 
Figure 1.7 Factors affecting pain perception and processing.  
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1.4.2   Pain Pathways in Diverticular disease 
(i)  Enteric nervous system 
Neuronal structure and neuro-chemical expression in resected acute and chronic diverticulitis 
specimens and endoscopic mucosal biopsies in asymptomatic and symptomatic diverticular disease 
patients have been investigated80. The resected specimens demonstrated increases in tachykinins, 
substance P and galanin in the submucosal plexus and circular muscle80. These findings are 
supported by other studies where altered muscular activity to acetylcholine, nitric oxide, 
endocannabinoids, tachykinins and substance P were found in resected DD specimens81-88. In 
Simpson et al¶V VWXG\80, nerve remodeling was also seen. In the SDD mucosal biopsies, the 
submucosal plexus also showed increased tachykinins, substance P and galanin as well as 
vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activated protein (PACAP) 
compared to the ADD group, but without any histological difference. The increase in galanin 
significantly correlated with frequency of defecation, supporting the role of neural changes in other 
gastrointestinal symptoms as well as pain80.  
 
An abnormal ENS has been found in other gastrointestinal conditions associated with pain and 
alerted motility e.g. IBS, slow transit constipation89, 90, and is thought to play a part in the 
development of diverticula and symptoms. This fits with multiple studies demonstrating altered 
contractile activity within the bowel, especially in the diverticula effected segment91-96. The 
contractions occur most commonly after food, which often triggers pain in symptomatic patients93.  
 
However histological studies of diverticular subjects have reported conflicting results. This is 
possibly because many reports do not distinguish those with prior diverticulitis and those without 
which may make a key difference. Some studies have reported few changes within the ENS  97, 
others have decreases in myenteric plexus nerves98 or increases in submucosal nerves99.  Sectioning 
the ENS using a cross-section is a poor way to visualize the myenteric plexus which is best 
evaluated using whole mounts. Therefore a study of patients with DD and 10 with rectal tumours, 
who underwent resection using this technique, is of interest. They  showed  that in the myenteric 
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SOH[XV WKH QHUYHV ZHUH WKLQQHU DQG RIWHQ µLQWHUUXSWHG¶ DQG WKHUH ZHUH D SDXFLW\ RI myenteric 
ganglia compared to the rectal tumour group100. Unfortunately the methodology of these studies 
was not the same, with different resection specimens included in the diverticular and control groups 
and different sample preparations and staining methods used.  Patient symptoms and reasons for 
resection were also not reported and no comparison was made between them and the neuronal 
changes, reducing the interpretation of the results.  
 
However a recent high quality histological study in which tissue was carefully laid flat and cut 
along the plane of the circular muscle to optimally display the myenteric plexus of 27 DD, with 
documented symptoms of diverticulitis, abdominal pain, changed bowel habit and/or bleed, has 
also shown decreased neuronal density in all neuronal plexus. Decreased ganglia and glial cells in 
the mesenteric and submucosal plexus, but an overall high glia to neuronal ratio (oligo neuronal 
hypoganglionosis), were also found101. These glial changes may be just as important as the 
neuronal ones, as there is increasing evidence that colonic glial cells not only support and protect 
the neuron, but can also influence its gene expression, phenotype, and neuro-chemical 
expression102. Unfortunately there are no studies that have shown whether these neuronal and 
muscular changes are present before the development of diverticula and or if they lead to 
symptoms. 
 
(ii)   Functional impact on sensory function 
Work at Nottingham and by other groups, suggests that SDD patients show visceral 
hypersensitivity to rectal barostat distension103, 104.This phenomenon, which also occurs in IBS, is 
defined as increased sensitivity to a stimulation, so that pain is perceived at a lower stimulus 
(reduced pain threshold) and/or  there may be increased pain to a stimulus (hyperalgesia) and/or 
pain to a stimulus that was previously not perceived as painful (allodynia)105, 106. In Humes et al104 
(2012), rectal barostat distension showed significantly reduced pain threshold to stimulation in the 
SDD group compared to ADD and healthy age and sex matched volunteers (HV). Mucosal samples 
also showed elevation in RNA expression of tachykinins and galanin receptors (GALR1 and 
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NK1R), TNF-alpha and IL-6 in the SDD group, suggesting that the development of painful DD is 
associated with these neuro-chemical changes and low level chronic inflammation104.  The theory 
that chronic inflammation has a role in the development of painful DD is supported by 
epidemiological work26, 28, 107, 108, which suggests that the development of visceral hypersensitivity 
in diverticular disease is related to a previous episode of diverticulitis (relative risk of 3.9)26.  
 
Similar post-inflammatory visceral hypersensitivity has been seen in animal models and humans 
with conditions such as IBS and IBD. In animal models, a controlled inflammatory event can lead 
to increased response to mechanical stimuli, with alterations in mechanosensitivity of afferents and 
changes in channel families such as transient receptor potential (TRP), purinergic receptor family 
(e.g. P2X3), acid sensing ion channels (ASIC), tetrodotoxin resistant sodium channels (e.g. 
NaV1.7-1.9) and rectifying potassium channels109-112. Animal models of TBNS induced 
inflammation have shown that these changes can be long standing and similar to those seen 
following diverticulitis, with raised galanin levels remaining above normal range for over 96 days 
post initial inflammatory insult80. However it is important to note that the animal model used and 
the development of visceral hypersensitivity, through psychological, inflammatory or other 
methods, can produce different results which may not always be applicable to human109. This is not 
a new phenomenon as post-inflammatory visceral hypersensitivity was first reported in the WWII 
after amoebic dysentery113, 114%XWLW¶VRQO\ZLWKLQWKHODVW\HDUVWKDWODUJHUHSLGHPLRORJLFDODQG
biochemical studies have shown a link between inflammation, occurrence of symptoms and neural 
changes115-117. 
 
One of the most recent and well documented examples is the Walkerton Health Study. 2300 people 
in Walkerton (Ontario, Canada) became ill after bacterial contamination (E. coli O157:H7 and 
Campylobacter species) RIWKHWRZQ¶VZDWHUVXSSO\RFFXUUHGLQ6HYHQSHRSOHGLHGas a result 
and there was a documented increase in conditions such as gastritis and IBS. After 2 years the 
incidence of IBS in the general population who had not suffered from gastroenteritis was 10.1%, 
compared to 36.2% in the affected group118. Although spontaneous recovery occurred in most 
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people, some people developed long term problems, with 14.3% - 15.4% reporting symptoms  at  6 
and 8 years respectively119. There was also an increased incidence in children affected (OR 4.6, 
95% CI 1.6 -13.3)120 and an increased incidence of dyspepsia (OR 2.30, 95%CI 1.63-3.26)121. Risk 
factors for developing symptoms include female sex, young age and severity of the initial 
gastroenteritis. Psychological co-morbidity also played a role.  In dyspepsia, smoking was also 
identified as a risk factor.  
 
Genetic risk factors for PI-IBS in Walkerton residents were assessed. Seventy-nine gene variants 
were identified from potential pathophysiological pathways including mucosal barrier function, 
innate immune system, response to bacterial motifs and the 5HT pathways. These include two Toll-
Like Receptor 9 variants, CDH1 (a tight junction protein) and IL6122. These findings fit with the 
observed increased intestinal permeability associated with irritable bowel syndrome, found in 
patients 2 years after the Walkerton gastroenteritis outbreak 123. 
 
(iii)  Gastrointestinal and peripheral immune functions 
It has been suggested that altered intestinal flora and mucosal barrier function may influence low 
grade chronic inflammation, with altered cellular, cytokine profile and/or response to stimulation 
lead to and maintaining visceral hypersensitivity in uncomplicated SDD. 
 
There is some evidence to support this theory as altered peripheral circulating immune cells and 
cytokines have been noted in IBS (IL-1beta, TNF-alpha, IL-6 and IL-8)124-129 and a small 
underpowered study in SDD130. However there have been reported differences between the 
literature, which may be due to the different types of IBS recruited, gender, age, use of antibiotics 
and genetic differences between study populations. 
 
Mucosal immune changes have also been noted in DD. In surgical specimens, significantly 
increased number of 5-HT producing cells have been reported131. But in a recent study, no 
differences were detected among a range of cytokines between 10 uncomplicated DD and 10 age 
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and sex matched controls132. However the study did not report any patient symptoms and with so 
few participants it is difficult to draw conclusions. Given the strong association with age it is 
important to note that  there are colonic immunological changes that occur with increasing age, 
including fewer immunocytes in rectal mucosa133 and reduced responses to antigen challenge from 
lymphocytes in the lamina propria134so any study of histology needs appropriately age-matched 
controls.  
  
In IBS, colonic biopsies have shown increased numbers of mast cells, enterochromaffin cells and T 
lymphocytes135-141. The most consistent changes relate to mast cells.  One influential study showed 
that the number of activated mast cells located in close proximity to mucosal nerve fibres 
correlated with pain symptoms139. Alteration of the immunological environment by infections or 
genetic predisposition can also influence the production of 5HT, expression of SERT and numbers 
of enterochromaffin cells142, 143. Similar studies with Trichinella spiralis infections can also lead to 
altered nerve responses to stretch which can be inhibited by ondansetron144, a 5HT3 receptor 
antagonist. 
 
Mast cell and gastrointestinal bacteria also produce proteases139, 145. Protease producing cells and 
release of proteases from colonic biopsies are greater in IBS patients139. These simulate protease 
activated receptors, e.g. PAR-2, which can lead to intestinal inflammation146, mucosal 
permeability147 and neuronal excitability in animals148, 149. Reduced PAR-4, which unlike the 
proinflammatory  PAR-2 protects against inflammation, has also been reported  in IBS mucosal 
biopsies150. 
 
(iv) Molecular basis of inflammation and Post-infective Hypersensitivity in IBS 
Host predisposition to development of IBS after an inflammatory event has been focused recently 
after the discovery of SNPs in IL-6, TLR9 and CDH1122. In other genetic susceptibility studies 
several genes related to mucosal barrier function, such as mucin related genes (prostate androgen 
regulated mucin like protein 1, PARM 1; and MUC20)151, 152, TLR-9152 and cytokines (tumour 
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necrosis ligand superfamily 15, TNFSF15 ± especially in C-IBS153, TNF-alpha G/A polymorphism 
and low IL10 producing phenotype154, 155) have been discovered.    
 
Altered mucosal barrier function, immunity and symptoms in IBS may be linked with observed 
changes in gastrointestinal flora156. Mucosal permeability123, 136, 157, 158 and increased expression of 
pathogen recognition receptors (TLRs 4 and 5)159 and innate immune activity (antibodies to 
flagellin and beta-defensin-2)160-162 have also been found in IBS patients and experimental models.  
There is some evidence that symptoms, barrier and immunological function and nociception can be 
improved with probiotics (reviewed in 156).  In IBS, gastrointestinal microbiota has been reported to 
be unstable within individuals, compared to the general population163, but may be due to 
differences in antibiotic use164 or diet. Antibiotic use itself has been associated with developing IBS 
(adjusted OR 3.70; 95%CI 1.80-7.60)165 RU3,,%6DIWHU WUDYHOHUV¶GLDUUKHD55&,-
15.3)166. Altered composition of gastrointestinal flora has also been reported in IBS, but with 
inconsistencies between studies167-171. However the enteric microbiota-gut-brain axis has been 
postulated as a mechanism for chronic pain and functional gastrointestinal disorders172. Thus, there 
has been increased interest recently in modification of gastrointestinal flora with use of antibiotic 
(e.g. rifaximin) and pre and pro-biotic therapies in diverticular and IBS156, 173-177. However no large 
RCTs have been published to date in DD or IBS.  
 
Many of these changes in immunological and neuro-chemical receptors and transmitters have not 
been directly implicated in diverticular disease, but they may be relevant as suggested by animal 
models and other post inflammatory painful conditions, such as PI-IBS and IBD.  
 
(v)  The Doral Horn and Spinal cord 
Spinal sensitization also occurs with up-regulation of neurotransmitters and receptors such as 
substance P, Galanin receptors, purinergic receptors and TLRs178-180. Although the mechanism by 
which these changes are produced and lead to altered pain processing and modulation is not well 
understood. There is also controversy over the role of astrocytes and microglia involvement in 
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visceral hypersensitivity. Increased microglial proliferation and activation to peripheral nerve 
injury or colonic inflammation or psychological stressors have been seen as well as visceral 
inflammation following thecal injection of microglial activators 181-184. It is also thought that 
descending central inhibitory or facilitatory modulation can also influence pain transmission at the 
spinal level.  
 
(vi) Central Pain Processing 
Although there have been no studies characterizing central brain responses in diverticular disease 
there is some evidence to suggest that alterations in pain processing may be present. Previous 
studies have shown significantly lower visceral sensitivity thresholds between symptomatic and 
asymptomatic patients with DD103. Patient surveys have identified that in those who have an 
increased tendency to report short-lived recurrent abdominal pain also have increased anxiety 
scores on the Hospital Anxiety and Depression scale (HAD)26 and higher scores on the Personal 
Health Questionnaire 12 (PHQ12)185, a measure of somatisation. This suggests a role for altered 
central processing. Sensitization in diverticular disease may be similar to IBS186, 187. Although, no 
fMRI or PET studies of patients with SDD have been reported, several studies in patients with 
chronic pain, such as IBS, have shown central alteration of pain processing188-192.  
 
In a review of imaging studies on patients with visceral pain, similar brain areas such as the INS 
and ACC were activated as reported in  healthy subjects as in patients, 73. Unfortunately many of 
the studies were not controlled for confounders such as previous exposure to the scanner 
environment, anticipation, psychological problems and other co-morbidities, anxiety level and 
gender, which makes interpretation of the results difficult.  
 
However in some studies in IBS, increased activity of the ACC, INS and emotional pain processing 
areas (amygdale, hypothalamus, infra-genual cingulated) were identified on anticipation of and on 
stimulation of the viscera190, 193-196. In healthy controls the ACC activation has been shown to be 
correlated with unpleasantness of rectal distension and anxiety197.  In IBS patients great activation 
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was seen in the ACC and the number of pixels activated was increased192. This activity has been 
correlated with anxiety score while the PFC and cerebella areas correlate with depression score on 
the HAD198.  
 
In chronic back pain, which can fluctuate in intensity, fMRI studies have shown that during rapid 
increase in pain, active centres include the INS, ACC, parietal cortices, and cerebellum. However, 
during periods of sustained pain, activity was seen in mPFC, AMYG and ventral striatum. Intensity 
of the perceived pain correlated with mPFC activity, while INS activity was associated with pain 
duration in years199. This suggested an engagement of internalized emotional processing regions 
(medial pain pathways) and long term maladaptive behavioral and psychological changes.  
 
Recent evidence also suggests IBS patients fail to show the normal activity seen during anticipation 
of pain in the INS, ACC, amygdala and dorsal brain stem which is presumed to prepare normal 
subjects for pain and reduce the overall sensation190, 200. Decreased activation of the dorsal pons 
region, which involved the periaqueductal gray (PAG), part of the DNIC pathways, has been 
reported in IBS and this might explain the visceral hypersensitivity188, 190, 200, 201. Most IBS patients 
also show hypervigilance202 possibly resulting from past experience. However repeated exposure to 
aversive stimuli can result in a habituated response so that IBS patients studied repeatedly over 1 
year do show normalization of their initially abnormal response203. This is thought to be due to 
higher cerebral modulation and reduced emotional/amygdala excitation of attention centers204.  
 
 Several factors are thought to modulate pain perception. Many of these appear to be dysfunction in 
chronic pain conditions. 
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1.5 Modulation of pain pathways in healthy and chronic pain subjects  
A variety of factors can influence perception of pain (see figure 1.7) 
 
1.5.1 Descending inhibition and facilitation 
This is a characterized and widely investigated brain network205, which appears to be important in 
many physiological processes206 and chronic pain conditions73, 207-214. It involves several 
interconnected brain regions including the endogenous opioid system, hypothalamus, rostral ACC, 
AMYG, the periaqueductal gray (PAG), nucleus raphe magnus locus coeruleus (LC), 
mesencephalic pentane reticular formation and rostral ventromedial medulla (RVM) 58, 205, 215-221. 
Ethnic222 and sex223 differences in descending inhibition of pain have also been described, and a 
recent meta-analysis suggests that  males having more efficient descending nociceptive inhibitory 
controls (DNIC) than females224. In two rat models, activation of the descending inhibitory 
pathways after spinal nerve ligation protects against the development of chronic pain after an acute 
insult215. This phenomenon may be important in human chronic pain development as pre-operative 
generalized hypersensitivity, as demonstrated by quantitative sensory testing, also appears to 
increase the risk of chronic pain following surgery214, 225-227. Increasing evidence also suggests that 
descending facilitation can also occur206, 228-230. Control of pain is through several mechanisms 
including opioid, serotonin, dopamine, noradrenaline and endocannabinoid pathways221, 231, 232. It is 
thought that in some chronic pain conditions, descending inhibition of pain can switch to 
facilitation228 and may act to maintain a chronic painful state233. Activation of these pathways is 
thought to underlie the therapeutic effects of tricyclic antidepressants. 
 
This is important in gastrointestinal pain as in a recent fMRI study in IBS showed a failure to 
decrease activation of the INS, supra-genual ACC, AMYG and dorsal brain stem in chronic pain 
groups190, 234. In IBS, pain rating was significantly inversely correlated with the dorsal brain stem 
activity, suggesting that IBS patients fail to activate the descending inhibitory pathways during 
pain anticipation, resulting in a greater pain experience190. It is not known if the descending 
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inhibitory pathways are affected in symptomatic DD or if these changes occur prior to or after an 
inflammatory event, such as diverticulitis.  
 
1.5.2 Attention, Distraction and Counter-stimulation  
Both visceral and cutaneous (somatic) pain can be influence by attention. Attention to a painful 
stimulus increases pain reporting and fMRI demonstrates corresponding activation in the S1, aINS, 
PFC and ACC 235-242. The mid cingulated cortex (MCC) is thought to be essential for attention pain 
modulation236, 238, 239, 241. There are few reports of attentional modulation in visceral stimulation in 
the lower gastrointestinal tract. Some studies involving oesophageal stimulation have suggested 
that the S1/S2, ACC, left MCC and right PFC are involved243, 244. Stimulation with another painful 
event has been shown to reduce the pain experience. Studies suggest that although counter 
stimulation may have a distraction component other effects, possibly mediated through the 
descending inhibitory pathways, may also play a role245. Top-down modulation and reduced 
emotional engagement of attentional pathways are thought to underlie habituation to perceived pain 
in IBS. Similar circuit interaction may be present in diverticular disease and be amenable to 
pharmacological or psychological intervention204.  
 
1.5.3 Anticipation, learned behavior and hypervigilance 
In Pavlovian conditioning models, the expectation of pain activates the ACC and PFC73, 246, which 
have connections to the descending inhibitory system described above.  Anticipation of a painful 
stimulus results in difference in brain activity in IBS compared to controls, with increased 
activation of attention and emotional network areas such as the frontal and posterior parietal 
areas200. Berman et al (2008)190 have shown altered activity to anticipated rectal distension in IBS. 
In healthy volunteers the INS, supra-genual ACC, AMYG, and dorsal brainstem (DBS) decreased. 
In IBS patients significant differences were found in the right posterior INS and DBS compared to 
healthy volunteers.   
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Several factors can influence anticipation of stimuli. Personality traits, such as neuroticism, have 
been shown correlated with activity in the INS, ACC, AMYG, parahippocampus and THAL during 
anticipation of pain247. Hyper-vigilance and altered response to the anticipation of pain are also 
thought to play a role in abdominal pain in IBS248.  
 
Many of these activated and deactivated areas have been associated with coping and corticolimbic 
inhibition of pain249. These areas were classically involved in pain modulatory responses and are 
thought to be involved in mechanisms of chronic pain249. IBS patients have also shown 
dysfunctional inhibition of pain with heterotrophic stimulation and anticipation of pain200. There 
are no studies that have previous examined anticipation of pain in DD.  
 
1.5.4 Emotion, Mood, Depression and Anxiety 
Emotional arousal appears to modulate both pain spinal reflexes as well as perception250. The INS 
is thought to play a role in integration of emotion and perception of pain, while the thalamus, PFC 
and AMYG may have a role in altering spinal reflexes. Other regions identified include the 
parahippocampal and brainstem regions251. Depressed mood has been shown to increase pain 
perception, with increased activity in the hippocampus, PFC and the subgenual ACC. Significant 
correlation was also found between increased pain intensity and the AMYG and inferior frontal 
gyrus252. Personality and anxiety trait also influence pain perception, with pre-stimulus functional 
connectivity between the brainstem and the INS determining if  stimulus is perceived as painful or 
not58. Other regions involved in anxiety and anticipation of pain include the entorhinal responses, 
which predicted activity within the mid INS and perigenual CC253. 
 
In IBS anxiety and depressed mood have been found to correlate positively with pain ratings. Brain 
region activation has also been found to correlate. Anxiety score is associated with activation of the 
anterior mid-CC and pregenual anterior CC, while depression score associates with activity in the 
PFC and cerebella regions198. During rectal stimulation, IBS patients also show more stress-
induced activation of INS, MCC, VL-PFC, but reduced modulation of INS activity during 
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relaxation compared to health volunteers194. This suggests that anxiety and depression may play a 
role in altered pain processing in chronic pain conditions but it is not known if these are primary or 
secondary effects.  
 
The brain gut axis is bidirectional with the gut stimulating the brain and central brain processes also 
influencing the function of the gastrointestinal tract254-256. In human and animal studies, 
psychological stress can alter gastrointestinal flora and mucosal permeability and can affect the 
development of anxiety-like problems and pain257-259 (Figure 1.8).  
 
Figure 1.8 Central and peripheral pathways in the brain gut axis 
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1.5.5 Other changes in chronic pain  
Other networks and structural changes have also been identified in chronic pain conditions. These 
include: 
 
(i) Resting state networks 
Activity of this default mode network (DMN) of nerves occurs at rest and is made up of the 
posterior CC, medial PFC and temporal regions260-262. During responses to tasks or stimuli, regions 
within the network deactivate. However, this network is altered in several psychological263-266 and 
neurological conditions267, 268. In fibromyalgia, the DMN has greater connectivity to the INS and 
the executive attention network than in healthy controls, suggesting that activity with these 
networks may contribute to spontaneous pain in this group269. There is some evidence to suggest 
that altered resting state networks also occur in gastrointestinal disorders. In functional dyspeptic 
patients, who underwent uncomfortable and sham gastric fundus distensions with H(2)(15)O-PET 
imaging, there was reduced posterior ACC activation and no or reduced deactivations in the 
AMYG and dorsal pons270. However, much of the current literature of DMN and pain has focused 
on back pain. In patients with chronic back pain, reduced deactivations have been shown in areas 
such as the medial PFC271 and altered correlations with other networks such as the insular cortices, 
angular gyri and the middle frontal gyrus orbital region. These regions have been linked with 
executive control and may explain some of the associated problems with chronic pain, such as 
depression, sleep disturbances and altered decision making ability272. Although it is likely that this 
network would also be disrupted, there are no previous studies examining it in irritable bowel 
syndrome or diverticular disease. 
 
(ii) Structural brain changes  
In patients with chronic pain the cortical thickness273, 274 and blood flow to this region is reduced, 
but can be increased by analgesia or symptom improvement. Grey matter changes have also been 
reported in other pain matrix regions in chronic pain conditions such as the AMYG, hippocampus, 
post central and superior frontal gyri, INS, prefrontal and ACC275-279. In fibromyalgia these changes 
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also correlate with disease duration and age280. In IBS changes in grey matter thickness have also 
been reported, with the hippocampus having thickened grey matter while the mid-cingulate cortex 
was thinned. The insular regions also showed altered thickness, with a reduction for IBS patients 
with a short duration of symptoms and increased in those who had long term pain281. White matter 
changes have also been detected in thalamocortical tracts and insular regions276, 279, 282. However 
similarities and differences in the regions affected have been seen between different conditions283-
285
. There is also suggestion that effective treatment may reverse these changes in some chronic 
pain286. It is not known if grey and white matter changes occur in diverticular disease and if these 
can be altered with treatment.  
 
(iii) Pain catastrophizing 
Pain catastrophizing is an altered response to pain associated with impaired coping. It has been 
characterized by heightened pain intensity287, 288, increased disability and difficulty disengaging 
from pain289. It appears to reflect emotional instability and to be a stable trait290. Pavlin et al 291 
have also shown that pre-surgery pain catastrophizing score (PCS) predict post surgery pain scores, 
suggesting that people with high PCS may be at risk of developing chronic pain. High PCS patients 
also exhibit increased pain vigilance292-294.  
 
In a Functional MRI study by Seminowicz and Davis295,  22 healthy individuals underwent 
electrical median nerve stimulation and 2 pain intensity levels and completed pain catastrophizing 
questionnaires. Results showed that PCS was not correlated with the lateral discriminative 
pathway, such as the SSI or II. However the medial pathway centres, such as DL-PFC, INS, rACC 
pre-motor and parietal cortices, were associated and, during more intense pain. Activation of the 
PFC during pain was negatively correlated with PCS. The group suggested this fitted with an 
attention model of pain catastrophizing, with mild pain activating the cortical vigilance network. 
The PFC decrease at higher pain intensities suggesting a reduction in cortical modulation that 
impedes changing from this network and activating descending inhibitory pathways that suppress 
pain intensity. The study suggests that individual pain cortical responses and PCS are independent 
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of health, i.e. correlative even without the existence of a chronic pain state e.g. fybromyalgia296. 
However it has been increasingly identified in many chronic pain disorders and may be linked with 
continuation of pain and associated psychological problems297-299. It is not known if pain 
catastrophizing is important in pain perception in diverticular disease. 
 
1.6 Aims and objectives 
Diverticulosis (DD) commonly affects those over 60 years of age with increasing prevalence in 
younger age groups. It is responsible for substantial morbidity in the UK, which is increasing as the 
population ages. The reasons are uncertain, making research into this condition of utmost 
importance. Furthermore a recent survey found that there is considerable associated symptom 
burden with 36% suffering recurrent abdominal pain. 
 
Visceral hypersensitivity plays a part in both IBS and DD4. It can occur because of:  
(i) Peripheral changes in afferent nerves causing increased firing   
(ii) Synaptic facilitation in the dorsal horn of the spinal cord  
(iii) Central hypervigilance5  
(iv) Impaired descending inhibitory or enhanced excitatory reflexes originating in the 
brain stem. 
 
Painful DD patients have changes in enteric nerve neuro-chemical coding with increases in 
tachykinins and galanin80, 300. This can be induced by inflammation, in animal models and is seen in 
colonic resections for chronic complicated DD80. The association of pain with previous episode of 
diverticulitis supports the theory of a peripheral nerve cause26. However, a central component to 
abnormal pain processing, as occurs in IBS195, has not been excluded in SDD patients301. 
Identifying the level within the nervous system where sensitisation arises is the key to successful 
targeting of treatment to either the gut or the brain301 
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While acute diverticulitis may be the initiating insult, a chronic low level inflammation and/or 
central changes in pain processing may be required to maintain visceral hypersensitivity. Whether 
anti-inflammatory agents acting at the level of the gut alone, such as mesalazine, could reverse this 
process is as yet unknown.  
 
To investigate these areas, I plan to undertake two studies 
1. Effects of somatic pain on cerebral activation using fMRI in symptomatic and 
asymptomatic DD and IBS patients  
2. Mechanistic RCT of mesalazine in painful DD 
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Chapter 2: Abnormalities of central processing of somatic and 
visceral pain in Diverticular Disease and Irritable Bowel 
Syndrome using functional magnetic resonance imaging (fMRI) 
 
2.1 Introduction 
2.1.1 Visceral and somatic convergence 
Visceral hypersensitivity has been demonstrated in many functional gastrointestinal conditions, 
including IBS302, 303 and recently in DD104. The gold standard method for eliciting pain in patients 
with visceral hypersensitivity is with a rectal barostat304.  In SDD the rectum has similar 
hypersensitivity to the sigmoid colon, where diverticular disease most commonly occurs103. 
However this technique is invasive and has produced varied fMRI and PET results depending on 
the technique73 used and analysis methods305.  In a mature patient population, with significant 
associated anxiety and morbidity306, volunteering for a procedure that is not going to provide 
significant additional diagnosis, treatment or financial benefits may be reduced307-309. Thus studies 
involving an invasive procedure and discomfort are likely to have significant recruitment problems 
in this group.  
 
In surgical conditions, such as cholecystitis or appendicitis, somatosensory changes in areas of 
referred pain have been demonstrated despite being pain free at assessment310, 311. This 
demonstrates somatovisceral convergence, with cutaneous hyperalgesia developing in the areas 
associated with input from painful or inflamed viscera. However, a phenomenon of localized 
and/or wide spread hypersensitivity has also been identified in patients with functional 
gastrointestinal and other disorders, suggesting altered descending inhibitory pathways189, 201, 302, 312-
321
. In IBS, visceral sensitivity has been significantly correlated to cutaneous thermal 
hypersensitivity312 7KLV LV WKRXJKW WR EH PDLQWDLQHG E\ FHQWUDO µWRS-down¶ HJ DQ[LHW\ 
hypervigilance VSLQDO HJ SDLQ LQKLELWLRQIDFLOLWDWLRQ GHILFLWV DQG SHULSKHUDO µERWWRP-XS¶
mechanism221, 312, 322. Similar chronic visceral and somatic hypersensitivity have been shown in 
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animal models following TNBS colitis323, 324.  However several differences in brain activation have 
been found between visceral and cutaneous painful events. 
 
2.1.2 Differences in cutaneous and visceral pain processing in healthy subjects 
Although many regions involved in somatic and visceral stimulation appear to be the same 
(secondary somatosensory cortex (S2), parietal cortices, THAL, basal ganglia and cerebellum),  
key differences have also been identified73, 235, 325-329. These are thought to be due to the greater 
emotional and autonomic effects of visceral compared to somatic pain. This include a series of 
studies by Strigo et al329, 330 where a heat stimulus applied to the skin was shown to increase 
bilateral aINS and ventrolateral PFC when compared to activations produced by visceral 
mechanical stimulation within the same dermatome region.  However greater activation was seen in 
the bilateral inferior S1 and primary motor cortices and rostral regions within the dorsal ACC with 
visceral compared to cutaneous stimulation. In a further study by Dunckley et al (2005), electric 
stimuli applied to the midline of the abdomen or the rectum showed similar activations in the PAG, 
parabrachial nucleus (PBN), nucleus cuneiformis (NCF) and the locus coeruleus (LCC)326. 
However PAG activation also correlated with anxiety rating on visceral stimulation. This area may 
have a greater role in the emotional unpleasantness of visceral compared to somatic pain326. Like 
visceral pain, somatic pain sensation is also influenced by modulators such as attention235, mood 
and emotion251, 331-335.  
 
Thus the use of cutaneous stimulation as a surrogate marker for visceral hypersensitivity may be 
useful in assessment of pain in SDD and prove more acceptable to the patient population allowing 
us to study a group of patients more representative of the whole population than if we had used 
rectal distension as our stimulus.  
 
2.1.3 Localized or Global hypersensitivity   
Difference in pain processing in IBS and other conditions has DOVR LGHQWLILHG SRVVLEOH µSDLQ
VLJQDWXUHV¶IRUJOREDOK\SHUVHQVLWLYLW\LQWKHFRQGLWLRQGXULQJDQWLFLSDWLRQDQGSDLQIXOHYHQWV73, 294. 
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Although this has not been investigated in SDD, it is possible that localized and/or global 
cutaneous hypersensitivity may be present in this group. Several brain regions have been identified 
as important in pain processing in health and other chronic pain groups.   
 
2.1.4 Background: brain regions involved in processing pain and anticipation of pain 
There is a very large body of literature describing brain areas and brain networks involved in 
processing pain stimuli (delivered using a wide range of methods and paradigms) and anticipation 
of pain. Over 1600 publications to date relate just to fMRI and pain. This section provides a brief 
background description of some of the key areas involved in these processes with particular 
reference to visceral pain conditions and thermal somatic pain paradigms. This background 
information will be then referred to along the discussion of the results of this study.  
 
(a)  Cingulate cortex. 
The ACC is of particular interest as the pACC is thought to be important in control of pain and its 
activity has been linked with the PAG and Pons336. As well as pain processsing337-340, the cingulate 
cortex activity has also been linked with attention241, 341, affective processing of painful stimuli 
reward probability and risk342, 343, avoidance learning344 as well as anticipation of pain345, 346.  
 
It is thought that the cingulate cortex can influence other brain regions involved in pain processing. 
This has been demonstrated in animal and fMRI studies. In rats conditioned to expect a painful 
stimulus with an auditory cue, significant increased ACC activity was identified during the 
anticipation phase of the study, while during the noxious phase activity was present in the ACC, S1 
and medial dorsal thalamus347. The correlations between these areas were also found to be 
increased during anticipated noxLRXVVWLPXOLFRPSDUHGWRXQDQWLFLSDWHGHYHQWVµ,QIRUPDWLRQIORZ¶
between the emotional and somatic brain areas was also enhanced347 by ACC anticipation activity. 
Uncertainty in a cue stimulus to an aversive stimulus has been shown to result in greater responses 
in the insula and amygdala compared to certain cues348. The activity of the ACC during the cued 
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anticipatory phase was found to be inversely associated with the insula and amygdala activity 
response to the aversive event348.  
 
Altered activities of the ACC and associated regions have also been demonstrated in chronic pain 
groups.  During cued anticipation of painful rectal distensions, deactivation of the insula, 
supragenual ACC, amygdala and brainstem have been shown using fMRI in controls but little 
deactivation in IBS patients190. Increased activation of the dorsal ACC has highlighted its 
importance in IBS192, 349. Treated IBS patients, who have reduced symptoms, demonstrate a 
reduction in dorsal ACC activation which supports this theory350, 351.   
 
Anticipation of pain can enhance synchronisation of activities of  the ACC and associated regions 
involved in pain processing and that emotional areas can influence nociceptive processing in 
somatosensory areas347 in health and chronic pain groups270. 
 
(b)  Insula 
The aINS is important in interoception (conscious sense of body condition)54, 352, 353, emotional 
awareness54, 354, magnitude of pain355, 356 and risk prediction61. The pINS is thought to be key in 
discriminative-sensory pain processing354, 357 and be somatotopically organised62. The INS and 
ACC have been identified in somatic358, 359 and visceral pain188, 303, 360 studies. Other areas are not as 
consistently activated in studies, such as the somatosensory cortices, thalamus and 
limbic/paralimbic areas73. Although neuro-anatomic pathways are known361, 362, the functional 
connectivity of these regions in pain anticipation and processing has not been fully elucidated363-365.   
 
The INS and S2 (contained within the parietal operculum, PO), as well as the inferior frontal gyrus 
(IFG) have also previous been implicated in anticipation of and pain processing366. The IFG is a 
gyrus of the frontal lobe which includes the pars opercularis, triangularis and orbitalis (Brodmann¶s 
areas 44, 45 and 47). The IFG is important in recognizing environmental changes, which may lead 
to painful situations as well as pain discrimination and pain related anxiety68, 367, 368. It is thought to 
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be important in the direction of attention towards pain perception369. The PO contains the S2 which 
interconnected with the insula, amygdala and hippocampus. The PO is thought to be important as a 
locus for pain perception and attention370-373 as well as being activated by pictures of painful 
events374, 375 and emotional modulation of pain during anticipation376. Functional connectivity has 
been identified between these areas during painful events366.  
 
The IFG, which is close to the insula, and in which areas of activation and deactivation can often 
overlap, has also been implicated in pain discrimination, attention, anxiety and environmental 
µWKUHDW¶PRQLWRULQJ68, 368. It has recently been shown to be more active when subjects have control 
over administration of painful stimuli than when they do not68. The PO has been shown to be active 
during many painful and non-painful sensory stimulation 377 as well as visual representations of 
pain374, 375. The INS, IFG and PO network is thought to play a role in affective processing and has 
been linked to other limbic areas such as the hypothalamus369, 378.   
 
Anticipation to touch mainly occurs in the anterior insula, while the sensation itself results in mINS 
and pINS activity54. Ploghaus et al have also demonstrated anticipation activity in the ACC, aINS 
and cerebellar cortices345, but this activity was anterior to the activity within these regions during 
noxious stimuli.  
 
In patients with somatoform pain disorder who were given painful thermal stimuli, increased 
activity was found in the aINS, parahippocampus and amygdala while decreased activity was 
identified in the VM-PFC and OFC compared to healthy controls379. In patients with IBS and 
fibromyalgia, bilateral aINS activity has been linked with increasing reported somatic pain 
independent of attention235. While the S2 activity was correlated with increasing reported visceral 
pain380. Arterial spin labelling studies of chronic pain in OA patients have demonstrated increase 
blood flow to several pain matrix regions at rest, including the INS and cingulate cortices, 
amygdala, hippocampus, thalamus, S1 and S2 and the brainstem (PAG and nucleus cuneiformis). 
Over several sessions, changes in the perceived pain that participants were experiencing correlated 
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with activity in the rostral and subgenual cingulate cortex, PFC, mINS, aINS, and pre-motor 
cortex381.  
 
(c) Amygdala, hippocampus and parahippocampus.  
The ACC and insula form part of the affective processing network along with the amygdala and 
hippocampus regions. Anxiety can influence perception of pain and the activity in the entorhinal 
cortex, which predicts the activity in the mINS (intensity coding) and perigenual cingulate 
(pgACC) (affective areas)382.   
 
Activation of the amygdala has also been found to be related to the passive duration of the 
anticipatory cue383. The Amygdala has been shown to deactivate during painful cutaneous371, 384, 385 
and visceral stimuli188, 190, 386.  However, activation of the amygdala during pain has also been 
found in some studies195, 385. Deactivation of the amygdala has been identified in animals and 
KXPDQV ,Q ERWK GLYHUVLRQ RI DWWHQWLRQ IURP WKH µIHDU RI SDLQ¶ RU µDFWLYH FRSLQJ¶ VWUDWHJLHV
decreases the pain experience and emotion circuit activities. This has been seen in numerous 
studies in humans56, 239, 364, 387-391. In a recent study383, lower amygdala activations and subjective 
pain experience were seen during active coping with a continuous performance task compared to 
inactivity (passive coping). This finding was most striking when using the reaction time as marker 
of engagement or attention with the task. Amygdala activity also increase by the duration of the 
anticipatory phase, which was independent of engagement in the task383.   
 
The deactivation of the amygdala and its interconnectivity with other regions is thought to be 
important in chronic pain conditions392 393. In a study of 28 patients with fibromyalgia (FM) and 14 
health volunteers (HV), who underwent subjectively calibrated pressure pain, a reduction in 
connectivity between the rostral ACC, amygdala, hippocampus and brainstem was identified 
compared to the healthy volunteers393. The thalamus also showed little connectivity to other brain 
regions in the FM group, but significant connections to the orbito-FC brain regions to the thalamus 
was identified in the HV. The authors suggested this demonstrated decreased activation of the brain 
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pain inhibitory network in the FM patients and that this was important in pain maintenance in the 
group.  
 
(d) Pre-Frontal cortex 
Appraisal is the emotional evaluation of impending stimuli and can be divided into low and high 
levels. Low level appraisal is a non-conscious, hard-wire and pre-attentive, while high level 
appraisal is conscious controlled and requiring memory and attention394. Attenuated mPFC/ACC 
and increased lateral PFC activity during anxiety and anticipation of painful events is suggestive of 
high level appraisal394. The mPFC and ACC are importing in evaluation of the self-relevance of 
stimuli, emotional awareness395 and attention to emotional stimuli395, 396. Regional blood flow has 
been found to be decreased during anticipation of painful shocks in normal healthy volunteers in 
the mPFC (BrodmaQQ¶V areas 10/32 and 24/25)395. This deactivation were inversely correlated with 
self rated anxiety and correlated with midbrain activity395.  
 
Control over events, such as self controlled painful stimuli, can also influence the perceived 
stimulus and related anticipatory anxiety. In self administered noxious stimuli, the ACC68, 397 and 
the dorsolateral (DL) and anterolateral (AL) PFC demonstrate higher activation68. Activation in the 
AL-3)& GXULQJ H[WHUQDOO\ PHGLDWHG VWLPXOL DOVR FRUUHODWHG ZLWK SDUWLFLSDQWV¶ Jeneral belief in 
control over their lives in healthy subjects68.  
 
Control and the nearness of threat are thought to be important in the modulation of key pain 
processing areas and the descending inhibitory pathways. Using PET in healthy volunteers with 
normal and capsaicin treated skin, principal component analysis suggests that the DL-PFC also 
modulates activity in the thalamus, ACC, OFC and aINS and perception of pain55. Also, in a maze 
pursuit paradigm, where healthy volunteers tried to evade a virtual predator which would capture 
and inflict pain, brain activity was found to alter from VM-PFC to the PAG on increasing 
SUR[LPLW\RIWKHµSUHGDWRU¶7KLVVKLIWZDVJUHDWHUZLWKincreased anticipation of pain. PAG activity 
was also correlated with degree of dread and decreased confidence in escape from capture398. 
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Anticipation of a learned pain-stimulus decreases the activity in the ACC and VM-PFC399. This 
may be because less appraisal is needed for stimuli which have already been encountered. 
 
The PFC is also important in expectation and, therefore, the placebo effect. The role of the DL-PFC 
in the placebo effect was examined using low level repetitive trans-cranial magnetic stimulation 
(TMS) to transiently inhibit the right or left DL-PFC in a heat-pain paradigm. Although pain 
experience was not affected the placebo effect was blocked, suggesting the DL-PFC is important in 
expectation and anticipation of pain400. Expectations of pain relief via a placebo during visceral 
stimulation also correlate with reduced activation of the thalamus, SS cortex, VL and DL-PFC 
during anticipation and in the thalamus during painful stimulation compared to the same 
participants when given a low expectation of pain relief. Participants who demonstrate a robust 
placebo effect have decreases in activation in the DL-PFC in anticipation and an in the SS cortex, 
thalamus and PCC during painful events compared to participants with low placebo effects401.  
 
(e)  Somatosensory cortex.  
The somatosensory context has been linked with sensory-discriminative pain pathways. However 
ipsilateral S2 has been previous implicated in anticipation and is enhanced by expectation of 
pain376. Magnetoencephalography (MEG) has been used to assess the SS cortices and S1 has been 
implicated in sensory and attention to painful stimuli, while in comparison the S2 only occurred 
during the noxious phase402. MEG has been used in health volunteers to assess the activity of the 
somatosensory cortices in anticipation of pain from distension of the oesophagus with an intra-
luminal balloon402. S1 and S2 showed bilateral asymmetrical activations were seen in the Beta 
bands. In S1 this was a continued increase during anticipation which continued with the pain but at 
a different frequency. Somatotopic representations of touch have been mapped in S1, S2 and in the 
operculo-insula cortex. Multiple somatotopic pain representations have also been mapped in the 
operculo-insula cortex for hand and foot to heat and pin-prick sensations 62, 63 and for muscular 
pain64, 403. In a study, which characterised individual response to a range of sub-threshold, threshold 
and painful stimuli, areas in the somatosensory, amygdala and insula cortices showed linear 
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relationship between activity and increasing painful stimulus404. The aINS and S2 have also been 
identified as key pain processing areas in psoriatic arthritis. Mechanical pain stimulus results in 
activity in the insula, S1 and S2, MCC and thalamus405. After anti-inflammatory medication pain 
intensity was correlated with activity in the aINS and S2, suggesting these areas are important in 
processing pain intensity405.  
 
(f)  Cerebellum 
Activity in the cerebellum has been demonstrated in many studies of pain73, 406-409, pre-attentive 
detection410 and anticipation of pain (ipsilateral posterior cerebellum) 345, 406. Initial fMRI studies 
suggested that cerebellar activations were related to the withdrawal behaviour and the motor 
pathways related to this response408 or to attention, verbal ratings and learning411, 412. However, the 
cerebellum is now thought to modulate nociceptive processing with several pharmacological and 
electric stimulation in animal models producing exacerbation and attenuation of noxious stimuli406. 
fMRI studies have shown different pattern of cerebellar activity to non-painful and painful 
stimuli413 and this is altered in patients with chronic pain states409.  It is also thought to have a role 
in affective pain processing218, 329, 409.  In healthy volunteers, areas within the cerebellum involved 
in processing of aversive heat stimuli and pictures are similar and have been suggested to be 
involved in general aversive processing and may involve both sensory and emotional networks414.  
 
In a recent study in 15 IBS and 12 healthy women, depression score, calculated from the HAD 
questionnaire, correlated with non-painful rectal distension activity in the CRUS I, II and VIIB of 
the right cerebellum and in the vermal lobule V during painful stimulations415. CRUS II and VIIB 
are thought to be involved in cognitive processing406. Anxiety was also correlated with CRUS II 
activity in non-painful distensions415. The cerebellum has also been implicated in chronic pain and 
associated psychiatric disorders406. 
 
 56 
(g) 7KHµGHIDXOWPRGH¶QHWZRUN 
Another theory for chronic pain is a failure of the brain to shift from the resting state default mode 
network to allow appropriate anticipation and modulation of emotional processing. This has 
previously been shown in IBS, where slow ramp tonic distensions result in increased activation of 
the insula, ACC and VM-PFC, and less deactivation in the VM-PFC, PCC and precuneus196. This 
suggests that IBS patients have an inability to shift from the default mode network and modulate 
emotional responses to visceral distension, unlike healthy volunteers196.   
 
The pACC has previously been implicated in pain control336. In a recent study it has also been 
found to be correlated positively with activity of the DMN in resting states416. In a study by 
Minassian et al 2012, 20 right handed subjects received electrical shocks to their right forearm417. 
This group demonstrated several DMN areas which were deactivated during the anticipation phase 
of the study and subsequently became active during the pain phase. These areas include the 
bilateral precuneus, PCC, hippocampus region, bilateral angular gyri and VM-PFC.  
 
In a separate study of 20 healthy subjects, the default mode network was assessed during rest 
anticipation and pain states.  A CHEP Medoc system was used to give a 12 sec heat pulse to the 
right forearm in 61 patients. Deactivation of classical DMN areas such as the mPFC, 
parahippocampus, precuneus and lateral temporal cortex, as well as non classical areas such as the 
pre-motor area, contra-lateral S1 and M1 and the superior frontal gyrus were also seen on fMRI418. 
Interestingly the group showed that there was greater range of deactivations at lower rather than 
KLJKHU SDLQ WKUHVKROGV DQG SRVWXODWHG WKDW WKLV ZDV WKH UHVXOW RI µSUHSDUDWion for escape from 
pain,418. However other groups have found the opposite, where increasingly demanding cognitive 
tasks and pain result in increased attention and decreased DMN activity419. In healthy volunteers 
and in FD similar regions deactivate during gastric distensions include the amygdala/hippocampus, 
ACC, PCC and precuneus, dorsal and ventromedial PFC, occipital and posterior temporal lobes. 
7KHVHVLPLODULWLHVVXJJHVW WKDW LQKHDOWKDQGGLVHDVH WKHUH LVDVKLIW IURP WKH µGHIDXOW-QHWZRUN¶ WR
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attention on the pain stimulus. Anterior MCC has been shown to be activated in HV and IBS 
during intestinal distension195, 420 and has been correlated with anxiety and fear of pain421.  
 
 
2.2 Hypotheses and aims of this study 
2.2.1 Aims 
The aims of the study are to determine differences in cortical and sub-cortical pain processing to 
thermal cutaneous stimuli in painful DD with comparison to non-painful DD and IBS.  
 
2.2.2 Hypotheses 
x SDD participants with a past history of acute diverticulitis will show peripheral 
hypersensitivity as demonstrated by greater activation of the S1 and 2, THAL and pINS 
compared to asymptomatic DD and IBS participants. 
x Painful DD with low PHQ12-SS scores will show enhanced response to painful 
stimulation of the foot (L5/S1) but not of the hand (C7/8), suggesting only localized 
hypersensitivity due to somato-visceral convergence 
x Painful DD with high PHQ12-SS scores will show enhanced responses to painful 
stimulation in both regions similar to IBS participants, suggesting  widespread or global 
hypersensitivity due to hyper-vigilance or derangement of the DNICs 
x Participants with IBS will demonstrate greater activation of affective and arousal areas 
similar to SDD patients with high PHQ12-SS scores suggesting a greater emotional 
engagement in pain processing. They will also demonstrate global hypersensitivity to 
stimuli as suggested by previous studies.  
x IBS and DD participants with high PHQ12-SS scores will have similar anticipatory 
responses to pain compared to non painful and painful DD with low PHQ 12 scores with 
evidence to suggest derangement of DNIC 
x A high PHQ12-SS and Pain catastrophizing score in participants will be associated with 
greater activation of affective and arousal areas to somatic stimulation  
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2.3 Methods 
 
2.3.1 Study approvals 
This study was assessed and approved by the Regional Ethics Committee (Nottingham committee 
2: REC Number: 09/H0403/43.) prior to commencing. The study was performed to GCP principles 
and sponsored by the University of Nottingham. The study was funded by a Wellcome Trust 
research training fellowship.  
 
2.3.2 Power calculation 
Based on the literature422 and our previous work using rectal barostat distension305, n = 12 subjects 
are required to show a >30% functional MRI difference in visceral sensation between groups which 
we considered clinically significant. We therefore aimed to recruit 20 subjects in each group to 
allow for possible 25% dropout and for scans excluded because of motion artifact.  
 
2.3.3 Participant recruitment 
Study participants with IBS, ADD and SDD were identified and recruited from gastrointestinal 
medicine and surgery clinics, databases of patients held at the NDDC, who had previously 
expressed interest in participating in research and local newspaper and bus adverts using 
standardized adverts, letters and information sheets. Participants who responded to the initial 
DSSURDFKZHUHFRQWDFWHGE\ WKHDXWKRUE\SKRQH7KHSDUWLFLSDQWV¶JDVWURLQWHVWLQDOGLDJQRVLVDQG
initial screening for inclusion and exclusion criteria (See Appendix 6.1) was performed by 
structured telephone questionnaire and consultation of hospital and general practitioner records, 
DIWHU REWDLQLQJ WKHSDUWLFLSDQW¶V ZULWWHQ FRQVHQW $OO VXLWDEOHSDUWLFLSDQWV ZHUH LQYLWHG WR D VWXG\
day. This one-off visit lasted 3 hours in duration and participants received an inconvenience 
allowance of up to £100. 
 
Participants attended the Sir Peter Mansfield Magnetic Resonance Centre at the University of 
Nottingham on 1 occasion, having completed validated questionnaires on gastrointestinal habits, 
hospital anxiety and depression scores, PHQ15 and pain catastrophizing score at home the night 
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EHIRUH1RQHRI WKHSDUWLFLSDQWV¶XVXDOPHGLFDWLRQVRUIRRGZHUHZLWKKHOGEHIRUHWKHYLVLWH[FHSW
for ondansetron (IBS participants), which has possible central effects and could have altered the 
brain responses423. Medical and MRI screening was rechecked and written consent was obtained on 
WKHGD\RIWKHVWXG\3DUWLFLSDQWV¶KHLJKWDQGZHLJKWZHUHDOVRDVVHVVHG 
 
2.3.4 MRI scanner and Medoc Peltier device 
All MRI was carried out on a state-of-the-art, research dedicated Philips Achieva 3T MRI scanner, 
sited at the Sir Peter Mansfield Magnetic Resonance Centre (Figure M2.1a). A Medoc PATHWAY 
Pain & Sensory Evaluation System (Medoc, Israel) was used for thermal stimulation of the hand 
and the foot (Figure M2.1b). This was equipped with a fMRI-compatible CHEPs (Contact Heat- 
Evoked Potential Stimulator) thermode probe (Figure M2.1c), with a 27 mm diameter thermode 
provided with a 10 meter cable and a filter that could be passed through the Faraday cage walls of 
the scanner room. The thermode was placed on the back of the hand (or foot) of the patients and 
maintained in place with its own Velcro strap and an additional sized tubi grip bandage (NHS 
supplies: D, E and G sizes, Supplies Codes: 1437, 1434, 1439, NHS catalog code: EGA 017, 
EGA019, EGA023) as shown in Figure M2.1d. 
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Figure M2.1: (a) The Philips Achieva 3T MRI scanner, sited at the Sir Peter Mansfield Magnetic 
Resonance Centre. On the scanner bed the 8-element parallel imaging head coil can be seen. On top 
of the coil there is the mirror that allowed patients to look at a screen where the cue signal was 
projected during the fMRI runs. (b) The Medoc peltier device. (c) The Medoc fMRI compatible 
CHEPs thermode7KH FRSSHUGLVN LV WKHSDUW WKDW ZDVSODFHG LQ FRQWDFW ZLWK WKHSDWLHQWV¶ VNLQ
held in place by the black Velcro strap and a tubigrip bandage as shown in (d). 
 
2.3.5 Sensory testing and thresholds 
Sensory testing was performed on the dorsum of the left hand and foot using the Medoc fMRI 
compatible pathway system. All testing was undertaken in the anteroom of the Philips 3T MRI 
scanner. Participants were positioned in a comfortable chair, orientated away from CHEPs 
computer screen to prevent confounding.  Participants were made comfortable with their arm 
supported on a table padded with pillows. 
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To measure limits of sensory threshold, Medoc designed software was used. Patients were given 
verbal instructions with demonstration as the CHEPs probe increased temperature by 1oC/second 
from 32oC to a maximum of 55oC. Once the response unit was activated the temperature of the 
probe rapidly decreased to baseline (32oC). Reassurance that the probe would not damage the skin 
was also given. Initially, for the first 4 temperature trials, participants were asked to press the 
UHVSRQVHXQLWZKHQWKHWHPSHUDWXUHµVWDUWHGWREHFRPHSDLQIXO¶$YHUDJHWHPSHUDWXUHYDULDWLRQDQG
standard deviation and a visual analogue score (VAS) of the pain intensity out of a score of 10 were 
UHFRUGHGDIWHUFRPSOHWLRQRIWKHWULDOVZLWKEHLQJµQRSDLQ¶µVOLJKWSDLQ¶DQGµVHYHUHSDLQ¶
The 4 temperature trials were then repeated, but participants were asked to activate the response 
unit when the\FRXOGµQRORQJHUWROHUDWH¶WKHWHPSHUDWXUHLQFUHDVHDQGUHVSRQVHGDWDZDVUHFRUGHG
as before.  
 
To measure responses at set temperature, participants were asked to score 3 grouped heat pulses. 
The heat pulses were all at a set temperature and 5 seconds iQGXUDWLRQZLWKVHFRQGVµUHVWSHULRG¶
between each at a baseline of 35oC. After 3 heat pulses were delivered participants were asked to 
rate the pain intensity using the VAS. A further 3 pulses were then delivered at a different 
temperature and the scoring repeated. Participants were deliberately not told the temperature of 
each three pulses or if the next set of temperatures would be higher or lower than the preceding set. 
They were advised only that they could give a VAS score for each 3 pulses which was the same, 
greater or less than previous. The 3 pulse blocks testing was continued until a VAS score of 6-7 
was given or the participant requested to stop i.e. they did not want higher heat pulses to be 
delivered.  
 
2.3.6 7KHµ9$6WHPSHUDWXUH¶ 
The temperature at which the subjects rated the pain intensity at a VAS score of 6 or 7 was 
GHVLJQDWHGDVWKHµ9$6WHPSHUDWXUH¶DQGWKLVWHPSHUDWXUHZDVXVHGDVLQGLYLGXDOWKUHVKROGIRUWKH
following study paradigm. This temperature threshold will be referred to throughout this 
GLVVHUWDWLRQDVµ9$6WHPSHUDWXUH¶ 
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$PLQXWHµWHVWUXQ¶FKHFNZDVWKHQSHUIRUPHGWRFRQILUPWKDWWKH9$6WHPSHUDWXUHVFRUHVZHUH
reproducible for that given individual and to assess if a standard temperature of 45oC could be used 
for the subjects a. This was achieved using a 2 minute protocol consisting of four 5 second stimuli 
(two VAS and two heat pulses at 45oC). These heat pulses were separated by a 25-30s second rest 
period. Participants were advised that the stimulus would be similar to those they would experience 
ZKHQLQWKHVFDQQHUDQGWKDWWKHVWLPXOXVZDVVXSSRVHGWREHµSDLQIXO¶7KH\ZHUHWROGWKDWLQWKH
VFDQQHU WKH\ ZRXOGQHHG UHPDLQ VWLOO WR UHGXFHPRYHPHQW DUWLIDFW DQG WKDW WKLV µWHVW UXQ¶ ZDV WR
ensure the temperatures used for the heat pulses could be tolerated. A VAS score was taken at the 
end of the 2 minute protocol for the participants overall pain intensity rating. If participants could 
not tolerate either temperature, they were adjusted down by 0.5oC and the protocol repeated until a 
tolerated temperature was selected. At least 0.5oC difference between the VAS temperature and the 
45°C or adjusted temperatures was maintained for the study paradigm protocols.  
 
2.3.7 Scanning protocol 
(a)  Participant positioning and instruction 
Functional MRI images were obtained using a 3T Philips Achieva scanner and 8-channel SENSE 
dedicated brain imaging coil (Figure M2.1).  
 
(b)  Visual cues 
All participants received standardized verbal information about the scanner and study and were 
shown the scanner. The receiver coil around the head of the subjects had an in-built mirror (Figure 
M2.1a) that allowed them, once positioned in the scanner, to see a projection screen in front of the 
magnet bore, which is commonly used to project visual stimuli and/or instructions during fMRI 
studies. In this study the participants were instructed to look at a small blue cross projected on the 
VFUHHQ 7KLV ZRXOG FKDQJH WR ZKLWH FURVV WR JLYH D YLVXDO µFXH¶ SULRU WR DQ\ KHDW VWLPXOXV 7KH
visual cue formed an important part of the paradigm design as would allow analysing the data for 
anticipation of pain. 
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Participants were asked to pay attention to the screen and to the heat stimulus when delivered. 
Participants were given ear plugs and headphones to dampen down the loud noise arising from the 
running imaging sequence and positioned supine on the scanner bed with the CHEPs probe 
DWWDFKHGWRWKHGRUVXPRIWKHOHIWKDQGRUIRRWDVIRUWKHVHQVRU\WHVWLQJ7KHVFDQQHUµQXUVHFDOO¶
alarm button was placed iQWKHSDUWLFLSDQW¶VULJKWKDQGLQFDVHWKH\QHHGHGWRFDOOIRUDWWHQWLRQ1R
music or other verbal stimulus was provided during image acquisitions. 
 
(c) Medoc Peltier paradigm and fMRI image acquisition 
Firstly, a set of T1 weighted scout images were taken to allow planning of the imaging study and 
an automatic calibration scan was run to set up the 8-element parallel receiver head coil. After this, 
a 2 minute training paradigm was performed. This allowed the participant to become familiarized 
ZLWKWKHVFDQQHUHQYLURQPHQWWRVHHWKHµFXHV¶RQWKHVFUHHQDQGWRUHFHLYHWZRVHFKHDWSXOVHV
similar to what they would experience during the actual study experiment. This allowed also the 
research staff to confirm that the scanner, presentation computers and Medoc CHEPS Pathway 
system were set up and synchronized correctly (Figure M2.2). The participants were then asked to 
give a prediction of the VAS rating they would give at the end of the first peltier paradigm. The 
main study experiment was then commenced using 1 of 2 study paradigms as described below. 
 
Two pseudo-randomized peltier paradigms were designed (Figure M2.3). The designs of the 
paradigms were based on our previous barostat paradigms305, other sensory studies79, 424 and 
sensory testing guidelines form the German research network on neuropathic pain425, 426. Each 
FRQWDLQHGILYHVHFRQGµ9$6WHPSHUDWXUH¶KHDWSXOVHVDQGILYHVHFRQGµo&¶RUHTXLYDOHQWDV
described above) with 25-VHFRQGVµUHVW¶SHULRGEHWZHHQHDFKµFXH¶DQGKHDWSXOVH3ULRUWRHDFK
heat pulse a 5-12 second visuaO µFXH¶ ZDV JLYHQ :LWKLQ WKH SDUDGLJPV WKHUH ZHUH DOVR WZR
DGGLWLRQDOEODQN QR WHPSHUDWXUH VWLPXOXV VHFRQGSHULRGVSUHFHGHGE\D VKRUW VHFRQG µFXH¶
7KHVH µEODQNV¶ ZHUH GHVLJQHG WR UHGXFH WKH SDUWLFLSDQW¶V DELOLW\ WR SUHGLFW WKH VXEVHTXHQW KHDW
pulses (Fig. M2.3).The sequence of timing of the cues and stimuli for each paradigm can be found 
in Appendix 6.2. 
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Figure M2.2 Set up and interconnections between computer systems 
 
 
Each paradigm lasted 8-9 minutes. After each paradigm the Medoc CHEPs probe was repositioned 
to the other site, e.g. the hand or foot, and the either paradigm 1 or 2 commenced. After the 2 
paradigms were completed, i.e. 1 on the hand and 1 on the foot, the participants were removed 
from the scanner and given a 15 minute break where they could mobilize around the department 
and drink water. They were then returned to the scanner for a further paradigm on the hand and 
foot and acquisition of a MRI structural image that would be later used for data processing.  
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The imaging module used for the thermal stimulation study was a single-shot, double-echo echo-
planar imaging (EPI), with a matrix of 80×77 and 40 slices covering the whole brain with no gaps 
between slices. The resolution was isotropic 3 mm × 3 mm × 3 mm and 177 dynamic scans (7,080 
images in total) were acquired during one single run on the foot or the hand. The images were 
originally from transverse plane but the stack was tilted along the AC-PC axis which helped 
minimising orbitofrontal artefacts from the nasal cavity. The scan parameters were repetition time 
TR=3s, echo times TE= 25ms and 50ms, fat suppression SPIR and 80° flip angle. The anatomical 
images acquired at the end were sagittal T1 weighted MPRAGE, 256×256 matrix, 160 slices with 
no gap between them, 1 mm × 1 mm × 1 mm isotropic resolution, repetition time TR=8.2 ms, echo 
time TE= 3.8 ms and 8° flip angle. This sequence lasted 4-5 minutes. The order of the stimulation 
site (e.g. hand or foot) and the paradigms e.g. paradigm 1 or 2) for each participant were 
randomized prior to commencing the study to avoid order effects.  
 
2.3.8 fMRI Image processing 
All fMRI images were analyzed using SPM8 (Wellcome Trust Centre for Neuroimaging, 
University College London [UCL], UK). Details of analysis methods can be found in Appendix 
6.4. Images were corrected for movement and slice timing and normalized to an EPI template, 
following by smoothing (8mm kernel). Box-Car general linear model (GLM) was used for the heat 
stimuli and cue. Each model was convolved with canonical haemodynamic response function 
(HRF). Individual motion parameters for each paradigm and subject were used as no interest 
covariates in the GLM. Blank stimuli were not included within the analysis. First level fixed effects 
analysis was performed for each participant. Motion parameter, image quality and questionnaire 
data were assessed for each participant and incomplete or poor quality datasets were removed from 
further analysis, leaving 14 subjects per group (see Appendix 6.3 for further information on 
subject selection) 6HFRQG OHYHO UDQGRP HIIHFWV 5); DQDO\VHV DW WKH JURXS OHYHO IRU WKH µ9$6
WHPSHUDWXUH¶ SXOVHV )'5 [false discovery rate] corrected for multiple comparisons at p<0.05, 
voxel threshold 5) and for the cue (uncorrected p<0.001, voxel threshold 5) were performed.  
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Figure M2.3 Paradigm design  
(A) Basic Paradigm design and Key 
 
 
(B) Paradigm designs 
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Figure M2.4 Study Sequence 
 
 
 
2.3.8 fMRI Image processing (continued) 
Further analyses were performed, including 2 sample t test of responsive areas between the hand 
DQG WKH IRRWZLWKLQHDFKJURXSDQG WKHµ9$6WHPSHUDWXUH¶DQGµFXH¶HYHQWVRQ WKHKDQGRU IRRW
between groups. Analysis of covariates of interest, including VAS rating during the study, VAS 
temperature used, anxiety and depression scores on the HAD questionnaire, total pain 
catastrophizing score, age and body mass index (BMI), was also performed. Regions of interest 
were identified for each analysis using the PickAtlas (version 2.4). 
 
 
2.3.9 Statistical Questionnaire analysis  
Participant questionnaire data was stored on Microsoft Office Access 2007 (Microsoft USA) and 
transferred to SPSS (version 15, IBM, Portsmouth UK) and GraphPad Prism (Version 5, California 
USA) for further analysis. Continuous group data was compared using nonparametric t test (Mann-
Whitney U). Significance of correlation between pain intensity ratings with questionnaire data was 
DVVHVVHG XVLQJ 6SHDUPDQ¶V UDQN FRHIILFLHQW 6WDWLVWLFDO VLJQLILFDQFH ZDV FRQVLGHUHG DW D S 
level.  
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2.4 Results 
 
2.4.1 Recruitment and demographic results 
 
(a)  Participant Recruitment 
The study started recruiting in February 2010 with the first participant to be scanned in March 
2010. Unfortunately the original Medoc Peltier CHEPS pathway system suffered a fault and a new 
Peltier was purchased from Medoc Israel. Therefore the first participant was scanned in May 2010. 
Participant recruitment was challenging and only 1-8 people recruited per month over a total of 19 
months. Recruitment rate is shown in figure R2.1 
Figure R2.1 Recruitment rate 
 
426 Potential participants, identified from clinics, advertisements and endoscopy lists were sent 
standardized information about the study leading to several enquiries and 74 participants being 
recruited. Reasons for volunteers declining or being excluded from participating in the study can be 
seen in figure R2.2. 
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Figure R2.2 Flow diagram of participant recruitment 
 
3 participants withdrew from the study: 2 after the sensory testing and before scanning and 1 at the 
break after the first scanning session.  
 
(i)  Demographics 
74 participants took part in the study with 20 in the asymptomatic (ADD), 18 in the IBS and 36 in 
the SDD group. The distribution of PHQ12 scores within the SDD group was assessed and the 
cohort divided into 2 subgroups: one with a total PHQ12 scored less or equal to 6 (n=19, low 
symptomatic or LSDD) and one group with a score greater or equal to 7 (n=17, high symptomatic 
or HSDD). Demographic data for all the groups can be seen in table R2.1 
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Table R2.1 Demographics for all participants 
Groups 
All subjects  
ADD 
N=20 
LSDD (PHQ <6) 
N=19 
HSDD (PHQ >7) 
N=17 
IBS 
N=18 
Female 50%  63.2%  70.6%  77.8%  
Previous Diverticulitis  10%  36.8%  29.4%  0%  
PMH psychiatric  25%  15.8%  17.6%  50%  
  
After analysis of questionnaires, MRI motion plots and images derived from 1st level analysis for 
each participant, several participants were excluded from further analysis. Groups of 14 
participants were created for each group based on the most complete data sets available.  A table of 
subjects and reasons for exclusion can be seen in Appendix 6.3. 
 
Demographic data for this subset, which underwent 2nd level RFX group analysis, is shown in table 
R2.2 
 
Table R2.2 Subset group demographics 
fMRI Analysis groups 
(n=14)  
ADD  LSDD (PHQ <6)  HSDD (PHQ >7)  IBS  
Female 42.5%  57.1%  78.6%  78.8%  
Previous Diverticulitis  0  50%  35.7%  0  
PMH psychiatric 28.6%  7.1%  21.4%  42.9%  
  
Further demographic analysis of the subset group included age and BMI and are shown in figure 
R2.3. Non-parametric t test (Mann Whitney U (MWU)) was used to confirm significant differences 
between groups.  
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Figure R2.3 Subset group age and BMI  
(Red bars on the BMI graph represent normal BMI ranges according to World Health 
Organisation427) 
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2.4.2 Questionnaires results 
 
(i) Participant gastrointestinal symptoms 
Pain duration was divided into pain lasting greater than 24 hours and pain lasting less than 24 
hours.  
 
(a) 3DLQODVWLQJKRXUV 
Both SDD groups reported pain lasting longer than 24hours more frequently than compared to the 
ADD and IBS groups (Figure R2.4). The incidence of pain lasting greater than 24hours (figure 
R2.4) was also increased in the High SDD (PHQ FRPSDUHGWRWKH/RZ6''JURXSPHQ  
 
Figure R2.4 Graphical representation of Incidence of Pain lasting >24hours reported on 
questionnaire by group over 1 year. 
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(b) 3DLQODVWLQJKRXUV 
For pain lasting less than 24 hours, there was a significant difference in the incidence and duration 
of pain between the ADD and both SDD and IBS groups (table R2.3)  
 
Table R2.3 Incidence of Gastrointestinal symptoms reported on questionnaire per group over 1 
year excluding pain lasting > 24 hours which was assumed to represent diverticulitis. Note the 
greater frequency and more prolonged pain in SDD compared to IBS. 
 
 
 
Add vs group  * p<0.05  ** p<0.001 *** p< 0.0001 
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  (c) Bowel habits 
7KHPHGLDQQXPEHURI WLPH WKHSDUWLFLSDQWV¶ ERZHOV ZHUHRSHQHG DQG WKH LQFLGHQFHVRI KDUGRU
loose stool were similar between all the groups. There was a trend for tenesmus in the high SDD 
group, but it did not reach statistical significance. However the  High SDD and IBS did report 
significantly more bloating compared to the ADD group (Figure R2.5), but there was no statistical 
difference between the SDD (p=0.0818) or IBS groups  (Low SDD p=0.2059 and High SDD 
p=0.5985). The incidence of bleeding was also different between the groups, with 64.3% of 
participants in the ADD group reporting bleeding during the last year compared to only 14.3% in 
the low SDD and 42.9% and 28.6% in the high SDD and IBS groups respectively (table R2.3). 
 
Figure R2.5 Graph representation of the incidence of bloating per week reported on questionnaire 
per group over the last year.  
 
 
(d) GP visits 
The median number of GP visits and the range is shown in table R2.3. No statistical difference was 
identified between the groups.  
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 (ii) Participant psychological questionnaire results 
(a) Physiological health questionnaire 12 (PHQ12) 
7KLV TXHVWLRQQDLUH ZDV XVHG WR GLYLGH WKH 6'' JURXS LQWR ORZ  DQG KLJK  VFRUHUV IRU
further analysis. The graph (figure R2.6) shows PHQ12 score for the IBS and the ADD groups as a 
comparison to the SDD groups. The red bar marks the cut off between the two SDD groups. 
Statistical significance was calculated using a non-parametric t-test (MWU). 
 
Figure R2.6 PHQ12 scores per Subset analysis groups 
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(b) Hospital Anxiety and Depression score (HADS) 
 
Figure R2.7 Hospital Anxiety Depression Score 
The graphs show the (A) Anxiety and (B) Depression Sub-score. The red broken line indicates the 
cut of between normal (below) and clinically significant anxiety and depression (above).  
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(c) Pain Catastrophizing Score (PCS) 
Pain catastrophizing score distribution for each subset group analysis is shown in figure R2.8. 
Significant difference in the total scale was identified between the low and high SDD groups. 
Figure R2.8 PCS per Subset analysis groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple significant correlations were identified between the PHQ12, HAD, and PCS 
questionnaires and age of the subjects (Table R2.4). 
 
Table R2.4 Correlations between questionnaires and ages of subjects 
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Sensory WHVWLQJ SULRU WR VFDQQLQJ SDUDGLJPV UHVXOWHG LQ LGHQWLI\LQJ D µ9$6 WHPSHUDWXUH¶ ZKLFK
consistently gave a VAS scores between 6 and 7. Despite this there was a variation in reported 
VAS at the end of the study paradigms themselves. This may have been to altered stress and 
anxiety caused by being in the scanner itself and was difficult to predict and control for. There was 
also strong correlation between the VAS scores given at the end of each paradigm for the hand and 
the foot (Figure R2.9:  r2=0.8425, p<0.0001) 
 
Figure R2.9 Correlation between Foot and Hand VAS scores. 
 
 
+RZHYHU WKHUHZDVQRVLJQLILFDQWFRUUHODWLRQEHWZHHQ WKH µ9$6 WHPSHUDWXUH¶ XVHGDQG WKH9$6
score for the hand or foot when compared with age, BMI, PCS score or depression component of 
the HAD questionnaire. There were no significant correlations either with BMI. Significant 
correlations are shown in table R2.5 
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Table R2.5 Correlation between Patient demographics, Questionnaires, VAS score during the 
paradigms and Vas Temperatures.  
 positive correlation,    negative correlation, n.s. not significant.  
 Temp (oC) PHQ12 HAD: 
Anxiety 
HAD: 
Depression 
PCS Age 
VAS Hand 
r2=0.1025 
 p=0.0109 
r2= 0.05660 
  p=0.659 
r2=0.05986 
 p=0.0403 
n.s n.s. n.s 
VAS Foot 
r2=0.1579 
 p=0.0043 
r2=0.05002 
  p=0.2247 
r2=0.04672 
 p=0.0759 
n.s n.s. n.s 
HAD 
Anxiety 
n.s. 
r2=0.4531 
  p<0.0001 
    
HAD 
Depression 
n.s. 
r2=0.2509 
  p<0.0001 
r2=0.3972 
 p<0.0001 
   
PCS n.s. 
r2=0.2142 
  p=0.0024 
r2=0.1598 
 p=0.0195 
n.s.   
Age n.s. 
r2=0.3080 
  p<0.0001 
r2=0.1598 
 p=0.0195 
r2=0.09445 
  p=0.0112 
r2=0.07182 
  p=0.0423 
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2.4.3 Sensory testing results 
Table R2.6 demonstrates the median and inter-quartile range (IQR) of the temperatures selected for 
the VAS temperature heat pulses and the mean VAS scores given at the completion of each study 
on the hand or foot. Although there was a trend for lower temperatures and higher VAS scores in 
the SDD and IBS groups for both the hand and foot, this did not reach significance. There were 
also no significant differences in VAS temperatures used or VAS scores between the hand and feet 
within each group.  
 
Table R2.6 Median VAS temperatures and scores per group 
Group Hand 
Median Temp. (oC) 
(IQR) 
Hand 
Median VAS 
(IQR) 
Foot 
Median Temp. (oC) 
(IQR) 
Foot 
Median VAS 
(IQR) 
ADD 45.40 
(43.50-46.75) 
6.0 
(4.75-8.13) 
45.50 
(43.38-46.00) 
7.25 
(4.88-8.50) 
LSDD 43.75 
(42.50-47.00) 
7.5 
(4.95-8.00) 
43.50 
(42.00-46.63) 
6.75 
(6.00-8.50) 
HSDD 43.75 
(41.88-45.75) 
8.25 
(6.00-8.50) 
43.75 
(41.88-44.88) 
7.50 
(5.63-8.75) 
IBS 43.75 
(42.38-45.63) 
7.25 
(6.00-8.50) 
44.50 
(43.13-46.13) 
7.75 
(6.38-8.00) 
 
 
As participants stopped sensory testing once a VAS score of 6-7 was identified, the relationship 
between VAS score and temperature is difficult to represent graphically. Therefore, a cumulative 
median has been created where the previous VAS scores for lower temperatures are added to the 
subsequent VAS score for the next temperature tested i.e. (ADD: mean VAS 40 + mean VAS 41 + 
mean VAS 42 etc) (Figure R2.10 (a) and (b)).   
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Figure R2.10 Cumulative VAS score per temperature used in sensory testing per analysis group (a) 
and for all participants (b). 
(a) Median Cumulative Vas score per temperature for Hand and Foot per analysis group 
(n=14 per group) 
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(b) Median Cumulative Vas score per temperature for Hand and Foot for all participants  (IBS 
N=18, ADD N=20, LSDD N=19, HSDD N=17) 
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2.4.4 fMRI Results 
 Both the VAS temperature and the µ45oC¶ temperature components of the  paradigm were planned 
to be used in for the analysis. This would have given functional brain comparisons for the groups at 
a consistent level of pain (VAS temperature stimulus) and at a consistent temperature (45oC 
stimulus). Unfortunately during the duration of the study it was found that few subjects were able 
to tolerate the 45oC stimulus and this had to be adjusted to allow any imaging to be obtained.  Thus 
the analysis performed is only of the VAS temperature.   
 
Despite this the study still generated a very large amount of fMRI results and summarising these in 
a comprehensible format suited for this dissertation was a challenge in itself.  For this purpose the 
main fMRI results were summarised here in tables subdivided by main functional (e.g. 
somatosensory, affective) and then anatomical (e.g. S1, anterior insula and left or right hemisphere) 
DUHD $FWLYDWLRQV DQG GHDFWLYDWLRQV ZHUH WKHQ UHSUHVHQWHG SHU SDWLHQW JURXS E\ DUURZV Ĺ DQG Ļ
respectively). 
 
(i) Group map descriptions for hand and foot stimuli  
Table R2.7 Group Maps 
2nd level random effect analysis of 14 subjects per group (FDR [false discovery rate] corrected, 
Voxel 7KUHVKROG  %HORZ DUH VLPSOLILHG UHVXOWV VKRZLQJ DFWLYDWLRQV Ĺ DQG GHDFWLYDWLRQV Ļ
within different brain regions for the VAS heat stimulus to the left foot (A) or hand (B) for each 
group (FDR corrected p<0.05) using a temperature which was rated 6-7 on 10 point visual 
analogue scale (VAS temperature. Areas which included both activations and deactivations are 
represented by ĹĻMost consistently activated areas are highlighted in yellow. 
 
Key: SMA: Supplemental Motor Area, PFC prefrontal cortex, ACC, anterior cingulate cortex, 
MCC mid cingulate cortex, PCC posterior cingulate cortex, S1 primary somatosensory cortex, S2 
secondary somatosensory cortex, Motor, Primary Motor cortex. DNIC descending nociceptive 
inhibitory or facilitatory controls. 
 84 
Table R 2.7 $$FWLYDWLRQVĹDQGGHDFWLYDWLRQVĻIRUthe VAS heat stimulus to the left foot 
using a temperature which was rated 6-7 on 10 point visual analogue scale (VAS temperature).  
 Area Side ADD LOW SDD HIGH  
SDD 
IBS 
 S1 
L 
    
Somatosensory R     
 S2 
L Ĺ ĹĻ Ĺ Ĺ 
 
R Ĺ Ļ Ĺ Ĺ 
Somatosensory 
Post-Ins 
L 
    
 
R 
    
 Mid-Ins L Ĺ Ĺ   
  
R 
 Ĺ Ĺ Ĺ 
Affective 
Ant-Ins 
L Ĺ   Ĺ 
 
R Ĺ Ĺ   
Affective 
ACC 
L Ļ  Ļ  
 
R 
 Ĺ   
Affective 
MCC 
L Ĺ  Ĺ  
 
R ĹĻ Ĺ Ĺ Ĺ 
 
PCC 
L 
  Ĺ  
 
R 
    
Affective 
Medial PFC 
L 
 Ļ Ļ Ļ 
 
R 
 Ļ  Ļ 
DNIC 
Lateral PFC 
L Ĺ ĹĻ ĹĻ ĹĻ 
 
R Ĺ ĹĻ Ļ Ļ 
DNIC Orbito-FC L  Ļ  Ļ 
  
R 
    
Somatosensory 
Lentiform Nuclei and Thalamus 
L Ĺ  Ļ ĹĻ 
 
R Ĺ Ļ Ļ Ļ 
Affective Amygdala 
(Hippocampus) 
L 
 Ļ Ļ Ļ 
 
R 
  Ļ ĹĻ 
 
Cerebellum 
L Ĺ Ĺ Ĺ ĹĻ 
 
R Ĺ  Ļ ĹĻ 
 
Inferior Parietal 
L Ĺ   Ļ 
 
R 
    
 
Temporal 
L ĹĻ ĹĻ ĹĻ ĹĻ 
 
R 
 Ļ ĹĻ  
 Motor L     
  
R 
    
 SMA L     
  
R Ĺ   Ĺ 
Somatosensory Post-central L Ļ Ļ Ļ Ļ 
 Gyrus R ĹĻ Ļ Ļ Ļ 
DNIC Subthalamic/ Brainstem  Ĺ Ĺ   
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Table R2.7 % $FWLYDWLRQV Ĺ DQG GHDFWLYDWLRQV Ļ IRU heat stimulus to the left hand using a 
temperature which was rated 6-7 on 10 point scale (VAS temperature stimulus.) Note the pattern is 
very similar to that seen with foot stimulus. 
 Area Side ADD LOW SDD HIGH  
SDD 
IBS 
 S1 L     
Somatosensory R     
 S2 L  Ĺ Ĺ  
 
R Ĺ Ĺ Ĺ Ĺ 
Somatosensory Post-Ins L     
 
R 
    
 Mid-Ins L  Ĺ Ĺ  
  
R 
 Ĺ Ĺ Ĺ 
Affective Ant-Ins L Ĺ  Ĺ  
 
R Ĺ   Ĺ 
Affective ACC L     
 
R 
 Ĺ   
Affective MCC L Ĺ Ĺ  Ĺ 
 
R 
  Ĺ  
 PCC L   Ĺ  
 
R 
    
Affective Medial PFC L Ļ Ļ Ļ Ļ 
 
R 
  Ĺ Ļ 
DNIC Lateral PFC L ĹĻ ĹĻ ĹĻ Ļ 
 
R ĹĻ Ļ Ļ ĹĻ 
DNIC Orbito-FC L Ļ Ļ  Ļ 
  
R 
 
Ļ 
 
Ļ 
Somatosensory Lentiform Nuclei and Thalamus L ĹĻ  Ļ Ĺ 
 
R ĹĻ 
 Ĺ Ĺ 
Affective Amygdala 
(Hippocampus) 
L 
 
Ļ Ļ Ļ 
 
R 
  Ĺ  
 Cerebellum L Ĺ Ĺ Ĺ ĹĻ 
 
R Ļ Ĺ ĹĻ ĹĻ 
 Inferior Parietal L Ĺ Ĺ Ĺ  
 
R 
    
 Temporal L  Ļ Ļ Ļ 
 
R Ļ Ĺ Ļ  
 Motor L     
  
R 
    
 SMA L Ĺ  Ļ Ļ 
  
R 
 Ĺ Ļ Ĺ 
Somatosensory Post-central 
Gyrus 
L Ļ ĹĻ Ļ Ļ 
 
R Ļ Ļ Ĺ ĹĻ 
DNIC Subthalamic/ Brainstem  Ĺ Ļ ĹĻ ĹĻ 
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(vi) Intra-Group Analysis: Differences between hand and foot VAS stimuli  
%HORZDUHVLPSOLILHGI05,UHVXOWVRI VDPSOH W WHVWFRPSDULQJDFWLYDWLRQVĹDQGGHDFWLYDWLRQV
Ļ when the VAS temperature stimulus is applied to the left hand or left foot (R2.9 A and B; 
uncorrected p<0.05). Most consistently activated areas are highlighted in yellow. 
 
Table R2.8 (A) Hand > Foot VAS Stimulus 
Areas where activations and deactivations are greater in the left hand than in the left foot.  
 Area Side ADD LOW SDD HIGH  
SDD 
IBS 
 S1 L     
Somatosensory R     
 S2 L Ĺ   Ļ 
 
R Ĺ Ĺ  Ĺ 
Somatosensory Post-Ins L     
 
R 
 Ĺ   
 Mid-Ins L     
  
R 
    
Affective Ant-Ins L     
 
R 
    
Affective ACC L Ĺ  Ļ Ĺ 
 
R 
 Ĺ Ļ Ĺ 
Affective MCC L Ļ    
 
R Ĺ Ĺ Ĺ  
 PCC L   Ļ  
 
R 
    
Affective Medial PFC L Ĺ  Ļ ĹĻ 
 
R 
  
Ļ 
 
DNIC Lateral PFC L Ĺ  Ļ  
 
R Ĺ Ĺ  Ĺ 
DNIC Orbito-FC L   Ļ  
  
R 
    
Somatosensory Lentiform Nuclei and Thalamus L    Ļ 
 
R 
 Ĺ   
Affective Amygdala 
(Hippocampus) 
L Ļ Ļ Ļ Ļ 
 
R Ļ Ļ Ļ Ļ 
 Cerebellum L ĹĻ Ĺ Ĺ Ĺ 
 
R 
 Ĺ  Ļ 
 Inferior Parietal L   Ĺ  
 
R 
    
 Temporal L Ļ Ļ Ļ Ļ 
 
R Ļ Ļ Ļ Ļ 
 Motor L     
  
R 
    
 SMA L Ĺ  Ĺ  
  
R Ļ Ĺ   
Somatosensory Post-central 
Gyrus 
L 
 
 
  
 
R Ĺ Ĺ Ĺ Ĺ 
DNIC Subthalamic/ Brainstem  Ļ Ļ  Ļ 
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Table R2.8 (B) Foot > Hand VAS Stimulus 
Areas where activations and deactivations are greater in the left foot than the left hand.  
 Area Side ADD LOW SDD HIGH  
SDD 
IBS 
 S1 L     
Somatosensory R     
 S2 L     
 
R 
  Ĺ  
Somatosensory Post-Ins L Ĺ  Ĺ  
 
R Ĺ  Ĺ Ĺ 
 Mid-Ins L     
  
R 
   Ĺ 
Affective Ant-Ins L    ĹĻ 
 
R 
   Ĺ 
Affective ACC L   Ĺ Ĺ 
 
R 
   Ĺ 
Affective MCC L   Ĺ Ĺ 
 
R 
  Ĺ Ĺ 
 PCC L     
 
R 
   
Ļ 
Affective Medial PFC L Ļ  Ĺ  
 
R 
  Ĺ Ļ 
DNIC Lateral PFC L Ļ Ļ Ĺ  
 
R 
  Ĺ Ļ 
DNIC Orbito-FC L     
  
R 
  Ĺ  
Somatosensory Lentiform Nuclei and Thalamus L  Ĺ Ĺ  
 
R Ĺ Ĺ Ĺ Ļ 
Affective Amygdala 
(Hippocampus) 
L 
 Ĺ Ĺ Ĺ 
 
R 
  Ĺ Ļ 
 Cerebellum L Ĺ Ļ Ĺ Ĺ 
 
R 
 Ļ   
 Inferior Parietal L     
 
R 
    
 Temporal L Ĺ Ĺ Ĺ Ĺ 
 
R ĹĻ 
 Ĺ  
 Motor L     
  
R 
    
 SMA L   Ĺ  
  
R Ĺ   Ĺ 
Somatosensory Post-central 
Gyrus 
L 
 
 Ļ 
 
 
R Ļ Ļ ĹĻ Ļ 
DNIC Subthalamic/ Brainstem  Ĺ  Ĺ Ĺ 
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(vii) Inter-Group Analysis: Differences between hand and foot response to heat rated 6-7 
on a 10 point scale (VAS temperature stimulus)  
%HORZDUHVLPSOLILHGI05,UHVXOWVRI VDPSOH W WHVWFRPSDULQJDFWLYDWLRQVĹDQGGHDFWLYDWLRQV
ĻEHWZHHQ WKH$''DQGRWKHUJURXSV LQ WKH)RRW $RU+DQG %ZKHQ WKH9$6 WHPSHUDWXUH
stimulus is applied (uncorrected p<0.05) (Table R2.9). The table is split into two parts. The first 
three results central columns are areas where there is a significant probability that activations and 
deactivations are greater in the ADD group compared to the others groups (ADD>). In the 
following three results columns on the right are areas where there is a significant probability that 
activations and deactivations are less in the ADD group compared to the others groups ( >ADD).  
 
Further bHORZ DUH VLPSOLILHG I05, UHVXOWV RI  VDPSOH W WHVW FRPSDULQJ DFWLYDWLRQV Ĺ DQG
deDFWLYDWLRQV Ļ EHWZHHQ WKH ,%6DQG6''JURXSV LQ WKH)RRW $RU+DQG %ZKHQ WKH9$6
temperature stimulus is applied (uncorrected p<0.05) (Table R2.10). The table is split into three 
parts. The first two results columns on the left are areas where there is a significant probability that 
activations and deactivations are greater in the IBS group compared to the SDD groups 
(IBS>SDD). In the two central results columns are areas where there is a significant probability 
that activations and deactivations are less in the IBS group compared to the SDD groups 
(SDD>IBS). The third two results columns on the right compare the significant differences 
between the SDD groups, where the probability of (de)activations is greater in the Low SDD group 
(LSDD>HSDD) or the High SDD group (HSDD>LSDD).  
 
The brain regions that have been used to create these tables can be large and contain many smaller 
subdivisions e.g. the thalamus is made of multiple nuclei. Therefore in some comparisons between 
the groups significant activation can be identified within both groups when compared to the other. 
For example in table R2.9(A) activation are seen in the S2 region in all the groups. This means that 
different parts of the S2 region was significantly activated, which can be seen in the more detailed 
tabulated co-ordinate data presented in Appendix 6.5.  
 
 89 
Table R2.9 Inter-Group Analysis: Differences between brain activations to VAS temperature 
stimulation of the left foot (A) or left hand (B) for different groups compared to ADD group. Many 
areas showed greater activation in SDD and IBS 
(A) Foot Vas Temperature 
 Area Side ADD> 
LSDD 
ADD> 
HSDD 
ADD> 
IBS 
LSDD> 
ADD 
HSDD> 
ADD 
IBS> 
ADD 
 S1 L       
SS R       
 S2 L Ļ    Ĺ Ĺ 
 
R Ĺ Ĺ Ĺ Ĺ Ĺ Ĺ 
SS Post-Ins L   Ļ    
 
R Ĺ     Ĺ 
 Mid-Ins L      Ĺ 
  
R 
     Ĺ 
Aff. Ant-Ins L    Ĺ  Ĺ 
 
R 
   Ĺ Ĺ  
Aff. ACC L   Ĺ  Ĺ Ĺ 
 
R 
   Ĺ Ĺ Ĺ 
Aff. MCC L  Ĺ   Ļ Ļ 
 
R 
   Ĺ Ĺ Ĺ 
 PCC L     Ĺ  
 
R 
      
Aff. Medial PFC L  Ļ Ĺ Ļ Ļ Ļ 
 
R 
 
Ļ 
 
ĹĻ  ĹĻ 
DNIC Lateral PFC L  Ļ ĹĻ ĹĻ ĹĻ ĹĻ 
 
R Ĺ Ļ  Ĺ Ĺ Ĺ 
DNIC Orbito-FC L   Ĺ   Ļ 
  
R 
     Ĺ 
SS Lentiform Nuclei and 
Thalamus 
L 
 Ĺ  Ĺ ĹĻ  
 
R 
 Ĺ Ļ Ĺ Ĺ Ĺ 
Aff. Amygdala 
(Hippocampus) 
L 
 
Ļ Ļ Ĺ Ĺ Ļ 
 
R 
 
Ļ Ļ Ĺ   
 Cerebellum L Ĺ Ĺ  Ļ Ļ Ĺ 
 
R 
   
Ļ Ļ  
 Inferior Parietal L  Ĺ ĹĻ    
 
R 
   Ĺ Ĺ  
 Temporal L Ļ Ļ Ļ ĹĻ Ĺ Ļ 
 
R ĹĻ ĹĻ ĹĻ Ļ ĹĻ ĹĻ 
 Motor L       
  
R 
      
 SMA L  Ĺ Ĺ    
  
R 
   Ĺ  Ĺ 
SS Post-central 
Gyrus 
L Ļ Ļ Ļ 
 Ĺ  
 
R Ļ Ļ 
 Ĺ Ĺ Ļ 
DNIC Subthalamic/ 
Brainstem 
  Ĺ  Ĺ Ļ  
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Table R2.9 Inter-Group Analysis: Differences between hand and foot VAS stimuli compared to 
ADD group. Highlighted areas show increased activation in DNIC areas in ADD versus HSDD and 
IBS. 
(B) Hand Vas Temperature 
 Area Side ADD> 
LSDD 
ADD> 
HSDD 
ADD> 
IBS 
LSDD> 
ADD 
HSDD> 
ADD 
IBS> 
ADD 
 S1 L       
SS R       
 S2 L  Ĺ Ĺ Ĺ   
 
R Ĺ Ĺ Ĺ   Ĺ 
SS Post-Ins L       
 
R 
   Ĺ  Ĺ 
 Mid-Ins L      Ĺ 
  
R 
      
Aff. Ant-Ins L Ĺ  Ĺ    
 
R 
   Ĺ  Ĺ 
Aff. ACC L  Ĺ    Ĺ 
 
R Ļ   Ĺ  Ĺ 
Aff. MCC L  Ĺ Ĺ   Ĺ 
+ R  Ĺ  Ĺ  Ĺ 
 PCC L    Ļ   
 
R 
   
Ļ 
  
Aff. Medial PFC L ĹĻ Ļ ĹĻ Ļ Ļ Ļ 
 
R Ĺ Ļ  Ļ Ĺ ĹĻ 
DNIC Lateral PFC L Ĺ Ĺ Ĺ Ļ Ļ Ļ 
 
R Ĺ ĹĻ Ĺ Ĺ Ļ Ĺ 
DNIC Orbito-FC L       
  
R 
  Ĺ Ĺ Ĺ Ĺ 
SS Lentiform Nuclei and 
Thalamus 
L 
 Ĺ Ļ Ļ Ĺ Ĺ Ĺ 
 
R 
 Ļ Ļ Ĺ Ĺ Ĺ 
Aff. Amygdala 
(Hippocampus) 
L Ĺ Ļ 
  Ĺ Ļ Ļ Ļ 
 
R Ļ Ļ Ļ ĹĻ ĹĻ 
 
 Cerebellum L  Ĺ  Ĺ Ĺ Ĺ 
 
R Ļ 
 Ĺ ĹĻ   
 Inferior Parietal L  Ĺ     
 
R 
   Ĺ Ĺ  
 Temporal L Ĺ Ļ Ļ ĹĻ ĹĻ ĹĻ ĹĻ 
 
R ĹĻ ĹĻ ĹĻ ĹĻ Ĺ Ĺ 
 Motor L       
  
R 
      
 SMA L Ĺ Ĺ Ĺ Ĺ  Ĺ 
  
R 
 Ĺ  Ĺ  Ĺ 
SS Post-central 
Gyrus 
L 
 
Ļ Ļ Ļ 
 
Ļ 
 
R Ļ Ļ 
 
Ļ Ĺ Ĺ 
DNIC Subthalamic/ 
Brainstem 
 Ĺ ĹĻ Ĺ    
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Table R2.10 Inter-Group Analysis: Differences between activation in response to left foot (A) and 
left hand cutaneous heat stimuli compared to IBS and SDD 
 (A) Foot VAS Stimulus 
 Area Side IBS> 
LSDD 
IBS> 
HSDD 
LSDD> 
IBS 
HSDD> 
IBS 
 S1 L     
SS R     
 S2 L Ĺ Ĺ   
 
R Ĺ Ĺ  Ĺ 
SS Post-Ins L Ĺ    
 
R 
 Ĺ   
 Mid-Ins L  Ĺ   
  
R 
    
Aff. Ant-Ins L Ĺ    
 
R Ĺ Ĺ Ĺ  
Aff. ACC L Ĺ    
 
R 
   Ĺ 
Aff. MCC L Ĺ Ĺ Ĺ Ļ 
 
R Ĺ Ĺ   
 PCC L     
 
R 
    
Aff. Medial PFC L  Ļ ĹĻ Ĺ 
 
R  Ļ Ļ 
  
DNIC Lateral PFC L Ĺ ĹĻ Ļ Ĺ 
 
R ĹĻ ĹĻ Ĺ Ĺ 
DNIC Orbito-FC L  Ĺ Ĺ  
  
R Ĺ Ĺ  Ĺ 
SS Lentiform Nuclei and Thalamus L     
 
R 
 Ĺ Ļ ĹĻ 
Aff. Amygdala 
(Hippocampus) 
L 
 
Ļ ĹĻ ĹĻ 
 
R 
 
Ļ ĹĻ ĹĻ 
 Cerebellum L Ĺ Ĺ   
 
R 
   
Ļ 
 Inferior Parietal L  Ļ   
 
R 
  Ĺ Ĺ 
 Temporal L Ĺ Ļ Ļ ĹĻ 
 
R Ĺ Ļ ĹĻ ĹĻ 
 Motor L     
  
R 
    
 SMA L  Ĺ Ĺ  
  
R 
 Ĺ   
SS Post-central 
Gyrus 
L Ļ Ļ 
 Ļ 
 
R Ļ ĹĻ Ĺ Ĺ 
DNIC Subthalamic/ Brainstem  Ĺ Ĺ  Ĺ 
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Table R2.10 Inter-Group Analysis: Differences between hand and foot VAS stimuli compared to 
IBS and SDD 
 (B) Hand VAS Stimulus 
 Area Side IBS> 
LSDD 
IBS> 
HSDD 
LSDD> 
IBS 
HSDD> 
IBS 
 S1 L     
SS R     
 S2 L     
 
R 
  Ĺ Ĺ 
SS Post-Ins L     
 
R 
    
 Mid-Ins L     
  
R 
  Ĺ  
Aff. Ant-Ins L Ĺ Ĺ   
 
R Ĺ Ĺ Ĺ Ĺ 
Aff. ACC L  Ĺ Ļ  
 
R 
 Ĺ  Ļ 
Aff. MCC L   Ĺ Ĺ 
 
R Ĺ Ĺ   
 PCC L    Ļ 
 
R 
    
Aff. Medial PFC L Ļ Ļ Ļ Ļ 
 
R 
 
ĹĻ Ĺ Ļ Ĺ 
DNIC Lateral PFC L Ĺ Ļ  ĹĻ 
 
R Ĺ Ĺ Ĺ Ĺ 
DNIC Orbito-FC L   Ĺ Ĺ 
  
R 
 Ĺ Ļ  
SS Lentiform Nuclei and Thalamus L Ļ Ļ Ĺ Ĺ 
 
R 
 Ĺ ĹĻ ĹĻ 
Aff. Amygdala 
(Hippocampus) 
L 
 
ĹĻ Ļ ĹĻ 
 
R Ļ Ļ Ļ ĹĻ 
 Cerebellum L  Ĺ Ĺ  
 
R 
 
Ļ ĹĻ Ĺ 
 Inferior Parietal L  Ļ  Ĺ 
 
R 
    
 Temporal L Ĺ ĹĻ ĹĻ ĹĻ 
 
R Ĺ ĹĻ ĹĻ ĹĻ 
 Motor L     
  
R 
    
 SMA L  Ĺ Ĺ Ļ 
  
R Ĺ Ĺ  Ļ 
SS Post-central 
Gyrus 
L 
 
ĹĻ Ļ 
 
 
R ĹĻ ĹĻ 
 Ĺ 
DNIC Subthalamic/ Brainstem   Ĺ ĹĻ Ĺ 
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Table R2.11 Inter-Group Analysis: Differences between activation in response to left foot (A) and 
left hand cutaneous heat stimuli between the SDD groups 
 (A) Foot VAS Stimulus 
 Area Side LSDD> 
HSDD 
HSDD> 
LSDD 
 S1 L   
SS R   
 S2 L Ĺ  
 
R 
 Ĺ 
SS Post-Ins L   
 
R Ĺ Ĺ 
 Mid-Ins L   
  
R 
  
Aff. Ant-Ins L   
 
R 
  
Aff. ACC L Ĺ  
 
R Ĺ  
Aff. MCC L Ĺ Ļ 
 
R 
  
 PCC L   
 
R 
  
Aff. Medial PFC L Ļ  
 
R ĹĻ  
DNIC Lateral PFC L ĹĻ  
 
R Ĺ Ĺ 
DNIC Orbito-FC L   
  
R 
  
SS Lentiform Nuclei and Thalamus L Ĺ  
 
R Ĺ  
Aff. Amygdala 
(Hippocampus) 
L 
  
 
R ĹĻ 
 
 Cerebellum L  Ĺ 
 
R Ļ  
 Inferior Parietal L   
 
R Ĺ  
 Temporal L Ļ Ĺ 
 
R ĹĻ Ĺ 
 Motor L   
  
R 
  
 SMA L Ĺ  
  
R Ĺ  
SS Post-central 
Gyrus 
L Ļ 
 
 
R ĹĻ Ļ 
DNIC Subthalamic/ Brainstem  Ĺ  
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Table R2.11 Inter-Group Analysis: Differences between left hand and left foot VAS stimuli 
between the SDD groups 
 (B) Hand VAS Stimulus 
 Area Side LSDD> 
HSDD 
HSDD> 
LSDD 
 S1 L   
SS R   
 S2 L Ĺ  
 
R Ĺ  
SS Post-Ins L Ĺ  
 
R Ĺ  
 Mid-Ins L   
  
R 
  
Aff. Ant-Ins L Ĺ  
 
R 
  
Aff. ACC L Ĺ  
 
R Ĺ  
Aff. MCC L Ĺ  
 
R Ĺ  
 PCC L   
 
R Ļ  
Aff. Medial PFC L ĹĻ Ļ 
 
R ĹĻ  
DNIC Lateral PFC L ĹĻ Ļ 
 
R Ĺ Ĺ 
DNIC Orbito-FC L   
  
R 
  
SS Lentiform Nuclei and Thalamus L Ĺ  
 
R Ĺ Ļ 
Aff. Amygdala 
(Hippocampus) 
L Ĺ Ļ 
 
R Ļ Ļ 
 Cerebellum L Ĺ Ļ 
 
R   
 Inferior Parietal L ĹĻ Ĺ 
 
R 
  
 Temporal L Ļ Ļ 
 
R ĹĻ 
 
 Motor L   
  
R 
  
 SMA L   
  
R Ĺ  
SS Post-central 
Gyrus 
L Ļ 
 
 
R ĹĻ Ĺ 
DNIC Subthalamic/ Brainstem  Ĺ  
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Tables R2.9 - R2.11 show that during painful stimulation of the left foot, the ADD had less 
affective pain processing compared to other groups. Comparison between the LSDD and ADD 
groups showed few areas of significant differences, but included the somatosensory processing and 
DNIC areas such as the right pINS and bilateral PCG and the right lateral PFC. In contrast the 
LSDD groups had greater activity in affective areas such as the bilateral aINS, right ACC and 
MCC, bilateral amygdala and hippocampal regions and PFC. 
 
During painful stimulus of the hand, the IBS group showed greater activation of the aINS 
compared to both SDD groups. The LSDD group demonstrated greater deactivation of the 
brainstem, orbito-PFC, cerebellum, and amygdala compared to the IBS group. Greater activity in 
the ACC and cerebellum was also seen in the IBS group compared to the HSDD group. However 
in the IBS and HSDD group both demonstrated increased activation and deactivation within 
different regions of the PFC, thalamus and amygdala suggesting wide spread but not identical 
activity within these regions.  
 
(viii) Covariates analysis of VAS hand and foot stimuli. 
In Appendix 6.6 are simplified fMRI UHVXOWV FRPSDULQJ DFWLYDWLRQV Ĺ DQG GHDFWLYDWLRQV Ļ
FRUUHODWLQJ ZLWK SDUWLFLSDQW¶V 9$6 VFRUH reported pain intensity out of 10 at the end of the 
scanning paradigm) or VAS temperature (temperature at pre-scanning sensory testing at which 
subjects gave a VAS score of 6-7) used as the stimulus on the foot (A) and hand (B) during the 
stimulus (uncorrected p0.01 voxel 5). Other covariants used include the hospital anxiety and 
depression score, PCS and PHQ questionnaire. All effects were identified using group maps as a 
masked for the data.  
 
(ix) Anticipation: group maps for the visual Cue stimulus 
Below are simplified fMRI UHVXOWV VKRZLQJ DFWLYDWLRQV Ĺ DQGGHDFWLYDWLRQV Ļ ZLWKLQGLIIHUHQW
brain regions for the visual cue for both the left hand and foot stimuli (A) (Uncorrected p<0.001, 
 96 
voxel threshold 5) (Table R2.12). Areas which included both activations and deactivations are 
represented by ĹĻ 
 
Table R2.12 shows that during anticipation of pain by group the ADD group showed activity in the 
insula cortex. A similar smaller activation was also seen in the LSDD group in the pINS and 
activations in the left ant and mid INS. In the HSDD and IBS group the right ant and mid INS and 
the left aINS were activated respectively.  This contrasted with the cingulate cortex were only the 
right MCC was activated in the ADD group compared to the mid and ant cingulate cortices in the 
other groups.  In the PFC the ADD group showed increased activity in the bilateral lateral PFC. 
This was similar to the other groups. Greater deactivation was also seen bilaterally in the amygdala 
in the ADD group but not the other groups. Activations and deactivations in other regions were 
similar between the different groups.  
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Table R 2.12 Group Maps 
$$FWLYDWLRQVĹDQGGHDFWLYDWLRQVĻIRUFXHYLVXDOVWLPXOXV for both left hand and foot 
 Area Side ADD LOW SDD HIGH  
SDD 
IBS 
 S1 L     
Somatosensory R     
 S2 L     
 
R 
    
Somatosensory Post-Ins L     
 
R Ļ Ļ 
  
 Mid-Ins L Ļ Ĺ   
  
R Ļ 
 Ĺ  
Affective Ant-Ins L Ĺ Ĺ  Ĺ 
 
R Ĺ  Ĺ  
Affective ACC L  Ĺ Ĺ Ĺ 
 
R 
    
Affective MCC L  Ĺ Ĺ Ĺ 
 
R Ĺ Ĺ Ĺ  
 PCC L     
 
R 
    
Affective Medial PFC L Ļ Ļ ĹĻ Ļ 
 
R Ļ Ļ Ļ ĹĻ 
DNIC Lateral PFC L ĹĻ ĹĻ  Ĺ 
 
R ĹĻ Ļ ĹĻ ĹĻ 
DNIC Orbito-FC L Ļ Ļ  ĹĻ 
  
R Ļ 
   
Somatosensory Lentiform Nuclei and Thalamus L Ĺ ĹĻ Ĺ Ļ 
 
R Ļ ĹĻ Ĺ  
Affective Amygdala 
(Hippocampus) 
L Ļ 
   
 
R ĹĻ Ļ 
 
ĹĻ 
 Cerebellum L Ĺ ĹĻ  ĹĻ 
 
R ĹĻ 
  
ĹĻ 
 Inferior Parietal L  Ĺ   
 
R 
    
 Temporal L ĹĻ ĹĻ   
 
R Ĺ ĹĻ Ĺ ĹĻ 
 Motor L     
  
R 
    
 SMA L Ĺ  Ĺ Ĺ 
  
R Ĺ  Ĺ Ĺ 
Somatosensory Post-central 
Gyrus 
L 
 
 
  
 
R Ļ  
 
Ļ 
DNIC Subthalamic/ Brainstem      
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(x) Intra-Group Analysis: Differences for the cue stimulus 
Below are simplified I05,UHVXOWVRI VDPSOH W WHVWFRPSDULQJDFWLYDWLRQVĹDQGGHDFWLYDWLRQV
ĻIRUWKHYLVXDOFXHR2.14. A and B; Uncorrected p<0.05, voxel threshold 5).   
Table R2.13. (A)  Hand > Foot Cue Stimulus 
$UHDVZKHUHDFWLYDWLRQVĹDQGGHDFWLYDWLRQVĻDUHgreater in the hand than the foot.  
 Area Side ADD LOW SDD HIGH  
SDD 
IBS 
 S1 L     
Somatosensory R     
 S2 L     
 
R 
    
Somatosensory Post-Ins L Ĺ  Ļ  
 
R Ĺ Ļ   
 Mid-Ins L Ĺ    
  
R Ĺ    
Affective Ant-Ins L Ĺ    
 
R Ĺ    
Affective ACC L Ĺ   Ĺ 
 
R 
    
Affective MCC L Ĺ    
 
R Ĺ   Ĺ 
 PCC L     
 
R 
    
Affective Medial PFC L Ļ Ļ  Ļ 
 
R Ļ Ļ 
 Ĺ 
DNIC Lateral PFC L ĹĻ Ĺ  Ļ 
 
R Ĺ   Ĺ 
DNIC Orbito-FC L    Ļ 
  
R 
    
Somatosensory Lentiform Nuclei and Thalamus L   ĹĻ Ĺ 
 
R Ĺ Ĺ Ĺ Ĺ 
Affective Amygdala 
(Hippocampus) 
L Ļ 
 
Ļ 
 
 
R Ļ 
   
 Cerebellum L   ĹĻ Ĺ 
 
R 
  
ĹĻ 
 
 Inferior Parietal L     
 
R Ĺ    
 Temporal L ĹĻ Ĺ ĹĻ  
 
R ĹĻ Ļ Ĺ  
 Motor L     
  
R 
    
 SMA L Ĺ    
  
R Ĺ Ļ   
Somatosensory Post-central 
Gyrus 
L Ĺ    
 
R 
 
Ļ 
  
DNIC Subthalamic/ Brainstem  Ļ    
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Table R2.13 (B) Foot > Hand Cue Stimulus 
$UHDVZKHUHDFWLYDWLRQVĹDQGGHDFWLYDWLRQVĻDUHJUHDWHULQWKHIRRWWKDQWKHKDQG 
 Area Side ADD LOW 
SDD 
HIGH  
SDD 
IBS 
 S1 L     
Somatosensory R     
 S2 L     
 
R 
    
Somatosensory Post-Ins L Ļ  Ļ  
 
R 
  
Ļ 
 
 Mid-Ins L   Ĺ  
  
R 
  
Ļ 
 
Affective Ant-Ins L  Ĺ   
 
R 
    
Affective ACC L   Ĺ  
 
R 
 Ĺ Ĺ  
Affective MCC L     
 
R 
  
Ļ 
 
 PCC L     
 
R 
    
Affective Medial PFC L   Ļ  
 
R Ļ 
 
Ļ Ļ 
DNIC Lateral PFC L Ļ  ĹĻ Ļ 
 
R 
 
Ļ ĹĻ Ļ 
DNIC Orbito-FC L     
  
R 
 
Ļ 
  
Somatosensory Lentiform Nuclei and Thalamus L     
 
R 
    
Affective Amygdala 
(Hippocampus) 
L 
  
Ļ 
 
 
R 
 
Ļ 
  
 Cerebellum L    Ļ 
 
R 
   
Ļ 
 Inferior Parietal L  Ĺ   
 
R 
    
 Temporal L ĹĻ   ĹĻ 
 
R Ĺ  Ļ  
 Motor L     
  
R 
    
 SMA L  Ĺ Ĺ  
  
R 
 Ĺ Ĺ  
Somatosensory Post-central 
Gyrus 
L 
 
 
  
 
R 
 Ĺ   
DNIC Subthalamic/ Brainstem      
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(xi) Inter-Group Analysis: Differences between cue stimuli  
%HORZDUHVLPSOLILHGI05,UHVXOWVRI VDPSOH W WHVWFRPSDULQJDFWLYDWLRQVĹDQGGHDFWLYDWLRQV
Ļ EHWZHHQ WKH $'' DQG RWKHU JURXSV GXULQJ FXH VWLPXOXV on both the left hand and foot 
combined (uncorrected p<0.05, voxel threshold 5) (Table R2.14 and figure R2.11). The table is 
split into two parts. The first columns are areas where there is a significant probability that 
activations and deactivations are greater in the ADD group compared to the others groups (ADD>). 
In the second columns are areas where there is a significant probability that activations and 
deactivations are less in the ADD group compared to the others groups (>ADD).  These show that 
during anticipation, the ADD group showed consistently decreased activity within the PFC, 
including the orbito-PFC compared to the other groups suggesting greater preparatory activity for 
pain stimulus. 
 
Table R2.15 are VLPSOLILHG VLJQLILFDQW UHVXOWV RI  VDPSOH W WHVW FRPSDULQJ DFWLYDWLRQV Ĺ DQG
GHDFWLYDWLRQVĻEHtween the IBS and SDD groups for the visual cue (Uncorrected p<0.05, voxel 
threshold 5). These are also represented in figure R2.12. The columns show areas where there is a 
significant probability that activations and deactivations are greater in the LSDD group compared 
to the HSDD groups (LSDD>HSDD). Differences between in IBS and SDD groups during the Cue 
stimulus can also be seen in Appendix 6.7. 
 
In table R2.15 and appendix 6.7, again mixed activation and deactivation throughout the PFC was 
seen during both hand and foot stimulation, when the SDD and IBS groups were compared. 
However during anticipation the IBS group had significant greater right L-PFC deactivation 
compared to the SDD groups while the SDD groups had greater M-PFC deactivation compared to 
the IBS group. When the SDD groups were compared greater activity was seen in the LSDD PFC 
compared to the HSDD. This suggests some preparatory activity in the IBS group. 
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Figure R2.11 Inter-Group Analysis: Differences between groups during the Cue stimuli on the left 
hand and foot combined compared to ADD group. Deactivations are depicted in the blue colour 
spectrum while activations are show in the red-yellow spectrum. Figure (A) depicts the 
deactivations in the ADD group which are statistically more significant than those in LSDD group 
while (B) shows the same comparison between the ADD and HSDD groups. Figure (C) shows the 
areas in the LSDD and HSDD groups which have statistically more significant activation than 
those in ADD group. 
(A) Greater deactivations in the ADD compared to  LSDD group during cue stimulus 
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(B) Greater deactivations in the ADD compared to  HSDD group 
 
  
 
(C) Greater activations in the LSDD and HSDD groups compared to the ADD group 
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Table R2.14 Inter-Group Analysis: Differences between cue stimuli for ADD group. 
 Area Side ADD> 
LSDD 
ADD> 
HSDD 
ADD> 
IBS 
LSDD> 
ADD 
HSDD> 
ADD 
IBS> 
ADD 
 S1 L       
SS R       
 S2 L    Ĺ   
 
R 
   Ĺ Ĺ  
SS Post-Ins L  Ļ     
 
R Ļ Ļ Ļ  Ĺ  
 Mid-Ins L   Ļ Ĺ   
  
R 
      
Aff. Ant-Ins L   Ļ  Ĺ Ĺ 
 
R 
   Ĺ   
Aff. ACC L  Ļ     
 
R 
   Ĺ   
Aff. MCC L   Ļ Ĺ   
 
R 
  
Ĺ Ļ Ĺ Ĺ Ĺ 
 PCC L       
 
R 
      
Aff. Medial PFC L Ļ Ļ Ļ Ļ Ĺ  
 
R Ļ Ļ Ļ Ļ Ĺ ĹĻ 
DNIC Lateral PFC L Ļ ĹĻ     
 
R Ļ ĹĻ Ļ Ĺ Ĺ Ĺ 
DNIC Orbito-FC L  Ļ Ļ    
  
R Ļ Ļ Ļ 
  Ĺ 
SS Lentiform Nuclei and 
Thalamus 
L 
 
Ļ 
 ĹĻ Ĺ Ĺ 
 
R 
   Ĺ Ĺ  
Aff. Amygdala 
(Hippocampus) 
L 
 
Ļ Ļ 
   
 
R 
 
Ļ Ļ 
   
 Cerebellum L Ĺ Ĺ Ĺ Ļ Ļ  
 
R Ĺ   Ļ  Ļ 
 Inferior Parietal L  Ĺ     
 
R 
      
 Temporal L ĹĻ ĹĻ ĹĻ    
 
R Ĺ ĹĻ Ĺ Ļ Ĺ Ĺ  
 Motor L       
  
R 
      
 SMA L Ļ ĹĻ ĹĻ Ĺ  Ĺ 
  
R 
   Ĺ Ĺ Ĺ 
SS Post-central 
Gyrus 
L Ĺ Ĺ     
 
R Ļ Ļ 
    
DNIC Subthalamic/ 
Brainstem 
     
Ļ 
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Figure R2.12 Inter-Group Analysis: Differences between Cue stimuli on both the left hand and 
foot combined between the LSDD and HSDD groups. Deactivations are depicted in the blue colour 
spectrum while activations are show in the red-yellow spectrum.  The Figure depicts the statistical 
comparison of significant difference in activations and deactivation in the LSDD compared to the 
HSDD groups. 
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Table R2.15 Inter-Group Analysis: Differences between cue stimuli for the SDD groups. 
 Area Side LSDD> 
HSDD 
HSDD> 
LSDD 
 S1 L   
SS R   
 S2 L   
 
R 
  
SS Post-Ins L   
 
R 
  
 Mid-Ins L   
  
R 
  
Aff. Ant-Ins L   
 
R 
  
Aff. ACC L Ĺ Ĺ 
 
R ĹĻ 
 
Aff. MCC L  Ĺ 
 
R Ĺ  
 PCC L   
 
R 
  
Aff. Medial PFC L Ļ  
 
R Ļ  
DNIC Lateral PFC L ĹĻ  
 
R ĹĻ  
DNIC Orbito-FC L Ļ  
  
R 
  
SS Lentiform Nuclei and Thalamus L  Ĺ 
 
R Ĺ Ļ Ĺ 
Aff. Amygdala 
(Hippocampus) 
L Ļ 
 
 
R Ļ 
 
 Cerebellum L ĹĻ  
 
R  Ļ  
 Inferior Parietal L   
 
R 
  
 Temporal L ĹĻ  
 
R Ļ 
 
 Motor L   
  
R 
  
 SMA L Ĺ  
  
R 
  
SS Post-central 
Gyrus 
L 
  
 
R 
  
DNIC Subthalamic/ Brainstem   Ļ 
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(xii) Covariates analysis of cue stimulus 
In the Appendix 6.8 DUH VLPSOLILHG I05, UHVXOWVFRPSDULQJDFWLYDWLRQV ĹDQGGHDFWLYDWLRQV Ļ
FRUUHODWLQJ ZLWK SDUWLFLSDQW¶V +$' DQ[LHW\ DQG GHSUHVVLRQ VFRUHV DQG IRU WKH 3&6 DQG 3HQ12 
scores (uncorrected p0.01). All effects were identified using group maps as a mask for the data.  
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2.5 Discussion 
 
2.5.1 Difference in responses to pain between the hand and foot within each group. 
The hypothesis that pain processing between the hand and the foot would be different in the LSDD 
group due to peripheral nerve changes but similar in the other groups due to normal or alteration of 
central pain processing could not be proven using this somatic thermal pain paradigm. There was 
no significant difference in the temperature used for stimulation of the hand or foot within or 
between the groups (Table R2.7). However, altered pain processing was seen (Table R2.8). Overall 
in the ADD group there appeared to be a greater emotional response to hand stimulation compared 
to the foot with significant activity in the cingulate and PFC during hand stimulation.  However 
there was associated increased activity of the DNIC with deactivations in brainstem and 
appropriate amygdala region deactivations associated with painful stimulation. In comparison there 
was greater affective activity associated with stimulation of the foot compared to the hand in the 
HSDD and IBS groups, with increased activity in the amygdala region, and cingulate cortices, and 
in the HSDD the PFC. Little difference was seen in the emotional pain processing areas in the 
LSDD group suggesting similar responses for both the foot and hand stimuli.  
 
The hand is particularly important for function and greater emotional input and fear of injury can 
be attached hence the response in ADDs was not surprising.  Interestingly in groups with altered 
pain states, a similar or greater affective pain component to foot stimulation was seen. This may be 
because the foot is sensitised due viscera-somatic conferences of sensory fibres within the same 
region of the spinal cord 302, 314, 315, 320, 428 or may be suggestive of an altered DNIC188, 200, 312, 429, 430 
and/or inability to adjust to threat of injury and emotional context242, 431.  There is evidence of 
greater emotional processing to visceral or muscular compared to cutaneous stimulation73, 303, 329, 
432
. Chronic pain groups also have greater affective pain processing, altered DNIC and responses to 
fear and threat than normal individuals221, 433, 434.  This could explain the differences in pain 
processing within different body areas seen in this study.  
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2.5.2 Responses to pain between groups 
There are marked similarities and differences between the groups during the pain (VAS 
temperature) experience (Tables R2.9-2.11). No significant differences were found in the VAS or 
temperature scores between each group (Table R2.6 and Figure R2.10). However there was a 
suggestion of increased thermal sensitivity in the cumulative VAS scores (Figure R2.10). In the 
tabulated group maps for the foot and hand painful stimulus activations and deactivations were 
seen in areas consistent with known pain pathways such as the anterior and mid insula, pre-frontal 
cortex, thalamus, cerebellum and in some groups the brainstem (Foot: ADD and LSDD, Hand: All) 
and amygdala (Foot and hand, LSDD, HSDD, IBS).  
 
When comparing the ADD to other groups during foot stimulation, there were interesting 
differences, especially in the affective pain processing. There were few areas of increased activity 
in the ADD compared to LSDD group. These are mainly present in somatosensory processing and 
DNIC areas such as the right pINS and bilateral PCG and the right lateral PFC. In comparison, the 
LSDD groups had greater activity in affective areas such as the bilateral aINS, right ACC and 
MCC, bilateral amygdala and hippocampal regions and PFC. Similar differences were found in the 
HSDD and IBS groups compared to the ADD group. Hippocampal activity has also been seen in 
patients with somatoform pain disorders even at moderate thermal pain levels379. 
 
During painful stimulation of the hand increased activation was seen in the ADD group in the S2, 
lateral PFC, thalamus, SMA and brainstem and deactivation in the right amygdala and hippocampal 
regions compared to the other groups. The LSDD group demonstrated greater deactivation in the 
PCC and medial PFC and PCG, and greater activation in the thalamus compared to the ADD 
group. The deactivation in the PCC may suggest movement of the SDD group away from the 
default pain network and greater attention to the pain stimulus, which will be further discussed 
below. The IBS group demonstrated increased activation in affective processing areas such as the 
mid INS, ACC and MCC compared to the ADD group. This suggested greater affective processing 
in the IBS group compared to the ADD group. The HSDD group showed little difference in activity 
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in the affective areas compared to the ADD group suggesting similar emotional processing of pain 
but potentially reduced activation of the descending inhibitory system as suggested by lack of brain 
stem activity221, 249.  
 
When comparing the chronic pain groups, the IBS group shows increased emotional processing 
with increased activity in the bilateral aINS and right aINS compared to the LSDD and HSDD 
respectively. Increased activity in the cingulate cortices and PFC cortices was also demonstrated 
compared to both groups.  However compared to the HSDD group there is increased deactivation 
of the bilateral amygdala or hippocampal regions and somatosensory areas such as the right pINS, 
right thalamus, and right PCG. The LSDD and HSDD group demonstrate a variety of areas of 
activation scattered throughout the affective and DNIC areas. 
 
In our study, increased activation was seen in the cingulate cortex in the LSDD, HSDD and IBS 
groups compared to the ADD group during pain and anticipation. This activation was greater in the 
IBS and LSDD group compared to the HSDD group during pain stimulation and anticipation.  In a 
H215O-PET study270 in which functional dyspeptics (FD) were compared to healthy volunteers392, 
the group found that during distension the FD group failed to activate the pACC which correlated 
negatively with anxiety levels. This supports the suspected role in attention and threat-association 
and its suspected modulation of amygdala and emotional circuits. Anxiety also correlated to 
activity in the dorsal pons/midbrain, which has been reported in IBS studies392. These findings may 
fit with our findings which showed a lack of significant ACC activation in the HSDD group in 
comparison to the LSDD and IBS groups.  Tack and colleagues speculated that activations in the 
locus coeruleus-parabrachial nucleus270, which is known to have projections to the cortices, 
LQFOXGLQJ WKHS$&&PD\EH LQYROYHG LQSDLQSURFHVVLQJ ,%6SDWLHQWV¶DQ[LHW\ VFRUHVKDYHEHHQ
correlated with anterior MCC and pregenual ACC activity during painful rectal distension, while 
depression scores correlate with activation of the PFC and cerebellum198. Altered aINS activation 
has also been found in other patient groups190, 435, 436 which support our findings. In IBS patients 
anticipating rectal stimulation, less deactivation was identified in the insula, supragenual ACC, 
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amygdala and brainstem compared to healthy controls190. In anorexia nervosa, greater activation of 
the aINS, as well as the DL-PFC and cingulate was found compared to healthy women undergoing 
anticipated painful heat stimuli435. Subsequent greater activation of the DL-PFC and decreased 
activation of the pINS during painful stimulation was also found. This influence of the aINS over 
subsequent pINS and caudate activation has previously been demonstrated and correlated with the 
perceived touch intensity437.  In MDD, decreased activity of the aINS was found along with 
increased activation in the VM-PFC, dorsal ACC, PCC and deactivation in the DL-PFC, SMA, 
mINS and cerebellum during anticipation of changes in stimulus intensity and/or cognitive demand 
was found compared to healthy controls436. This suggested that MDD patients were unable to 
effectively prepare to anticipated changes in environment. Similar depressive and anxiety 
symptoms may be influencing the activities found in the HSDD and IBS groups.  
 
The reported amygdala responses agree with the findings in our study which showed greater 
significant activation of the amygdala regions in the LSDD, HSDD groups compared to the ADD 
group during foot pain stimulation. Greater deactivations in the ADD compared to the HSDD and 
IBS group during pain stimulation of the foot and also during anticipation of pain.  
 
In our study the PFC was split into lateral, medial and orbito-PFC activity to allow ease of analysis 
between groups. We found greater deactivation in the M- and L-PFC in the ADD compared to the 
HSDD but mixed activation and deactivation in the SDD and IBS groups when compared to the 
ADD group during foot stimulation. Again the hand was more complicated and this may be due to 
the greater level of emotional processing of hand stimuli by the ADD group.   
 
$OWHUDWLRQ LQ µHIIHFWLYH FRQQHFWLYLW\ RI WKH HPRWLRQDO DURXVDO FLUFXLWU\¶ (rostral and subgenual 
cingulate cortex, amygdala and locus coeruleus) rather than afferent sensory processing (insula, 
thalamus, OFC, dACC) or cortical modulation (PFC and parietal cortex)are thought to underlie the 
symptoms and perceived pain in IBS438. Our finds suggest the amygdala and hippocampus regions 
may also be important in SDD symptoms as well, especially for those with high PHQ12 scores. 
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In our simplified tables the cerebellum has been presented as a single area and therefore some of 
the detail in specific areas of activation and deactivation will be lost. In general the ADD group 
demonstrated greater left sided activation of the cerebellum during foot stimulation, while the SDD 
groups had significant deactivation bilaterally. However during hand stimulation, this effect 
seemed to be reverse. This may be related to the altered emotional processing for hand stimulation 
in the ADD group which has been suggested by other studies218, 329, 409, 414. This altered cerebellum 
activity agrees with  studies in other chronic pain groups, such as lower back pain subject, when 
shown pictures of potentially painful events439.  
 
2.5.3 Covariates with pain processing  
During painful stimuli the VAS score showed little correlation between the groups with any 
specific region (see Appendix 6.6). However in the foot, the temperature used did significantly 
correlate with pINS activation in all groups. In the HSDD and IBS groups increased correlation of 
cortical activity was seen in the cingulate cortices and in the LSDD, HSDD and IBS groups in the 
PFC.  
 
During the pain stimulus for the foot there was little correlation of cortical activity with anxiety 
score for the ADD or LSDD groups, except the MCC and cerebellum and, in the ADD group, the 
PFC. The number of correlated areas increased in the ADD for the pain stimulus in the hand 
especially in the cingulate cortex and PFC. This compared to the HSDD and IBS groups which had 
correlated activity with anxiety score during pain stimulus in the insula, cingulate and prefrontal 
cortices. Some correlation was detected in the cerebellum and amygdala regions as well.  
 
In the ADD group, there were only a few areas which correlated with depression. Other groups 
showed greater number of active regions. For the pain stimulus to the foot increased correlated 
activity was mainly seen with the HSDD and IBS groups in the PFC and cerebellum and in the IBS 
group the MCC and aINS. In the hand painful stimulus more areas were correlated in the LSDD 
and HSDD groups including the aINS and mINS, PFC, amygdala (HSDD) and cerebellum.  
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The PHQ12 questionnaire score is a marker of somatisation while the PCS is a measure of 
catastrophizing. Somatisation LVGHVFULEHGE\%URZQHWDODVµWKHWHQGHQF\WRH[SHULHQFHVRPDWLFRU
YLVFHUDOVHQVDWLRQVDVPRUHLQWHQVHQR[LRXVRUGLVWXUELQJ¶RUµVRPDWRVHQVRU\DPSOLILFDWLRQ¶369, 440. 
Pain catastrophizing LV D µQHJDWLYH FRJQLWLYH±DIIHFWLYH UHVSRQVH WR DQWLFLSDWHG RU DFWXDO SDLQ¶441. 
Both can be associated with anxiety and depression hence assessing possible correlation of cortical 
responses to pain with these scores was valuable.  Little significant correlations were found for the 
ADD group and PCS score. However significant correlations were found for the ADD group and 
PHQ12 score especially in the hand stimulus. In comparison increased correlation was observed in 
LSDD with PHQ12 and PCS scores, especially in the cingulate cortex and PFC during pain. The 
HSDD and IBS groups also showed greater areas of activity correlated with PCS and PHQ12 score. 
In the pain stimulus this included the insula, cingulate cortex, PFC amygdala and cerebellum. 
Catastrophizing, when controlling for depressive symptoms, has been linked with activity in the 
cerebellum and mPFC (anticipation), dorsolateral PFC and dACC (attention) and lentiform 
nuclei296. 
 
2.5.4 Responses to anticipation of pain 
During the cue stimulus, significant differences were seen throughout the insula, anterior and mid 
cingulate and SMA when anticipation of pain in the hand was compared to anticipation of pain in 
the foot (i.e. hand > foot) (Table R2.13). However similar activity in the PFC was seen in all 
groups except the HSDD. The ADD group also showed deactivation within the amygdala and 
brainstem which was not seen in others groups. This suggested that although the ADD group had a 
greater emotional anticipatory response to pain in the hand compared to the foot, deactivation of 
the amygdala and the brainstem, which is thought to be part of the descending inhibitory system, 
occurred correctly. When anticipation of pain in the foot was compared to anticipation of pain in 
the hand (e.g. foot > hand), significant activity was seen in the posterior (deactivation) and mid 
insula (activation) and the ACC (activation) compared to other groups. Greater deactivation was 
also seen in the PFC in the HSDD group. This suggested again a greater emotional anticipation of 
foot stimulation in the HSDD group compared to the other groups. However, unlike the anticipated 
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hand stimulation of the ADD group, compensatory deactivation of the amygdala or the brainstem 
was not seen. The lack of significant difference between the LSDD and IBS group anticipated 
stimulation of the foot and hand suggests similar anticipated responses in both limbs.  
 
Comparison between the groups is quite complex (Tables R2.14-15 and Figures 2.11-12), but the 
overall suggestion is that that there is a range of emotional processing in the SDD and IBS groups 
compared to the ADD groups which may explain some of the mechanisms of anticipation and pain 
in SDD.  
 
Compared to the other groups the ADD group showed greater deactivations in the right pINS and 
PFC. Significant differences in deactivation were also seen in the ADD group in the amygdala 
regions compared to the HSDD and IBS groups and right PCG compared to the LSDD and HSDD 
groups.  Increased activity in affective areas such as the MCC in the LSDD and right ACC and 
aINS activity was found in all groups compared to the ADD group. Increased activation of the 
thalamus and SMA and deactivation of the cerebellum was also seen in all in groups compared to 
the ADD group. This suggests again a greater emotional response to anticipated pain and reduced 
preparatory and modulatory activity.  
 
When comparing the SDD groups with the IBS group significant differences in deactivations of the 
pINS, right medial and lateral PFC and activation of the cerebellum were identified in the IBS 
compared to the HSDD group.  However significant activations of the right ant and mid insula and 
deactivations in the pINS and MCC were found in the LSDD group compared to the IBS group. 
Significant differences in deactivations in affective areas such as the amygdala region, mPFC, as 
well as temporal lobe and activations in the SMA were also found in the LSDD compared to the 
IBS group. The HSDD had fewer differences, but also included deactivations in the mPFC.  
 
During anticipation of pain, the LSDD group showed much greater differences in activation of 
affective areas such as the ACC, mPFC and amygdala as well DNIC areas such as the lateral PFC 
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and right thalamus compared to the HSDD group (Table R2.15 and figure R2.12). There were few 
areas of significantly greater activity in the HSDD group compared to the LSDD group, but these 
included the thalamic regions and brainstem.  
  
Thus in anticipation of pain there are several key regions found to have altered activity during 
anticipation between the groups including the insula, cingulate cortices, PFC, amygdala and 
hippocampal cortices, somatosensory cortices, thalamus and brainstem/PAG345, 442-445. The 
functional connectivity between these areas, especially the aINS and brainstem before the stimulus 
is applied, is thought to be important in the subsequent experience of pain58.   
 
In our study greater insula activation was found in the LSDD, HSDD and IBS groups compared to 
the ADD group, where deactivation of the pINS was identified. Greater insula activation was also 
identified in the aINS and pINS in the IBS compared to the LSDD and HSDD groups. This 
suggests that in the SDD and IBS groups greater emotional awareness of the anticipated stimulus 
was present, which may have influence subsequent stimulus perception.  This is supported by a 
VWXG\E\7UDFH\¶Vgroup431. Their study of perceived threat of painful stimuli in healthy volunteers 
showed that the in high threat conditions more threshold stimuli were perceived as painful and this 
could be predicted by activity in the aINS during the anticipation phase431. This study also showed 
LQFUHDVHGIXQFWLRQDOFRQQHFWLYLW\EHWZHHQ WKHD,16DQG0&&VXJJHVWLQJD µVDOLHQFHQHWZRUN¶431.  
High confidence in pain beliefs also correlated with right aINS, post MCC and inferior parietal 
activity during pain anticipation446. Correlation between expected pain and activity in the ACC, 
PFC, INS and thalamus has also been identified, with manipulation of anticipated pain affecting 
subsequent activity in the INS, S1 and ACC447.  
 
Anticipation and expectation is thought to be important in IBS. Patients with IBS can be normal or 
hypersensitive to rectal distensions. When comparing these groups using fMRI similar patterns of 
brain activation are found between normo-sensitive and controls groups, while hypersensitive 
individuals have greater INS activation and decreased deactivation of the pgACC during rectal 
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distension. However during the anticipatory phase greater activation of the right hippocampus was 
found in normo-sensitive IBS patients compared to controls. The differences between the IBS 
groups may be due to differences in expectation and rectal afferent input448. fMRI has also shown 
that the hippocampus is activated during anticipation of a painful event by a visual cue382. 
Correlation between individual anticipation rating and hippocampal activation during anticipation 
has also been identified79. 
 
There was greater deactivation in the amygdala and hippocampal regions in the LSDD and ADD 
groups during anticipation when compared to the HSDD and IBS groups.  This suggests better 
coping strategies in the ADD and partially in the LSDD compared to the other groups383, 449.  
 
As part of the DNIC pathway, deactivation of the brainstem would be expected during the 
anticipatory phase190. Deactivation in the ADD group anticipatory phase was not associated with a 
significant deactivation in the brainstem region in our study, as has been described in other 
studies190.  This may be because of: (1) whole brain rather than ROI analysis; (2) no respiratory and 
cardiac gating was used when images were acquired; and (3) difficult resolution of activity within 
the region when whole brain images are being acquired. However increased significant activation 
in the subthalamic regions and brainstem was seen in comparisons between the IBS, LSDD and 
HSDD groups during pain stimulation (Table R2.9-R2.11). Interestingly deactivation was also seen 
in the HSDD group in this region during comparison with the ADD, IBS and LSDD during 
anticipation (Table R2.12, Figure  R2.11 and Appendix 6.7). The exact region involved is difficult 
to elucidate due to the problems mentioned above and further investigation of DNIC pathways in 
SDD may be warranted.  
 
During the anticipation phase greater left sided cerebellum activation was seen in the ADD group 
compared to the other groups. In the IBS group greater activation was also seen during anticipation 
compared to the HSDD group. In the LSDD group greater mixed activation and deactivation was 
seen when compared to the IBS and HSDD groups during anticipation.  
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In our study we were unable to show significant differences using our analysis method for evidence 
of altered PCC and precuneus GHDFWLYDWLRQ WR PDNH µGHIDXOW PRGH QHWZRUN¶ LQIHUHQFHV )XUWKHU
analysis with ROI may be necessary to identify this potential mechanism in SDD. 
 
2.5.5 Covariates with anticipation of pain 
Temperature and VAS score were not used as covariates for the cue stimulus as the patients were 
unaware of the temperature they would receive. Therefore, the HAD scores, PHQ12 and pain 
catastrophizing scores were used as correlates for anticipation of pain (Appendix 6.8). 
 
During the anticipation phase, little correlation with anxiety scores was seen for the ADD group 
except deactivations in the lateral PFC and amygdala. However many more areas in the LSDD 
group correlated, especially in the ACC and PFC. This compared to the HSDD group, which had 
activation in the right mINS, right MCC and amygdala and deactivation in the PFC. The IBS had 
similar correlated activity to the HSDD group except anxiety also correlated with deactivation in 
the pINS and right amygdala. These findings suggested that anxiety has an influence over key areas 
in anticipation and pain processing. Many of the regions described above have been previously 
implicated in anxiety effects during anticipation of unpleasant events. Activity within the S2 and 
insula regions was most prominent in the IBS and HSDD groups, but not correlated with activity 
found in the ADD or LSDD groups. This finding is supported by a study in which anticipation of 
aversive images in anxiety prone and normal anxiety subjects demonstrated bilateral aINS activity 
when cued for adverse images, but this was greater in the right insula in the anxiety prone group450. 
Using functional connectivity analysis the insula was involved in a network consisting of frontal 
DQGSDULHWDO OREHV LQ WKH DQ[LHW\SURQH JURXS7KLV VXJJHVWHG WKDW DQ[LHW\ FRXOG OHDG WR µJUHDWHU
anticipatory reactivity450. This again supports the frontal and parietal region anxiety correlated 
activity seen here in the LSDD, HSDD and IBS groups. In a study of 17 IBS subjects the brain 
responses underlying the placebo effect were assessed during rectal distensions using fMRI.  A 
QHZµGUXJ¶ZKLFKZDVLQIDFWVDOLQHZDVLQIXVHGLQWo patients and HV. A similar number of IBS 
and HV had placebo effect to the infused saline. However, a high HADS anxiety score was 
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predictive of a weak placebo effect. During the placebo effect greater activity was identified in the 
affective areas such as the INS, MCC, and VL-PFC in IBS patients compared to healthy controls. 
VLPFC was also increased during anticipation of pain in the IBS patients451. 
 
Other regions have also been implicated in anticipation of pain. In the LSDD and HSDD group, 
activity in the ACC and MCC was identified. The cingulate cortices are thought to be important in 
anticipation of pain and influences activity within others regions. In one study, uncertainty in the 
anticipation of potentially painful events resulted in greater intensity in the ACC and cluster size in 
the PO and pINS activation during non-painful stimuli in healthy volunteers376. Participants 
reported these non-painful stimuli as being more unpleasant suggesting the ACC and the PO and 
S,16 DQG LPSRUWDQW LQ WKH µPRGXODWLRQ RI DIIHFWLYH DVSHFW RI VHQVRU\ SHUFHSWLRQ¶ ZKHQ WKHUH LV
uncertainty about an expected stimulus376. Connectivity between the insula and the amygdala has 
also been identified in anxious anticipation of auditory stimuli452. In the amygdala and hippocampal 
regions significant anxiety correlated deactivation were identified in the ADD and IBS groups 
while significant activation was seen in the HSDD group and no activity was correlated in the 
LSDD group. The right insula has been correlated with individual subjective experience for any 
type of stimulus, while the amygdala was mainly active during anticipation of aversive stimuli452. 
The entorhinal complex is connected to affective areas such as the perigenual cingulate cortex and 
the mINS and is thought to prime affective responses to anticipated events382. Activation of the 
hippocampus during anticipation has also been shown to be associated with activation of the 
INS/IFG/PO network during the following painful event369.   
 
The hippocampal network has been shown to respond differently to painful thermal stimuli 
depending on the preceding anxiety of an anticipated painful stimulus. In our study, cued 
deactivations in the right amygdala/hippocampal region were correlated with anxiety in the ADD 
and IBS groups but activation was found to be correlated in the HSDD group.  In healthy 
volunteers anticipation of a painful shock resulted in activity in the hypothalamus, PAG, caudate, 
precentral gyrus, insula, VL-PFC, DM-PFC, ACC and thalamus453. Although greater correlations 
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were found in the Insula, PFC thalamus and brainstem in the other groups, the ADD group did have 
an anxiety correlated deactivation in the PCG similar to this study. The group also found that a 
linear relationship between activity over the safe and strong anticipatory trials in the bilateral INS, 
ACC and IFG.  
 
Anxiety and anticipation of pain have also been studied in patient groups. High neuroticism 
individuals had exaggerated anxiety and reduced brain activation to high and medium anticipatory 
trials453. In an study of anticipation of hyperventilation tasks, which resulted in unpleasant 
physiological symptoms, all participants activated the aINS and OFC and rostal and dorsal ACC 
and DM-PFC454. However in participants with a high fear of unexplained symptoms a greater 
activation of these areas was demonstrated454. This study showed similar brain regions are activated 
in anticipation of internal as well as external threats454. Similar anxiety correlated activity in the 
ACC was found in our LSDD group, and in the mPFC in our LSDD and HSDD group.   
 
Stress results in changes in activity in the INS, MCC and VL-PFC in IBS subjects, suggesting 
altered emotional modulation of visceral sensation194. These has been partly accounted for by 
higher anxiety levels in IBS patients, except for the PFC and insula194. Anticipation of pain, and 
anxiety associated with it, has also been investigated in 8 healthy volunteers using midazolam455. 
Volunteers were cued with different coloured lights to expect a painful heat stimulus or warm non 
painful stimulus. At baseline, when only saline was given, the pain stimulus itself produced greater 
activity in the ACC, bilateral aINS and pINS, thalamus, S1, motor cortex, pre-frontal cortex, 
cerebellum and brainstem than to warm stimuli. During the anticipation phase of the pain versus 
the warm stimulus, the ACC, contra-lateral aINS, ipsilateral S2 and pINS were activated. 
Midazolam effected the activation to pain anticipation especially in the aINS, ACC and S2 on 
region of interest analysis but did not affect the activations during the pain itself455. These studies 
support the role of the insula in sensory and affective aspects of touch437, 455 and that alterations in 
anticipation can result in altered affective and perceived sensation. 
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In the anticipation phases correlated activity included significant activations in affective areas such 
as the bilateral ACC with anxiety and depression in the LSDD group. Scattered activity was found 
for the HSDD group in the insula, cingulate cortices, PFC, amygdala and brainstem for both 
anxiety and depression. In the IBS group significant activity was mainly associated with anxiety 
score, but significantly correlated activations were seen in the right S2 and left aINS and 
deactivations found in the left MCC and right PCG with depression score. Depression and chronic 
pain are closely associated with 75% of patients who suffer with depression reporting chronic 
pain456, while 30-60% of patients with chronic pain have depressive symptoms457. Depression is 
associated with passive coping mechanisms including helplessness, lack of control and rumination 
which may influence the emotional processing of chronic and experimentally induced pain458-461.  
 
A recent study in MDD patients demonstrated increased activity on ROI analysis in the amygdala 
and on whole brain analysis in the aINS, IFG, dorsolateral ACC, and dorsolateral PFC during 
anticipation of a painful event while control subjects showed greater activity in the caudate, 
precuneus, PCC and ventral brainstem. This activity correlated with depression is similar to our 
study, which showed activity within the aINS in the IBS and HSDD groups. Activity in the OFC 
was seen in the LSDD group only, while the LSDD and HSDD demonstrated activity within the 
cingulate cortices.  In the HSDD group, cerebellar activity was also associated with depressive 
symptoms, which has also been found to be correlated with depressive symptoms in IBS patients 
undergoing rectal distensions415.  However we did not find a similar correlation with anticipation of 
pain and depressive symptoms in our IBS group.  
 
Significant correlations were found for the ADD group and PHQ12 score in the anticipation phase 
in the right INS, bilateral OFC and thalamus and deactivation in the right amygdala/hippocampal 
regions. In comparison increased correlations between LSDD and PHQ12 and PCS scores, 
especially in the cingulate cortex and PFC during pain and anticipation phases.  
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The HSDD and IBS groups also showed areas of correlated activity with PCS and PHQ12 score in 
the anticipation phase with scattered activity detected in the pINS (IBS), MCC (HSDD) and PFC. 
The correlation of hippocampal region deactivation in the IBS group with PCS and in the right 
amygdala/hippocampal region in the ADD and LSDD and bilaterally in the IBS groups with 
PHQ12 fits with other studies. Hippocampal activity has been shown to be increased during 
H[SHFWDWLRQ RI SDLQ DQG GXULQJ WKH SDLQIXO HYHQW LWVHOI DQG FRUUHODWHG ZLWK WKH SDUWLFLSDQW¶V
µVHQVLWLYLW\WRH[SHFWDQF\¶462.  However in another study, participants with a range of somatisation 
score on the symptom checklist 90 (revised SCL-90-R) were subjected to low and high anxiety 
visual cued shocks. fMRI imaging identified that there were smaller differences in hippocampal 
activation in those with a high somatisation score for different level of cues compared to low 
somatisation participants369.  This suggests that high hippocampal activity even in low anxiety 
situations may influence pain expectation and processing.    
 
The association of PCS and PHQ12 with anxiety is also thought to be important. The inability to 
differentiate different levels of activity in the Insula, IFG and PO during high and low anxiety 
anticipation of pain was related to reported daily physical symptoms of participants in Gondo et 
DO¶V 2012 study369.  This suggests that participants with high number of reported symptoms may be 
FRQWLQXRXVO\ µDQ[LRXV¶ DQG KDYH D KLJK EDFNJURXQG DFWLYLW\ ZLWKLQ WKHVH NH\ DUHDV UHVXOWLQJ LQ
minimal change in activity during pain anticipation. This may be why there are few areas which 
correlate with PCS and PHQ12 in the ADD group, who have low anxiety state, and in the HSDD 
who may have a continued high anxiety state.  
 
Although there are no studies of pain catastrophizing in diverticular disease, other chronic pain 
groups have been studied. An fMRI study of 12 subjects with fibromyalgia and 14 healthy controls 
was used to identify the association of anticipation of pain, catastrophizing and altered cerebral 
pain processing.  They found that catastrophizing behavior was increased in FM patients but not 
during the anticipation of experimental pain. Also FM patients showed increased activation of the 
PAG, posterior parietal cortex and DL-PFC during anticipation of pain463.   
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Although not assessed in our study, other personality traits can also influence pain perception. 
Neuroticism is also correlated with depression and anxiety disorders. During anticipated painful 
oesophageal distension positive correlation was found between the levels of neuroticism and brain 
areas involved in cognitive and emotional processing such as the parahippocampus, thalamus, ACC 
and insula. However during the pain stimulus negative correlation was found with these areas, 
suggesting potential maladaptive coping strategies in neurotic individuals247.  These areas are 
similar to those found with PCS and PHQ12 scores covariates in the LSDD and HSDD groups. 
This suggests that many of the questionnaires and traits that have been used so far often have 
significant correlations between them and may be measuring similar traits and cerebral mechanisms 
underlying chronic abdominal pain.  
 
 2.5.6 Summary of findings  
Enteric infection or long lasting mucosal inflammation in inflammatory bowel patients is not 
always associated with development of abdominal pain or IBS like symptoms464-467   Development 
of IBS like symptoms is probably a combination of altered gut flora, genetic susceptibility, immune 
modulation and personality trait464, 468.  Differences between IBS and Diverticular disease have 
recently been highlighted by Spiller (2012)469 . However similar mechanism for the development 
and maintenance may exist between IBS and SDD.  Our theory suggests that the LSDD group were 
peripherally sensitised while the HSDD group were centrally sensitised like the IBS group.  
 
In our study there was increase activity in the pINS in the ADD and HSDD group but not the 
LSDD group in the foot compared to the hand, suggesting some increased sensory input for the 
foot. However this finding was not significantly different in the group comparisons and our theory 
that increased peripheral signals due to sensitisation of pain fibres within the bowel in the LSDD 
cannot be confirmed from our results. This is similar to previous studies which have been 
performed between 8 patients with ulcerative colitis (UC), 7 with IBS and 7 healthy volunteers 
showing activations were identified for all groups in the aINS and dACC. However there are few 
subjects in our study groups which may reduce the power in identifying this increased peripheral 
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input. Also our study gave stimuli at the same VAS score and not the same temperature which may 
have reduced the activations seen. 
 
,Q0D\HU¶VVWXG\195 the IBS group did show greater activation of affective processing areas such as 
the amygdala, hypothalamus, rostal ACC and dorsal medial PFC. In our study both the IBS and 
HSDD showed greater affective pain processing compared to the ADD group with greater activity 
in the INS (IBS), ACC and MCC, and less amygdala deactivation  during pain. However when 
comparing the IBS group to the SDD groups, greater activation of the INS and MCC were seen. 
During anticipation phases the HSDD and IBS groups were similar while increased activity in the 
right INS, MCC and deactivation in the amygdala was seen in the LSDD compared to the IBS 
group. This suggesting although similar, the altered central activities found in IBS are not identical 
to those in SDD groups 
 
 In our study the LSDD and ADD groups were also different with greater PFC activity in the ADD 
group and increased amygdala activity in the LSDD group in anticipation and increased activation 
of the PFC and deactivation of the amygdala in the LSDD during pain.  This suggests that although 
the LSDD group has greater similarity in activation and deactivation to the ADD than the other IBS 
and HSDD group, it is not identical suggesting some element of altered central pain processing. 
Thus due to the artificial splitting of the SDD group according to their PHQ12 score, we in fact 
may have a heterogeneous mix of subjects in each group: The LSDD group with a predominance of 
peripheral sensitised subjects but with some with central components as well and; The HSDD 
group mainly central sensitised subjects in the HSDD group but also potentially a few peripheral 
sensitised subjects as well. The difference between the HSDD and IBS group may also be 
explained by this theory and also by the fact that many of the IBS subjects had received prior 
treatment for IBS by gastroenterology specialists while the HSDD group had not.  
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2.5.7 Limitations with the study 
There were some limitations to the study. 
(i) Patient selection 
(a) Diagnosis of GI disorder 
DD participants who took part in the study had diverticulosis confirmed on endoscopy, barium 
enema or CT scan. Of those who were symptomatic, some reported having had a previous episode 
of diverticulitis with either GP diagnosis or admission to hospital. However not all participants 
with diverticulitis had had it confirmed with CT or other imaging or biochemical tests. A prior 
episode of diverticulitis, which is hypothesised WR FDXVH D SHULSKHUDO µVHQVLWL]DWLRQ¶ UHVXOWLQJ LQ
some patients in having chronic pain, was not used as a part of the inclusion criteria due to 
experience of recruitment difficulties from prior studies. Visceral and cutaneous hypersensitivity is 
known only to affect a subset of patients with IBS316, 317. However no investigations to confirm the 
extent of the DD or visceral hypersensitivity in IBS or DD104 were performed. This may explain 
why no significant thermal hypersensitivity was identified in this study.   
 
The PHQ12 score was used to divide the SDD group into 2 groups. The PHQ12 scores gave a bell 
shaped distribution and the cut off to give equal numbers in the LSDD and HSDD was between 6 
and 7. Although the PHQ12 has previously been used to successfully divide patients in IBS and 
DD with suspected peripheral and central, the cut off was different306. The SDD may potentially be 
a heterogeneous mix of subjects which become similar towards the cut off mark. Thus in the SDD 
groups there is potential for some participants to have a peripheral, central or mixed pain 
processing picture which may reduce the contrast seen between the groups in terms of images and 
VAS scores with temperature changes.  
 
As mentioned above, IBS patients were recruited from gastroenterology clinics. Many had 
experience of undertaking studies and had been treated with a range of medications. Thus the IBS 
subjects who were recruited may not demonstrate the expected pain processing as more medical 
naive counterparts such as those with SDD.  
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 (b) Gender 
Pain processing is different between men and women and has been hypothesised as why there is a 
greater female predominance in chronic pain disorders. However, women have greater anxiety 
sensitivity, compared to men, which may influence pain perception and processing. In our study 
this is important as there were a greater proportion of female participants within the symptomatic 
groups compared to the asymptomatic DD group.  
 
Differences between the structure and function of male and female brain have been found in 
healthy subjects with experimental pain470 and/or in individuals with chronic pain conditions such 
as  migraine471. In healthy volunteer studies of visceral pain, similar rectal sensory thresholds and 
pain ratings have been found. In ROI analysis similar activations in the SS, INS DL-PFC and 
thalamus have been seen. However, on whole brain analysis women have been found to have 
greater activity in the cerebellum, and medial frontal gyrus during stimulation and in the DLPFC 
and middle temporal gyrus during anticipation of pain compared to men472. Animal studies have 
suggested that oestrogen may affect the ACC resulting in greater pain sensitivity473.  Similarly, in 
visceral distension pain similarities were identified within the DL-PFC, INS, SS and thalamus on 
ROI analysis.  However  on whole brain analysis increased activation in the dorsolateral PFC and 
middle temporal gyrus as found in women during anticipation and in the cerebellum and medial 
frontal gyrus during pain472. 
 
However, using nociceptive flexion reflexes and somatosensory evoked potentials, Goffaux et al 
suggest that variations in gender pain perception can be contributed to changes in thalamocortical 
processing which effect appraisal and emotional pain processing474. When they controlled for trait 
anxiety, they found that differences in cortical activity between men and women were lost474. A 
recent review also suggests that studies of biopsychosocial factors influencing pain difference in 
men and women are mixed and that further study is needed to try and explain any underlying 
causes475. 
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(c) Age 
In our study the IBS and HSDD were significantly younger than the ADD and LSDD group. 
Although this is due to the nature of the conditions, with IBS mainly occurring in patients within 
their 20-40yrs and DD in the over 60yrs, it may still have influence our results. Age related reasons 
for confounding in our results include the increased risk of cardiovascular disease which may alter 
blood flow dynamics. Although we tried to control for this by excluding potential participants with 
a cardiovascular disease history, there is still potential for undiagnosed participants to have entered 
the groups. Also older people tend to be on multiple medications, many of which the effect of 
blood flow dynamics is not known or are only now being elucidated476, 477.  
 
Age itself is also thought to influence pain perception. Age related changes in brain volume in 
areas involved in pain processing have been identified478. DNIC response has also been found to 
negatively correlated with age479. However the implication of these changes are not known, but 
caution should be used when interpreting our results.  
 
(ii) Group Size 
Although this study overall had 74 participants with 14 subjects in each group, it is still a small 
study and it is difficult to take the conclusions formed here and apply them to the population at 
large. The areas identified do fit with the current theories of which areas of the brain should be 
activated and deactivated during anticipation but further study of this group is required or inclusion 
of this data into large meta-analysis but more substantial generalisations can be made. 
 
(iii)  Perception  
No significant differences in cutaneous perception were seen between the study groups. This is 
despite known altered visceral sensation previously documented in DD and altered cutaneous314-316, 
322, 480
 and visceral sensitivity315, 322, 349 been demonstrated by several groups in IBS and animal 
models324. Studies by Verne and colleague has suggests that viscera-somatic overlap of 
hypersensitivity may also occur in IBS as we hypothesised in DD302, 317. However in this study 78 
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patients were assess with 57 controls to identify this, which is greater than the numbers used in our 
study. This may be one reason why our sensory testing results were not significant between the 
groups317. Also the scale we used from 1 to 10 may have been limiting.  A continuous, patient 
operated or variable system, which allows rating of each individual pain stimuli, may have been 
more useful.  
 
,W¶V DOVR LPSRUWDQW WR QRWH WKDW RXU I05, UHVXOWV DUH RI 9$6 WHPSHUDWXUH VWLPXOXV 7KLV LV D
subjective reported pain stimulus which aimed to be consistent across all study groups. This was 
assessed in the scanner anteroom, before entering the scanner. It is possible that subjective rating of 
this temperature may have changed due to individual anxiety or other factors once placed in the 
scanner and may be the reason for altered VAS scores at the end of each paradigm. Unfortunately 
we were unable to perform further analysis of fMRI brain responses to a consistent temperature of 
45oC as mentioned in the results. This additional analysis may have aided interpretation of our 
VAS temperature results and allowed a better assessment of group thermal sensitivity at a cerebral 
level rather than subjectively reported.  
 
(iv) Analysis and resolution 
As mentioned previously, this study use whole brain secondary level analysis without masking 
within the brain. This allowed identification of regions that we would not have hypothesised and 
looked for on other techniques, such as ROI analysis. However this technique did give greater risk 
of false discovery and made the data less robust to withstand correction for multiple comparisons. 
When analysis beyond the group maps was performed, few of the results withstood correction for 
multiple comparisons. Thus is it possible that some of our activated regions may be false. Also we 
did not gate our image collection to compensate for respiratory and cardiovascular movement 
which could have affected the images obtained from smaller areas such as the brainstem.  
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This is why we have only discussed larger regions of activation in areas which have previously 
been identified by several studies. Thus we feel that despite this potential flaw our findings are still 
valid.  
 
2.5.8  Future directions 
The study is important as it is the first to suggest both peripheral and central sensitisation in 
symptomatic diverticular disease patients. The PHQ12 questionnaire may also be a helpful simple 
tool to try and divide patients into those with peripheral and central components. This would help 
treatment in this group by allowing selection of peripherally acting, such as mesalazine, or centrally 
acting, as amitriptyline, medications. However further trials are needed to confirm the use of the 
PHQ12 for this purpose.  
 
The PHQ12 score may also be useful in other general surgical and gastroenterology conditions and 
an adjunct to clinical judgement in complex cases. In patients who are requesting surgery for 
symptoms, such as pain, the PHQ12 may be helpful in deciding in those where there is a central 
component to their symptoms and that surgery may not be as beneficial. This would help in the 
counselling process for surgery and potential exploration of other treatment options. It would also 
help in consent process. This is important as evidence of central sensitisation in patients has been 
shown to influence the outcomes of surgery214. Thus future studies in a range of different 
conditions could use modified versions of the PHQ15 or 12 score.  
 
The MRI techniques used in this study are not new. However there is potential to use them to 
further research diverticular disease.  This includes using MRI data and correlating altered pain 
processing with genetic variables. Correlation of pain processing changes and gene SNPs or alleles 
or binding of key receptors is starting to explore chronic pain processing beyond structural and 
functional MRI. These techniques may also identify genetic481 or neuro-chemical changes482, 483. In 
trigeminal neuralgia and FM decreased mu-opioid receptor binding in the nucleus accumbens482, 484, 
amygdala and dorsal cingulate484 has been shown to be altered in patients compared to controls. 
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However increase levels of glutamate and glutamine in the posterior gyrus and lower myo-inositol 
levels in the sensori-motor and hippocampal areas have also been identified in FM patients485. 
Similar studies could also be performed in SDD and may lead to development of better assessment 
tools, research options and potential treatments. There is also potential to investigate the central and 
peripheral action of known and new medications to identify those that may have beneficial effects. 
One study in IBS patients has already shown that amitriptyline reduces activation of the ACC 
during painful rectal distensions and stress486. Pregabalin and SSRI have also been shown to 
influence the activity in amygdala, ACC and insula during anticipation of emotive visual images487, 
488
. Similar studies with cognitive behavior therapies may also be helpful, and are starting to be 
performed in other conditions489. In IBS, anticipatory activity in bilateral orbito-PFC and medial 
temporal gyrus, predicts greater symptom improvement after 3 weeks of 5HT3R antagonist 
Alosetron490. Thus some anticipatory and descending control may be important in success of 
medication in chronic pain conditions. Our findings in SDD and IBS groups may therefore help in 
the development of further studies to look at the effects of both central and peripherally acting 
medications in these groups.   
 
In our study, identification of the S1 and S2 regions were challenging and it was difficult to 
reliably identify these areas. Further analysis is needed to assess them.  
 
Further research is also needed to identify the underlying causes of diverticular disease and the 
development of SDD to try and understand the genetic and psychological predisposition that may 
influence its development, such as have been undertaken for IBS after the Walkerton outbreak122. 
Other influences such as obesity can also be studied using clinical and imaging techniques. 
Although this study has started to describe the heterogeneity of SDD, there is still and long way to 
go to fully understand how pain is processed in this condition and what techniques we may use to 
diagnose and treat it successfully.  
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Chapter 3: Mechanistic randomised controlled trial of Mesalazine 
in symptomatic diverticular disease 
 
3.1 Introduction 
Although painful diverticular disease is relatively common, there has been little research in the 
underlying mechanisms and treatment of pain. Recent studies by Humes et al and Simpson et al 
have demonstrated an association between increased mucosal galanin and cytokines in DD13, 26, 80, 
491
. However the mechanisms underlying this chronic low level inflammation are not fully 
understood. Nevertheless, several treatment options have been traditionally suggested. These 
include: 
 
3.1.1 Surgery 
Previous surgical interest on DD has focused on prevention of complications following acute 
diverticulitis or for the surgical treatment of complicated disease.  In diverticulitis, surgery was 
aimed at preventing recurrence, future complications and to improve quality of life. However, 
recent studies failed to show an improvement in the quality of life in those post-surgery492-497. 
 
The experience of pain depends in most cases on both a peripheral organ based pathology and the 
transmission of pain impulses from the organ to the central nervous system and ultimately the 
cerebral cortex. Some studies in IBS suggest an improvement of pain symptoms on local 
anaesthetic administration to the rectum, and suggest that tonic impulses from the affected organ 
maintain symptoms and global hypersensitivity498. Other studies on chronic pain groups suggest 
that effective treatments such as hip replacement for painful osteoarthritis may resolve central 
associated structural changes such as grey matter atropy499, 500. However in DD, one study suggests 
that painful symptoms persist even after surgery to remove the affected segment, implying that the 
central component predominates in at least some DD patients493. Further study is required in this 
area along with improvement in classification and reporting of DD patient groups. However it may 
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suggest that in some patients, the surgery itself, previous DD inflammatory events or the individual 
SUHGLVSRVLWLRQPD\UHVXOWLQSHUVLVWHQWµSKDQWRP¶SDLQGULYHQSULPDULO\E\FHQWUDODEQRUPDOLWLHVLQ
pain processing.  
 
3.1.2 Medications  
A variety of dietary supplements and medications are prescribed for DD though the evidence base 
for most is very weak when judged by modern standards501, 502. They include: 
 
(i) Fibre e.g. bran, ispaghula and methylcellulose 
There has been only one small cross over randomized control trial for the effect of bran, ispaghula 
husks or placebo in symptomatic DD503 and only one small RCT of methylcellulose compared to 
placebo in symptomatic DD504. No significant effect was reported in the improvement of 
abdominal pain, evacuation of stool or general symptoms over the duration of the studies. There 
was also a significant withdrawal rate from the studies. Although fibre has been a traditional 
treatment for diverticular disease, and has implication in its aetiology, there is no evidence that it 
relieves the symptoms in symptomatic disease505.  
 
(ii) Laxatives 
The effect of lactulose has been compared to high fibre diet in one small RCT506. Unfortunately the 
study was not placebo controlled and outcomes were not clearly defined. So although fibre and 
lactulose may help with constipation  there is no strong evidence to support their use in treating 
pain or other symptoms501. 
 
(iii)  Antispasmodics 
Although antispasmodics are commonly used in patients with recurrent abdominal pain, there have 
been no RCTs to support their use in diverticular disease.  
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(iv) Antibiotics 
Rifaximin is a non-absorbable antibiotic that has received particular interest in the treatment of 
symptomatic diverticular disease and is thought to act on gastrointestinal flora as well as mucosal 
inflammation. There have been 4 RCT studies of rifaximin and dietary fibre, but no RCTs of 
rifaximin alone vs. placebo. In 3 of the studies507-509, the rifaximin was given in 7 day per month 
pulse treatments with daily fibre over 12 months. All showed some benefit in symptoms, which 
included pain. However, although randomized, these studies were not blinded and were not placebo 
controlled. There has been a small double-blind cross over study in 64 symptomatic DD patients 
using 20g/day of dietary fibre, with 1200mg/day of rifaximin or placebo. The study found that 
global symptoms scores, abdominal pain, bowel habit and bloating were improved with rifaximin. 
However the medications were only taken for 14 days with a 30 day washout in-between, which 
reduced interpretation of results and the long term benefits. Unfortunately none of these trials 
provide adequate evidence for the use of pulsed or long term antibiotics in SDD.   
 
(iv) Mesalazine (5-aminosalicyclic acid, 5-ASA) 
There has been increasing interest in the use of mesalazine to eliminate symptoms in symptomatic 
diverticular disease and to prevent recurrences of diverticulitis though good quality studies are still 
lacking (Table I3.1).  
 
Mechanism of action 
The mechanism of action of mesalazine is not fully understood. It is thought to act mainly within 
the colon being delivered to the colon where around 1/3rd is absorbed by the mucosa. Its 
effectiveness is dependent on its mucosal concentration, with very little systemic distribution510-512. 
It appears to have anti-inflammatory, anti-oxidant, anti-tumour and bacterial effects513-521 516, 522 but 
the key to its clinical benefits is unclear.   
 
In the mucosa, 5-ASA anti-inflammatory mechanisms include immune-regulation by inhibiting 
nuclear factor kappa B (NFkB), RelA/p65, IkB degradation and other signaling pathways 523-532, 
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inhibiting production of cytokines, eicosanoids, TNF-alpha and interferon binding533, 534. Inhibition 
of cellular proliferation and invasion and induction of apoptosis has also been identified in 
diverticular disease 535 and models of malignancy 536-538 as well as inhibition of lipid peroxidation. 
5-aminosalicyclates also act as free radical scavengers539, 540. 5-ASA has been shown to inhibit 
epidermal growth factor receptor signalling in colorectal cancer (CRC) cell lines 541 and can 
increase cell death in non-adherent CRC HT-29 cell suspensions, by caspase dependant and 
independent pathways542.  It has been shown to alter inflammatory cells543 and mediators, such as 
TNF-alpha, IL-1Beta and TGF-beta512, 544-548, PPAR-gamma549, cyclooxygenase/prostaglandin 
pathways515, 550, platelet activating factor551, matrix metalloprotineases552, Toll-like receptor 
pathways553, superoxide dismutase553, trefoil factors529, heat shock proteins, heme oxygenase 1 
activity554 and  mucosal barrier function553.     
 
The mucosal barrier function has been implicated in several gastrointestinal diseases such as celiac  
IBD555, 556, IBS557, during normal aging process558 and stressful events559. Thus mesalazine has the 
potential to act on peripheral immune and barrier function which have been implicated in IBS and 
diverticular disease. It has also been shown to reduce fecal bacteria number560 and this antibacterial 
action may also contribute to its beneficial effects in both colitis and DD. 
 
Clinical studies 
Although there have been no robust RCT of mesalazine in SDD, there has been a study of 
mesalazine in IBS. In a small open label prospective study by Andrews et al (2011)560, 12 women 
with diarrhoea predominant IBS received 1.5g BD of mesalazine for 4 weeks. The study found that 
67% of patients had a favorable response on global relief score and that faecal bacteria decreased. 
However this returned to baseline during the 4 week wash out period after the medication was 
stopped. There was an increase in bacterial species such as Firmicutes and bacteroidetes, especially 
in responders. This suggests that changes in gut bacterial populations may influence mucosal 
immune functions and contribute to pain relief. A separate cross-sectional study looking at the 
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colonic mucosa showed decreased mucosa-associated bacteria in IBD patients treated with 
mesalazine, despite ongoing mucosal inflammation1.  
 
 Clinical studies of Mesalazine plus other agents 
Other clinical studies looking at the effectiveness of mesalazine have used it in combination with 
other medications502 (Table I3.1). 
 
(a) Probiotics 
There have been several studies, using L casei or VSL#3 450billions/day treatment for 10 
days/month with and without mesalazine561, 562 or balsalazide563. Although benefit was found with 
mesalazine and probiotics, the results of these studies are difficult to interpret. This is because the 
studies were open-labeled, the treatment regimes were pulsed and patients had also been previous 
treated with a course of mesalazine and rifaximin prior to commencing the study.  
 
(b) Rifaximin 
Several studies have used a combination of rifaximin and 5-ASA with comparison to rifaximin 
alone or to varying doses of rifaximin or mesalazine502, 564-566. Treatment was given in pulses of 7 to 
10 days per month. All reported improvement in global symptom scores or bowel habit and 
reduction in the occurrence of diverticulitis. Although many of these studies have high numbers of 
participants, the study designs make it difficult to compare results between trials and identify the 
true effect of mesalazine alone. Many trials use pulsed treatments of 10 to 15 days per month rather 
than continuous, even though a study suggested greater efficacy of treatment in the continuous 
rather than pulsed groups (per protocol: 77.8% vs. 56.3%)567. Interestingly 5% of participants broke 
SURWRFRO LQ WKH µSXOVHG¶ PHGLFDWLRQ JURXS DQG ZHUH ZLWKGUDZQ 6RPH WULDOV did not use 
randomization of participants and failed to perform endoscopy at the beginning of the study to 
confirm the presence of diverticular disease and exclude any other gastrointestinal conditions568.  
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All the above studies have focused on symptoms reported by the participants. There have been few 
mechanistic studies to compliment the change in reported symptoms in diverticular disease. 
However there has been a recent mechanistic double blind placebo controlled RCT of mesalazine 
in IBS patients543. This Italian study involved 20 patients with Rome II criteria IBS to placebo or 
mesalazine (800mg TDS) for 8 weeks. Colonoscopy and mucosal biopsies from the proximal 
descending colon were performed at the beginning and end of the study. The results demonstrated a 
decrease in inflammatory cells in the mesalazine treated group. On subtype analysis the only 
significant decrease was found in the TRYP+ mast cells. Significant decreases in inflammatory 
mediators IL-1beta, tryptase and histamine were also demonstrated. There was no significant 
reduction in reported symptoms except general wellbeing and treatment satisfaction  
 
It is important to note that this study was small, with only 10 participants in each treatment arm so 
the study was not powered to detect differences in symptoms. The IBS patients included with all 
subtypes i.e. mixed, diarrhoea and constipation predominant IBS. Although these factors could 
KDYHZHDNHQHGWKHVWXG\¶VSRZHU Corinaldesi HWDO¶VVWXG\543 does suggest potential benefit in IBS 
and encouraged us to explore its use in diverticular disease. This review of the literature shows that 
better evidence is required such as can only be obtained with a well designed placebo controlled 
double blinded RCT of mesalazine in symptomatic diverticular disease.  
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Table I3.1 Tabulated open labelled non-placebo controlled studies of mesalazine in SDD 
 Number Treatment Follow up and Results 
Gatta et al 
2011568 
 
Total: 149 
Mesalazine = 
67 
Controls = 82 
Pulsed 10 days per month 
Non randomised  
Duration: 5 years 
M = 50 completed study 
C = 75 completed study 
No significant difference 
in development of 
diverticulitis. Symptom 
changes not reported. 
Tursi et al 
2008562 
 
Total 71 M1: Mesalazine 800mg 
10days/month 
M2: Mesalazine 1.6g 
10days/month 
LM1: Mesalazine 800mg + 
lactobacillus casei 16 
billion/day  10days/month  
LM2: Mesalazine 1.6g + 
lactobacillus casei 16 
billion/day  10days/month 
L: lactobacillus casei 16 
billion/day  10days/month 
Duration:  24 months 
88% symptom free. 
Not significant difference 
between groups. 
Comparato 
et al 2007566  
Total: 268 
R1 = 66 
R2 = 69 
M1 = 67 
M2 = 69 
R1 Rifaximin 200mg BD 
R2 Rifaximin 400mg BD 
M1 Mesalazine 400mg BD 
M2 Mesalazine 800mg BD 
Duration:  12 months 
M1 vs. R1 p=0.04 
M2 vs. R2 p<0.0001 
V0 vs. Vend significant 
for all except R1 
Improvements on global 
symptom score, tenesmus, 
bloating, diarrhoea, 
bleeding, frequency and 
wellbeing after 12 months. 
Overall mesalazine had 
greater symptom 
improvement than 
rifaximin 
Tursi et al 
2007567 
Total 40 
Randomised 
to Grp A or B 
1:1 
Grp A: Mesalazine 1.6g/day 
Grp B: Mesalazine 1.6g/day 
for 10 days per month 
Duration:  8 weeks 
treatment and 21  months 
follow up 
34 completed study 
At 24 months: 
Symptom free p<0.05 
77.78% in Grp A 
56.25% in Grp B 
Symptom Recurrence 
p<0.005 
5.56% in Grp A 
31.25% in Grp B 
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Table I3.1 continued. Tabulated open labeled non-placebo controlled studies of mesalazine in 
SDD 
 Number Treatment Follow up and Results 
Tursi et al 
2006 561 
Total:  90 
 
M: Mesalazine 1.6g/day 
L: L. Casei DG 16 billion/day 
15 days per month 
LM: Mesalazine 1.6g/day + L 
Casei DG 16 billion/day 15 
days per month 
Duration 12 month 
85 patients completed 
study 
88.2% symptom  free [IIT 
analysis]  
M = 76.7% 
L = 76.7% 
LM = 96%       p<0.05 
Symptom Recurrence = 
11.1% 
Di Mario et 
al 2005569  
Total: 170 
R1: 39 
R2: 43 
M1: 40 
M2:  48 
R1: Rifaximin 200mg BD 
R2: Rifaximin 400mg BD 
M1: Mesalazine 400mg BD 
M2: Mesalazine 800mg BD 
....For 10 days per month 
Duration: 3 months 
Global symptom score 
used decreased in all 
groups but R1 p<0.0001.  
Greatest decrease in 
symptoms in mesalazine 
groups p<0.001 
 
 
3.2 Aims 
To undertake a pilot mechanistic, 2-group parallel design, randomized controlled trial of anti-
inflammatory treatment (Mesalazine) in individuals with symptomatic diverticular disease to 
identify biomarkers to assess the relationship between inflammation and symptoms. 
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3.3 Methods 
 
3.3.1 Trial Design 
This mechanistic double blinded, randomised [1:1], parallel group pilot study of Mesalazine in 
symptomatic DD was initially designed in 2007 and approved by the Regional Ethics Committee 
and Medicine and Healthcare Regulatory Authority (REC reference: 07/Q2403/83 and EudraCT 
Number: 2006-006198-26).  The protocol was published on ClinicalTrials.gov (NCT00663247) in 
April 2008. There were no deviations from the original study protocol. The trial was conducted in 
accordance with Good Clinical Practice (GCP) guidelines.  
 
3.3.2 Participants 
(i) Recruitment methods 
Participants were identified from colorectal surgery and gastroenterology outpatient clinics at 
Nottingham University Hospitals and Royal Derby Hospital (UK), endoscopy lists at Nottingham 
University Hospitals and from databases of individuals with diverticular disease who had 
previously expressed an interest in participating in clinical research, held at the National Institute of 
Health Research Nottingham Digestive Disease Biomedical Research unit (NIHR NDDC BRU). 
Additional recruitment was achieved via approved advertisements on hospital notice boards and 
local newspapers (Nottingham Evening Post, Recorder and Metro). All potential participants were 
contacted using a standardized letter and study participant information sheet. Written consent was 
gained prior to any further contact or in accessing potential participants hospital or general 
practitioner (GP) records to confirm a diagnosis of diverticular disease. Only participants who had 
1 or more diverticulum present in the descending or sigmoid colon on barium enema, flexible 
sigmoidoscopy or colonoscopy or on CT scan were eligible for the study. Structured telephone or 
face-to-face interviews and patient Hospital and GP records were also used to confirm other 
eligibility criteria (Table M3.1).  
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Table M3.1 Inclusion and exclusion criteria 
Inclusion Criteria 
1. Symptomatic diverticular disease with short lived recurrent abdominal pain for 1 hour or 
longer on 3 or more days a month for 3 or more months. 
2. 18 ± 85 years of age. 
3. Signed informed consent 
4. Presence of at least one diverticulum in the left colon 
 
Exclusion Criteria 
1. Pregnant or lactating women. 
2. Severe co-morbidity, alcoholism or drug dependence or inability to give informed 
consent. 
3. Contraindications to use of Mesalazine, including 
a. Renal failure 
b. Liver failure 
4. Inability to stop NSAIDs (non-steroidal anti-inflammatory agents) or long term 
antibiotics. 
5. The use of specific concomitant medications: 
a. Immunosuppressants, e.g. azathioprine, 6-mercaptopurine, methotrexate, 
cyclosporine or any other experimental drugs 
b. Non-steroidal anti-inflammatory drugs (NSAIDs) for more than 2 weeks 
cumulatively (exceptions: acetylsalicylic acid d 100 mg/d and paracetamol for 
analgesic use are allowed) 
c. Oral, rectal or intravenous corticosteroids 
d. Oral antibiotics: e.g. metronidazole, ciprofloxacin (exceptions: these medications 
are allowed for a 7 to 10 day course only, if deemed necessary for conditions 
unrelated to study disease) 
e. Mesalazine-containing or -releasing drugs (e.g. mesalazine, olsalazine, 
 139 
sulfasalazine, balsalazide) 
f. Laxatives, anti-diarrheal or anti-spasmodic drugs as permanent treatment (i.e. > 1 
week) 
g. Analgesics as permanent treatment (i.e. > 1 week), except if deemed necessary 
for conditions unrelated to study disease 
6. Presence of other gastrointestinal inflammatory conditions such as ulcerative colitis, 
&URKQ¶VGLVHDVHDQG&RHOLDFGLVHDVH 
 
3.3.3 Study Setting and interventions 
The study took place between September 2008 and January 2011at the NIHR NDDC BRU, based 
DW WKH 4XHHQ¶V 0HGLFDO &HQWUH 1RWWLQJKDP 8QLYHUVLW\ +RVSLWDOV 1RWWLQJKDP 8. (OLJLELOLW\
criteria were confirmed prior to obtaining written consent from all participants. Participants 
received up to £150 to cover out of pocket expenses for the duration of the study. The study lasted 
3 months and was divided into screening (2 weeks pre-medication) and medication (12 weeks, 5 
visits) periods (Figure M3.1).  
 
Visit 0 - Screening and Baseline measurements 
Participants completed previously validated questionnaires regarding their bowel habit, abdominal 
pain, somatic symptoms (PHQ-15: patient health questionnaire 15)570 and anxiety and depression 
(Hospital Anxiety and Depression score (HADS))571. Clinical history and examination, with 
measurements of pulse rate, rhythm and character, blood pressure, temperature, saturations, height 
and weight, were performed. Blood samples were taken for baseline full blood count (FBC), urea 
and electrolytes (UE), liver function tests (LFTs), coagulation (Coag) and for super sensitive C-
reactive protein (SS-CRP) and peripheral blood inflammatory cytokines. Blood for SS-CRP and 
cytokines was centrifuged at 25oC for 10 minutes at 2000g to allow separation of the serum. The 
serum was removed using sterile pipette (Eppendorf, Research Physio Care Concept, Germany) 
and the sample stored in eppendorfs at -20oC immediately to prevent degradation.  Urine sample 
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was also collected and tested using URS-100 and/or Combur 7 dipsticks (Teco Diagnostics, CA, 
USA, and Roche, Switzerland). A 2.5 - 5ml urine aliquot was stored at -80oC. 
 
Figure M3.1 Schematic of interventions and follow up during Trial.  
 
 
 
Participants also had the option to undergo an unprepared flexible sigmoidoscopy either at the 
screening visit or at the subsequent visit 1, in 2 weeks time. The flexible sigmoidoscopy was 
performed in dedicated research facilities within the NIHR NDDC BRU by accredited practitioners 
using an Olympus scope (CF 240L Olympus, Essex UK) and Stack (CV 260 SL EVIS, Olympus, 
Essex UK). Six biopsies were taken from the sigmoid around the ostia of diverticula and six from 
the rectum using forceps (2.4m Cold Captura Biopsy Forceps, DBF-2.4-230-20-S G5606, 
Limerick, Ireland): Two were immediately placed in cyrotubes (NUNC CyroTubes [363401], 
Thermo Fisher Scientific, Langenselbold, Germany) and frozen in liquid nitrogen, two placed in 
1.5ml of RNA later (R0901, Sigma-Aldrich, Dorset, UK) for 24-48 prior to being frozen at -80oC 
DV SHU PDQXIDFWXUHU¶V LQVWUXFWLRQV DQG  SODFHG LQ IRUPDOLQ SRWV  )RUPDOGHK\GH *HQWD
Medical, York, UK) for histological assessment.  
 
During the subsequent 2 weeks, participants completed daily diaries documenting the duration and 
intensity of their abdominal pain, general wellbeing, bloating and bowel habits, including scores of 
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bowel frequency and consistency, using the Bristol Stool Chart (Please see Appendix 6.9 for 
example of diary sheets). They also collected a stool sample 24hrs prior to attending for their next 
visit. If a sample was not obtained in time, participants were able to return a sample using secure 
pre-paid envelopes by post. Stool samples were stored at -20oC upon receipt.  
 
Medication: Visit 1 
Medication was dispensed on study visit 1, approximately 2 weeks after the screening visit, and 
after participant diaries were checked. Three grams of medication, either mesalazine or placebo, 
were taken each morning by participants for the duration of the study. 
 
All participants had 24hr access to a medical health professional during their participation and 
follow up. Adverse events were treated and recorded as per GCP and study protocols.   
 
Medication: Visits 2-5 
Subsequent follow up visits for monitoring and data collection were performed at 2 or 4 weekly 
intervals as per the protocol (Table M3.2 and Figure M3.1), to allow early detection of rare 
mesalazine complications, such as renal or liver impairment, and aplastic anaemia or pancytopenia. 
Prior to each visits participants completed a 7 day diary of bowel function and abdominal pain and 
collected and stored a stool sample. Participants returned any used medication at each visit and 
were issued with further medication to last until their next visit (+6 days in case of in-adverted 
delays in returning). This allowed recording of left-over trial medication returned at the follow-up 
visits and the final visit as well as by checks of the diary by the investigator as a measure of 
compliance. At each study visit, apart from visit 1, urine was collected and tested to detect any 
renal impairment. An aliquot of urine was stored at each visit in -80oC freezer. Participants were 
also asked at each visit if they had satisfactory relief from their diverticular symptoms.  
 
At visit 5, additional questions were included if they thought they were taking the mesalazine or 
placebo and if tKH\ ZRXOG FRQWLQXH WKH PHGLFDWLRQ ,I SDUWLFLSDQWV GLG ZLVK WR µFRQWLQXH¶ WKH
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medication, their care was transferred to National Health Service Gastroenterology Department or 
their general practitioner, where they were prescribed mesalazine and appropriate monitoring could 
also take place. Also on the final visit, additional blood was taken for final SS-CRP and cytokines 
and a further unprepared flexible sigmoid endoscopy with 6 biopsies taken from the sigmoid and 
rectum, as for baseline. At the end of the study, all unused medication underwent documented 
destruction by the Clinical Trials Pharmacy according to local policy. Receipts of medication 
destruction were set to Dr Falk Pharma for confirmation.  
 
Table M2.2. Visit schedule. 
Visit Visit no. Day no. Week no. Time window [days] 
Screening visit Visit 0 Day -14 Week -2 NA 
Baseline Visit 1 Day 0 Week 0 NA 
Interim visit Visit 2 Day 14 Week 2 r 6 
Interim visit Visit 3 Day 28 Week 4 r 6 
Interim visit Visit 4 Day 56 Week 8 r 6 
Final visit Visit 5 Day 84 Week 12 r 6 
 
3.3.4 Laboratory methods 
(i)  RNA Methods 
RNA was extracted from 1 sigmoid colorectal tissue biopsy in RNA later, which had been stored 
since collection in dedicated -80oC tissue storage facilities at the FRAME laboratory (Nottingham 
Medical School, Nottingham UK). All samples were extracted within a 2 week period after 
completion of follow up of all the trial participants. TRI reagent® (Sigma Aldrich USA 
Pcode101078497 T9424) extraction of RNA, Qiagen column clean up of RNA (Qiagen USA Cat 
No 74106)  and creation of cDNA were performed in the FRAME laboratory under the supervision 
of Dr A Bennett, using standardized protocols, which can be found in Appendix 6.10.  
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(ii) Gene card  
Custom made 96 gene micro-fluidic gene cards (Format 96a; P/N 4342259, Applied Biosystems, 
California USA) were constructed after review of potential molecular pathways involved in chronic 
inflammation and nociception in diverticular disease, irritable bowel syndrome and inflammatory 
bowel disease. Each card was designed to analyze 96 genes with no repeats, from 4 cDNA samples 
simultaneously. Housekeeper genes, which were chosen to be consistently expressed during the 
trial duration, included 18s, Beta-Actin, ribosomal protein large PO (RPLPO) and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1). A full list of genes selected for the gene cards can be found 
in Appendix 6.11. 
 
Micro-fluidic cards were loaded and analysed DVSHUPDQXIDFWXUHU¶VLQVWUXFWLRQV572. In brief, 60ul of 
cDNA was created using 1ug of RNA and Superscript III reverse transcriptase (Invitrogen USA 
Cat No 18080- DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV XO RI '(3& 'LHWK\O 
pyrocarbonate: Sigma-Aldrich USA D5758) treated HPLC grade water and 110ul of Universal 
Taqman master mix (P/N 4304437, Applied Biosystems, California USA) was added to create a 
final volume of 220ul. The micro-fluidic gene card has 8 wells, with 2 wells for each of the 4 
samples. 100ul of the samples were placed in their corresponding wells and the plate centrifuged 
twice at 1200rpm for 1 minute using a Sorrall ST40 centrifuge (Thermoscientific, Loughborough 
UK). The plate was sealed with a plate sealer (Model 4331770 Rev A.5, Applied Biosystems 
California USA) and loaded into the 7900HT Fast Real Time PCR system analyser (Applied 
Biosystems California USA).  
 
Initial analysis to generate CT values was undertaken using RQ manager software (Version 1.2 
Applied Biosystems California USA). As more than 10 cards were used, this analysis was 
undertaken in two stages. Corrections to the automated analysis were performed to ensure that all 
thresholds and baselines were identical between the analysis groups.  
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CT values were then exported as text files and incorporated into an Excel spread sheet (Microsoft) 
to allow assessment of the housekeepers and calculation of the geometric mean and relative 
quantification (RQ). The sample used as the baseline for RQ analysis was RXB05 sigmoid 
baseline, as this sample demonstrated good expression with only 2 genes failing to amplify.  
 
(iii) Histology 
Sigmoid colon and rectal biopsies preserved in formalin histology pots were transferred to the 
Histology Department at Nottingham University Hospitals. All samples were preserved in paraffin 
blocks and ȝP VHFWLRQV FXW DQd mounted on slides. The samples were dried for 20 minutes at 
room temperature and then at 60oC for 20 minutes. Samples were stained by Dr Claire Hawkes in 
dedicated Immunohistochemistry (IHC) Laboratories at the Nottingham University Hospitals for 
lymphocytes (CD3), macrophages (CD68), proliferating cells (KI67) and endochromaffin cells 
(Serotonin, 5HT) using a Bond Max automated staining processor (Leica Microsystems) (Please 
see Table M2.3 for antibodies and dilutions).   
 
Stained slides were scanned at *20 (5HT) or *40 (CD3, CD68, KI67) magnification using a 
NanoZoomer 2.0-HT (Hamamatsu, Japan) in the Photography Division of the Pathology 
Department at Nottingham University Hospitals. Tissue architecture was also examined with 
haematoxylin and eosin (H & E) stained sections by a consultant pathologist, Dr A Zaitoun.  
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TableM2.3 Immunohistochemistry antibodies and dilutions. 
Target Antibody Dilution Notes 
KI67 Clone MIB1, NCL-L-KI67-
MM1, Leica Microsystems, 
Milton Keynes, UK.  
1:50 Antigen retrieval for 30 minutes with ER2 
(AR9640), a ready-to-use EDTA based 
pH9.0 solution  
CD68 Clone KP1, M0814 Dako 
UK Ltd.  
1:3000 Antigen retrieval for 20 minutes  with ER1 
(AR9961), a ready-to-use citrate based 
pH6.0 solution 
CD3 NCL-L-CD3-565, Leica 
Microsystems, Milton 
Keynes, UK.   
1:100 Antigen retrieval for 20 minutes with ER2 
(AR9640), a ready-to-use EDTA based 
pH9.0 solution 
5HT clone 5HT-H209,  M0758, 
Dako UK Ltd.  
1:200 Enzyme pre-treatment for 10 minutes 
 
(iv) Histology assessment 
All scanned slides were assessed using NanoZoomer digital pathology virtual slide viewer software 
(Hamamatsu, Japan). Coefficients of variation were verified to be <0.1 and reproducibility >90% 
for each IHC stain prior to assessment of the samples (see Appendix 6.12). All slides were 
anonymised by the Pathology Department prior to staining. This prevented participant 
identification by the researchers performing the cell counts. The protocols for cell counting for 
each stain are: 
 
CD3 
CD3 positive cells appeared dark brown. Only cells with positive staining and an identifiable 
nucleus were counted. Cells within the epithelium and lamina propria were assessed, with areas 
adjacent to lymphoid follicles being excluded (Figure M3.2A). Up to 15 randomly selected areas of 
epithelia and lamina propria were assessed and number of cells per mm2 calculated and used for 
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further analysis. Care was taken to include equal amounts of superficial (sub-epithelial) and deep 
lamina areas when measuring the lamina propria.  
 
CD68 
CD68 positive cells appeared dark brown. Only cells with positive staining and an identifiable 
nucleus were counted.  Cells within the lamina propria were assessed, again with areas adjacent to 
lymphoid follicles being excluded (Figure M3.2B). Up to 15 randomly selected areas of lamina 
propria were assessed and number of cells per mm2 calculated and used for further analysis. Again, 
when measuring the lamina propria, care was taken to include equal amounts of superficial (sub-
epithelial) and deep areas.  
 
KI67 
KI67 positive cells appeared dark brown.  Only cells with positive staining and an identifiable 
nucleus within the epithelium were assessed, with areas adjacent to lymphoid follicles being 
excluded. Up to 15 randomly selected areas of epithelia were assessed and number of cells per mm2 
calculated and used for further analysis.  
 
5HT 
Only cells within the crypt mucosa were assessed. 5HT positive cells appeared dark brown.  Up 15 
crypts per slides were measured and divided into deep and superficial segments (Figure M3.2C). 
The number of positively stained cells in each area was recorded along with the deep and 
superficial areas, the perimeter of each segment and the length of the crypt. The number of cells per 
mm2 per segment was calculated and used for further analysis.  
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Figure M3.2  Histological assessment of (A) CD3, (B) CD68 and (C) 5HT using NanoZoomer 
digital pathology virtual slide viewer software at *20 Magnification.  
 
(A) CD3 epithelial measurements 
 
 
(B) CD68 lamina propria Measurements 
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Figure M3.2 continued. Histological assessment of (A) CD3, (B) CD68 and (C) 5HT using 
NanoZoomer digital pathology virtual slide viewer software at *20 Magnification.  
 
 (C) 5HT crypt epithelial Measurements 
 
 
(v) Faecal calprotectin 
The assessment of Faecal Calprotectin was performed by Dr Louise Hawke at the Department of 
Pathology (Nottingham City Hospital, Nottingham University Hospitals, UK).  The baseline and 
final visit stool samples were extracted using the device for stool collection (Calprest collection 
device, Code 9062, Eurospital, Trieste, Italy). Faecal Calprotectin analysis was carried out by 
(/,6$ &DOSUHVW NLW &RGH  (XURVSLWDO 7ULHVWH ,WDO\ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions.  
 
(vi) Super Sensitive CRP 
Serum samples were frozen at -20oC and transferred to Leeds Teaching Hospital for processing, via 
to Biochemistry Laboratories at Nottingham University Hospitals using their standardized protocol.   
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(vii) Liquid chromatography and mass spectroscopy 
Extraction of samples, analysis and interpretation of results was performed by Dr Srinivasarao 
Ravipati and Prof D Barrett between 20/12/2012 to 22/12/201. The method used was developed by 
Dr A Wong (Biochemical Sciences, University of Nottingham). The data were analysed in 
GraphPad prism using a paired non-parametric T-test (Wilcoxon).  
 
3.3.4 Outcomes 
The primary endpoint was the difference in change in galanin and/or galanin receptor 1 expression 
from 0 (baseline) to 12 weeks (Visit 5) or on withdrawal between mesalazine & placebo treated 
groups. This end point was chosen based on previous work suggesting increased galanin and 
galanin receptor 1 mRNA and protein in patients with symptomatic diverticular disease80, 491. 
Secondary endpoints included differences between mesalazine and placebo groups with respect of 
changes from 0-12 weeks or withdrawal of: (1) mRNA of inflammatory cytokines, (2) cell counts 
of CD3, CD68, 5HT (serotonin) and KI67 positive cells, (3) Faecal calprotectin and (4) Abdominal 
pain, stool frequency and mean stool consistency. 
 
Galanin and Tachykinin staining for protein 
Multiple attempts at staining for galanin, its receptors and for tachykinin receptors were performed. 
Despite the use of several different commercially available antibodies, we were not successful and 
could not replicate the results of Simpson et al80, Simpson et al performed their staining at a 
specialist laboratory in Lund, Sweden, with antibodies which were not commercially available. 
Other groups have reported similar problems in the reliability of antibodies87, 573-575. Thus we will 
only report changes in gene expression.  
 
3.3.5 Sample Size Calculation 
The aim of this pilot study was to identify inflammatory markers which may be useful in 
distinguishing painful symptomatic diverticular disease patients with low grade inflammation in 
whom Mesalazine may be an effective treatment. No prior study has looked at markers of 
inflammation in diverticular disease and so no formal power calculation can be performed. A prior 
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study using just 21 ulcerative colitis patients found a significant effect of Mesalazine  on the levels 
of mucosal interleukin 1 (IL-1)576. Therefore given a sample size of 40, it should be possible to 
detect a significant difference between two groups (i.e. mesalazine and placebo). 
 
3.3.6 Randomization and Blinding 
The mesalazine granules (Salofalk) and placebo were manufactured and packaged by Dr Falk 
Pharma and were identical in packaging, colour VL]H DQG WDVWH 7KH SDUWLFLSDQWV¶ randomisation 
numbers were generated by Dr Falk Pharma prior to commencement of the study and consecutively 
allocated as participants were recruited into the study. All medication was stored in the Clinical 
7ULDOV3KDUPDF\ 4XHHQ¶V0HGLFDO&HQWUH8QLYHUVLW\RI1RWWLQJKDP8.SULRU WRGLVSHQVLQJ WR
the participants at each study visit. The code was kept in a sealed envelope in case of adverse 
reactions, when it could be opened by the Clinical Trials Pharmacy. The code was not broken 
during the duration of the study and the envelopes were only opened after completion of laboratory 
sample assessment. This maintained the blinding of all participants and clinical trial staff in the 
NDDC BRU and Clinical Trials Pharmacy.  
 
3.3.7 Statistical Analysis 
As this study is a pilot study of only 40 participants, no interim analyses were performed during the 
study. All questionnaire, genetic, biochemical and histological data was stored in Microsoft Office 
Access 2007 (Microsoft USA) database and transferred to SPSS (version 15, IBM, Portsmouth 
UK) and GraphPad Prism (Version 5, California USA) for further analysis. To determine whether 
randomisation had been successful the baseline characteristics of the two groups and the 
withdrawals were compared using Mann-Whitney U. The outcome measures of principal interest 
assessed in the biopsy samples taken at the screening visit and at final visit (3 months) in a per 
protocol analysis.  As the study was not powered to assess efficacy of mesalazine in pain relief, an 
intention to treat analysis was not performed. A paired non-parametric T-test (Wilcoxon signed-
rank test) was used in per-protocol analysis to compare between the baseline and final measures in 
the placebo and mesalazine group.  Statistical significance was p<0.05 level.  
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3.4 Results 
 
3.4.1 Participant Recruitment  
43 participants were recruited to the study between September 2008 and January 2011. Participants 
attended screening visits and follow up visits over a 3 month period as per protocol (Table M2.2). 
If a participant withdrew prior to commencing medication, the medication intended for them was 
re-allocated to the subsequent participant who completed the screening period. Ethical Approval 
was granted in August 2010 to recruit up to 50 participants to allow for the withdrawals prior to 
commencing medication. However once 40 participants had received medication the trial was 
closed to further recruitment, maintaining the study numbers as per the original protocol. One set of 
VWXG\PHGLFDWLRQZDVµVSRLOHG¶GXULQJWKHVWXG\UHVXOWLQJLQSDUWLFLSDQWVVWDUWLQJPHGLFDWLRQas 
part of the trial.  
 
Recruitment for the study offered challenges, as many potential participants with painful SDD are 
treated by GPs in the community. Our initial poor recruitment rates were improved by targeting 
these potential participants through newspaper advertisements and via the Primary Care Research 
Network (PCRN). Figure R3.1 demonstrates the recruitment rate and the improvements obtained 
by using these alternative recruitment methods.  
 
3.4.2 Participant Flow, Exclusions and Losses  
Two subjecWVZLWKGUHZGXULQJWKHZHHNEDVHOLQHSHULRGGXHWRµUHVROXWLRQRIWKHLUV\PSWRPV¶RU
did not respond to further attempts to contact by the research team. Two more were withdrawn by 
the research team; 1 who was unable to tolerate an unprepared flexible sigmoidoscopy to obtain 
initial colorectal biopsy samples and 1 for an unrelated musculoskeletal problem, requiring further 
investigation by a NHS rheumatology team (Figure R3.2).   
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Figure R3.1 Annotated graph of recruitment rate for Mechanistic RCT. 
 
Purple arrows indicate time at which recruitment interventions were initiated. All interventions 
were Ethical and Local Research and Development office approved. DRH = Derby Royal Hospital, 
PCRN = Primary Care Research Network. 
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Figure R3.2 Flow Diagram Overview of participants recruited to the Trial. 
 
Advertisements include newspaper and hospital poster boards. Clinics are those based at 
Nottingham University Hospitals.  PCRN = Primary Care Research Network.  
 
During the 12 week medication period of the study, 6 participants withdrew. Figure R3.3 outlines 
the withdrawals which occurred in each treatment arm. Four of these were for worsening 
abdominal pain or recurrence of original symptoms. The worsening abdominal pain resolved after 
stopping medication in each participant, but reoccurred with re-challenge. All these subjects were 
withdrawn with agreement between the participant and the research team. One participant had a 
change in family circumstances which prevented further travel to the NDDC BRU and asked to be 
withdrawn.  
 
A further participant suffered a severe adverse event 2 weeks after commencing study medication 
(Visit 2). This was detected by the researcher after the participant mentioned symptoms of 
breathlessness on exertion, which had started before recruitment into the study but the participant 
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had not mentioned during screening. This symptom had subsequently become worse during the last 
2 weeks before the visit.  The participant had given a previous history of DVT, but investigations 
confirmed only a slight troponin rise of 0.070 ng/ml (upper limit normal 0.040 ng/ml), a normal 
ECG and a negative D-Dimer. The participant was admitted to the Nottingham University 
Hospitals where a cardiac echo, exercise tolerance test and CT Pulmonary Arteriogram (CTPA) 
were performed.  These confirmed a diagnosis of a pulmonary embolism and the participant was 
commenced on warfarin. The participant ceased their medication on admission to hospital and was 
subsequently withdrawn from the study by the research team. Due to the onset and participant risk 
factors, the adverse event was classified as unrelated to the study. During the analysis phase the 
participant was found have been allocated to the placebo arm of the study.  
 
During the final visit, 2 participants disclosed that they had not consistently taken or had 
prematurely stopped the medication. The reasons for this were not clear. One of these participants 
also withdrew consent for the final endoscopy and biopsies, although they did complete the 
questionnaires and provide blood and stool samples. The other informed the study team that she 
had not taken the medication for 5 days previously, which lead to some data loss during the 
analysis.  
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Figure R3.3 Participant Flow diagram and withdraws per treatment arm.  
 
IHC = Immunohistochemistry, RNA = colorectal biopsy RNA analysis.  
 
3.4.3 Baseline Data 
The baseline characteristics of the mesalazine and placebo groups are demonstrated in table R3.1 
A-E. As a considerable number of the withdrawals were from the mesalazine group, demographic 
data on the withdrawal group has also been included. However, 1 participant withdrew prior to 
collection of demographic data and before commencing medication, so only 10 out of the 11 
withdrawal subjects have been reported.  
 
Table R3.1A-B demonstrates the age range, sex, body mass index (BMI) and prevalence of a past 
medical history of diverticulitis, abdominal surgery, psychiatric history and smoking prevalence of 
the placebo, mesalazine groups as well as the withdrawals. The diagnosis of diverticulitis was 
based on hospital records, CT reports or on interview with the participant giving a history of 
>24hours of abdominal pain, fever and a prescription of antibiotics. The final column in table 
R3.1A and B includes p values for the continuous (Mann Whitney U, MWU) or categorical (Fisher 
Exact test) data. Participant method of diagnosis and recruitment into the study is shown in Table 
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R3.2 A-B. As pain experience can be influenced by social situation, demographic data on marital 
status was also collected Table R3.3. 
Table R3.1 Demographics and Co-morbidities of participants per group.  
 Placebo (A) 
N=18 
Mesalazine (B) 
N=14 
Withdrawn 
N=10 
P Value 
A vs. B 
A: Demographics 
Median Age 
(Yrs) (Range) 
66 yrs 
(32-80) 
64.5 yrs 
(45-77) 
62.5 yrs 
(43-74) 
P = 0.3417 
MWU 
Male (%) 9 
(50%) 
2 
(14.3%) 
7 
(70%) 
P = 0.0608 
Fishers exact 
BMI  (Kg/M2)  
(Range) 
28.94 
(23.59-35.01) 
32.98 
(20.10-48.96) 
26.82 
(20.06-34.21) 
P = 0.0800 
MWU 
Diverticulitis 
diagnosis 
6 
(33.3%) 
6 
(42.9%) 
2 
(20%) 
n.s. 
B: Co-morbidity 
Anxiety or 
Depression 
2 
(11.1%) 
4 
(28.5%) 
3 
(30.0%) 
P=0.3649 
Fisher Exact 
Prev. Abdominal 
Surgery 
13 
(72.2%) 
13 
(92.9%) 
6 
(60.0%) 
P=0.3589 
Fisher Exact 
Smoking 
     None 
     Ex-smoker 
     Smoker 
 
7 (38.8%) 
7 (38.8%) 
4 (22.2%) 
 
6 (42.9%) 
6 (42.9%) 
2 (14.3%) 
 
5 (50.0%) 
4 (40.0%) 
1 (10.0%) 
 
n.s. 
Operations include: appendectomy, total abdominal hysterectomies, surgery for an ectopic 
pregnancy, sterilisation, laparoscopy (+/- adhesiolysis), cholecystectomy, hernia repairs, lipoma 
removal, removal of un-descended testicle and TURP. n.s. = not significant 
 
 157 
Table R3.2 Method of diagnosis and recruitment of participants in Placebo, Mesalazine groups and 
withdrawn groups.  
A: Diagnosis Method Placebo 
N=18 
Mesalazine 
N=14 
Withdrawn 
N=10 
BE 7 
(38.9%) 
4 
(28.6%) 
3 
(30%) 
CT 0 4 
(28.6%) 
1 
(10%) 
Endoscopy 11 
(61.1%) 
5 
(35.7%) 
6 
(60%) 
Missing Data 0 1 
(7.1%) 
0 
B: Recruitment Method 
Advert 11 
(61.1%) 
7 
(50%) 
8 
(80%) 
Clinic 3 
(16.7%) 
4 
(28.6%) 
2 
(20%) 
Database 1 
(5.6%) 
0 
 
0 
Royal Derby Hosp 1 
(5.6%) 
3 
(21.4%) 
0 
PCRN 2 
(11.1%) 
0 0 
BE = Barium Enema, Endoscopy = flexible sigmoidoscopy or colonoscopy,  
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Table R3.3 Marital status of participants in per group.  
Social Support Placebo 
N=18 
Mesalazine 
N=14 
Withdrawn 
N=10 
Married or 
Living as married 
12 
(66.7%) 
11 
(78.6%) 
7 
(70%) 
Living with Friend 0 1 
(7.1%) 
0 
Divorced 2 
(11.1%) 
1 
(7.1%) 
1 
(10%) 
Widow 3 
(16.7%) 
1 
(7.1%) 
0 
Single 1 
(5.6%) 
0 2 
(20%) 
 
(a) Baseline Gastrointestinal symptoms 
Both gastrointestinal pain and bowel habit were assessed at baseline. Gastrointestinal pain was 
GLYLGHGLQWRµDWWDFNV¶RISDLQODVWLQJGD\RUORQJHUDQGRWKHUHSLVRGHVRISDLQRUGLVFRPIRUWWKDW
occurred during their normal bowel habit.  
 
(i) Pain > 24hrs duration 
A pie chart demonstrating the incidence of pain lasting greater than 24hrs per treatment arm and 
withdrawals is shown in Figure R3.4.   
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Figure R3.4 ,QFLGHQFH RI 3DLQ  KRXUV duration per treatment group over the last 12 months 
prior to recruitment into study.  
 
However although some of the participants answered that they did have pain lasting for >24 hours, 
they then answered further questions with estimates of their longest and typical attack of pain at 
values less than 24 hours. These results are shown in Table R3.4 and represented graphically in 
Figure R3.5. Figure 3.5B shows a biphasic distribution suggesting the while most patients with 
recurrent pain had short-lived pain some had bouts lasting several days suggesting a somewhat 
different mechanism. 
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Figure R3.5 Participants estimation of the duration of their (A) longest and (B) typical attacks of 
Pain. NB: In (A) 1 data point in the mesalazine group lies beyond the axis boundaries at 1440 hrs 
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Table R3.4 Participant Answers to questions on pain greater than 24 hours in duration.  
 Placebo 
 (A) 
Mesalazine 
 (B) 
Withdrawn 
 
P Value 
A vs. B 
Yes: Pain >24hrs: 
(%) 
16 
(88.9%) 
14 
(100%) 
9 
(90.0%) 
 
Est. pain >24hrs 
Longest Attack (%) 
10 
(55.6%) 
10 
(71.4%) 
7 
(70.0%) 
 
Est. pain >24hrs 
Typical (%) 
5 
(27.8%) 
8 
(57.1%) 
6 
(60.0%) 
 
All Longest Attack 
Median Duration 
(hrs) (Range) 
60 
(0.50-720) 
24 
(3.0-1440) 
120 
(3.0-8760) 
P=0.9834 
All Typical Attack 
Median Duration 
(hrs) (Range) 
3 
(0.08-144) 
15 
(0.17-120) 
72 
(2-8760) 
P=0.7067 
Est. = estimate 
Two subjects in the placebo and 1 in the withdrawal group did not experience pain >24 hours but 
did report shorter lived episodes. 
 
(ii) Pain with normal bowel habit 
7KHQXPEHURIGD\VSHUPRQWKRISDLQ WKDWRFFXUUHGZLWKRXWFKDQJHV WR WKHSDUWLFLSDQWV¶QRUPDO
bowel habits and the duration of that pain is shown in Table R3.5. Not all participants experienced 
pain as part of their normal bowel habit. However based on paUWLFLSDQWV¶ answers to questions on 
pain lasting longer than 24 hours as well as pain during normal bowel habit, all fulfilled the pain 
inclusion criteria for the study.  It is worth noting that the median duration of a typical attack in 
those withdrawing was 3 days suggesting that they may have had more severe symptoms. 
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Participants were also asked if they believed any dietary groups may influence their gastrointestinal 
symptoms, such as consuming fibre, fruit and vegetables or dairy foodstuffs. These are also shown 
in Table R3.5. 
 
Table R3.5 Participants reporting and their estimation of pain duration during episodes of normal 
bowel habit and their beliefs on exacerbating factors.  
 Placebo 
 (A) 
Mesalazine 
 (B) 
Withdrawn 
N=10 
P Value 
A vs. B 
Yes: Pain with 
normal bowel 
habit (%) 
15 11 8  
Median Pain 
days/mnth (IQR) 
16 
(4.0-30.0) 
7 
(4.0-30.0) 
18 
(5.3-30.0) 
n.s. 
Median Pain 
duration 
(hrs) (IQR) 
3 
(1.0-24.0) 
4.5 
(2.0-24.0) 
16 
(4.1-24.0) 
n.s. 
Affected by Bran 3 
(16.7%) 
3 
(21.4%) 
4 
(40.0%) n.s. 
Affected by Fruit 8 
(44.4%) 
9 
(64.3%) 
6 
(60.0%) n.s. 
Affected by Dairy 3 
(16.7%) 
6 
(42.9%) 
2 
(20.0%) n.s. 
 
The extent of which pain interfered with participants lives was indicated on the questionnaire by 
the number of participants who visited their GP or were admitted to hospital because of their 
gastrointestinal symptoms.  Participants also gave an estimate how many days they had to stay at 
home in bed over the last year. This information is presented in Table R3.6. 
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(iii) Bowel Habit 
Baseline bowel habit over the last year was assessed by questionnaire, with participants asked to 
estimate their bowel frequency and incidence of other symptoms per week (Table R3.7).  This was 
used to confirm prospectively collected stool diaries.  
 
Table R3.6 Hospital Admissions, GP Visits and Bed Days per study group.  
 Placebo 
 (A) 
Mesalazine 
 (B) 
Withdrawn 
N=10 
P Value 
A vs. B 
GP visits: Yes (%) 10 
(55.6%) 
9 
(64.3%) 
6 
(60%) 
n.s. 
Median Number of 
GP Visits (range) 
1 
(0-52) 
1 
(0-15) 
1 
(0-7) 
n.s. 
Hospital 
Admissions 
Yes (%) 
4 
(22.2%) 
6 
(42.9%) 
1 
(10%) 
n.s. 
Stay in bed (Home) 
(%) 
6 
(33.3%) 
9 
(64.3%) 
4 
(40%) 
P=0.1527 
Fisher exact 
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Table R3.7 Baseline bowel habits per study group over the last 12 months (retrospective) 
% affected 
(Median 
days/week)[Range] 
 
Placebo 
 
Mesalazine 
 
Withdrawn 
 
P Value 
Median BO/day 
(range) 
1.5 
(0.29-5.0) 
2 
(0.64-10.0) 
1.5 
(0.57-3.0) 
n.s. 
Loose Stools 
(number  per week) 
55.6% 
3 
(0-7) 
71.4% 
2.25 
(0-7) 
50% 
0 
(0-5) 
n.s. 
Hard Stools 
(number  per week) 
72.2% 
1 
(0-7) 
57.1% 
2 
(0-7) 
50% 
1 
(0-7) 
n.s. 
Strain 
(times per week) 
55.6% 
0.25 
(0-5) 
57.1% 
2 
(0-7) 
40% 
1 
(0-7) 
n.s. 
Urgency 
(times per week) 
44.4% 
0 
(0-7) 
50% 
0.5 
(0-7) 
20% 
0 
(0-5) 
n.s. 
Tenesmus 
(times per week) 
66.7% 
1.5 
(0-7) 
85.7% 
2.25 
(0-7) 
70% 
1 
(0-7) 
n.s. 
Incontinence 
(times per week) 
 
16.7% 
0 
(0-2) 
21.4% 
0 
(0-1) 
40% 
0 
(0-1) 
n.s. 
Mucus 
(times per week) 
16.7% 
0 
(0-3) 
42.9% 
0 
(0-7) 
60% 
0.25 
(0-7) 
n.s. 
Bloating 
(times per week) 
61.1% 
3 
(0-7) 
71.4% 
2.25 
(0-7) 
70% 
4.5 
(0-7) 
n.s. 
Blood  
(Number affected, %) 
3 
(16.7%) 
6 
(42.9%) 
2 
(20.0%) 
n.s. 
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3.4.4 Analysis Groups 
As mentioned previously, one participant in the mesalazine group stopped the medication 5 days 
prior to the end of the study. As it was only 5 days of continuous missed medication at the end of 
the study, we decided to include her data in the study up until visit 4. Her final biopsy sample was 
processed for RNA gene card but the data has not been included in the analysis as it is uncertain if 
5 days of missed medication would potentially influence changes in gene expression. One further 
participant in the mesalazine group also failed to complete their visit 5 diary prior to completing the 
study. In this case participant diary information up to visit 4 was included in the analysis. As the 
participant had continued medication until visit 5 all biological samples were used in the per-
protocol analysis.  
 
Thus 18 participants in the placebo and 13 participants in the mesalazine group were used in   
analysis of mechanistic endpoints. For Baseline characteristics and end point symptom assessment, 
18 participants in the placebo and 14 participants in the mesalazine group were included.  
 
3.4.5 Endpoints and Outcomes 
Mechanistic endpoints were achieved using the gene card to calculate the relative quantity. Four 
housekeeper genes were employed to be used in RQ calculation. These are genes to should remain 
unchanged by the interventions. However on statistical analysis of CT values for the house keepers, 
HPRT1 was significantly different between groups using one-way ANOVA (Kruskal-Wallis test) 
(p=0.0080). Paired t-test (Wilcoxon Signed-Rank Test) between baseline and final samples per 
treatment arm identified significant differences between the placebo (18S, p = 0.0009) or the 
mesalazine groups (RPLPO, p = 0.0266) in 2 further housekeeper genes which were excluded. 
Therefore all gene card RQ values were calculated using Beta-Actin (BA) as the housekeeper 
(Figure R3.6).  
 
Non-parametric test were used for all gene card statistical calculations due to the small sample size 
which reduced the confidence in assuming normal distribution of the data. Samples which were 
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greater than 3 standard deviations away from the mean were excluded. No genes became 
significant or not from these exclusions. 
 
Figure R3.6 Graph of CT value distribution of Housekeeper genes between study treatments arms. 
ANOVA using Kruskal-Wallis test 
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(a) Primary Endpoint 
The primary endpoint was the change in expression of galanin receptor 1 (GALR1) expression 
from baseline (pre) to final (post) visit due to mesalazine. No significant difference was identified 
(Table R3.8).  
 
Table R3.8 Relative Quantification of GALR1 RNA from sigmoid biopsies per study 
treatment arm.  
Gene Placebo Mesalazine 
 Pre 
N=17 
Post 
N=18 
 Pre 
N=14 
Post 
N=13 
 
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
GALR1 
 
2.253 
(1.61-2.65) 
1.916 
(0.88-3.29) 
0.4210 1.970 
(1.19-3.18) 
1.374 
(0.85-2.57) 
0.1465 
 
(b) Secondary Endpoints 
(i) RNA analysis 
The results have been organized to reflect the pathways of interest or linked genes on which the 
gene card was originally designed. Significant results have been highlighted in bold.  
 
a. Pain associated receptors and pathways 
Several other neurochemical transmitters, receptors and pathways, apart from GALR1, were 
analysed and shown below in Table R3.9.  
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Table R3.9 Gene Card analysis of sigmoid colonic samples at baseline and final visit per treatment 
arm ± Pain associated Receptors and Pathways. Wilcoxon Signed-Rank Test 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
GALR2 1.157 
(0.82-2.76) 
1.397 
(0.61-2.19) 
0.3165 1.375 
(0.99-2.62) 
1.522 
(1.07-2.04) 
0.7869 
Bradykinin Receptor 
BDKRB2 1.419 
(1.21-1.89) 
1.394 
(0.83-1.90) 
0.2066 1.182 
(0.83-2.01) 
0.7459 
(0.58-1.33) 
0.0046 
Endocannabinoid Signalling 
CNR2* 0.3523 
(0.27-0.47) 
0.3787 
(0.18-1.03) 
0.8498 0.5845 
(0.18-1.06) 
0.3249 
(0.22-0.49) 
0.1099 
MGLL 1.880 
(1.67-2.45) 
1.863 
(1.14-2.65) 
0.8961 1.530 
(1.13-3.64) 
1.038 
(0.75-1.94) 
0.0171 
NAPEPLD 1.805 
(1.40-2.33) 
1.624 
(0.96-2.30) 
0.0979 1.519 
(0.99-3.22) 
0.9221 
(0.66-1.31) 
0.0007 
Serotonin (5HT) Signalling 
HTR4 0.9756 
(0.83-1.51) 
1.263 
(0.79-1.76) 
0.5713 1.197 
(0.66-1.97) 
0.8621 
(0.69-1.57) 
0.4973 
SLC6A4 1.008 
(0.49-1.53) 
0.4318 
(0.19-0.88) 
0.0815 0.9134 
(0.73-1.53) 
0.5449 
(0.28-0.87) 
0.0681 
TPH1 1.532 
(0.94-2.59) 
1.314 
(1.02-1.97) 
0.2959 1.419 
(0.95-2.79) 
0.9606 
(0.74-1.71) 
0.0803 
* N is reduced to 17 for the placebo group.  
IQR is interquartile range. 
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Table R3.9 Continued. Gene Card analysis of sigmoid colonic samples at baseline and final visit 
per treatment arm ± Pain associated Receptors and Pathways. Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
Tachykinin Receptors 
TACR1 0.3457 
(0.22-0.64) 
0.4668 
(0.26-0.63) 
0.5713 0.6325 
(0.37-1.22) 
0.4254 
(0.29-0.81) 
0.3394 
TACR2 1.461 
(0.56-2.65) 
1.042 
(0.76-2.02) 
0.8498 1.833 
(0.96-2.17) 
2.113 
(1.17-2.69) 
0.6848 
Transient Receptor Potential Channels 
TRPA1 2.207 
(1.30-3.04) 
2.032 
(1.26-2.74) 
0.5700 2.108 
(1.64-2.94) 
1.402 
(0.82-1.76) 
0.0171 
TRPV1 1.346 
(1.09-1.94) 
1.368 
(0.94-1.90) 
0.5136 1.432 
(0.95-2.12) 
0.7200 
(0.58-1.60) 
0.0574 
TRPV4 0.8971 
(0.57-1.57) 
0.8188 
(0.47-1.27) 
0.3604 0.9204 
(0.58-1.53) 
0.7840 
(0.49-1.14) 
0.1677 
Nerve Growth Factor (NGF) Signalling 
NGF 2.106 
(0.77-3.41) 
1.519 
(0.80-3.21) 
0.8961 1.821 
(0.83-3.89) 
2.173 
(1.27-3.26) 
0.6355 
NGFR 0.5130 
(0.33-0.93) 
0.6019 
(0.41-0.90) 
1.0000 0.6593 
(0.40-1.02) 
0.4475 
(0.38-0.53) 
0.1677 
NTRK1 0.7232 
(0.31-1.21) 
0.9197 
(0.45-1.23) 
0.5713 0.6162 
(0.30-1.02) 
0.5893 
(0.30-0.97) 
0.7869 
*  N is reduced to 17 for the placebo group.  
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b. Arachidonic acid Pathway (Table R3.10) 
Table R3.10 Gene Card analysis of sigmoid colonic samples at baseline and final visit per 
treatment arm ± Arachidonic acid Pathways. Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
Lipoxygenases 
ALOX 12 0.5187 
(0.13-0.87) 
0.3285 
(0.13-0.99) 
1.0000 0.4619 
(0.06-0.96) 
0.1682 
(0.04-0.57) 
0.0479 
ALOX 5 0.7831 
(0.62-1.22) 
0.9174 
(0.53-1.37) 
0.9653 1.002 
(0.67-2.65) 
0.5747 
(0.50-0.92) 
0.0012 
ALOX 15 1.055 
(0.54-2.99) 
1.475 
(0.59-2.13) 
0.8276 0.9200 
(0.67-2.16) 
0.6000 
(0.50-1.08) 
0.2439 
ALOX15B 3.232 
(1.55-5.31) 
2.426 
(1.41-4.74) 
0.1169 4.002 
(2.19-7.01) 
2.757 
(2.18-3.91) 
0.0803 
ALOX5AP 0.9717 
(0.73-2.00) 
1.102 
(0.67-1.72) 
1.0000 1.164 
(0.84-1.71) 
0.8888 
(0.64-1.41) 
0.1099 
Leukotrienes 
LTA4H 1.816 
(1.04-3.06) 
2.289 
(1.72-3.51) 
0.6013 2.739 
(1.47-3.48) 
2.583 
(2.00-3.26) 
0.6355 
LTB4R 0.9183 
(0.78-1.50) 
0.8554 
(0.61-1.39) 
0.1507 0.8711 
(0.62-1.53) 
0.6859 
(0.50-1.37) 
0.2439 
LTC4S 1.297 
(0.80-1.78) 
1.340 
(0.80-1.58) 
0.7605 1.230 
(0.91-2.17) 
1.050 
(0.78-1.62) 
0.7869 
Phosphodiesterases 
PDE4B 0.6052 
(0.39-0.98) 
0.6496 
(0.39-0.74) 
0.4859 0.7303 
(0.50-1.05) 
0.4073 
(0.31-0.60) 
0.0034 
PDE4D 1.278 
(1.05-1.94) 
1.487 
(1.06-1.78) 
0.7605 1.402 
(1.03-1.89) 
1.452 
(0.93-1.87) 
0.7354 
*  N is reduced to 17 for the placebo group.  
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Table R3.10 Continued. Gene Card analysis of sigmoid colonic samples at baseline and final visit 
per treatment arm ± Arachidonic acid Pathways. Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
Prostaglandins 
PTGES2 0.9289 
(0.93-1.41) 
1.041 
(0.61-1.35) 
0.5713 1.220 
(0.73-2.05) 
0.5498 
(0.52-1.05) 
0.0017 
PTGES 0.8089 
(0.54-1.32) 
0.8915 
(0.57-1.34) 
0.4080 1.071 
(0.89-1.92) 
1.027 
(0.83-1.24) 
0.0803 
PTGS1 1.121 
(0.86-1.53) 
1.063 
(0.63-1.64) 
0.3165 1.035 
(0.86-1.97) 
0.8106 
(0.48-1.07) 
0.0005 
PTGS2 0.8578 
(0.53-1.25) 
0.7827 
(0.50-1.04) 
0.2763 0.8345 
(0.61-1.53) 
0.4170 
(0.30-0.71) 
0.0266 
PTGER1 1.210 
(0.71-1.74) 
1.135 
(0.67-2.06) 
0.5136 1.988 
(0.93-2.35) 
0.9720 
(0.72-1.35) 
0.0215 
PTGER3 1.158 
(0.51-1.79) 
0.9481 
(0.53-1.14) 
0.0674 1.129 
(0.82-2.18) 
1.107 
(0.54-1.87) 
0.7869 
Thromboxanes 
TBXA2R 1.212 
(0.88-1.92) 
1.154 
(0.80-1.69) 
0.3838 1.842 
(0.98-3.14) 
0.9917 
(0.74-2.00) 
0.1677 
TBXAS1 1.599 
(1.03-2.51) 
1.594 
(0.86-2.21) 
0.5136 1.643 
(0.99-2.71) 
0.9434 
(0.68-1.35) 
0.0002 
Others 
PLA2G2A 0.9765 
(0.42-1.52) 
0.9838 
(0.40-1.70) 
0.9653 0.7582 
(0.45-1.39) 
0.4604 
(0.31-0.98) 
0.0574 
EPHX2 1.711 
(1.12-2.09) 
1.708 
(1.12-2.67) 
0.8617 2.052 
(1.12-2.77) 
1.170 
(0.85-1.53) 
0.0574 
*  N is reduced to 17 for the placebo group.  
 
  
 172 
c. Cytokines, inflammatory mediators and cell migration markers (Table R3.11) 
Table R3.11 Gene Card analysis of sigmoid colonic samples at baseline and final visit per 
treatment arm ± Inflammation and cell migration pathways. Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
Interleukin 1 family 
IL1B 0.7416 
(0.47-1.40) 
1.092 
(0.37-1.49) 
0.2575 0.9633 
(0.37-1.96) 
0.6220 
(0.37-1.01) 
0.0024 
IL1RN 1.245 
(0.50-2.14) 
0.9245 
(0.42-1.86) 
0.2397 1.125 
(0.77-1.59) 
0.6921 
(0.55-0.98) 
0.0024 
Tumour Necrosis Factor Family 
TNF* 0.6611 
(0.47-1.05) 
0.6341 
(0.34-1.15) 
0.2977 0.9170 
(0.61-1.40) 
0.4435 
(0.36-0.69) 
0.0034 
TNFSF10A 1.266 
(1.00-2.30) 
1.650 
(0.72-2.28) 
0.7939 1.571 
(0.96-2.74) 
0.8645 
(0.72-1.51) 
0.0012 
TNFSF10 1.166 
(0.94-1.39) 
1.315 
(0.70-1.59) 
0.6319 1.119 
(0.70-1.61) 
0.7356 
(0.50-1.09) 
0.0024 
TNFSF15 1.258 
(1.05-2.01) 
1.195 
(0.61-1.87) 
0.4080 1.656 
(1.03-2.73) 
0.6662 
(0.45-1.44) 
0.0017 
Transforming Growth Factor Beta Family 
TGFB1 1.086 
(0.71-1.92) 
1.277 
(0.75-1.65) 
0.8617 1.274 
(0.78-2.09) 
0.7495 
(0.60-1.37) 
0.0081 
TGFBR1 1.364 
(0.97-2.01) 
1.308 
(0.99-1.77) 
0.2959 1.514 
(0.91-2.43) 
0.8380 
(0.64-1.51) 
0.0081 
TGFBR2 1.237 
(0.93-1.67) 
1.444 
(1.02-1.71) 
0.9653 1.452 
(0.77-2.06) 
0.7351 
(0.61-1.31) 
0.0046 
*  N is reduced to 17 for the Placebo Group. ++ N is reduced to 11 in the Mesalazine Group 
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Table R3.11 Continued. Gene Card analysis of sigmoid colonic samples at baseline and final visit 
per treatment arm ± Inflammation and cell migration pathways. Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
Interferon gamma 
INFG* 0.2105 
(0.11-0.55) 
0.1692 
(0.07-0.33) 
0.8129 0.2109 
(0.12-0.37) 
0.1638 
(0.14-0.30) 
0.2734 
Interleukins 
IL2 1.223 
(0.59-2.07) 
1.620 
(0.59-2.27) 
0.5421 1.418 
(0.65-2.18) 
0.7911 
(0.49-2.01) 
0.1272 
IL6 0.3339 
(0.16-0.84) 
0.3988 
(0.16-1.01) 
0.5136 0.3791 
(0.19-0.87) 
0.2646 
(0.20-0.62) 
0.4548 
IL8* 0.4706 
(0.33-0.77) 
0.4880 
(0.34-0.66) 
0.4548 0.7753 
(0.55-1.32) 
0.4836 
(0.23-1.11) 
0.3757 
IL10 1.114 
(0.50-1.82) 
1.124 
(0.74-1.62) 
0.8961 1.095 
(0.72-1.60) 
0.6988 
(0.52-1.22) 
0.4143 
IL17A* 0.5148 
(0.25-1.08) 
0.3299 
(0.12-0.65) 
0.2763 0.6033 
(0.05-0.99) 
0.3640 
(0.07-0.76) 
0.8394 
IL23A 0.3503 
(0.28-0.46) 
0.3600 
(0.20-0.56) 
0.7605 0.5219 
(0.36-0.74) 
0.3061 
(0.21-0.75) 
0.4143 
*  N is reduced to 17 for the Placebo Group. ++ N is reduced to 11 in the Mesalazine Group 
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Table R3.11 Continued. Gene Card analysis of sigmoid colonic samples at baseline and final visit 
per treatment arm ± Inflammation and cell migration pathways. Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
Chemokines and receptors 
CMKLR1 1.531 
(0.92-2.15) 
1.521 
(0.67-2.07) 
0.4331 1.732 
(0.99-2.10) 
0.8651 
(0.61-1.32) 
0.0046 
MCL1 1.749 
(1.31-2.82) 
2.100 
(1.18-2.59) 
0.7939 2.146 
(1.09-2.93) 
0.9454 
(0.74-1.91) 
0.0081 
CCL11 3.490 
(0.65-7.00) 
2.614 
(1.36-6.27) 
0.8276 1.555 
(1.28-5.16) 
1.999 
(1.45-3.55) 
0.6848 
CCL2 1.403 
(0.73-2.35) 
1.581 
(1.14-1.99) 
0.5136 1.415 
(0.94-1.98) 
1.026 
(0.80-1.72) 
0.9460 
KITLG 1.289 
(0.90-2.36) 
1.541 
(1.18-1.73) 
0.9653 1.422 
(0.95-2.15) 
0.9693 
(0.64-1.52) 
0.1465 
Call migration Receptors and Ligands 
MADCAM1 0.9788 
(0.69-1.45) 
1.198 
(0.57-2.09) 
0.4859 1.103 
(0.83-2.12) 
0.8550 
(0.59-1.64) 
0.0215 
 
VCAM1* 0.5868 
(0.50-1.45) 
0.8385 
(0.52-1.09) 
0.7764 0.9736 
(0.55-1.35) 
0.4717 
(0.35-0.76) 
0.0012 
SELE*,++ 0.8699 
(0.45-1.41) 
0.5690 
(0.25-1.96) 
0.8871 0.6249 
(0.25-1.16) 
0.4383 
(0.17-1.30) 
0.8984 
ICAM1 0.4206 
(0.34-0.64) 
0.4536 
(0.27-0.83) 
0.5136 0.5373 
(0.29-0.81) 
0.5468 
(0.30-0.65) 
0.5879 
*  N is reduced to 17 for the Placebo Group. ++ N is reduced to 11 in the Mesalazine Group 
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d. Pattern recognition receptors Table R3.12) 
Table R3.12 Gene Card analysis of sigmoid colonic samples at baseline and final visit per 
treatment arm ± Toll-Like Receptor (TLR) Pathways. Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
TLR2 1.202 
(0.62-1.66) 
1.051 
(0.63-1.94) 
1.0000 1.170 
(0.74-1.98) 
0.7130 
(0.60-1.14) 
0.0327 
TLR4 1.377 
(0.94-2.49) 
1.465 
(1.05-1.94) 
0.3604 1.537 
(1.01-1.96) 
0.8932 
(0.70-1.52) 
0.0479 
TLR5 1.255 
(0.78-2.11) 
1.278 
(0.80-1.70) 
0.8961 1.413 
(0.94-2.25) 
0.9781 
(0.69-1.56) 
0.0574 
TLR7 1.120 
(0.70-1.73) 
1.096 
(0.73-1.31) 
0.3604 1.306 
(.99-1.78) 
0.8202 
(0.66-1.19) 
0.0266 
TLR8 1.064 
(0.61-1.67) 
0.9126 
(0.48-1.30) 
0.2227 1.803 
(1.01-2.18) 
0.7961 
(0.46-1.76) 
0.0398 
TLR9* 0.4506 
(0.34-0.73) 
0.5264 
(0.30-0.68) 
0.4488 0.7991 
(0.39-1.17) 
0.4976 
(0.32-0.64) 
0.0215 
MYD88 1.765 
(1.51-2.66) 
1.678 
(1.22-2.44) 
0.6013 1.780 
(1.15-2.99) 
1.134 
(0.90-1.76) 
0.0105 
TOLLIP 1.754 
(1.48-2.44) 
2.100 
(1.26-2.41) 
0.9306 2.073 
(1.08-3.15) 
1.278 
(0.93-1.88) 
0.0803 
NOD2 0.8938 
(0.76-1.57) 
1.021 
(0.60-1.55) 
0.6632 1.359 
(0.79-1.96) 
0.5925 
(0.40-0.94) 
0.0002 
*  N is reduced to 17 for the placebo group.  
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e. Tight junctions, Cytoskeleton and Extracellular matrix (Table R.2.13) 
Table R3.13 Gene Card analysis of sigmoid colonic samples at baseline and final visit per 
treatment arm ± Tight junctions, cytoskeleton and extracellular matrix pathways.  
Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
CLDN2* 1.232 
(1.04-2.26) 
1.466 
(0.85-2.09) 
0.2366 1.589 
(0.93-2.94) 
0.7469 
(0.55-1.52) 
0.0266 
MUC1 1.070 
(0.90-1.75) 
1.064 
(0.60-1.43) 
0.2763 1.043 
(0.72-2.17) 
0.7260 
(0.35-1.23) 
0.0105 
MUC3A:3B 0.9571 
(0.85-1.58) 
1.182 
(0.50-1.55) 
0.6013 0.8763 
(0.64-1.86) 
0.6878 
(0.20-1.29) 
0.0327 
Tight Junction Proteins 
TJP1 1.803 
(1.26-2.62) 
1.622 
(1.04-2.15) 
0.0210 1.427 
(0.94-2.54) 
0.9285 
(0.61-1.64) 
0.0017 
TJP2 1.753 
(1.62-2.49) 
2.270 
(1.28-2.69) 
0.5421 1.958 
(1.07-3.47) 
1.310 
(0.81-1.74) 
0.0681 
Matrix Metalloproteinases 
MMP2 1.303 
(0.82-1.57) 
1.367 
(0.84-1.85) 
0.7605 1.352 
(0.71-1.90) 
0.7690 
(0.49-1.33) 
0.8961 
MMP9 0.3518 
(0.29-0.52) 
0.3347 
(0.16-1.18) 
0.9653 0.4848 
(0.27-1.04) 
0.5800 
(0.33-0.73) 
0.4973 
*  N is reduced to 17 for the placebo group.   
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f. Other Pain Related Genes (Table R3.14) 
Table R3.14 Gene Card analysis of sigmoid colonic samples at baseline and final visit per 
treatment arm.. Wilcoxon Signed-Rank Test. 
Gene Placebo Mesalazine 
 Pre Post  Pre Post  
 Median 
(IQR) 
Median 
(IQR) 
P value Median 
(IQR) 
Median 
(IQR) 
P value 
F2RL1(PAR2 
receptor) 
1.841 
(1.40-2.34) 
1.571 
(1.20-2.08) 
0.4080 1.944 
(1.49-3.37) 
1.056 
(0.77-1.25) 
0.0007 
FPR2* 0.3096 
(0.21-0.88) 
0.4003 
(0.21-0.54) 
0.6701 0.6899 
(0.38-0.86) 
0.2195 
(0.13-0.50) 
0.0081 
PPARG 2.130 
(1.66-3.25) 
1.946 
(1.23-2.55) 
0.0553 1.692 
(1.17-3.24) 
1.068 
(0.83-1.86) 
0.0061 
SOD1 1.234 
(0.83-1.68) 
1.258 
(0.82-1.80) 
0.7939 1.238 
(0.72-1.88) 
0.8718 
(0.70-1.38) 
0.0171 
NOS2* 1.068 
(0.71-1.43) 
0.8621 
(0.58-1.10) 
0.1183 0.9210 
(0.48-1.69) 
0.6364 
(0.42-0.83) 
0.0479 
CYP2J2 1.650 
(1.07-2.14) 
1.436 
(1.05-1.95) 
0.8276 1.665 
(1.00-2.38) 
1.152 
(0.74-1.63) 
0.0942 
*  N is reduced to 17 for the placebo group.   
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(ii) Histology 
Coefficients of variation were calculated per stain used prior to further histological assessment 
(Table R3.15).  
 
Table R3.15 Variation of Coefficients and reproducibility per immunohistochemistry antibody. 
Stain Number of 
samples assessed 
Number of Areas 
per sample 
Mean Coefficient 
of variance 
Reproducibility 
(%) 
5HT 5 10 0.0223 97.8 
CD3 
Epith 
3 10 0.027 97.3 
CD3 LP 3 10 0.053 94.7 
CD68 4 10 0.062 93.8 
KI67 
SUPF 
3 10 0.078 92.2 
KI67 
DEEP 
3 10 0.057 94.3 
 
 
 Changes within the epithelium (Epith.), lamina and superficial (S/crypt) and deep (D/crypt) crypt 
mucosa are shown in Table R3.16. One sample from the baseline placebo group was lost and not 
processed. Two samples from the Mesalazine baseline group contained minimal tissue present and 
could not be assessed except for CD68 and CD3. Other sample losses were due to artefacts such as 
folding of the sample.   
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Table R3.16 Histological results of sigmoid biopsies from each arm of the study at baseline (Pre) 
and Final visit (Post). Wilcoxon Signed-Rank Test. 
Stain Placebo (A) Mesalazine (B) 
 Pre Post  Pre Post  
 Median 
(cells/mm2) 
(IQR) 
Median 
(cells/mm2) 
(IQR) 
P 
value 
Median 
(cells/mm2) 
(IQR) 
Median 
(cells/mm2) 
(IQR) 
P 
value 
CD3 
Epith. 
N=17 
511.4 
(363.0-610.9) 
N=17 
374.9 
(224.2-576.6) 
 
n.s 
N=14 
351.8 
(247.3-540.0) 
N=13 
397.9 
(288.0-609.0) 
 
n.s. 
CD3 
Lamina. 
1275 
(893.3-1465) 
1030 
(828.5-1444) 
n.s 1037 
(843.4-1406) 
1051 
(753.6-1621) 
n.s. 
CD68 N=17 
1665 
(1484-1806) 
N=17 
1631 
(1316-1854) 
 
n.s. 
N=14 
1703 
(1384-1942) 
N=13 
1744 
(1463-2118) 
n.s. 
KI67 
S/crypt 
N=17 
79.1 
(56.2-246.1) 
N=17 
98.0 
(0.0-202.5) 
 
n.s. 
N=12 
60.3 
(0-199.4) 
N=13 
65.3 
(0-148.2) 
 
n.s. 
KI67  
D/crypt 
2297 
(1757-3156) 
1913 
(1349-2910) 
n.s. 1817 
(1585-2427) 
2091 
(1409-2970) 
n.s. 
5HT  
S/crypt 
N=17 
104.2 
(64.7-165.3) 
N=16 
92.2 
(77.7-112.3) 
 
n.s. 
N=12 
103.7 
(61.4-139.2) 
N=13 
86.96 
(61.4-139.2) 
 
n.s 
5HT  
D/crypt 
277.8 
(220.6-367.2) 
342.7 
(212.0-397.4) 
n.s. 346.8 
(298.3-484.1) 
392.2 
(264.8-555.3) 
n.s. 
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(iii) Faecal Calprotectin 
One of the mesalazine final visit samples was inadequate and not processed.  Results are shown in 
table R3.17.  
 
(iv) Super sensitive CRP 
1 sample form the mesalazine group was excluded from analysis as the value was greater than 20 at 
both baseline and follow up visits. It is not certain why the CRP was consistently raised, but may 
be due to upper respiratory tract infections (Baseline) and/or urinary problems (Visit 4) that the 
participant disclosed during the study.  Results are shown in table R3.18 
 
Table R3.17 Results of Faecal Calprotectin ELIZA analysis of samples from each arm of the study 
at baseline (Pre) and Final visit (Post). Wilcoxon Signed-Rank Test. 
 Placebo (A) Mesalazine (B) 
 Pre 
N=18 
Post 
N=18 
 Pre 
N=14 
Post 
N=13 
 
 Median 
(mg/kg) 
(IQR) 
Median 
(mg/kg) 
(IQR) 
P 
value 
Median 
(mg/kg) 
(IQR) 
Median 
(mg/kg) 
(IQR) 
P 
value 
Calprotectin 15.60 
(15.60-
40.83) 
15.60 
(15.60-
21.80) 
0.2324 30.67 
(15.60-
62.80) 
31.98 
(15.60-
62.38) 
0.3750 
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Table R3.18 Results of Super sensitive C reactive protein (SS-CRP) analysis of samples from each 
arm of the study at baseline (Pre) and Final visit (Post). Wilcoxon Signed-Rank Test. 
 Placebo (A) Mesalazine (B) 
 Pre 
N=18 
Post  
N=18 
 Pre  
N=13 
Post 
N=13 
 
 Median 
(mg/l)  
(IQR) 
Median 
(mg/l)  
(IQR) 
P value Median 
(mg/l)  
(IQR) 
Median 
(mg/l)  
(IQR) 
P value 
SS-
CRP 
1.13 
(0.56-2.87) 
1.78 
(0.72-4.01) 
0.7939 1.780 
(0.50-3.69) 
1.81 
(0.89-5.40) 
0.2036 
 
(v) Liquid Chromatography and Mass Spectroscopy (LCMS) 
The results for LCMS are shown in table R3.19. Due to small sample size, 2 rectal and 1 sigmoid 
samples were combined to maximise detection of different arachidonic acid pathway components. 
Only arachidonic acid (AA), prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), 12-
hydroxyeicosatetraenoic acid (12-HETE), linoleic acid (LA), thromboxane-B2 (TXB2), 
arachidonoyl ethanolamide (AEA), 2-arachidonoyl glycerol (2-AG), N-palmitoyl ethanolamide 
(PEA), N-oleoyl ethanolamide (OEA) and leukotriene-E4 (LTE4) were detectable.  As detection 
was difficult, the number of samples (N) that were detected and used in analysis is given for each 
result in table R3.19. 
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Table R3.19 Results of LCMS analysis of samples from each arm of the study at baseline (Pre) 
and Final visit (Post). Wilcoxon Signed-Rank Test. 
 Placebo (A) Mesalazine (B) 
 Pre Post   Pre  Post  
 Median 
(pmol/ml)  
(IQR) 
Median 
(pmol/ml) 
(IQR) 
P value Median 
(pmol/ml) 
(IQR) 
Median 
(pmol/ml) 
(IQR) 
P 
value 
AA N=12 
9.50 
(7.6-20.8) 
N=12 
15.60 
(10.2-23.6) 
0.7695 N=11 
10.80 
(9.3-26.8) 
N=11 
10.20 
(9.5-36.4) 
0.9658 
PGE2 N=13 
3.90 
(2.4 ± 12.4) 
N=14 
6.95 
(3.5 ± 9.3) 
1.000 N=11 
6.70 
(3.4 ± 9.0) 
N=10 
4.60 
(2.5 - 8.8) 
0.6250 
PGD2 N=13 
3.77 
(2.4-12.2) 
N=14 
7.02 
(3.9-9.2) 
0.9097 N=11 
7.01 
(3.4-9.0) 
N=11 
4.37 
(2.4-8.7) 
0.4648 
2AG N=14 
183.4 
(120.8±419.0) 
N=15 
205.1 
(165.8-331.5) 
0.7148 N=11 
270.9 
(142.8-327.9) 
N=10 
204.4 
(102.0-325.3) 
0.6250  
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Table R3.19 continued. Results of LCMS analysis of samples from each arm of the study at 
baseline (Pre) and Final visit (Post). Wilcoxon Signed-Rank Test. 
 Placebo (A) Mesalazine (B) 
 Pre Post   Pre  Post  
 Median 
(pmol/ml)  
(IQR) 
Median 
(pmol/ml) 
(IQR) 
P value Median 
(pmol/ml) 
(IQR) 
Median 
(pmol/ml) 
(IQR) 
P 
value 
TXB2 N=13 
2.40 
(1.20-3.8) 
N=14 
3.40 
(2.1-4.7) 
0.2661 N=11 
2.7 
(2.0-3.9) 
N=10 
2.8 
(1.3-5.0) 
0.7695 
LTE4 N=13 
78.00 
(49.5-177.0) 
N=14 
148.5 
(100.5-430.5) 
0.1294 N=11 
73.00 
(66.0-156.0) 
N=11 
109.0 
(55.0-207.0) 
0.4648 
AEA N =14 
28.50 
(23.7 - 50.1) 
N =14 
40.55 
(23.2 - 60.7) 
0.2634 N=11 
39.20 
(24.3 - 53.6) 
N=9 
29.00 
(25.2 - 46.1) 
0.9102 
OEA N=14 
9.85 
(3.1 - 33.0) 
N=14 
13.40 
(7.8 - 38.2) 
0.1099 N=11 
6.40 
(3.8 ± 19.8) 
N=9 
10.90 
(3.4 ± 34.8) 
0.1289 
PEA N=15 
5.00 
(2.8 ± 15.7) 
N=14 
5.55 
(2.4 ± 17.3) 
0.6257 N=10 
3.30 
(1.3 ± 7.0) 
N=10 
4.50 
(1.7 - 11.6) 
0.4961 
LA N=13 
77.60 
(61.0-318.5) 
N=13 
260.2 
(123.1-347.5) 
0.1016 N=11 
126.7 
(96.4-182.5) 
N=11 
135.1 
(103.8-332.9) 
0.5771 
5-HETE N=14 
24.45 
(19.0-56.7) 
N=14 
33.80 
(8.5-57.8) 
0.5879 N=11 
32.20 
(25.6-53.9) 
N=10 
24.65 
(5.8-86.9) 
0.7695 
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(vi) Participant Symptoms 
Participant symptoms were calculated from diary sheet prospectively collected during the study 
period. Median values were calculated from scores given between 0 and 10.  Two participants in 
Mesalazine Group did not complete visit 5 diary and values for visit 4 used instead (IXZ024 and 
RWP033). Some participants did not report bloating as a normal symptom. Therefore results on 
those who complained of bloating initially as well as bloating for all subjects have been reported. 
The difference between the baseline and final (Visit 5) scores are presented in table R3.20. The 
median pain duration per day (shown as VAS on 0-10 scale) per study group is shown graphical in 
figure R3.7. 
 
Figure R3.7 Median pain duration per day per group occurring during the trial.  
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Table R3.20 Changes in participant gastrointestinal symptoms from diary sheets at baseline (Pre) 
and final visit (Post). Wilcoxon Signed-Rank Test. 
Gene Placebo  Mesalazine  
 Pre 
N=18 
Post 
N=18 
Wilcoxon Pre 
N=14 
Post 
N=14 
Wilcoxon 
 Median 
Score 
(Range) 
Median 
Score 
(Range) 
P value Median 
Score 
(Range) 
Median 
Score 
(Range) 
P value 
Pain 
Intensity 
4.0 
(0-6) 
2.5 
(0-6) 
0.5979 2.0 
(0-6) 
0 
(0-6) 
0.1366 
Pain 
Duration 
1.0 
(0-5) 
0.65 
(0-4) 
0.1919 0.75 
(0-20) 
0.125 
(0-5.5) 
0.0413 
Stool 
Frequency 
2.0 
(0-3.5) 
2.0 
(1-4) 
0.7393 2.0 
(1-8) 
2.0 
(1-8) 
0.5236 
Stool 
Consistency 
4.0 
(3-6) 
4.0 
(1-6) 
0.4729 3.975 
(2-6.5) 
3.750 
(2-5) 
0.1452 
All Bloating 4.0 
(0-6) 
2.5 
(0-10) 
0.6617 1.5 
(0-8) 
1.5 
(0-8) 
0.5065 
Reported 
Bloating 
N=11 
5 
(2-6) 
N=12 
4.5 
(0-10) 
0.4154 N=9 
5 
(0.5-8) 
N=9 
3 
(0-8) 
0.1604 
General 
Wellbeing 
7.0 
(5-10) 
7.0 
(4-10) 
1.00 6.75 
(1.5-10) 
8.0 
(3-10) 
0.5474 
Pain etc. 0 = none 10 = severe; General well being 0 = unwell, 10 = excellent 
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(vii) Participant Beliefs 
At each visit participants were asked if they had relief or not from their diverticular symptoms 
during the last 2 or 4 weeks. Figure 3.8 demonstrates the percentage of participants who indicated 
they did have relief per group.   
 
Figure 3.8 Percentage of participants who had relief from symptoms per visit per study treatment 
arm.  
 
 
NB: Placebo N= 18, Mesalazine N=14 except visit 5, where data from the participant who ceased 
medication early was not included (N=13). 
 
At the end of the study, without breaking the blinding of participants or researchers, the participant 
was asked if they thought they were taking the Mesalazine or the placebo during the study. These 
results are presented graphically in figure R3.9. Fisher exact test (Taking Mesalazine vs. Taking 
placebo) demonstrated a p value 0.0914. 
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Participants were also asked whether they would continue to take the medication if offered.  This 
data is represented in figure R3.10 and was not statistically significant.  
 
Figure R3.9 Graphical UHSUHVHQWDWLRQRISDUWLFLSDQWV¶EHOLHIVDERXWWKHVWXG\PHGLFDWLRQWKH\ZHUH
taking during the trial. 
  
 
Figure R3.10 Graphical representation of the percentage of participants wanting to continue the 
study medication they were taking beyond the duration of the trial.  
 
 
  
 188 
3.4.6 Complications and side effects 
Out of all participants who entered the study 14 subjects (N=19, 73.7%) in the placebo and 16 
subjects (N=20, 80%) in the mesalazine group reported new symptoms during the study. The 
majority of these were unrelated to the study. In the mesalazine group 5 subjects were thought to 
have side effects from the mesalazine medication (N=20, 25%). Four participants developed 
increasing abdominal pain which necessitated withdrawal from the study and were discussed 
above. A further participant developed diarrhoea with mesalazine. The participant had relief of 
other symptoms from the study and was keen to stay within the trial. Therefore the dose of the 
medication was reduced from 3g to 1g during the last 4 weeks of the study with good effect.   
 
Important to note is 1 participant in the mesalazine arm of the study who reported abdominal pain 
and raised temperatures, consistent with an episode of acute diverticulitis. The participant consulted 
their own GP and was prescribed a 5 day course of metronidazole and cephalexin, which resolved 
the pain. The participant did not contact the research team during these events, and there was no 
imaging or biological samples to confirm the diagnosis. However the participant did continued her 
medication throughout this period. Other symptoms reported by participants in the study are shown 
in table R3.21 and are similar between groups.  
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Table R3.21 Reported new symptoms during the study period by group.  
Symptoms attributed to mesalazine medication are shown in italics 
Symptoms Placebo Group Mesalazine Group 
Gastrointestinal Diarrhoea and Vomiting illness*2 
New Abdominal Pain *3 
        e.g.  upper or right sided  
Diarrhoea  
Constipation *3 
Nausea 
Perianal pain 
Reflux  
Diarrhoea and Vomiting illness 
New Abdominal Pain *5 
 
Diarrhoea  
Respiratory tract ,QIHFWLRQHJµ&KHVWLQIHFWLRQ¶ 
Flu like Illness 
Infection e.g. Sinusitis,  
Flu like Illness 
Neurological  
and 
Musculoskeletal 
Headaches *2 
Leg Cramps  
Dizziness 
Myalgia 
Headaches *2 
Leg Cramps  
Dizziness 
µ7LQJOLQJ¶LQOHJV 
Genitourinary  Haematuria  
UTI 
Other Bruising 
Breast discomfort 
Dental abscess 
Palpitations 
Hot Sweats 
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3.5 Discussion 
 
3.5.1 Synopsis of the key findings 
This pilot study was designed to look at the mechanistic effects of mesalazine in SDD. The study 
was not powered to identify efficacy of mesalazine in improving patient symptoms or for 
performing an intention to treat analysis.  Although the sample size is small, this study has 
demonstrated some marked gene changes within the mesalazine but not the placebo groups.  
Interestingly these are all located within gene families or pathways which support the anti-
inflammatory effects of mesalazine. These mechanisms of mesalazine have become of increasing 
interest recently, especially its anti-cancer activities577 and may contribute to its effects in visceral 
pain reported in other open labeled studies562, 566-569, 578.  
  
3.5.2 Comparison with relevant findings from other published  
(A) Gene card results 
(a) Pain associated receptors and pathways 
There have not been any previous studies which have identified neurochemical and/or receptor 
changes that occur with mesalazine. Galanin and galanin receptor 1 (GALR1) expression have 
previously been shown to be increase in animal models of visceral pain and in patients with 
symptomatic diverticular disease80, 300. It was from this work that we chose changes in Galanin 
receptor 1 as our primary end point for the study. However these studies were in patients with 
diverticulitis, and these findings have not reached significance in further studies of SDD by our 
group491. This may be why no significant difference in GALR1 and GALR2 was found in the 
mesalazine group between the first and final visit (Table R3.8 and 3.9).  GALR1 is expressed on 
smooth muscle and colonic epithelial cells as well as nerves, and is thought to be important in fluid 
secretion and motility579. It can also be up-regulated by NFkB activation and down-regulated by 
NFkB inhibitors, such as dexamethasome579. The GALRs detected in our study will be from 
epithelial cell expression rather than nerves, where the associated mRNA transcripts are found 
within the dorsal horn cell bodies and not the mucosa. As galanin and GALR1 anti-human 
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antibodies are unreliable, it is difficult to assess any nerve associated galanin changes in our 
study491. 
 
(i) Tachykinins 
Tachykinin receptors are found in the enteric nervous system, smooth muscle, epithelium and 
immune cells580. Our previous studies showed Substance P80  and its receptors, TACR1 and 
TACR2104 are up-regulated in SDD and animal models of colitis80, 300, 491. They are also thought to 
have a role in IBS, with TACR1 antagonists improving mood and pain ratings and emotional 
arousal circuits on fMRI imaging581. However no studies have investigated the effect of 
mesalazine. In our study Mesalazine did not appear to alter their expression. This may be because 
mRNA from the enteric and afferent nervous system would not have been included in our biopsies 
and changes in neuronal expression would not have been identified. Unfortunately TACR1 
antibodies are unreliable and it was not possible to examine changes in neuronal expression in our 
study491. 
 
(ii) Bradykinin Receptors 
Bradykinin is an inflammatory mediator in the gastrointestinal system and Bradykinin receptor B2 
(BDKRB2) has been identified on submucosal ganglia in the distal rat colon582. These receptors are 
up-regulated in animal models of colitis583 but their expression in DD and IBS has not been 
assessed. In our study, BDKRB2 was significantly decreased compared to other nociceptive 
receptors (Table R3.8 and 3.9). No other studies have assessed the effect of 5-ASA on the 
Kallikrein-kinin system, but a decrease in BDKRB2 would support the anti-inflammatory effects 
associated with Mesalazine. BDKRB2 have also been shown to be up-regulated by pseudomonas 
aeruginosa inflammation via an NFkB pathway584 and act via NFkB to increase IL6 expression in 
synovial fibroblasts585. Also in cultured human coronary artery cells, BDKRB2 expression was 
down-regulated with decreased cell proliferation586. As Mesalazine has been shown to decrease 
cellular proliferation535, 544, 587 and inhibit NFkB activity530, these mechanisms could be involved in 
the decrease in BDKRB2 we observed.  
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(iii) Transient Receptor Potential receptors 
Although TRPA1 is commonly associated with gastrointestinal motility and pain, it also influences 
anion secretion588, 589.  In our study TRPA1 was significantly decreased from visit 1 to 5 while the 
change in TRPV1 was of borderline significance (p0.0574, Table R3.9) in the mesalazine group. 
TRPV1 and TRPA1 on nerves fibres have been implicated in pain in human gastrointestinal 
conditions590-592, and are up-regulated in experimental animal models of inflammation588, 589, 593, 594. 
However it is unlikely that the change in mRNA in our study is due to changes in expression on 
gastrointestinal nerves as the mRNA that produces these receptors comes from the nerve cell body 
located in the dorsal root ganglion. As well as unmyelinated enteric nerves, TRPV1 and A1 are 
expressed as chemo receptors in epithelial and enterochromaffin cells and smooth muscle layers594. 
Therefore the mRNA changes must be due to alteration of TRPV1 and TRPA1 in immune and 
epithelial cells. This and any altered expression on nerve terminals would need to be confirmed 
with immune-fluorescence methods. Unfortunately reliable commercially available anti-human 
antibodies for TRPV1 and TRPA1 are limited. 
 
The effects of mesalazine on TRPV1 and TRPA1 have not previously been reported but their 
decreased mRNA does support the known anti-inflammatory and potential anti-nociceptive   
activity of mesalazine.  The reduction in TRPV1 and TRPA1 mRNA expression may be either as a 
direct action of mesalazine or through by downstream effects from other mesalazine affected genes. 
There are many genes which could be involved as TRPV1 and TRPA1 can be sensitised by 
bradykinin and tryptases via PAR2595, 596 and have been linked to endocannabinoids and serotonin 
pathway597. 
 
(iv) Endocannabinoids 
The endocannabinoid system is thought to be important in gastrointestinal inflammation and pain 
processing, by interaction with TRP, PPARalpha and other receptors598. Endocannabinoid receptors 
are found in epithelium, submucosa and muscle as well as the enteric nervous system598, 599. There 
are many enzymes involved in the manufacture and elimination of endocannabinoids such as, 
 193 
MGLL (monoglyceride lipase) which acts to hydrolase 2-AG and NAPE-PLD which is important 
in the creation of anadamide598.  
 
Endocannabinoid receptor agonists have previously been shown to inhibit contractions in colonic 
muscle strips from controls to a greater extent than strips from DD patients88. A potential 
endogenous endocannabinoid, anandamide, has also been found at increased levels in DD 
compared to controls88. Increased expression of CBR2 in SDD compared to ADD has also been 
identified491. Endocannabinoids may also have a role in other gastrointestinal conditions as 
different alleles of FAAH enzyme (C385A), which is the rate limiting step in anandamide 
metabolism, is associated with D-IBS600. Treatment of diarrhoea in D-IBS by endocannabinoid 
receptor agonist dronabinol, have also shown to be influence by different SNPs of endocannabinoid 
receptor 1 (CNR1)601, 602.  The endocannabinoid system has also been implicated in UC, with 
expression of key enzymes and receptors in the mucosa, submucosa, muscle and enteric plexus 
changing with severity of inflammation599.  
 
In our study expression of CBR2 was not altered in the mesalazine group, but there was a 
significant decrease in MGLL and NAPE-PLD. This is in contrast to a study of treated UC patients 
which found an association between 5-ASA and increased expression of MGLL and CBR2599. 
However in this study most subjects included were treated with steroids or other 
immunomodulators as well as 5-ASA. This along with the different disease process underlying UC 
makes interpretation of their results and comparison with our study difficult.  In other studies in 
UC, increased anandamide levels, but not 2-$*KDYHEHHQIRXQGLQXQWUHDWHG8&SDWLHQWV¶PXFRVD
and animal models of colitis treated with 5-ASA using LC-MS603. However gene changes were not 
assessed. The finding in 2-AG in this study supports our LC-MS analysis, where no difference in 2-
AG was found between groups. However we did not see a change in anandamide (AEA). This may 
be again due to the different disease process and use of cell lines. Also, although we have 
demonstrated a reduction in MGLL and NAPE-PLD, which manufacture 2-AG and anandamide, 
we have not investigated the enzymes involved in their breakdown.  It is hypothesised that increase 
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anandamide levels may be due to 5-ASA inhibition of COX-2, reduced oxidation and further 
processing603, 604. This may explain the counterintuitive decrease in MGLL and NAPE-PLD in our 
study with the maintenance and/or increase in some endocannabinoids in other studies603. Thus, 
further assessment of the endocannabinoid system would be required in larger RCTs of mesalazine 
to confirm our findings and hypothesis.  
 
(v) Serotonin pathway 
Using immunocytochemistry, increase in 5HT producing cells in resected DD specimens has 
previously been reported131. In contrast decreased 5HT transporter SERT, but not tryptophan 
hydroxylase 1 (TPH1) mRNA, the rate limiting enzyme in 5HT manufacture, or numbers of 5HT 
positive cells have also been reported in mucosa of patients with a history of diverticulitis within 
the last 6 months605. In a recently published study from our group, no significant difference was 
found in the number of 5HT positive cells in SDD or ADD groups491.  However in IBS, there is 
evidence of increased mucosal serotonin availability in IBS with diarrhoea (IBS-D) and 5HT3 
receptor antagonists have been shown to relieve symptoms606-608. No studies have identified 
alteration in components of the serotonin pathway with mesalazine. In our study a trend to 
decreased SERT (SLC6A4) and TPH1 was identified and may underlie some of the motility effects 
associated with mesalazine. However larger mechanistic RCT are needed to confirm these findings.  
 
(b) Arachidonic acid pathway 
Increased expression in prostaglandin E synthase has been recently  identified in SDD compared to 
ADD491. As Mesalazine and other 5-ASA are known to alter the Arachidonic acid pathway, its 
effect on these pathways may be important in treatment of pain in this group.  In our study 
significant decreased mRNA expression was found for lipoxygenases (ALOX12 and ALOX5), 
prostaglandins (PTGES2 [prostaglandin E synthase 2], PTGS1 [COX-1], PTGS2 [COX-2] and 
PTGER1 [Prostaglandin E receptor 1]) and for thromboxane synthase 1 (TBXAS1). A trend for 
reduced expression was also found for prostaglandin E synthase (PTGES), 15-lipooxygenase type 
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II (ALOX15B), phospholipase A2 and epoxide 2 hydrolase (EPHX2). However no difference was 
found for enzymes involved in the leukotriene pathway (LTA4H, LTB4R, LTC4S).  
 
The changes in prostaglandin pathways fit well with the literature. 5-ASA compounds have been 
found to inhibit COX-2 expression and prostaglandin E2 production in a colorectal cancer (CRC) 
cell line (HT-115), even when the cells are stimulated with TNFalpha and IL-1B544. Mesalazine has 
also been shown to inhibit COX-2 expression and production of PGE2 in TNBS treated colitic 
mice609. 5-ASA has also been show to inhibit thromboxane A2 activity and 5-lipoxygenase610-612, 
which agrees with our study findings. 
   
However, when 5-ASA was added to a suspension of isolated colonic mucosal cells from healthy 
volunteers there was a reduction in LTB4 but not PGE2 synthesis 613.  This is in contrast to our 
work. However it is supported by another study in an animal model of colitis, where 5-ASA 
compounds have been shown to reduce PGE2 and TBX2 production and a non significant decrease 
in LTB4 release614.  
  
Unfortunately the changes in gene expression were not supported by our liquid chromatography 
and mass spectroscopy results of AA pathway products which is discussed below.  
 
(c) Cytokines and inflammatory mediators 
Several cytokines have been linked to DD and other painful gastrointestinal conditions. In a recent 
study by Humes et al, who used genetic techniques and biopsies from unprepared colon, an 
increase in TNFalpha was found in symptomatic compared to asymptomatic DD individuals491. 
This finding is supported by a small study which demonstrated increased TNFalpha mRNA in 
Symptomatic DD compared to healthy volunteers with and without diverticulosis615. 
Polymorphisms in another member of the TNF superfamily, TNFSF15 have also been associated 
with both IBD and IBS (OR 1.37, especially constipation predominant OR 1.79) and with the 
higher risk allele resulting in increased TNFSF15 mRNA in rectal mucosa153. 
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In our study, a reduction in mRNA was seen in TNF (TNFalpha, TNFSF10, TNFSF10A and 
TNFSF15), TGFbeta (TGFB1, TGFBR1 and TGFBR2) and IL-1beta (IL1B and IL1RN) gene 
families following 3 months of mesalazine. Our findings agree with the current literature of the 
effects of mesalazine with down regulation of IL-1B, TNFalpha and NFkB pathways reported by 
several studies in experimental animals529, 552, 553, 616, 617 and in vitro cells577, 618-620. In one contrary 
study, IL-1B increased with 5-ASA in rheumatoid synovial fibroblasts in vitro619 however other in 
vitro studies using colorectal cell lines HCT116 and colonic fibroblasts have shown that 5-ASA 
inhibits TGF-beta 1 downstream signalling, which is independent of PPAR-gamma621.  
 
Other cytokines (IFNgamma, IL2, IL6, IL8, IL10, IL17 and IL23A) were not altered by mesalazine 
in our study. Whether these cytokines play a part in SDD is unclear. A recent study examined 
endoscopic biopsies from 10 SDD (excluding those with a past history of or suspected 
diverticulitis) and 10 controls. Cytokines were measured using a chemiluminescent multi-
parametric assay for IL-2, 4, 5, 8, 10, 13, 12, IFNgamma and TNFalpha132, with no difference was 
found between the groups. This is contrary to our previous study which showed an increase in 
TNFalpha and IL6491 in patients with symptomatic compared to asymptomatic diverticular disease. 
These studies are all small and underpowered to show clear differences given the inherent 
variability in patient groups. 
 
Other studies have identified an effect of 5-ASA drugs on cytokine production. These include a 
study using cultured monocytes stimulated by endotoxin, where 5-ASA reduced IL-1 and TNF 
synthesis but not IL-6622, and in peripheral blood mononucleocytes from patients with beryllium 
sensitisation or chronic beryllium disease, where 5-ASA inhibits production of IFNgamma and 
TNFalpha when the cells were stimulated with beryllium618. In many of these studies the ability of 
5-ASA to decrease cytokine release or production comes from isolated cell lines, which highly 
express these products, or by artificial stimulation of the cells. In our study, the biopsy samples 
were not cultured or stimulated and so the ability of 5-ASA to suppress up-regulation of genes or 
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release of pre-made cytokines through stimulation could not be assessed. This may account for the 
difference between our results and others which report cytokine changes.   
 
(d) Pattern recognition receptors 
Some of the most striking and consistent changes with mesalazine were seen in the expression of 
these receptors, which have not previously been studied in diverticulosis and SDD. Their ability to 
recognise bacterial and otKHUµDODUPIDFWRUV¶DQGLQIOXHQFHWKHLPPXQRORJLFDOUHVSRQVHVXJJHVWVD
possible role in the low grade chronic inflammation responsible for SDD symptoms13, 80. They may 
also play a role in the maintenance of chronic inflammation in other conditions. In IBS, TLRs are 
thought to play a role in IBS symptoms and gut mucosal permeability623, with genetic variants in 
TLR9 being independent risk factor for developing IBS152 and PI-IBS122.  Different TLR9 alleles 
may interact with other SNPs, such as PR domain zinc finger protein (PRDM1), an inflammation 
regulator protein, to alter mucosal barrier functions and transit through the colon152. 
 
In our study, the mRNA expression of TLR 2, 4, 7, 8 and 9 and co-signalling factor MYD88 were 
reduced in the mesalazine group after treatment. This is in contrast to one small open labelled study 
of mesalazine with and without lactobacillus casei DG which showed no effect of TLR4 
expression, except when the L Casei was administered rectally, which caused both TLR4 and IL-ȕ
to be reduced624. In another small study in UC patients treated with 5-ASA and steroids or 5-ASA 
and azathioprine, TLR4, MYD88 and NFkB protein expression was increased in the 5-ASA and 
steroid treated patients but not the 5-ASA and azathioprine group compared to healthy controls625. 
However, these differences in results may be due to the different pathological processes underlying 
UC and diverticular disease, or a  combination of drugs or confounding by indication (so that the 
increase in TLR4 reflected increased severity causing increased steroid use)  and the small sample 
size (7 to 13 subjects per group625). These western blotting results were also not confirmed with 
other techniques such as IHC or RT-PCR and biopsies were taken from prepared colons. These 
solutions can be irritative and may have altered expression. The healthy controls selected were also 
had abdominal pain and had been diagnosed with IBS. Since TLR expression have been found to 
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be altered in this patient group623, they may also not have been the most ideal control sample to 
compare.  In contrast Cell lines treated with 5-ASA have shown a down regulation of other TLR 
associated genes, such as TRAF3, which supports our findings513.  
 
Another pattern recognition receptor is NOD2. Identified in 2001, it is of increasing interest in as 
genetic variants have been linked to inflammatory bowel disease626 and malignancy, but so far it 
has not been found to be associated with IBS627. There are no previous studies examining the 
expression of NOD2 in diverticular disease. NOD2 appears to reduce bacterial translocation and 
production of TNF and IFNgamma, suggesting it has a protective role in inflammation628. In our 
study, the expression of NOD2 was decreased in the mesalazine group, which would initially 
appear counter-intuitive. However 5-ASA alters bacterial profiles560 and invasiveness516 and 
reduces mucosal permeability553. This may reduce the bacterial stimuli to the mucosa leading to a 
down regulation of NOD2. However further work is required to confirm this hypothesis.  
 
(e) Tight junctions, cytoskeleton and extracellular matrix 
Mucosal barrier is altered in IBS123, 157, 629-631, with polymorphisms of molecules involved in control 
of tight junctions, being implicated in the risk of developing of PI-IBS122. Other groups have shown 
that IBS mucosal supernatants also alter barrier function in epithelial monolayers and disrupt tight 
junctions632. However mucosal barrier function, permeability and tight junctions have not been 
assessed in diverticular disease. Several different components, such as mucin layers, tight junctions 
(such as Zona occludens, claudins and occludin), extracellular matrix proteins, immune and nerve 
cells are important in maintaining the intestinal barrier homeostasis633, 634.  
 
(i) Tight Junction Proteins 
In IBS, mRNA levels of Zona occludens 1 (ZO-1) and occludin have been found to be reduced by 
some groups629 but not others630. PAR-2 has been implicated in barrier function disruption as the 
effect of IBS supernatants is lost in PAR2 knockout animals632 and Vibrio Cholerae derived ZO1 
toxin is also thought to cause tight junction disassembly through PAR-2635. Claudin 2 forms part of 
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the tight junction complex but, unlike other claudins, producing pores to allow paracellular 
diffusion and increased mucosal permeability636-638. It is up-regulated by IL6639 and TNFalpha640-642 
and has been shown to be up-regulated in active &URKQ¶V and UC636, 642. There are no studies which 
have examined tight junctions in diverticular disease.  
 
In our study TJP1 (ZO-1) mRNA expression was reduced in the mesalazine and controls groups, 
while TJP2 (Zona occludens 2, ZO-2) was also reduced but did not reach significant in the 
mesalazine group. This may be a spurious result, especially as the decrease would appear counter 
intuitive, as 5-ASA compounds protect intestinal permeability in animal models of colitis. Both 
Mesalazine and balsalazide decreased mucosal injury to dextran sodium sulphate and mucosal 
permeability553. Balsalazine showed reduced disruption of the mucosal and tight junction on 
electron microscopy553, while Immunofluorescence of occludin, showed that mesalazine, attenuated 
its disruption and irregular distribution within the cells643.  Thus it would be expected that with 5-
ASA, ZO-1 and ZO-2 mRNA levels would increase. However, in a study of IBS, mRNA levels 
were shown to be unchanged but protein levels were reduced and the distribution of ZO-1 and 
occludin within the cell was altered in IBS patients compared to controls630. Thus the lack of 
protein data needs to be considered when comparing our results with others studies.  
 
In our study Claudin-2, was significantly decreased in the mesalazine treated group. A decrease in 
Claudin-2 is associated with a decrease in mucosal permeability and would complement the 
decrease in TNFalpha mRNA seen in our study. Although the expression of claudin-2 with 5-ASAs 
has not been assessed, other anti-inflammatory agents, such as NSAIDS, inhibit the expression of 
Claudin 2 mRNA, while up-regulating other tight junction proteins associated with decreased 
mucosal permeability (Claudin 1, 4 and occludin)644.  Our results are in keeping with a reduction in 
the mucosal permeability in diverticular disease which would fit with the known action of 
mesalazine. However further clinical and biomolecular work in assessing mucosal permeability in 
different subgroups of diverticular disease and with mesalazine is needed to confirm these findings 
and hypothesis.  
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(ii) Mucins and Matrix Metalloproteinases 
Mucin is produced by goblet cells and acts as a protective barrier between the luminal contents and 
the epithelia645. There are 5 mucin genes (MUC 1, 2, 3, 4 and 5AC) expressed in the colon646, 
which can be further modified post transcription by glycosylation. MUC-2 is the major gel forming 
mucin produced. MUC-1 has also been implicated in barrier function in knock out animal 
models647, 648. Although MUC-1 and MUC-3 mRNA expression have been found to be reduced and 
increased in erosive oesophageal reflux respectively649, there is little information about their role in 
IBS or diverticular disease.  In contrast, the turn-over of extracellular matrix by matrix 
metalloproteinases (MMP) are thought to be important in the development of diverticular disease23. 
Altered expression of MMPs have previously been identified in complicated DD21, 23, 491 and 
IBD650.  
 
In our study both MUC-1 and MUC-3A and B were significantly decreased in the mesalazine 
treated group. Mucin-2 (MUC-2) has been shown to be decreases in animal models of colitis, 
which is reversed by 5-ASA651, but there have been no studies on MUC-1 or 3 and 5-ASAs.  
However an animal study using probiotic VSL#3 has shown increased mucus production and 
MUC2 gene expression but not MUC1 or 3652. This was not replicated in an in-vitro cell line 
model652, but suggests that bacterial components may stimulate the production of mucin genes. 5-
ASA exerts an antibacterial effect 653 and reduces invasiveness516, which might result in a 
secondary decrease in mucin mRNA expression as seen in our study.  
  
The mRNA expression of MMP9 or MMP2 was not significantly different between the groups in 
our study. However 5-ASA decreases changes in MMP2 and 9 in animal models of UC, which was 
induced by iodoacetamide552. In-vitro cell lines treated with 5-ASA513 and COX-2 inhibitors654 
have also shown a decrease in MMP2 and 9 enzyme activity. TNFalpha has also been shown to 
increase expression of MMP9 in vitro655 and in &URKQ¶V disease, the use of TNFalpha inhibitors has 
been also demonstrated to decrease MMP9, while increasing MMP2656. PPARgamma agonists also 
reduced MMP9s657, suggesting that 5-ASA can act through PPARgamma and TNFalpha to 
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influence MMP9 expression552. With the above studies, a change in MMP9 may have been 
expected but this lack of change in our study may again be due to the small numbers. Larger 
studies may be identified in significant change.  
 
The control of barrier function in the intestine is complex633, 634, but involves several pathways 
which are known to be influenced by 5-ASAs such as TNFalpha, IL-1B, TLRs, PAR-2 and NFkB 
(see above). Thus one of the actions of mesalazine in alleviating pain in SDD may be through 
altering intestinal barrier function, by influencing mucin and tight junction protein levels and 
distribution. But further assessment is required to confirm the effect of mesalazine on ZO-1 and 
other tight junction and mucin components. The small but significant decrease in the control group 
for ZO-1 may have occurred by chance or due to changes in stress or other psychological factors 
not specifically measured during the study but which have been shown to influence intestinal 
permeability634. This and the potential effects of 5-ASAs on mucosal permeability require further 
study.    
 
(f) Other genes 
(i) Cell migration and apoptosis 
The understanding of the role of chemokines and cell adhesion molecules  in diverticular disease 
and IBS is limited, although E-selectin has recently been shown to be up-regulated in SDD 
compared to ADD patients491. 5-ASAs influence of cell migration molecule expression is also not 
well understood. Our study has shown a significant decrease in the expression of VCAM-1 and 
MAdCAM-1. Thus is supported by one study which suggests 5-ASA can decrease the up-
regulation of P and E Selectin and VCAM-1 in LPS stimulated mouse intestinal tissues658. In dental 
pulp cells, PPARgamma, which is thought to interact with 5-ASA, can also decreased production 
of MMPs, ICAM1 and VCAM1657. However another study has shown that 5-ASA have no effect 
on the expression MAdCAM1 in epithelial monolayers, which was induced by TNFalpha659. These 
differences may be due to the type of stimulation and/or cell lines used compared to our in-vivo 
work.  
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Our study also showed down-regulation of CMKLR1 (also known as ChemR23) and MCL-1. 
CMKLR1 has been associated with migration of macrophages and dendritic cells in vitro and with 
pro and anti-inflammatory effects660, 661. Its expression can be regulated by TNFalpha, IFNgamma, 
IL-1B, IL-6 and TGF-B198. MCL-1 (myeloid leukaemia cell differentiation protein), part of the 
BCL-2 (B Cell lymphoma 2) family of genes, is important in protecting cells from apoptosis and is 
of interest in cancer therapies662. Sulphasalazine but not Mesalazine has been found to down 
regulate BCL-2 and induce apoptosis in T lymphocytes from &URKQ¶V patients663. However the 
effect of mesalazine on CMKLR1 and MCL-1 has not been previously investigated, but its 
decrease may be due to down regulation of it or other genes known to be effected by 5-ASA or due 
to alteration in cell populations within the GI tract.  
 
(ii) Protease-activated receptor 2 (PAR2, gene F2RL1) 
Protease-activated receptor 2 (PAR2, gene F2RL1) has been of increasing interest in IBS as it can 
induce mechanical hypersensitivity and alter gut permeability147 by re-organization of tight junction 
proteins664.  Another protease-activated receptor, PAR4, has been found to modulate pain by 
inhibiting the actions of PAR2 and TRPV4 in nerves665, but can be pro-inflammatory666. In the GI 
tract, mRNA levels of PAR2 appear to be similar in IBS colonic tissue as in controls147, 664, but 
PAR4 mRNA is decreased and expression of tryptase and trypsin, activators of PAR2, are 
increased. Immunofluorescence studies have identified PAR4 on mast cells, with decreased 
expression found in PI-IBS667. Meanwhile, PAR2 has been linked to increased neuronal excitability 
in culture148 and in chronically stressed mice infected with citrobacter rodentium668. However 
PAR2 and PAR4 roles in diverticular diseases have not been published. In our study PAR2 
(F2RL1) mRNA expression was significantly decreased in the mesalazine group. PAR4 (F2RL3) 
was so poorly expressed that results were excluded from further analysis. No studies using 5-ASA 
compounds have reported changes in expression of PARs, but the decrease in PAR2 is in keeping 
with the anti-inflammatory properties of mesalazine and might contribute to the reduction in pain 
we observed.  
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(iii) PPARgamma 
PPARgamma has many functions in the GI tract. It is highly expressed in many cells including 
activated macrophages669.  Disruption of PPARgamma in macrophages increases susceptibility of 
colitis in animal model of IBD528. PPARgamma can also be found on epithelial cells, which are 
important in IBD models670. Activated PPARgamma suppresses NFkB activity, a key inflammatory 
nuclear transcription factor, and reduced inflammatory mediators671. There is evidence that 
PPARgamma is down-regulated in experimental inflammatory bowel animal models, which can be 
restored by PPARgamma agonists and probiotics.  Previous studies have suggested that in colonic 
epithelial cell lines, 5-ASA increases the expression of PPARgamma at mRNA and protein 
levels527. This was identified only after a short incubation of 12 hours. 5-ASA has also been shown 
to result in translocation of PPARgamma from the cytoplasm to the nucleus after 24hours of 
incubation with colonic epithelial cells527. In an animal experiment of PPARgamma and 5-ASA in 
radiation colitis, rats were treated with or without 5-ASA for 7 days, prior to irradiation exposure. 
The 6 control animals, who did not have irradiation and where treated with 5-ASA, showed a slight 
not non-significant rise in PPARgamma mRNA549. Interestingly, STAT3, which is part of a 
signalling pathway involved in inflammation672, 673 , was significantly elevated in this study549. 
 
In contrast in our in vivo study, the mRNA expression of PPARgamma was decreased (Table 
R3.14). However, our in-vivo study was of 3 months duration and it is not known if 5-ASA 
induced increases in PPARgamma expression described above are maintained long term or if these 
changes are cell specific.  
 
$OWKRXJKZHGLGQ¶WLGHQWLI\DQ\VLJQLILFDQWFKDQJHVLQ IHC slides, our sample size was small and 
the antibodies used for macrophages (CD68) and T lymphocytes (CD3) would not have 
distinguished between the sub-classifications of cells or their activation states. Therefore it is 
possible that mesalazine increases PPARgamma mRNA and/or activity in some cells, as suggested 
by other studies527, 538, 674, but it may also alter the immune cell populations within the colonic 
mucosa resulting in an overall decrease in the total PPARgamma mRNA of the biopsy. This 
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hypothesis is supported by a study of mesalazine in IBS, where decreased mast cell numbers were 
identified in the mesalazine treated group543. PPARgamma is expressed in mast cells and thought to 
effect their maturation, function and release of mediators675, 676. Mast cells have been linked to 
bloating and µG\VPRWLOLW\-OLNH G\VSHSVLD¶677 and proximity to nerve fibres139 in IBS, supporting 
their involvement in patient symptoms. 5-ASA compounds have also been found to decrease mast 
cell mediator release as well678, 679, offering a potential mechanism of action. Mast cell tryptase was 
not stained for in our study, but future work should include this histological assessment. 
 
(iv) INOS 
INOS (NOS2) was found to be significantly decreased in the mesalazine group in our study. This 
finding is supported by animal studies609, 680 and in human epithelial cells681. In the human study, 
cultured epithelial cell lines were stimulated with IL-1B and IFNgamma and 5-ASA compounds. 5-
ASA was found to inhibit iNOS production and the expression of mRNA and protein681. This 
enzyme can be induced by inflammation and its reduction supports the anti-inflammatory 
properties of mesalazine.  
 
(v) Superoxide dismutase (SOD1) 
SOD1 is a cytoplasmic copper/zinc superoxide dismutase and is part of an antioxidant defence 
system.  SOD1 has also been shown to be up-regulated and correlates with disease activity in active 
&URKQ¶V Disease, but is down-regulated in UC with anaemia682. It is decreased by corticosteroids 
treatment682. In contrast, Balsalazine, another 5-ASA, has been found to increase the activity of 
SOD in mice with DSS-induced colitis553. Mesalamine has also been found to increase manganese-
SOD in rat non-transformed small intestine cell lines683. However in both these studies 5-ASA was 
only given for a short time prior to analysis for SOD. Thus in the long term, 5-ASAs may act 
through anti-inflammatory and antioxidant activities to reduce SOD1 activity. However this finding 
would need to be confirmed. 
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(vi) Phosphodiesterase 4 (PDE4B and PDE4D) 
We found a significant decrease in PDE4B but not PDE4D. Phosphodiesterase 4 (PDE4B and 
PDE4D) is important in cAMP breakdown and is found in many inflammatory cells. A recent study 
suggests that PDE4B is increase in SDD compared to ADD491. PDE4 inhibitors are already used in 
other chronic inflammatory conditions, such as chronic obstructive pulmonary disease (COPD), 
and have been linked to decreased TNFalpha expression in peripheral blood mononuclear cells684.  
A small animal model of colitis also suggests that PDE4 inhibitors can reduce inflammation and 
mediators such as TNFalpha and TGF-B1685 and there has been recent interest in selective PDE4 
inhibitors in IBD686 64. However, although a decrease in PDE4 links with the anti-inflammatory 
effects of mesalazine, no previous studies have examined the effects of 5-ASA on PDE4 but our 
data suggest that this might contribute to its anti-inflammatory effect. 
 
(vii) Formyl peptide receptor 2 (FPR2) 
FPR2 acts as a G protein coupled receptor for, among 30 others, lipoxin A4 and annexin, which 
have been implicated in the promotion and resolution of inflammation687, 688. FPR2 (which are also 
known as FPRL-1) are located on immune cells, such as neutrophils and macrophages, and are 
involved in cellular adhesion, migration and diapedesis. Some FPR2 ligands, e.g. lipoxin A4 and 
annexin, have shown anti-migration influences688. Mast cells also have FPR2 receptors, with 
annexin 1 inhibiting their activity688.  Pro-inflammatory signals from this receptor are thought to 
act through NFkB, while anti-inflammatory activities by SOC-2, TRAF2 and TRAF6, desensitising 
the cell to classical stimuli from TLR receptors.   
 
FPR2 has been implicated in several inflammatory diseases such as asthma, rheumatoid arthritis, 
$O]KHLPHU¶VFRURQDU\DUWHU\DQG &URKQ¶V disease. Its expression has been shown to be increased in 
the mucosa of &URKQ¶V disease and in THP-1 cells treated with LPS or IFNgamma, which fits with 
an up-regulation of lipoxin signalling in inflammation689. In our study, FPR2 was significantly 
down regulated in the mesalazine group. However there have been no other studies of 5-ASA and 
FPR2. The reduction in FPR2 expression may be related to the reduction in TNFalpha and TLRs 
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which are known to up-regulate its expression688. This would correspond to the anti-inflammatory 
mechanism of mesalazine, leading to a down-regulation of natural resolution of inflammation (or 
anti-inflammatory) mechanisms which are up-regulated in an inflammatory event. However further 
studies would need to confirm these findings. 
 
 (B) Cell Counts 
In Humes et al, no difference was found between SDD and ADD 5HT and CD3 cell counts491.  
This agrees with our work where no difference was found between V1 and V5 and stained cell 
numbers/area (Lymphocytes CD3, Macrophages CD68, Enterochromaffin cells 5HT or Cellular 
proliferation KI67) in the mesalazine and placebo groups.  Interestingly no significant difference 
ZDVIRXQGLQ&'DQG&'LQWKH&RULQDOGHVLHWDO¶VVWXG\RIPHVDOD]LQHLQ,%6DVZHOODOWKRXJK
they did report a marked reduction in Mast cells543.   
 
Tursi et al reported a significant decrease in number of KI67 stained cells in the whole crypt in 20 
patients with symptomatic diverticular disease who were treated with mesalazine for 1 year535. This 
is supported by studies of colorectal carcinoma and the reduction in proliferation seen on 
mesalazine treatment513, 538, 544, 690. A reduction in KI67 staining was not seen in our study and may 
be due to several factors. Firstly our study only has 13 subjects in the mesalazine group which may 
have been too small to identify a significant change. Secondly our study was of shorter duration 
that 7XUVLHW DO¶VDQGGLGQRW LQFOXGHDQ LQLWLDO WUHDWPHQWZLWK ULID[LPLQ7KLUGO\RXUFHOO FRXQWV
were derived using computer assistance and expressed as an area rather than a percentage of 
positive stained cells. All of these may have contributed to our lack of significant results.  
   
(C) Calprotectin and SS-CRP 
Faecal calprotectin (FC) is released from inflammatory cells, mainly neutrophils, during cell 
activation or death. It is stable in faeces over several days and has been found to correlate with 
inflammation and disease activity in a variety of gastrointestinal conditions, such as IBD and 
colonic polyps691-697.  
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In 2009 Tursi et al698 found increased FC levels in patients with diverticulitis and SDD when 
compared to HV and IBS patients. They also showed a decrease in FC in patients treated with 
mesalazine and rifaximin for 10 days followed by mesalazine alone for 8 weeks. This is in 
contrasts to our study where no difference was found in the treatment of placebo group for faecal 
calprotectin. However it is important to note that, the FC in 7XUVL¶V study was detected using CAL 
Detect (Sofar SpA Milan Italy). This is a semi-quantitative method that gives 1 to 4 bands of colour 
to indicate FC concentration rather than the gold standard quantitative ELIZA method. In our 
study, we used an ELIZA (Calprest) technique which gives a more accurate quantitative 
measurement. Also in our study, patients did not require to have a prior proven episode of 
diverticulitis. Thus it is possible that in some of our patients central pain processing changes may 
be important in their pain experience rather than peripheral low level inflammation. Thus in some 
subject their initial and final calprotectin levels may have been low and no change would have been 
identified in their FC. This and the use of rifaximin in 7XUVL¶V study may explain the difference in 
our results. In both studies only a small number of patients were assessed. Thus FC should be 
assessed in larger studies to confirm its usefulness in SDD and in identifying and predicting which 
patients may benefit from and/or are responding to treatment with mesalazine.  
 
CRP is an acute phase reactive protein which can be increased by a wide range of inflammation or 
trauma related stimuli. SS-CRP, which allows detection of CRP below the standard reference range 
and is a marker of micro-inflammation, has been shown to be increase in a study of IBS and HV699. 
It has been shown to be decreased in an open study of 20 patients with Ankylosing spondylitis who 
were treated with mesalazine for 24 weeks, but this reduction did not reach significance700. 
Although CRP may have uses in diagnosing and monitoring treatment of acute diverticulitis, its 
role in the monitoring of SDD treatment has not been demonstrated. Experience in &URKQ¶V disease 
suggests that it is likely to be less sensitive than fecal calprotectin701. In our study no change was 
found in SS-CRP between time points or treatment groups, but larger studies are required to 
confirm this finding. 
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 (D) Liquid Chromatography and mass spectroscopy 
In our study, LCMS results showed no difference between the time points within or between the 
treatment groups despite the fact that many of the enzymes involved in the manufacture and 
destruction of these products were altered in the mesalazine group. This may be because the rectal 
and sigmoid biopsy samples used in the analysis were small and difficult to assess. Also many of 
the studies, which demonstrated a change in prostaglandins and leukotrienes, used single cell 
cultures, such as leucocytes, and/or stimulated the production of arachidonic acid pathway products 
e.g. ionophore A23187611, 612, 702, 703. Some studies also suggest that different 5-ASA compounds 
may inhibit different enzymes within the AA pathway to different extent, which makes comparison 
of mesalazine with other 5-ASA difficult612, 704, 705. This may explain our inability to detect a 
significant change in these important inflammatory compounds and that future studies may require 
other techniques such as cell culture and stimulation of patient samples to demonstrate the changes 
inflammatory products resulting from the altered gene expression. 
 
(E) Patient Symptoms 
Our study was not powered to detect significant changes in reported patient symptoms, but we did 
find a significant decrease in the median duration of pain in the mesalazine group (Figure R3.7). 
No other significant change in symptoms, including general overall wellbeing, bloating, stool 
frequency or consistence or bloating was identified. There was evidence of a significant placebo 
effect, with reported improvement in pain relief in both the placebo and mesalazine groups (Figure 
3.8). The placebo effect was also identified in the fact that 50% of patients taking placebo believed 
they were taking mesalazine, compared to 78.6% in the mesalazine group (Fig R3.9).  
 
This is the first double blinded, placebo controlled RCT of mesalazine in SDD. Few other studies 
of mesalazine in SDD have been randomised. In 2010 Gatta et al published a meta-analysis of 3 
studies of mesalazine in SDD, which showed symptomatic benefit. However these where open 
labelled studies and not placebo controlled. Humes et al published a systematic review in 2011502. 
In this only 2 RCT of mesalazine and rifaximin were identified, both of which were open labelled, 
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with little detail on the method of randomisation or power calculations used502. Both used a non-
validated global symptom score to show significant benefits for the mesalazine, which was given as 
a pulsed rather than continuous medication566, 569.  Other open labelled or non-blinded studies (table 
I3.1) have suggested benefit of mesalazine with varying length of follow up.  
 
,Q&RULQDOGHVLHWDO¶V543 RCT of mesalazine in 20 IBS patients a significant improvement in general 
well being but not abdominal pain, bloating or bowel habits was reported. This agrees with a 
prospective study by Andrews et al653 of 12 women with PI-IBS, who had improved number of 
days of discomfort, increased bowel movement satisfaction on a global relief questionnaire.  In a 
larger RCT of mesalazine in 360 IBS patients, which included all IBS types, significant changes in 
pain intensity and duration were identified706. Both these studies support our findings of an 
improvement in pain and general well being with mesalazine.  
 
3.5.3 Limitations of the present study  
There are several limitations to our study which include its small size and limited 3 month duration. 
This was because the study was powered to assess biochemical changes to mesalazine and not 
symptom improvement. Thus there was significant placebo effect, with many subjects in the 
placebo group reporting improvement in their symptoms (Figure R3.7-3.9), although these did not 
reach significance (Table R3.19).  
 
There was also a female predominance in the mesalazine group (p=0.0608). This primarily 
occurred as male subjects developed adverse events and withdrew from the study. All female 
withdrawals were due to protocol violations or social circumstances. Poor tolerance of daily 
mesalazine has been highlighted in other gastrointestinal conditions, such as IBS707, and 
inflammatory conditions, such as Ankylosing spondilitis700. In a recent RCT meta-analysis of 5-
ASA medications in UC, the frequency of abdominal pain or dyspepsia with mesalazine ranged 
from 1-27% (median 4%)  and diarrhoea from 1-9% (median 2%)708. In a 5 year observational open 
labelled study from Gatta et al568, 16.8% of patients in the mesalazine group withdrew. This is 
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similar to a meta-analysis of several small open labelled studies of mesalazine in SDD and 
recurrent diverticulitis, where the incidence of abdominal pain was reported as 13 (n= 81, 16%) and 
2 (n=20, 10%) mesalazine patients578. In our study 15% of participants (3/20) withdrew due to 
exacerbation of pain and 5% (1/20) reported diarrhoea in the mesalazine group, which is within the 
reported incidence of these complications708. However the gender difference between the groups is 
unlikely to have altered our biochemical results as at baseline both final analysis groups had no 
significant difference in their gene, stool or blood marker expressions. 
 
The inclusion criteria for our study included patients diagnosed with at least 1 diverticulum in their 
left colon and abdominal pain which was thought to be related to it after investigation. Participants 
did not require a confirmed episode of diverticulitis and in our study only 6 participants in each of 
the final analysis groups had a history of diverticulitis. As the pain in diverticular disease may be 
similar to that in IBS, having a mix of  peripheral and central processing changes434, 709, 710, it is 
likely that our study population included participants with predominantly central and well as those 
with predominantly peULSKHUDO µSDLQ VHQVLWLYLW\¶ 7KLV GRHV QRW QHFHVVDULO\ SUHYHQW PHVDOD]LQH
having beneficial effect in DD since mesalazine appears to be effective in IBS706 where peripheral 
factors are likely to be less obvious than central ones. There is undoubtedly an interaction between 
central psychological and peripheral mucosal factors in IBS and this may also be true in 
symptomatic DD where a peripherally acting drug like mesalazine may still be effective.  It is still 
unknown how peripheral and central factors contribute to the sensation of pain and if selective 
treatments of one will affect the other. Mesalazine is poorly absorbed and is thought to act locally 
within the gastrointestinal tract. Thus Mesalazine may only have effect on those patients who have 
a predominantly peripheral component to their pain and thus our results may be diluted by 
inclusion of patients with a predominant central pain component. However this hypothesis and the 
potential to identify subjects though biopsy or questionnaires needs further investigation by larger 
randomised control trials of longer duration.  
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It will also be interesting to look at the results of trials of mesalazine in IBS, where larger numbers 
of participants with PI-IBS and other IBS types have been included. As PI-IBS may have similar 
underlying pain mechanisms to post-diverticulitis pain, this may support the use of mesalazine for 
patients with a peripheral pain component, with alternative such as amitriptyline for those with 
central pain486, 711, 712. Alternatively alteration of peripheral inputs in all patients may help to reduce 
central pain processing changes434, 709.   
 
3.5.4 Summary of the clinical and research implications of the work, 
This study has implications for future research and clinical practice.  It has increased our 
understanding of the actions of mesalazine, suggesting alteration in keys genes within the 
arachidonic acid pathway, cytokines and inflammatory pathways. Importantly we have shown 
previously unknown actions on pattern recognition receptors, mucosal barrier function genes and 
other key genes such as PAR2 and FPR2 which have become of increasing interest in 
gastrointestinal disorders such as IBS and IBD150, 713, 714. Although larger studies are needed to 
confirm these results in other DD patients and diseases, these findings will aid inform future 
studies on the action of mesalazine and will help the development of future research and design of 
medications in the future.   
 
This is the first RCT of mesalazine in diverticular disease, and although not powered to assess 
symptomatic improvement, has shown a reduction in the median numbers of hours of pain 
experienced by patients with SDD. This agrees with other open labelled studies and will support 
the design and powering of much larger multicentre RCTs into the symptomatic improvement of 
SDD. As SDD patients are a heterogeneous group and probably have both peripheral and/or central 
pain mechanisms, it is unlikely that mesalazine will provide effective pain relief for all suffers. 
However by assessing larger group of SDD patients with validated questionnaires and focused 
biomedical investigations, it may become possible to select which patients will respond to different 
PHGLFLQDODSSURDFKHVEDVHGRQ WKHLU µELRPDUNHUV¶%\FODULI\LQJSDLQPHFKDQLVPV IXUWKHU IXWXUH
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treatments can be devised to help selected groups with different pain mechanisms allowing more 
personalised medical care.  
 
However future work on the effectiveness of symptomatic relief and cost benefit need to be 
undertaken before mesalazine can be offered as a standard treatment to patients with SDD.  
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Chapter 4: Conclusions 
 
This study was designed to identify the processes which underlie pain in SDD. Our hypothesis was 
that  a spectrum of both peripheral and central pathologies were involved, with those that had a 
more peripheral problem having abdominal symptoms only while those with multiple symptoms 
throughout the body, having an altered central pain processing. The first study has supported this 
hypothesis. Although a statistically significant difference in sensory pain threshold was not 
demonstrated between the groups, fMRI imaging has shown greater emotional processing during 
pain and reduced anticipatory inhibitory responses in the HSDD groups. However this is not as 
clear cut as we had anticipated which may be due to subject selection and demonstrate a spectrum 
of mixed peripheral and central changes as well as those with only peripheral or central 
components.  
 
In the second study, mesalazine showed interesting effects on reducing genes expression associated 
with inflammation in SDD patients. A reduction in the median number of hours of pain per week 
was seen. The study was not designed to allow intention to treat analysis but has shown promising 
results which will need to be consolidated with future large scale studies. 
 
Both these studies also have implications for future research and suggest tailored approach to SDD 
patient treatment. The means of identifying each patients underlying pain process remains a 
challenge. Our studies have suggested that the PHQ12 may be one simple measure of doing this, 
but again needs to be confirmed with further larger studies.  A rectal biopsy to identify biomarkers 
is another potential means and may assist in identifying the type of medication required for patients 
with a predominant peripheral pain component.  
 
The identification of possible peripheral and central treatments is a challenge and requires further 
understanding of the underlying pathogenesis of pain in SDD beyond the scope of the work 
presented here. The mesalazine study has been useful in identifying potential targets for treatment 
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in SDD by highlighting several gene pathways which were down regulated. These have not 
previously been identified in SDD, but are becoming of increasing interest in IBS715, 716 and IBD.  
 
Firstly it would be important to compare the inflammatory, pattern recognition receptor pathways 
and cell membrane permeability in SDD as well as healthy controls to confirm our findings. 
Mucosal permeability and pattern recognition of gut microbiota is of increasing interest in IBS717-
719
 and work to assess gut permeability with biological and imaging techniques in SDD would be a 
potential avenue to explore. Currently, stool samples from the mesalazine and fMRI study are 
being processed using gene cards to assess the different types of microflora in ADD and SDD 
patients and changes which can occur with mesalazine. Whether other treatments combined with or 
separate from mesalazine, such as probiotics, can also help in treatment of SDD patients could also 
be suggested from further work in this area. 
 
One area we did not examine in the study was changes to peripheral nerves and whether mesalazine 
can alter these. The mucosal biopsies would not have contained any RNA from the sensory 
peripheral nerves supplying the mucosa or other layers of the bowel. Unfortunately we were not 
able to establish a reliable staining method to identify nerve fibres or receptors in the tissue. It may 
be that, by altering the ongoing inflammation in the bowel, any nerve changes would have 
reversed. Again further work needs to be carried out. We still have remaining samples from the 
study in storage under our studies original ethical approval. It may be possible, if a reliable 
technique is established, to perform this assessment at a future date, give appropriate ethical 
approvals. The gene changes identified in the mesalazine study as well as work in other conditions 
such as IBS would help design this work further. Further studies to see if mesalazine or other 
central or peripheral medications would be possible, if peripheral nerve assessment in biopsy 
samples or fMRI imaging techniques of spine cord are reliably established.  
 
The fMRI study also suggested central pain processing changes. These techniques in identifying 
altered pain processing are important as it may allow us to assess different medications or CBT 
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techniques to see if they can produce prolonged reduction in pain processing486, 489, 499. Work by 
others has also suggested that prolonged pain can also alter the structure of the brain274, 279, 282. The 
long term effects of pain related brain changes are not currently clear. Work is currently being 
performed to identify any structural brain changes in our study group using the T1 weighted 
images. Brain pain changes have also been shown to be reversed once the cause of pain is 
treated499, 500. If brain related changes are identified in SDD, the effect of mesalazine or other 
treatments in reversing this could be assessed using MRI.  
 
Other mechanism of pain can also be investigated.  With recent epidemiological studies suggesting 
that obesity may play a role in the development of symptoms in SDD720-722, we have started a 
project using MRI imaging of the abdomen to quantify visceral and subcutaneous fat and peripheral 
blood adipokines. This will allow correlation with patient symptoms and may suggest new 
potential mechanisms and targets for treatment.  
 
Understanding the mechanisms of pain in SDD is still behind that of other gastrointestinal 
conditions such as IBD and IBS. However with the increasing aging population and obesity, an 
increase in SDD is anticipated.  With a greater appreciation of chronic symptoms related to SDD7, 
further work in this area and cross fertilisation of ideas between chronic gastroenterology and other 
chronic pain condition would be beneficial. This work has continued to progress our understanding 
of the condition but much further work is needed to understand the mechanisms. However this 
work does suggest that both peripheral and central pain processes are important and that treatment 
for patients with SDD will probably involve a tailored approach.  
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Chapter 6: Appendices 
 
6.1 Inclusion and exclusion criteria for fMRI study participants 
List 6.1.1 Inclusion (a) and exclusion (b) criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List 5.1.1 continued: Inclusion (a) and exclusion (b) criteria 
  
(a) Inclusion Criteria: 
Participants must have either: 
x Symptomatic diverticular disease with short lived recurrent abdominal pain on 3 or 
more days a month and the condition confirmed on endoscopy/ telescope test, 
barium enema or CT scan. 
x Asymptomatic diverticular disease, with no abdominal pain but the condition has 
been confirmed on endoscopy/ telescope test, barium enema or CT scan. 
x Irritable bowel syndrome, which has been diagnosed by a gastroenterologist at the 
hospital using  ROME II or III criteria. 
x No abdominal problems e.g. a healthy participant. 
x 18 ± 85 years of age. 
x Right handed ± define as writing or drawing with the right hand.  
x Signed informed consent. 
 
(b) Exclusion Criteria: 
General exclusions 
x Pregnant or lactating women. 
x Severe co-morbidity; e.g. heart failure, respiratory failure, alcoholism or drug 
dependence. 
x Inability to give informed consent.  
x Participation in any other study on Nottingham University campus in the last 3 
months. 
MRI exclusions 
x Have a metallic implant e.g.  
o Cardiac pacemaker 
o Implanted cardiac defibrillator 
o Metallic heart valves 
o Aneurysm clips 
o Carotid artery vascular clamp 
o Neurostimulator 
o Insulin or infusion pump or implanted drug infusion device 
o Non-removable cochlear, otologic, or ear implant 
x Ever been shot or have shrapnel inside the body 
x Ever had metallic fragments in the eye 
x Claustrophobia  
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List 6.1.1 Inclusion (a) and exclusion (b) criteria 
 
  
 (b) Exclusion Criteria: 
 
Inflammatory exclusions 
x Inability to stop NSAIDs (non-steroidal anti-inflammatory agents), antibiotics or 
immunosuppressant drugs 
x Presence of other gastrointestinal inflammatory conditions such as ulcerative 
FROLWLV&URKQ¶VGLVHDVHDQG&RHOLDFGLVHDVH 
x Previous abdominal surgery (other than appendectomy, hysterectomy, 
cholecystectomy and sterilisation, hernia repair) 
 
Somatic exclusion   
x Peripheral neuropathy (e.g. diabetic, alcohol) 
x Broken skin 
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6.2 Timings and durations of paradigm stimuli 
 
Figure 6.2.1 Durations from Start of Paradigm 
 
45oC VAS CUE 
Paradigm 1 72 
197 
284 
407 
451 
23 
150 
242 
331 
495 
15 
60 
141 
186 
234 
276 
321 
402 
444 
483 
Paradigm 2 113.4 
240.4 
282.4 
368.4 
452.4 
24.4 
70.4 
155.4 
320.4 
495.4 
12.4 
60.4 
108.4 
144.4 
228.4 
276.4 
315.4 
357.4 
444.4 
486.4 
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6.3 MRI Peltier participant subset selection 
 
Central pain processing analysis to cutaneous heat stimulus applied consecutively to the hand and 
foot in: 
 
IBS patients (IBS) 
Asymptomatic Diverticular disease patients (ADD) 
Symptomatic Diverticular disease patients 
 Low somatisation on PHQ12 score <6 (LSDD) 
 High somatisation on PHQ12 score >7 (HSDD) 
 
All participants recruited 
Number  IBS ADD LSDD HSDD 
MRI No Data-
base ID 
MRI 
No 
Data-
base 
ID 
MRI No Data-
base ID 
MRI No Data-
base ID 
1 4134 61 7352  62 7503 64 7499 65 
2 6829 41 7574  67 7601 63 7631 68 
3 7509 58 7769  59 7630 70 7632 66 
4 7623 69 7787  50 7738 57 7788 56 
5 7838 46 7801  53 7827 54 7845 51 
6 7883 43 8255  33 7882 48 7918 28 
7 7904 38 8346  8 7935 31 8155 35 
8 7992 40 8354  6 8031 29 8196 30 
9 7993 39 8418  10 8372 3 8235 32 
10 8003 42 8429  11 8420 14 8253 36 
11 8021 15 8522  25 8428 13 8258 34 
12 8173 5 8523  23 8552 24 8373 7 
13 8205 45 8595  20 8590 18 8680 75 
14 8250 4 8685 73 8593 16 8682 71 
15 8075 44 8598  1 8594 22 7903 26 
16 7846 47 7799  55 8596 21 8032 27 
17 7873 49 8276  37 8600 74 8592 17 
18 6536 60 8647  19 8681 2   
19   8389  9 7820 52   
20   8599 72     
(Bold = patients excluded due to; abnormal scan, medication e.g. lorazepam, insufficient data on 
questionnaires to confirm group status) 
 
  
254 
 
Analysis 
All patient images have been processed to correct for movement artefact, echos combined in 
matlab and normalised and smoothed to 8mm. All images were checked to look for additional 
movement artefact that was not identified in the processing graphs and the scans removed from 
further analysis. Participants included in subset analysis: 
6.3.1 IBS 
IBS Foot 
45oc? 
Hand 
45oC? 
Foot 
p1 
Footp
2 
Handp1 Hand 
p2 
Notes 
No MRI 
No 
1 4134 _/ _/ _/ _/ _/ _/  
2 6829 _/ _/ _/ _/ _/ _/  
3 7509 _/ _/ _/ _/ _/ _/  
4 7623 _/ _/ _/ _/ _/ _/  
5 7838 _/ _/ _/ _/ _/ _/  
6 7883  no _/ _/ _/ _/  
7 
7904 
_/ _/ _/ _/ _/ _/ Vas scores 4 but 
consistent (F1 score 
missing) 
8 7992 _/ _/ _/ _/ _/ _/  
9 7993 no no _/ _/ _/ _/  
10 8003 _/ _/ _/ _/ _/ _/  
11 8173 _/ _/ _/ _/ _/ _/  
12 8205 _/ _/ _/ _/ _/ _/  
13 8250 no no _/ _/ _/ _/  
14 8075 no _/ _/ _/ _/ _/  
 7846 N/A N/A N/A N/A N/A N/A  
 7873 N/A N/A N/A N/A N/A N/A  
 6536 N/A N/A N/A N/A N/A N/A  
 8021 _/ _/ _/ _/ _/ no H2 vas 0 
 
6.3.2 ADD 
ADD Foot 
45oc? 
Hand 
45oC? 
Foot 
p1 
Footp
2 
Handp1 Hand 
p2 
Notes 
No MRI 
No 
1 7352 _/ _/ _/ _/ _/ _/  
2 7574 _/ _/ _/ _/ _/ _/  
3 
7769 
_/ _/ _/ _/ _/ _/ VAS scores 
consistently 1 or 2 
for all 
4 7787 _/ _/ _/ _/ _/ _/  
5 7801 _/ _/ _/ _/ _/ _/  
6 8255 no _/ _/ _/ _/ _/  
7 8346 no _/ _/ _/ _/ _/  
8 8354 _/ _/ _/ _/ _/ _/  
9 8418 no no _/ _/ _/ _/  
10 8522 _/ _/ _/ _/ _/ _/  
11 8523 no no _/ _/ _/ _/  
12 8595 _/ _/ _/ _/ _/ _/  
13 7799 _/ _/ _/ _/ _/ _/  
14 8276 _/ _/ _/ _/ _/ _/  
 8647 no _/ no _/ _/ _/ F1 vas score 0  
rest 5-7 
 8389 N/A N/A N/A N/A N/A N/A  
 8599 N/A N/A N/A N/A N/A N/A  
 8429 no no _/ no _/ no  
 8685 no no no _/ no no  
 8598 no _/ no no _/ _/  
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6.3.3 LSDD 
 
LSDD Foot 
45oc? 
Hand 
45oC? 
Foot p1 Footp
2 
Handp1 Hand 
p2 
Notes 
No MRI 
No 
1 7601 _/ _/ _/ _/ _/ _/  
2 7630 _/ _/ _/ _/ _/ _/  
3 7738 _/ _/ _/ _/ _/ _/  
4 7827 _/ _/ _/ _/ _/ _/  
5 7882 _/ _/ _/ _/ _/ _/  
6 8031 _/ _/ _/ _/ _/ _/  
7 8372 no no _/ _/ _/ _/  
8 8428 no _/ _/ _/ _/ _/  
9 8552 no no _/ _/ _/ _/  
10 8590 no no _/ _/ _/ _/  
11 8593 no no _/ _/ _/ _/  
12 8596 no no _/ _/ _/ _/  
13 8600 no no _/ _/ _/ _/  
14 8681 no no no _/ _/ _/  
 7820 N/A N/A N/A N/A N/A N/A withdrew 
 7503 _/ _/ No - ? 
missing 
_/ _/ _/ 1ST Subject F1 
scan lost due to 
peltier fault. 
 7935 no no _/ _/ No - 
bad 
_/ H2 vas score 1 and 
H1 3 
 8594 no no _/ No-
missin
g 
_/ No- 
missing 
withdrew 
 8420 no no _/ no _/ _/ ? H1 peltier fault 
not f2 
 
6.3.4 HSDD 
HSDD Foot 
45oc? 
Hand 
45oC? 
Foot 
p1 
Footp
2 
Handp1 Hand 
p2 
Notes 
No MRI No 
1 7499 _/ _/ _/ _/ _/ _/  
2 7631 _/ _/ _/ _/ _/ _/ VAS 3-4 but 
consistent 
3 7632 _/ _/ _/ _/ _/ _/  
4 7788 _/ _/ _/ _/ _/ _/ VAS 3-4 but 
consistent 
5 7845 _/ _/ _/ _/ _/ _/  
6 7918 _/ _/ _/ _/ _/ _/  
7 8155 no no _/ _/ _/ _/  
8 8196 no _/ _/ _/ _/ _/  
9 8235 _/ _/ _/ _/ _/ _/  
10 8253 no no _/ _/ _/ _/  
11 8258 _/ _/ _/ _/ _/ _/  
12 8373 no no _/ _/ _/ _/  
13 8680 no no _/ _/ _/ _/ VAS 4-5 but 
consistent 
14 8682 no no _/ _/ _/ _/  
 7903 NA NA NA NA NA NA  
 8032 NA NA NA NA NA NA  
 8592 NA NA NA NA NA NA  
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6.4 Notes for processing double echo data 
 
Written July 2010 by Kay Head using first version of spm8, 4D datasets and using the MR Centre 
cluster computer (logged into modred) and updated by Jan Smith in December 2011. 
Knowledge of processing in spm8 is assumed ± so only details of the double echo combination are 
given here. 
 
Summary of process... 
 
Convert PAR/REC data to IMG/HDR floats (ptoa ±f) 
spm8 realign first echo 
Give echo2 the same realignment parameters 
spm8 reslice echo1, reslice echo2 
Run double echo matlab script  
Spm8 normalise and smooth 
Create 1st level model / estimate model / create contrasts 
Create 2nd level model / estimate model / create contrasts 
Making Masks 
2-Sample T test Comparisons 
Using Covariates 
 
Details of method ... 
 
 
Convert PAR/REC data to IMG/HDR floats (ptoa ±f) 
 
With only one set of PAR/REC data in any particular directory you can type... 
 
ptoa ±f  * -this turns data to IMG/HDR data in float format 
 
In window1 type spm8 (choose fMRI option) 
 
spm8 realign first echo 
 
Click Realign (estimate) 
In Data 
        Session 
Select the first echo only) 
RUN 
 
Give echo2 the same realignment parameters 
 
In window2 copy the .hdr and .mat files from the first echo to the second 
i.e.  cp *echo01.hdr *echo02.hdr 
     cp *cdecho01.mat echo02.mat 
This is a trick to pass the realignment parameters to the second echo 
In spm8, run 
 
spm8 reslice echo1, reslice echo2 
 
Realign (reslice) 
In Data 
 Session 1± select first echo data 
 Session 2 ± select second echo data 
RUN 
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Run double echo matlab script  
 
In window2 type  
 
Type fslview 
Load in one of the echo02 files. Look for an intensity value that indicates the maximum 
background noise level ± this should be around 10000-50000 and note this down. 
Exit 
 
type matlab - then choose option L 
type DGGSDWKµKRPHIUDQFLVPDWODE'(GH¶)  
type de (this should run the script) 
 
select your first echo, second echo, type in the echo times and the noise level value 
 
Output files 
ss_map  simple summation 
ws_map summation of echos using t2*map create from the dataset 
?  4D dataset of t2* values 
?  average t2*map 
 
It is recommended to use the weighted summation for the rest of your processing 
 
 
Spm8 normalise and smooth 
 
Normalise the all images to a set template so they can be compared: 
Click on Normalise in SPM8 ± select estimate and write 
For each subject/ scan paradigm create a separate module in the batch editor. 
In each module: 
(1) 6HOHFWWKHPHDQ«LPJILOHIRUWKH6RXUFH,PDJH 
(2) 6HOHFWDOOFRUUHVSRQGLQJUSHOW«ZVBPDSLPJILOHVIRUWKH,PDJHWR:ULWHWKHPHDQLPJ
and ws files need to be for the same subject and paradigm) 
(3) For the template images navigate to the opt/magres/spm8/templates/ and select EPI.nii file 
 
Save file and press Run 
This will produce wr files 
 
Smoothing 
For fMRI, an 8mm3 smoothing is applied is allow some overlap between activation areas to occur 
and reduce the chance of missing a significant activation. 
In SPM8 click on smooth 
In the batch editor create modules for each subject and paradigm 
)RUWKH,PDJHVWR6PRRWKHGVHOHFWDOOWKHZUSHOW«ZVBPDSLPJ 
Change the FWHM to [8 8 8] 
 
Save file and press Run 
This will produce swr files 
 
Quit SPM8 and go into each subject and paradigm file to create separate smooth_8mm folders:  
mkdir smooth_8mm 
Copy the swr files into the new directory: cp swr* smooth_8mm 
 
Now it is time to create the 1st level random effects (RFX) Model 
Make files for the results of the model which will be spm.mat files 
258 
 
Go into each subject file to create a results folder: mkdir combined_results 
 
Create model / estimate model / create contrasts 
1st level random effects (RFX) Model 
 SPM8 and select specify 1st level 
In the batch editor create a module for each subject 
In each module: 
x Directory (where the model will be saved): select the combined_results file that you have 
just created 
x Timing parameters:  
o Units for design:  seconds 
o Interscan interval: 3 (this is the TR interval) 
o Microtime resolution: 16 
o Microtime onset:  1 
x Data and design 
o Click on data and design header and create a subject/session for each paradigm 
e.g. footp1 footp2 handp1 handp2 
x Subject/session: in each of these you need to enter the timings for the events e.g. cues or 
heat pulses and select the corresponding paradigm files and movement covariates which 
are not of interest but need to be taken into account when the model is created 
o Scans: select the smoothed images from the Smooth_8mm 
 Click on the X next to scans 
 A new window will appear 
 Navigate in to the appropriate subject and paradigm folders using the 
left hand box 
 The directory and folder you are in is shown in the box next to DIR at 
the top of the window 
 Click on the smooth_8mm file 
 Under the right hand box is a box with .*  .  
x Type swr.* so that only the swr files are selected 
 The box immediately underneath this contains a 1.  
x Type 1:199 in this box or any number which is greater than the 
number of files in that folder. In the peltier study there are 177 
files per paradigm used per site 
 Press return 
 The right hand box will be populated with all the swr files in the folder 
 Press REC under the left hand box and these selected swr files will be 
moved to the bottom box. 
 Press done and the window will disappear and the number of files 
selected will appear in the Scan row.  
o Click on Conditions 
 In the small grey box below click on new condition until you have 
created  3 conditions this is for the 45oC, VAS and cue events 
 Go back to the current module box above and below the condition 
header click on; 
x Name: enter e.g. 45, VAS or cue 
x Onsets: click on this and then edit value below 
o A new window should appear. Enter the times in 
seconds for the condition events for the appropriate 
paradigm: 
 
 
 
 
 
259 
 
 45 VAS CUE 
Paradigm 1 72 
197 
284 
407 
451 
23 
150 
242 
331 
495 
15 
60 
141 
186 
234 
276 
321 
402 
444 
483 
Paradigm 2 113.4 
240.4 
282.4 
368.4 
452.4 
24.4 
70.4 
155.4 
320.4 
495.4 
12.4 
60.4 
108.4 
144.4 
228.4 
276.4 
315.4 
357.4 
444.4 
486.4 
 
o Duration:  5 
o Time modulation: No Time modulation 
x Repeat for each condition 
 Click on multiple regressors (to exclude movement artefact) 
x Navigate to appropriate subject and paradigm folder and select 
the USBSHOW«HFKRW[WILOH 
 Repeat for each paradigm for each subject 
1% LW LV HVVHQWLDO WR VHOHFW WKH FRUUHFW ILOHV DQG FRUUHVSRQGLQJ USBSHOW«HFKRW[W ILOHV DQG WR
make sure these match the paradigm condition event times that have been entered or the model will 
be wrong. 
Once all the subject and paradigms have been completed save the model file and then press run. 
 
Estimate the model 
In SPM8 click on estimate 
Create a new module for each subject 
Load to spm.mat file created from the model above 
Method: Classical 
Click run to estimate the model 
 
Defining contrasts 
The model is designed as below 
  
Paradigm 1 
Contrasts of interest  Movement artefact 
45  VAS  CUE  X  Y  Z  A  B  C  
 
In the peltier study the order of the paradigms in the model was foot paradigm 2, foot paradigm 1, 
hand paradigm 2 and hand paradigm 1 
When creating contrasts click on the results tab in SPM8 and in the new window navigate to the 
spm.amt model file. Click on the file and select done. 
A new window will appear. 
Click on define contrasts 
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To look at the maps for combined feet VAS events you need to name the contrast in the top box 
and enter in the box below 
0 1 0 0 0 0 0 0 0 0 1 (the highlighted 0 are for the movement artefact) 
 
For the combined Hand vas events enter: 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
 
Alternatively you can create a model with the model estimation and a standard list of contrasts built 
in. In the model file go to the header under batch editor and click on spm.  
Go down the list until stats. 
Click on model estimate and the estimation module will appear in the module list.  
In this model highlight the files selected and click dependency. 
A new window will open with all the model modules in order. 
Click on the appropriate factorial design module from the list. 
 
Return to the spm button below the batch editor header and use the drop down box to select stats 
again. 
This time select contrast manager.  
A new contrast manager module will appear in the module list. 
Click on this 
Highlight the select spm.mat file and click on the dependency button 
Select the appropriate model estimate module from the list which appears in the new window. 
Click on contrast session and create new contrasts for all the events you are interested in. For the 
paradigm study 10 contrasts were created. Negative contrasts will identify areas which deactivated, 
while positive contrasts identify activations to the event. 
 
Name    F1F2VAS     Con 1 
T contrast Vector 0 1 0 0 0 0 0 0 0 0 1 
 
Name    F1F2VASNEG     Con 2 
T contrast Vector 0 -1 0 0 0 0 0 0 0 0 -1 
 
Name    F1F2CUE     Con 3 
T contrast Vector 0 0 1 0 0 0 0 0 0 0 0 1 
 
Name    F1F2CUENEG     Con 4 
T contrast Vector 0 0 -1 0 0 0 0 0 0 0 0 -1 
 
Name    H1H2VAS     Con 5 
T contrast Vector 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
 
Name    H1H2VASNEG     Con 6 
T contrast Vector 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 0 0 0 -1 
 
Name    H1H2CUE     Con 7 
T contrast Vector 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
 
Name    H1H2CUENEG     Con 8 
T contrast Vector 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 0 0 0 -1 
 
Name    F1F2H1H2CUE     Con 9 
T contrast Vector 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
 
Name    F1F2H1H2CUENEG    Con 10 
T contrast Vector 0 0 -1 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 0 0 0 -1 
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Make sure you select the µGRQ¶WUHSOLFDWH¶ IRUWKHµUHSOLFDWHRYHUVHVVLRQ¶IRUHDFKFRQWUDVW 
 
Viewing the model 
View each model click on results in spm8 
A new window will appear. 
Navigate to the model file spm.mat you are interested in 
Select file and click on done 
A new window will appear with the contrasts listed 
Click on the contrast of interest 
In the window below the spm window click on options as follows 
 Mask : no mask 
 Stats: you can choose between corrections for multiple comparisons such as family wise 
error (FWE), FDR and or uncorrected 
 P value: keep the recommended value or alter this depending on the strength of the map 
blobs 
 Voxel threshold: keep as recommended to change to 3 to reduce VPDOO µDFWLYDWLRQ¶GRWV
and to sharpen the map 
The map will appear in the graphics window 
 
All model images for the subjects should be visualised to make sure movement artefact has been 
corrected satisfactorily and the images are of good quality. 
 
 
2nd level model for the group activation maps 
Create folders for the combined model in the main directory: 
mkdir combined_results 
cd combined_results 
mkdir add high_sdd low_sdd ibs 
Go into each file in turn and create folders for each contrast 
mkdir f1f2cueneg f1f2cuepos f1f2vasneg f1f2vaspos h1h2cueneg h1h2cuepos h1h2vasneg 
h1h2vaspos f1f2h1h2cueneg f1f2h1h2cuepos 
 
Type spm8 and select fMRI 
Create a 2nd level effect model for all the contrasts as above ± click on specify 2nd-level 
 
Directory ± select appropriate directory created above e.g. /combined_results/add/f1f2vaspos 
 
Click on scans and then select files ± in the new window go to each patient folder and the 1st level 
model results file and pick up the con files for that condition in all subjects in the study e.g. f1f2vas 
positive (con_1) or h1h2vas positive (con_5) etc 
 
Do not add covariates 
 
Add a model estimation after each factorial design 
Go to spm on the top of the Batch editor window ± go to stats and select model estimate 
In the module list click on model estimation 
Click on select spm.mat and then on dependency on the bottom right of the window 
A New window will appear. Click on the appropriate factorial design specification file and then 
o.k. 
 
You need a new model estimate for each factorial design specification 
 
Add a contrast for the group maps 
Go to spm on the top of the Batch editor window ± go to stats and select contrast manager 
In the module list click on contrast manager 
Click on select spm.mat and then on dependency on the bottom right of the window 
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A New window will appear. Click on the appropriate model estimate file and then o.k. 
Make contrast as before-  
Name:  grpmap  
Contrast: 1  
 
Save the model in the main or combined_results directory 
 
Click on the green arrow to run the model 
 
Once model completed 
Click on results 
In results window  
No mask 
P value FDR p0.05 or uncorrected p0.001 as strength of blobs allows  
Voxel threshold 3 
 
Check to make sure pictures o.k. 
To create a list of the active brain regions use the stats window in which you selected the statistic 
test and p value etc DQGFOLFNRQWKHµZKROHEUDLQ¶WDE 
A list will appear below the brain maps 
Hover the mouse cursor over the list on the screen and press the right hand button on the mouse ± 
several options will appear. Select the print list option and the list will appear in the modred 
window. 
Click on the modred window on the header bar and then right click in the same area. A window and 
OLVWZLOODSSHDU6HOHFWµFRS\DOOWRFOLSERDUG¶ 
 
Open notepad and then paste the copied clipboard. The list should appear with other text which can 
be edited to just leave the list. 
 
Save as a text file. 
 
2SHQ0LFURVRIWH[FHODQGLPSRUWWKHVDYHGWH[WILOH0DNHVXUH\RXVHOHFWµ'HOLPLWHG¶DQGWKHQKLW
QH[W,QWKHQH[WZLQGRZVHOHFWµWDE¶DQGµVSDFH¶RSWLRQVDQGWKHQµILQLVK¶7KHOLVWVKRXOGDSSHDULQ
the excel window.  
 
The x y z co-ordinates are always at the right hand side. However in active areas, where there are 
several peaks, a list of minor peaks will appear under the major peak. These values and co-
ordinates can be shifted to the left. Therefore drag this row to the right so that all the x y z co-
ordinates line up in the same columns on the right hand side. 
 
To determine what brain region the co-ordinate refers to you need to use the pick atlas.  
7RORDGWKHSLFNDWODVJRWRWKHPDLQQDPHGZLQGRZRIVSPDQGFOLFNRQµZIXSLFNDWODV¶WDEXQGHU
the spm for functional MRI. 
A new window will load. 
At the bottom of the window is several boxes to enter co-ordinates and in the middle a list of the 2 
option boxes which determine how the brain areas are expressed. Select one to be the TA 
%URGPDQQ¶V areas + and the other to be AAL. 
 
Enter the x, y, and z co-ordinates for each activate into the middle row of boxes on the left marked 
as MNI. Press go at the end of the row and the brain regions will appear. You can check the 
location by looking for the pale blue spot that appears over the brain image above. 
 
Write the brain region adjacent to the co-ordinates in the excel file.  
 
To do further comparisons such as inter and intra group, a mask is sometimes needed so only the 
brain areas of interest and selected and the power of the maps is improved. 
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Making a mask: 
Create folders for the masked data: 
mkdir masks 
cd masks 
mkdir cueneg cuepos vasneg vaspos 
in each of these folders make directories for the foot and hand ± mkdir feet hand 
 
Type spm8 and select fMRI 
Create a 2nd level effect model for all the subjects for the e.g. cue or negative vas for the hand and 
foot ± click on specify 2nd-level 
 
Directory ± select appropriate directory created above e.g. /masks/vaspos/feet 
 
Click on scans and then select files ± in the new window go to each patient folder and the 1st level 
model results file and pick up the con files for that condition in all subjects in the study e.g. f1f2vas 
positive (con_1) or h1h2vas positive (con_5) etc 
 
Do not add covariates 
 
Add a model estimation after each factorial design 
Go to spm on the top of the Batch editor window ± go to stats and select model estimate 
In the module list click on model estimation 
Click on select spm.mat and then on dependency on the bottom right of the window 
A New window will appear. Click on the appropriate factorial design specification file and then 
o.k. 
 
You need a new model estimate for each factorial design specification 
 
Save the model in the masks directory 
 
Click on the green arrow to run the model 
 
Once model completed 
Click on results 
Make contrast as before- grpmap, 1  
In results window  
No mask 
P value none p 0.001  
Voxel 3threshold 3 
 
Check to make sure pictures o.k. 
 
Click on imCalc to make into binary files 
Input images ± select spmT_0001 for 1 of masks e.g. vasneg feet 
Output file e.g. vasnegfeet_ 308 
Output directory e.g. /masks/vasneg/feet/ 
Expression = i1>3.08      (to get a p0.001) 
 
Do not change the other settings 
 
Save and run model 
 
Repeat steps above but change the output file name and the expressions to 
Output file e.g. vasnegfeet_ 258 
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Expression = i1>2.58      (to get a p0.005) 
 
Output file e.g. vasnegfeet_ 235 
Expression = i1>2.35      (to get a p0.01) 
 
Check binary images by hit display and select output file(s) from above 
 
When combining 2 binary models e.g. hand and foot vas positive to make a combined model select 
imcalc again 
In the input file select both images of the same p value to be combined: 
Input images ± select vasposfeet_ 258.img and vasposhand_258.img 
Output file e.g. sumf1f2h1h2vaspos_ 258 
Output directory e.g. /masks/vaspos/ 
Expression = i1+i2       
 
By adding the binary models some of areas will become 2 (e.g.1+1) 
To convert them all back to 0 or 1 again o back into imCalc 
Input images ± sumf1f2h1h2vaspos_ 308 
Output file e.g. finalf1f2vaspos_binary_308 
Output directory e.g. /masks/vaspos/ 
Expression = i1>1      
 
NB In the peltier study - f1f2h1h2cuepos mask called vaspos_... by mistake! But are in the 
masks/cuepos/feet/ directory. 
 
2-sample-t-tests 
Using a mask in inter-group and intra-groups comparisons 
For the comparisons between the groups and for the hand and foot comparisons within a group a 
mask is needed to exclude brain areas with no activations and to increase the power in those areas 
which activate or deactivate. 
 
Foot_Hand Comparison 
In modred create folders for the new comparisons 
mkdir comp_handfeet 
cd comp_handfeet 
mkdir add low_sdd high_sdd ibs 
In each of these folders make folders for the comparisons e.g. 
cd add 
mkdir vaspos vasneg cuepos cue neg 
 
Once folders are made: 
Type spm8 and select fMRI 
 
Select 2nd level effects 
,QWKHEDWFKHGLWRUFUHDWHPRGXOHVIRUDOOWKHFRPSDULVRQVHJYDVSRVFXHSRVYDVQHJ«« 
 
In each module 
x Directory: Navigate and select the folder for the comparison e.g. 
comp_handfett/add/vaspos 
x Click on design and in the box below click on 2-sample-t-test 
x A list of group 1 and group 2 scans will appear 
o In group 1 select all the contrast files for the subjects in the group as 
previously that correspond to the e.g. handvaspos ± con5 
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o In the group 2 select all the contrast files for the subjects in the group as 
previously that correspond to the e.g. feetvaspos ± con1 
x Do not add a covariate 
x Under the masking heading click on explicit masks 
x Navigate to the mask folders and select the combined hand and foot vas mask 
created earlier. Select the 308 mask first. If iWGRHVQ¶WZRUN\RXFDQJREDFNDQG
try the looser 258 etc masks instead.  
x Do not change the other parameters 
x Add a model estimate and contrast manager as previous 
x In the contrast manager you will need 2 contrasts 
o Group 1 vs. Group 2 i.e. areas where the hand has greater activations or 
deactivations compared to the foot.  
 Name the contrast e.g. hand_foot 
 Contrast [1 -1] 
o Group 2 vs. Group 1 i.e. areas where the foot has greater activations or 
deactivations compared to the hand.  
 Name the contrast e.g. foot_hand 
 Contrast [-1 1] 
o Repeat with the other modules 
o Save the model and press run 
o Check the images as before selecting the hand_foot contrast initially and 
then repeat the processing by selecting the results tab again but selecting 
the foot_hand contrast instead. The maps should be different. The blobs 
will be weaker than for the group maps made above and you may have 
to use fdr with a reduced p value to p=0.1 or even uncorrected and 
reduce the p value to p=0.01 or p=0.05 to see blobs.  
o You can also create lists of active areas and identify the using the pick 
atlas as above. 
 
The mask is designed so that only the positive differences are seen on the maps and not negative 
contrasts from the other group. This will allow you to be confident that what you are seeing is just 
the areas where there is greater activation or deactivation for the group with the main contrast (i.e. 
1) 
 
Intergroup contrasts 
To look at differences between groups repeat the same steps for the hand and foot comparisons 
above but creating new folders for the contrast. 
Mkdir comp_groups 
Cd comp_groups 
Mkdir add low_sdd high_sdd ibs 
Go into each of these e.g. 
Cd add 
Make folders for each contrast e.g. 
Mkdir f1f2vaspos f1f2vasneg h1h2vaspos h1h2vasneg f1f2h1h2cuepos f1f2h1h2cueneg 
 
In the module you will need to compare many contrasts e.g. f1f2vaspos, f1f2vasneg, h1h2vaspos, 
h1h2vasneg, f1f2h1h2cuepos, f1f2h1h2cueneg, 
 
Make modules for all of these 
Select the 2-sample-t-test in the design heading as before 
o In group 1 select all the contrast files for the subjects in the group e.g. 
ADD as previously that correspond to the e.g. f1f2vaspos ± con1 
o In the group 2 select all the contrast files for the subjects in the group 
e.g. IBS as previously that correspond to the e.g. f1f2vaspos ± con1 
Add the mask to the module and model estimate as above 
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In the contrast manager make sure you name the contrasts as per the group e.g. if grp 1=ADD and 
Grp 2 =IBS so: 
Contrast 1 
x Name the contrast e.g. ADD_IBS 
x Contrast [1 -1] 
Contrast 2 
x Name the contrast e.g. IBS_ADD 
x Contrast [-1 1] 
 
Save the model and press run. 
Look at the maps, activation list and identify the areas with the pick atlas as above.  
 
Using covariates 
These allow you to see if there is any significant correlation between the e.g. anxiety score on 
questionnaires to the brain map activations.  
 
start by creating new folders for the covariate of interest e.g. anxiety 
mkdir anxiety 
cd anxiety 
mkdir add low_sdd high_sdd ibs 
In each of these folders make folders for the comparisons e.g. 
cd add 
mkdir f1f2vaspos f1f2vasneg h1h2vaspos h1h2vasneg f1f2h1h2cuepos f1f2h1h2cueneg 
  
Go into spm8 and select fMRI 
Select modules for all the contrasts as above 
,QHDFKPRGXOHVHOHFWWKHDSSURSULDWHIROGHUIRUWKHFRQWUDVWLQWKHµGLUHFWRU\¶ 
 
In the design select the 1-sample -t ±test 
 
7KLVZLOOFUHDWHRQO\µJURXS¶LQZKLFKWRVHOHFWWKHFRQILOHV 
Add the con files for the group and contrast of interest e.g. all the subjects in ADD for the 
f1f2vaspos (con1) 
 
Click on covariate 
In the box below click on new covariate  
Under the covariate a list of vector, name, interactions and centering will appear 
Click on name and then edit at the bottom of the window 
In the new window that appear label the covariate e.g. anxiety 
 
Click on vector and then edit 
In the new window enter the list of anxiety scores from the questionnaire 
e.g. 7 
 4 
 8 
 0 
 
The order of the anxiety scores must correspond to the order in which the con files from each 
VXEMHFWZKHUHVHOHFWHGLQWKHµJURXS¶ ILOHVDERYHHJ LIVXEMHFWZDVORDGHGILUVW WKH ILUVW 
number in the covariate anxiety list must be subjects 08789 score and so on. 
 
Leave the interactions and centering as per recommendations 
 
NB. Do not add an explicit mask for this model 
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Set up the other modules, add model estimation files and contrast manager 
In the Contrast manager set up 2 contrasts 
Contrast 1 
x Name the contrast e.g. grp_map 
x Contrast [1 0]  
Contrast 2 
x Name the contrast e.g. anxiety 
x Contrast [0 1] 
 
Save and run the model 
 
To look at the maps for the covariates you need to increase the power by masking using the 
grp_map contrast. 
 
Select results and navigate to the covariate and event of interest e.g. f1f2vaspos 
Select and load the file as previously 
In the contrast window select the anxiety contrast (e.g. contrast 2) 
 
In the stats window it will ask for mask 
Previously you should have selected no for this. This time click on yes and the contrast window 
will reappear again.  
Select the grp_map as the contrast. 
 
For the statistical power you may have to use fdr or uncorrected with a reduced p value as with the 
other comparisons above. 
 
Select voxel threshold to 3 as previously 
 
You can make list of the active areas and brain locations using the pick atlas as above.  
 
For each covariate you are interested in make a new model repeating the steps above and creating 
new folders for each.  
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6.5 Inter-Group Comparison functional MRI tables 
 
ADD VS LSDD activations during VAS temperature stimulus left Foot  
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 9 0.013 2.35 2.22 34 -28 6 13 right insula (post) 
Frontal 33 0.007 2.62 2.45 36 26 26   right inferior tri frontal 
 5 0.019 2.18 2.07 56 -10 18   right rolandic operculum (s2) 
Cerebellum 51 0.014 2.34 2.21 -20 -30 -28   left cerebellum (4,5) + pedicle 
 5 0.041 1.8 1.74 0 -48 -26   vermis 10 
Temporal 7 0.037 1.85 1.78 56 -8 -2 22 right superior temporal 
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LSDD VS ADD activations during VAS temperature  stimulus left foot 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 1081 0.001 3.66 3.26 32 0 -2   right putamen, insula (ant), amygdala 
 17 0.028 2 1.91 -40 20 2 13 left insula (ant) 
Cingulate 32 0.013 2.37 2.24 4 -22 40   right mid cingulum 
 84 0.019 2.19 2.09 4 28 22 24 right anterior cingulum 
Frontal 101 0.002 3.22 2.93 -48 6 18   left inferior operculo-frontal (?s2) 
 
208 0.002 3.09 2.83 8 18 52 6 
right supplemental motor area, superior medial frontal, mid 
cingulum 
 
427 0.002 3.08 2.82 52 18 12 45 
right frontal (inferior operculo-frontal, mid and inferior tri) 
(s2) 
 93 0.005 2.74 2.54 46 12 48   right frontal (mid and inferior operculo-) 
                   
 61 0.016 2.26 2.14 40 2 36   right precentral 
 5 0.035 1.88 1.81 50 10 20   right inferior operculo-frontal 
Thalamus and caudate 
424 0.003 3 2.76 -16 6 0 
putamen & 
med. globus 
pallidus left pallidum and putamen 
Subthalamic & 
Brainstem 141 0.007 2.66 2.48 -2 -24 -6   left  upper brainstem/thalamus and vermis (3) 
Temporal 13 0.018 2.2 2.09 -38 16 -20   left superior temporal pole 
Amygdala & HippoC 30 0.019 2.17 2.07 -20 0 -16 34 left amygdala 
Parietal 301 0.005 2.74 2.55 42 -56 46 40 right inferior parietal 
 121 0.006 2.73 2.54 64 -22 32   right supra marginal 
 19 0.007 2.63 2.45 12 -72 40 7 right precuneus 
S1 & S2 133 0.002 3.12 2.85 42 -30 58   right post and precentral 
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ADD VS HSDD activations during VAS temperature stimulus left Foot  
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Cingulate 76 0.006 2.73 2.53 0 -22 34   left mid cingulum 
Frontal 23 0.012 2.38 2.24 -2 14 50 6 left supplemental motor area 
 6 0.025 2.05 1.96 22 -18 68 6 right precentral 
Thalamus and caudate 59 0.01 2.49 2.34 2 -18 6 pulvinar right and left thalamus 
Subthalamic & 
Brainstem 110 0.001 3.45 3.1 -20 -28 -32   left brainstem 
 36 0.008 2.6 2.43 -14 -22 -12   left brainstem 
 16 0.017 2.25 2.13 8 -24 -32   right brainstem 
Cerebellum 62 0.013 2.37 2.23 -32 -44 -30   left cerebellum (6) 
Temporal 10 0.04 1.82 1.75 56 -6 -2   right superior temporal (s2) 
Amygdala & HippoC 13 0.022 2.1 2.01 52 -22 24   right supra marginal 
Parietal 6 0.029 1.98 1.9 -52 -46 50 40 left inferior parietal 
 5 0.037 1.85 1.78 -62 -46 36 40 left supra marginal 
 8 0.012 2.38 2.25 10 -52 68 7 right precuneus 
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HSDD VS ADD activations during VAS temperature stimulus left foot 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 106 0.011 2.43 2.29 36 18 -2 47 right insula (ant) 
Cingulate 11 0.032 1.93 1.85 6 32 20 24 right ant cingulum 
 12 0.034 1.89 1.82 -6 2 30   left ant cingulum 
 6 0.036 1.87 1.8 16 16 36 32 right mid cingulum 
 
11 0.026 2.04 1.95 -6 -28 24 
Post. corpus 
callosum  & 
cingulum   
Frontal 263 0.003 3.04 2.79 32 44 4 10 left inferior tri frontal and right mid frontal 
 59 0.008 2.57 2.41 52 32 22   right inferior tri frontal 
 26 0.012 2.41 2.27 -48 8 18   left inferior operculo-frontal (s2) 
 54 0.013 2.36 2.23 36 -2 42 6 right precentral 
 8 0.013 2.35 2.22 -38 -2 44   left precentral 
 22 0.022 2.11 2.01 34 -18 60   right precentral 
Thalamus and caudate 
160 0.004 2.82 2.61 -26 10 2 
putamen & lat. 
globus 
pallidus left putamen and pallidum 
 307 0.009 2.54 2.38 32 0 -2 putamen right putamen 
Temporal 147 0.002 3.12 2.85 -50 -4 -6 38 left superior temporal + pole (s2) 
 6 0.044 1.76 1.71 66 -40 22   right superior temporal 
Amygdala & HippoC 121 0.013 2.34 2.21 -36 12 -20 amygdala left superior temporal pole and amygdala 
Parietal 32 0.017 2.22 2.11 42 -46 48   right inferior parietal and supramarginal 
 6 0.03 1.97 1.89 -44 -40 26   left supra marginal 
 6 0.04 1.81 1.75 66 -22 34 2 right supra marginal 
S1 & S2 28 0.01 2.49 2.33 60 -12 22   right postcentral (s2) 
 19 0.019 2.19 2.08 -60 -16 28 3 left postcentral 
 
  
272 
 
ADD VS IBS activations during  VAS temperature  stimulus left Foot  
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Cingulate 8 0.033 1.91 1.84 2 38 12 24 left ant cingulum 
Frontal 75 0.004 2.92 2.69 -8 28 34 9 left superior medial frontal 
 15 0.014 2.32 2.2 -28 52 16   left mid frontal 
 30 0.027 2.02 1.93 -2 14 48 6 left supplemental motor area 
 3 0.031 1.94 1.87 -46 22 -8   left inferior orbito-frontal 
 10 0.031 1.94 1.86 54 -4 40   right precentral 
 3 0.034 1.9 1.83 -50 20 -10 47 left inferior orbito-frontal 
 5 0.038 1.83 1.77 52 -14 22   right rolandic operculum (s2) 
Temporal 56 0.002 3.27 2.96 66 -18 2   right superior temporal (s2) 
 13 0.024 2.08 1.98 40 22 -26 38 right superior temporal pole 
Parietal 8 0.024 2.07 1.98 -54 -40 50 40 left inferior parietal 
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IBS VS ADD activations during VAS temperature stimulus left foot 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 1744 0 3.74 3.32 52 8 20 13 right (insula mid/post) inferior operculo-frontal, (s2) 
 109 0.005 2.75 2.55 -38 18 4 13 left insula (ant) 
 57 0.024 2.06 1.97 -50 2 22   left precentral, insula (mid) and rolandic operculum (S2) 
Cingulate 30 0.008 2.59 2.42 -6 4 30   left ant cingulum 
 
49 0.018 2.2 2.09 8 -30 26 
Post corpus 
callosum  right mid cingulum 
 22 0.024 2.07 1.98 8 26 28 32 right ant cingulum 
Frontal 325 0 3.75 3.32 48 38 -10   right inferior orbito-frontal 
 64 0.004 2.85 2.63 52 34 26   right inferior tri frontal 
 120 0.006 2.73 2.53 10 0 50   right supplemental motor area 
 59 0.007 2.62 2.45 10 -10 66 6 right supplemental motor area 
 48 0.008 2.56 2.4 36 -2 40 6 right precentral 
 39 0.009 2.5 2.35 34 -20 60   right precentral 
 8 0.016 2.26 2.14 -46 40 16 46 left mid frontal 
 50 0.02 2.16 2.06 34 40 14   right mid frontal 
 20 0.021 2.13 2.03 8 28 54   right superior medial frontal 
 5 0.038 1.84 1.78 12 -24 48   right supplemental motor area 
Thalamus and caudate 10 0.029 1.98 1.9 18 4 0 putamen right pallidum 
 24 0.015 2.29 2.17 16 -12 2   right thalamus 
Cerebellum 7 0.026 2.04 1.95 -40 -48 -38   left crus (1) cerebellum 
 179 0.002 3.21 2.92 -2 -20 -4 red nucleus  vermis (3) 
 40 0.011 2.45 2.3 4 -60 -32   vermis (8) 
 52 0.006 2.71 2.52 -20 -48 -30   left cerebellar pedicle and cerebellum (6) 
Temporal 3 0.018 2.2 2.09 30 -28 16 13 right heschl 
 13 0.006 2.67 2.49 56 -56 0   right mid temporal 
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IBS VS ADD Activations during VAS temperature stimulus left foot continued 
Parietal 6 0.036 1.87 1.8 60 -42 24   right supra marginal 
 9 0.027 2.01 1.93 12 -70 42   right precuneus 
 430 0.001 3.53 3.16 66 -22 26 40 right supra marginal 
 301 0.001 3.34 3.02 -52 -42 34 13 left supra marginal and superior temporal 
 217 0.003 2.98 2.74 -46 -6 -6 22 left superior marginal 
Occipital 
5 0.042 1.79 1.73 -6 -28 24 
Post corpus 
callosum left)/ 
post cingulum   
 
ADD VS  LSDD  Deactivations during  vas  stimulus left Foot  
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Temporal 18 0.024 2.08 1.98 -40 -38 8   left superior temporal and rolandic operculum (s2) 
 8 0.013 2.35 2.22 54 -54 -18 20 right inferior temporal 
Parietal 23 0.006 2.7 2.51 -28 -24 62   left precentral 
S1 & S2 281 0.002 3.27 2.97 44 -28 58 2 right post and precentral 
 329 0.004 2.9 2.67 -38 -32 58 3+4 left post and precentral 
Occipital 232 0.004 2.91 2.69 -36 -82 16   left mid occipital 
 97 0.005 2.77 2.57 40 -72 -12   right inferior occipital 
 121 0.015 2.3 2.17 -46 -70 -8   left inferior occipital 
 92 0.023 2.08 1.99 38 -76 18 19 right mid occipital 
 6 0.021 2.13 2.03 -30 -70 -4 19 left lingual 
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LSDD  VS ADD  Deactivations during VAS temperature stimulus left foot 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Frontal 90 0.001 3.55 3.18 -20 56 16   left superior frontal 
 757 0.001 3.42 3.08 6 54 12 10+9 left and right superior medial frontal 
 22 0.014 2.33 2.21 -16 40 50   left  frontal (superior and superior medial) 
 16 0.019 2.19 2.09 -42 20 32   left inferior operculo-frontal 
Cerebellum 16 0.011 2.45 2.3 -22 -28 -26   left cerebellum (4,5) 
 33 0.014 2.31 2.19 30 -38 -28   right cerebellum (4,5) 
Temporal 403 0.004 2.89 2.67 -48 -56 22   left mid temporal, angular and mid occipital 
 11 0.007 2.66 2.48 66 -12 -12 21 right mid temporal 
 51 0.01 2.47 2.32 48 0 -36 20 right inferior temporal 
Parietal 24 0.017 2.24 2.12 -32 -62 60   left superior parietal 
 55 0.026 2.04 1.95 -8 -60 42   left precuneus 
 20 0.035 1.88 1.81 -8 -56 10   left precuneus 
Occipital 34 0.022 2.11 2.01 12 -82 26   right cuneus 
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ADD VS HSDD Deactivations during VAS temperature stimulus left Foot  
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Frontal 30 0.001 3.56 3.18 -36 20 24   left inferior tri frontal 
 10 0.011 2.44 2.3 -50 22 30   left inferior tri frontal 
 8 0.024 2.08 1.99 10 48 24   right superior medial frontal 
 10 0.038 1.84 1.77 -26 14 54   left mid frontal 
 22 0.025 2.05 1.96 34 -18 60   right precentral 
 16 0.021 2.12 2.03 30 -22 44   right precentral 
 5 0.04 1.81 1.75 -28 6 46   left mid frontal 
 5 0.042 1.79 1.73 28 16 48 8 right mid frontal 
 7 0.044 1.76 1.71 -14 50 0   left superior medial frontal 
Temporal 28 0.019 2.17 2.07 -54 -40 -14   left mid temporal 
 15 0.023 2.08 1.99 52 -54 -18 20 right inferior temporal 
 5 0.025 2.06 1.96 -26 -14 -34   left fusiform 
 39 0.03 1.95 1.88 24 -38 -14   right fusiform 
 334 0.004 2.87 2.65 -48 -66 -10   left inferior temporal 
 34 0.007 2.66 2.48 -30 -58 -12   left fusiform 
 50 0.007 2.65 2.47 -54 2 -18   left mid temporal 
 14 0.008 2.56 2.4 34 -10 -40 20 right fusiform 
 10 0.039 1.83 1.77 -32 -16 -26   left fusiform 
 5 0.042 1.79 1.73 -62 -14 -12 21 left mid temporal 
Amygdala & HippoC 65 0.022 2.11 2.01 -32 -36 -12   left parahippocampus 
 15 0.03 1.97 1.89 26 -12 -22 hippoC right hippocampus 
 71 0.016 2.27 2.15 -36 -36 12   left parahippocampus 
 6 0.042 1.79 1.73 -24 -8 -20 amygdala left hippocampus 
Parietal 35 0.024 2.07 1.98 -18 -64 48 7 left superior parietal 
S1 & S2 93 0.001 3.43 3.08 62 -8 22 43 right postcentral 
 362 0.001 3.41 3.07 -32 -18 50   left pre and postcentral 
 24 0.006 2.68 2.5 -60 -10 30   left postcentral 
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ADD VS  HSDD Deactivations during VAS temperature stimulus left Foot continued 
Occipital 383 0.003 3.06 2.8 18 -70 -12   right lingual, fusiform and inferior occipital 
 90 0.009 2.54 2.38 38 -76 8   right mid occipital 
 83 0.013 2.38 2.24 22 -86 28 19 right superior occipital 
 20 0.029 1.97 1.89 -34 -82 14   left mid occipital 
 
HSDD VS ADD Deactivations during VAS temperature stimulus left foot 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Cingulate 27 0.02 2.16 2.06 -8 -42 48   left mid cingulum 
Frontal 6 0.015 2.3 2.17 -28 28 34   left mid frontal 
 15 0.019 2.19 2.08 0 54 38   left superior medial frontal 
 17 0.026 2.03 1.95 0 -38 66   paracentral lobule 
 30 0.001 3.36 3.04 -20 54 18   left superior frontal 
Thalamus and caudate 6 0.035 1.88 1.81 -12 -30 4 pulvinar left thalamus 
Subthalamic & 
Brainstem 6 0.032 1.92 1.85 -8 -30 -36   left brainstem 
Cerebellum 9 0.008 2.58 2.41 -24 -28 -28   left cerebellum (4,5) 
 33 0.014 2.33 2.2 24 -38 -30   right cerebellum (4,5) 
 5 0.021 2.12 2.02 -34 -36 -30   left cerebellum (6) 
 5 0.025 2.04 1.96 4 -48 4   vermis (4,5) 
Temporal 53 0.014 2.32 2.2 42 4 -34   right mid temporal and pole 
 5 0.021 2.14 2.04 -20 -46 -16   left fusiform 
 11 0.023 2.09 2 -28 -4 -34   left fusiform 
Parietal 35 0.02 2.15 2.05 -40 -72 48   left angular 
 5 0.023 2.09 2 -52 -66 40 39 left angular 
 9 0.031 1.94 1.87 -34 -60 58 7 left superior parietal 
 21 0.008 2.57 2.41 10 -54 66 7 right precuneus 
 14 0.025 2.05 1.96 10 -48 48   right precuneus 
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ADD VS IBS Deactivations during VAS temperature stimulus left Foot  
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 104 0.003 2.93 2.7 -38 -38 16 13 left insula (post) and superior temporal 
Frontal 124 0.007 2.65 2.47 -36 -20 54 4 left precentral 
 18 0.008 2.59 2.42 -36 20 22   left inferior tri frontal 
 38 0.01 2.49 2.34 34 -20 60   right precentral 
Thalamus and caudate 7 0.039 1.82 1.76 20 28 -6   right caudate 
Cerebellum 17 0.017 2.23 2.12 24 -52 -34   left cerebellar pedicle 
Temporal 6 0.038 1.84 1.78 -4 -46 64   left precuneus 
 116 0.006 2.73 2.53 -50 -54 -20 19+20 left inferior temporal 
 55 0.006 2.7 2.51 28 -30 16 13 right heschl 
 20 0.014 2.33 2.2 50 -46 -6   right inferior temporal 
 8 0.016 2.27 2.15 54 -54 -18 20 right inferior temporal 
 235 0.008 2.59 2.42 32 -60 -12   right fusiform, putamen and lingual 
 13 0.021 2.12 2.03 34 -10 -40 20 right fusiform 
 38 0.023 2.09 2 -32 -20 -28   left fusiform 
 8 0.027 2.01 1.92 -30 -60 -6   left fusiform 
 14 0.029 1.97 1.89 -46 -24 -12   left mid temporal 
Amygdala & HippoC 120 0.007 2.66 2.48 22 -34 -2   right hippocampus 
 65 0.009 2.54 2.38 -20 -38 -6   left parahippocampal 
 15 0.018 2.21 2.1 38 -18 -20   right hippocampus 
       
  
          
Parietal 6 0.029 1.97 1.89 -26 -68 42   left inferior parietal 
S1 & S2 65 0.006 2.68 2.5 -40 -32 58   left postcentral 
Occipital 236 0.005 2.74 2.55 -34 -82 14 13 left occipital (mid and superior) 
 236 0.01 2.47 2.32 24 -84 20   right occipital (superior  and mid) and mid temporal 
 162 0.005 2.77 2.57 -18 -84 -4   left lingual 
 25 0.031 1.94 1.87 -40 -72 0   left mid occipital 
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IBS VSADD Deactivations during VAS temperature stimulus left foot 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Cingulate 6 0.036 1.87 1.8 -4 -42 48   left mid cingulum 
Frontal 470 0.002 3.25 2.95 8 54 14 10 right  frontal (superior medial  and superior) 
 37 0.006 2.67 2.49 -16 40 50   left superior frontal 
 41 0.012 2.41 2.27 -28 28 34 8+9 left mid frontal 
 10 0.017 2.23 2.12 -44 28 -12   left inferior orbito-frontal 
 6 0.029 1.97 1.89 -42 22 34 9 left mid frontal 
Cerebellum 
197 0.011 2.45 2.3 4 -52 2 
corpus 
callosum + 30 vermis (4,5) and right precuneus and calcarine 
Temporal 6 0.023 2.08 1.99 -66 -30 -10 21 left mid temporal 
 4 0.028 1.99 1.9 44 16 -34 38 right mid temporal pole 
 10 0.03 1.97 1.89 64 -10 -12   right mid temporal   
Amygdala & HippoC 24 0.024 2.07 1.98 -24 -24 -18   left parahippocampus 
Parietal 95 0.006 2.7 2.51 -32 -60 60   left superior parietal 
 47 0.019 2.18 2.07 -52 -70 34 19+39 left angular 
 150 0.011 2.42 2.28 -10 -56 10   left precuneus 
 70 0.016 2.26 2.14 4 -70 54   right precuneus 
 26 0.018 2.2 2.09 -8 -58 48 7 left precuneus 
S1 & S2 3 0.036 1.86 1.8 52 -12 36   right postcentral 
Occipital 5 0.037 1.85 1.79 -14 -88 40 19 left superior occipital 
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ADD VS LSDD activations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 5 0.038 1.84 1.78 -26 20 12   left insula (ant) 
Cingulate 15 0.029 1.98 1.9 -6 -32 26   left post cingulum 
Frontal 103 0 3.86 3.4 38 26 30   right mid frontal 
 16 0.008 2.58 2.41 -44 46 16 10 left mid frontal 
 17 0.01 2.49 2.33 -28 56 22 10 left superior frontal 
 65 0.01 2.47 2.32 54 -12 20   right rolandic operculum (S2) 
 15 0.011 2.44 2.3 -2 16 56 8 left supplemental motor area 
 38 0.013 2.35 2.22 40 -30 22   right rolandic operculum 
 5 0.019 2.18 2.07 14 32 36   right superior frontal 
 9 0.019 2.18 2.07 -52 -4 46 6 left precentral 
Subthalamic & 
Brainstem 15 0.012 2.38 2.24 2 -20 -22   right brainstem 
Cerebellum 14 0.036 1.87 1.8 2 -38 -28   vermis 
Temporal 6 0.024 2.07 1.98 62 -52 22   right superior temporal 
Amygdala & HippoC 30 0.013 2.36 2.23 -40 -8 14   left amygdala/left mid temporal 
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LSDD VS ADD activations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 9 0.041 1.8 1.74 34 24 -2   right insula (ant) 
Cingulate 243 0.001 3.43 3.09 4 30 18 24 right ant cingulum 
 219 0.005 2.8 2.59 16 16 38   right mid cingulum 
Frontal 216 0.005 2.81 2.6 36 42 16 10 right frontal (mid  and inferior tri) 
 37 0.011 2.42 2.28 -12 8 48 32 left supplemental motor area 
 44 0.02 2.17 2.06 -48 0 16   left rolandic operculum (s2) 
 11 0.038 1.84 1.78 46 42 -12 11 right inferior orbito-frontal 
 6 0.045 1.75 1.7 8 2 54 6 right supplemental motor area 
Thalamus and caudate 
734 0.001 3.64 3.24 -2 -18 -8 
red nucleus, 
ventral lateral 
nucleus, 
medial globus 
pallidus right thalamus 
 10 0.02 2.17 2.06 12 8 -4 putamen right pallidum 
 
6 0.041 1.8 1.74 10 -16 10 
medial dorsal 
nucleus right thalamus 
Cerebellum 439 0 3.99 3.49 -32 -60 -26   left cerebellum (6) 
 179 0.004 2.84 2.62 -4 -80 -20   left crus (1) cerebellum 
 8 0.018 2.21 2.1 24 -72 -26   right cerebellum (6) 
 42 0.025 2.05 1.96 0 -52 -16   vermis (4,5) 
 6 0.039 1.83 1.76 0 -60 -26   vermis (8) 
Temporal 5 0.041 1.8 1.74 -54 -36 14   left superior temporal 
 7 0.034 1.89 1.82 50 4 -18   right mid temporal pole 
 265 0.003 3.04 2.79 54 -20 4   right superior temporal   
 12 0.029 1.98 1.9 -32 -26 4   left heschl 
Amygdala & HippoC 1418 0.001 3.55 3.18 34 2 -18 28 right amygdala, insula (post), superior temporal pole 
 
709 0.003 2.97 2.73 -36 12 -18 
47/12 and 
putamen left putamen and amygdala 
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LSDD VS ADD activations during VAS temperature stimulus left hand continued 
Parietal 220 0 3.93 3.45 62 -22 32   right supra marginal 
 84 0.012 2.39 2.25 -58 -28 36   left supra marginal 
 255 0.014 2.34 2.21 46 -44 44 40 right supra marginal and inferior parietal 
 22 0.031 1.95 1.87 44 -38 56 40 right inferior parietal 
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ADD VS HSDD activations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Cingulate 116 0.004 2.89 2.66 -4 -24 30 23 left and right mid cingulum 
 
250 0.005 2.74 2.55 -6 22 32   
left mid cingulum and left and right supplemental motor 
areas 
 79 0.007 2.66 2.48 12 28 34 9 right mid cingulum 
 
12 0.019 2.17 2.06 -2 24 16 
Corpus 
callosum left anterior cingulum 
 8 0.038 1.84 1.77 6 -26 48   right mid cingulum 
Frontal 690 0 4.25 3.67 -44 46 16 10 left frontal (mid + inferior tri) 
 311 0.003 2.98 2.74 34 34 28   right frontal (mid + inferior tri) 
 24 0.01 2.47 2.32 -14 2 62   left supplemental motor area 
 44 0.015 2.28 2.16 -42 -4 14 13 left rolandic operculum(s2) 
 29 0.018 2.22 2.1 -60 4 18 44 +  45 left precentral and inferior operculo frontal 
 46 0.022 2.12 2.02 36 22 10 13 right inferior tri frontal 
 6 0.022 2.12 2.02 -38 40 34   left mid frontal 
 6 0.028 2 1.92 44 -2 18   right rolandic operculum (s2) 
 10 0.034 1.9 1.83 48 48 8 46 right mid frontal 
Thalamus and caudate 
8 0.031 1.94 1.86 -10 -4 4 
ventral ant. 
nucleus left thalamus 
Subthalamic & 
Brainstem 94 0.001 3.37 3.04 0 -22 -24   brainstem 
 277 0.001 3.29 2.98 6 -38 -30   brainstem + left and right cerebellar pedicle 
Cerebellum 107 0.012 2.38 2.25 0 -22 4 optic tract vermis (4,5) 
 7 0.027 2.02 1.93 -46 -58 -30   left crus (1) cerebellum 
Temporal 53 0.003 3.05 2.79 30 14 -28 38 right superior temporal pole  
 116 0.007 2.65 2.47 62 -4 0 22 right superior temporal   + rolandic operculum 
 167 0.008 2.57 2.4 58 -48 16 13+21 right temporal (superior and mid) 
Parietal 170 0.002 3.1 2.83 52 -20 24   right supra marginal 
 45 0.007 2.65 2.47 -50 -26 22 22 left supra marginal  
 27 0.013 2.35 2.22 -64 -36 30 40 left supra marginal 
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HSDD VS ADD activations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Frontal 18 0.006 2.68 2.49 -12 -20 70 6 left paracentral lobule 
 9 0.024 2.06 1.97 30 48 6   right mid frontal 
 23 0.033 1.91 1.84 34 24 -12   right inferior orbito-frontal 
Thalamus and caudate 
155 0.002 3.07 2.81 -24 -6 0 
putamen + 
lateral globus 
pallidus left pallidum 
 50 0.004 2.87 2.65 30 -10 -2 putamen right putamen 
 70 0.009 2.53 2.37 14 -18 0   right thalamus 
Cerebellum 13 0.029 1.98 1.9 -4 -82 -16   left cerebellum (6) 
Temporal 84 0.002 3.25 2.95 52 4 -16 21 right mid temporal pole 
 202 0.002 3.16 2.88 -50 -8 -6 21 left superior temporal + pole 
 10 0.03 1.96 1.88 -32 -26 4   left superior temporal 
Amygdala & HippoC 16 0.02 2.16 2.05 22 -12 -14   right hippocampus 
Parietal 215 0.007 2.64 2.46 40 -50 50 40 right inferior parietal and supra marginal 
S1 & S2 29 0.028 1.99 1.91 62 -18 36   right postcentral 
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ADD VS IBS activations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 154 0.008 2.59 2.42 -46 22 -6   left  insula (ant) and inferior orbito-frontal 
 9 0.029 1.97 1.89 -36 4 -2   left insula (mid)/putamen 
Cingulate 67 0.006 2.67 2.49 0 -12 34   left mid cingulum 
 28 0.012 2.39 2.25 0 -36 26   left post cingulum 
Frontal 249 0.001 3.34 3.02 -2 14 52 6 left supplemental motor area and frontal (superior medial) 
 140 0.004 2.85 2.64 -44 46 16 10 left frontal (mid  and inferior tri) 
 109 0.004 2.83 2.62 60 4 34 6 right precentral 
 69 0.008 2.6 2.43 48 24 -4   right inferior orbito-frontal 
 12 0.01 2.48 2.33 -56 12 24 45 left inferior operculo-frontal 
 15 0.032 1.93 1.86 52 -14 22   right rolandic operculum (s2) 
 41 0.014 2.34 2.21 -26 50 22 10 left superior frontal 
 43 0.015 2.29 2.17 48 16 40 9 right mid frontal 
 17 0.025 2.06 1.97 -48 18 6 45 left frontal (inferior tri  and inferior operculo-) (s2) 
 11 0.026 2.03 1.94 -2 32 46 8 left superior medial frontal 
Subthalamic & 
Brainstem 47 0.005 2.79 2.58 2 -20 -22   right brainstem 
Cerebellum 17 0.033 1.92 1.85 38 -76 -24   right crus (1) cerebellum 
Temporal 136 0.004 2.92 2.69 66 -16 2 21+ 22 right superior temporal 
 50 0.004 2.86 2.65 58 12 -4 22 right superior temporal pole 
 14 0.029 1.98 1.9 -62 -12 8   left superior temporal and heschl 
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IBS VS ADD activations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Insula 421 0.001 3.45 3.1 48 6 -18 21+22 right insula (ant) and superior temporal pole (s2) 
 69 0.005 2.79 2.59 28 -26 12 13 right insula (post) and heschl 
 10 0.025 2.06 1.97 30 32 -4   right insula (ant) 
Cingulate 16 0.02 2.16 2.05 -10 28 18 24 left ant cingulum 
 9 0.02 2.15 2.05 10 -24 32   right mid cingulum 
 
44 0.014 2.31 2.19 6 22 18 
corpus 
callosum right ant cingulum 
 14 0.021 2.14 2.04 8 40 24 9 right ant cingulum 
 9 0.022 2.11 2.02 14 20 34   right mid cingulum 
 14 0.025 2.06 1.97 -14 -24 36   left  mid cingulum 
Frontal 7 0.038 1.84 1.78 42 20 12   right inferior tri frontal 
 528 0 5.11 4.21 34 40 14   right  frontal (mid and inferior orbito-) 
 100 0.001 3.45 3.1 -14 -22 70 6 left paracentral lobule 
 23 0.003 2.95 2.72 -14 6 46 32 left supplemental motor area 
 84 0.004 2.87 2.65 48 6 16   right inferior operculo-frontal 
 89 0.009 2.51 2.35 14 4 52   right supplemental motor area 
 16 0.017 2.24 2.13 38 -4 44 6 right precentral 
 10 0.018 2.21 2.1 10 30 52   right superior medial frontal 
Thalamus and caudate 48 0 4.35 3.74 20 -8 10 putamen right putamen 
 53 0.014 2.32 2.19 30 -4 12   right putamen 
 6 0.017 2.22 2.11 -24 12 12   left putamen 
 
9 0.021 2.14 2.04 -14 -6 -8 
medial globus 
pallidus left pallidum 
Cerebellum 9 0.013 2.37 2.24 -40 -52 -38   left crus (1) cerebellum 
 173 0.001 3.3 2.99 -8 -50 -28   left cerebellar pedicle and vermis (4,5,8) 
Temporal 195 0.006 2.7 2.51 -50 -4 -8 38 left superior temporal 
 17 0.028 1.99 1.91 -38 8 -24   left superior temporal pole 
 6 0.021 2.14 2.04 60 -54 -2   right mid temporal 
 
287 
 
IBS VS ADD activations during VAS temperature stimulus left hand continued 
Parietal 386 0.001 3.32 3.01 -48 -40 32   left supra marginal and temporal (superior) 
 131 0.002 3.08 2.82 62 -24 30 40 right supra marginal 
 180 0.003 2.96 2.72 50 -42 36   right supra marginal 
 136 0.004 2.86 2.64 -16 -42 64 4 left precuneus 
 15 0.035 1.88 1.81 58 -44 24 40 right supra marginal  
S1 & S2 61 0.023 2.09 1.99 22 -42 66   right postcentral 
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ADD VS LSDD De activations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Frontal 11 0.019 2.19 2.08 -16 8 50 32 left superior frontal 
 77 0.002 3.11 2.84 2 20 -4   right olfactory/ant cingulum/caudate 
Cerebellum 5 0.038 1.83 1.77 16 -72 -16   right cerebellum (6) 
Temporal 681 0.002 3.09 2.82 24 -44 -2 37 right lingual and fusiform 
 66 0.013 2.36 2.23 -62 -58 -8 37 left  temporal (inferior and mid) 
 9 0.022 2.1 2.01 50 -44 -8   right mid temporal 
 7 0.03 1.95 1.88 44 -46 0   right mid temporal 
Amygdala & HippoC 235 0.01 2.46 2.31 -34 -36 -8   left hippocampus 
 10 0.019 2.19 2.08 32 -6 -22   right hippocampus 
 8 0.04 1.82 1.75 42 -32 -6   right hippocampus/right mid temporal 
S1 & S2 18 0.028 1.99 1.91 44 -30 46 40 right postcentral 
Occipital 758 0 3.73 3.3 -36 -88 14 31 left mid occipital (mid + superior) and calcarine 
 328 0.007 2.67 2.48 18 -88 24 18+30 right superior occipital and calcarine 
 51 0.007 2.61 2.44 -50 -70 -12 19 left inferior occipital 
 198 0.01 2.5 2.35 -26 -80 0 18 left mid occipital and lingual 
 100 0.014 2.33 2.2 36 -76 16   right mid occipital 
 15 0.024 2.08 1.99 -14 -90 14 18 left superior occipital 
 35 0.025 2.05 1.96 6 -76 -2   right lingual 
 8 0.031 1.93 1.86 22 -74 32   right superior occipital 
 34 0.032 1.93 1.85 44 -76 -6   right inferior occipital 
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LSDD VS ADD Deactivations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Cingulate 7 0.038 1.84 1.78 -4 -44 26   left post cingulum 
 6 0.039 1.83 1.76 6 -40 30   right post cingulum 
Frontal 244 0 3.73 3.31 -30 22 42   left frontal (mid and inferior operculo-frontal) 
 499 0.001 3.58 3.2 -4 62 28 10 left superior medial frontal 
 311 0.002 3.07 2.81 -10 56 6   left superior medial frontal 
 10 0.008 2.55 2.39 18 32 38   right superior frontal 
 25 0.014 2.33 2.2 -48 26 4 45 left inferior tri frontal 
 13 0.019 2.18 2.07 -28 38 42   left mid frontal 
Cerebellum 64 0.015 2.3 2.18 30 -38 -30   right cerebellum (4,5) 
Temporal 117 0.001 3.41 3.08 56 2 -34   right  temporal (inferior and mid pole) 
 45 0.005 2.78 2.57 -46 2 -34 21 left temporal (inferior  and mid) 
 6 0.032 1.92 1.85 -26 -4 -38 36 left fusiform 
 16 0.006 2.72 2.53 -16 -14 -28   left parahippocampus 
 43 0.025 2.04 1.95 26 -4 -32 20 right parahippocampus and fusiform 
Parietal 966 0.001 3.51 3.14 -12 -56 40   left precuneus and superior parietal 
 131 0.004 2.9 2.68 -10 -58 12   left precuneus 
 7 0.037 1.86 1.79 18 -70 60   right  superior parietal 
S1 & S2 8 0.012 2.38 2.25 -56 -12 46 3 left postcentral 
 5 0.014 2.32 2.19 62 -4 36   right postcentral 
Occipital 589 0.005 2.78 2.57 -38 -70 30 39 left mid occipital and angular 
 91 0.007 2.6 2.43 50 -68 26   right mid occipital 
 
  
290 
 
ADD VS HSDD Deactivations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Cingulate 11 0.03 1.96 1.88 -14 46 16 10 left anterior cingulum 
Frontal 22 0.005 2.78 2.57 30 14 54 8 right  frontal (mid + sup) 
 34 0.029 1.98 1.9 -22 20 54   left superior frontal 
 22 0.005 2.78 2.57 30 14 54 8 right  frontal (mid + sup) 
 34 0.029 1.98 1.9 -22 20 54   left superior frontal 
 8 0.032 1.92 1.85 -8 -26 68   left paracentral lobule 
Thalamus and caudate 6 0.007 2.62 2.44 -28 -14 -2 putamen left putamen 
 6 0.035 1.88 1.81 8 20 -4   right caudate 
 5 0.03 1.96 1.89 -10 18 4 caudate head left caudate 
Subthalamic & 
Brainstem 24 0.031 1.94 1.87 2 0 -10   right brainstem 
Temporal 28 0.014 2.32 2.19 -64 -18 -10 21 left mid temporal 
 36 0.02 2.16 2.05 50 10 -26 38 right mid temporal pole 
 17 0.024 2.07 1.98 28 -66 52 7 right superior temporal 
 57 0.008 2.58 2.41 -56 0 -16 38 left mid temporal and superior pole 
 84 0.01 2.49 2.34 56 -12 -14   right mid temporal 
Amygdala & HippoC 748 0.004 2.9 2.67 38 -22 -18   right hippocampus, parahippocampus and lingual 
Parietal 70 0.014 2.33 2.2 -18 -60 56   left superior parietal and inferior temporal 
S1 & S2 134 0.003 2.96 2.72 -38 -36 64   left postcentral 
 40 0.004 2.91 2.69 42 -32 44 40 right postcentral 
 20 0.009 2.55 2.38 -62 -10 30 4 left postcentral 
 47 0.01 2.46 2.31 62 -10 32   right postcentral 
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ADD VS HSDD Deactivations during VAS temperature stimulus left hand continued 
Occipital 389 0.002 3.23 2.94 -24 -82 36 19 left occipital (sup + mid) 
 305 0.003 2.97 2.73 20 -88 36 19 right superior occipital 
 100 0.006 2.7 2.52 40 -84 16 19 right mid occipital 
 138 0.008 2.56 2.4 -50 -70 -12 19 + 37 left inferior occipital and temporal 
 17 0.032 1.93 1.85 -36 -88 14   left mid occipital 
 8 0.035 1.88 1.81 -28 -74 -4   left lingual 
 45 0.036 1.87 1.8 0 -64 12   left calcarine 
 
 
HSDD VS ADD Deactivations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Frontal 169 0.008 2.58 2.41 -30 22 40 9 left mid frontal 
 127 0.013 2.37 2.24 0 58 32 10 left frontal (superior medial and sup) 
 12 0.039 1.82 1.76 28 32 34 9 right mid frontal 
Temporal 7 0.009 2.5 2.35 -44 -16 -22   left inferior temporal 
Amygdala & HippoC 31 0.005 2.74 2.55 -16 -14 -28   left parahippocampus 
 15 0.031 1.94 1.87 26 -4 -30   right parahippocampus 
Parietal 12 0.008 2.59 2.43 58 -60 28   right angular 
 33 0.016 2.26 2.14 -32 -62 26 39 left angular 
 60 0.022 2.1 2.01 -52 -58 28   left angular 
 39 0.024 2.08 1.98 -14 -54 40   left precuneus 
 
7 0.039 1.83 1.77 14 -38 4 
corpus 
callosum right precuneus 
Occipital 8 0.026 2.03 1.94 -48 -78 28 39 left mid occipital 
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ADD VS IBS Deactivations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Frontal 37 0.002 3.11 2.84 -18 6 50 32 left superior frontal 
 109 0.003 2.96 2.72 -8 -28 68 6 left paracentral lobule 
 8 0.031 1.94 1.86 -16 40 20 9 left superior medial frontal 
Thalamus and caudate 678 0 4.08 3.55 -12 20 4 caudate head left  and right caudate and frontal 
Temporal 210 0.002 3.08 2.82 52 10 -24 38 right mid temporal pole 
 14 0.019 2.17 2.07 -52 0 -18   left mid temporal 
 10 0.022 2.11 2.01 56 -6 -14   right superior temporal 
Amygdala & HippoC 3937 0 4.31 3.71 26 -40 4   right hippocampus, cingulum (post) and heschl 
S1 & S2 43 0.012 2.38 2.25 -30 -34 64   left post and precentral 
 18 0.022 2.12 2.02 -34 -28 40   left postcentral 
 17 0.03 1.96 1.88 -28 -44 56   left postcentral 
Occipital 2678 0 4.31 3.71 -22 -84 32 7+18 left occipital (superior  and mid) 
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IBS VS ADD Deactivations during VAS temperature stimulus left hand 
Brain regions Cluster 
p(FDR) 
Peak 
punc 
Peak  
p(FDR) 
Peak T 
equiv Z 
X Y Z %URGPDQQ¶V 
area 
AAL 
Frontal 587 0.002 3.21 2.92 -2 58 32 10 left  frontal (superior medial and superior) 
 45 0.016 2.27 2.15 -30 36 42 9 left mid frontal 
 23 0.017 2.25 2.13 -48 28 2   left inferior tri frontal 
 29 0.021 2.14 2.04 -44 22 44   left frontal (mid  and inferior tri) 
 6 0.024 2.07 1.97 -34 14 34   left mid frontal 
 6 0.031 1.95 1.87 24 46 42 9 right superior frontal 
Cerebellum 34 0.015 2.29 2.17 6 -48 0 29 vermis (4,5) and right lingual 
Temporal 35 0.003 3.02 2.77 -62 -20 -14   left mid temporal 
Amygdala & HippoC 43 0.01 2.48 2.33 -26 -26 -16   left parahippocampus 
Parietal 115 0.002 3.2 2.91 -30 -70 56 7 left superior parietal 
 494 0.011 2.45 2.3 -8 -52 42 7 left precuneus 
 5 0.03 1.96 1.88 6 -56 66   right precuneus 
S1 & S2 7 0.014 2.33 2.2 -56 -16 48 3 left postcentral 
Occipital 326 0.001 3.49 3.13 -18 -64 8   left calcarine and precuneus 
 72 0.017 2.24 2.13 -48 -78 28   left mid occipital and angular 
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6.6 Covariate analysis of the brain activity during the VAS temperature 
stimulus 
6.6.1 VAS score and actual VAS temperature oC analysis 
Table A6.61 Covariates analysis of the brain activity during the painful VAS stimulus using 
the post-scanning VAS SDLQ VFRUH RXW RI  DQG WKH DFWXDO µ9$6¶ WHPSHUDWXUH ZKLFK ZDV
applied to the left foot (A) or left hand (B).   Ĺ = significant activation, Ļ significant deactivation, ĹĻ 
both significant activation and deactivations within the same brain region.  
 (A) Foot stimulus  
   VAS SCORE Temperature (oC) 
 Area Side ADD LSDD HSDD IBS ADD LSDD HSDD IBS 
 S1 L         
SS R         
 S2 L         
 
R 
 
Ĺ Ĺ 
     
SS Post-Ins L     Ĺ Ĺ Ĺ  
 
R 
    
Ĺ Ĺ  Ĺ 
 Mid-Ins L       Ĺ  
  
R 
       
Ĺ 
Aff. Ant-Ins L        Ĺ 
 
R 
  
Ĺ 
   Ļ Ĺ 
Aff. ACC L    Ļ     
 
R 
      
Ĺ 
 
Aff. MCC L  Ļ     Ĺ Ĺ 
 
R 
 
Ĺ Ļ Ĺ 
    
Ĺ 
 PCC L         
 
R 
    
Ļ 
   
Aff. Medial PFC L  Ļ Ļ Ļ   Ļ  
 
R 
 
Ļ Ĺ Ĺ Ļ    
DNIC Lateral PFC L  Ļ   Ļ  Ĺ  
 
R 
 
Ĺ  Ĺ 
 
Ļ  Ĺ Ĺ 
DNIC Orbito-FC L  Ļ     Ĺ Ĺ 
  
R 
  
Ĺ Ļ 
   
Ĺ 
SS Lentiform Nuclei 
and Thalamus 
L 
      
ĹĻ 
 
 
R 
  
Ĺ 
     
Aff. Amygdala 
(Hippocampus) 
L 
   
Ĺ 
    
 
R 
      
Ĺ Ĺ 
 Cerebellum L  Ĺ ĹĻ    Ĺ  
 
R 
    
   Ļ 
 Inferior Parietal L  Ļ       
 
R 
  
Ĺ 
 
Ļ 
   
 Temporal L ĹĻ Ĺ Ĺ ĹĻ Ĺ  Ĺ Ĺ 
 
R Ĺ 
 
ĹĻ Ĺ Ĺ Ĺ 
  
 Motor L         
  
R 
        
 SMA L         
  
R Ĺ Ĺ 
    
Ĺ Ĺ 
SS Post-central 
Gyrus 
L 
 
Ļ Ļ 
     
 
R 
 
Ĺ 
  
Ļ 
   
DNIC Subthalamic/ 
Brainstem 
 
Ĺ 
 
Ĺ 
 
Ļ 
 
 Ĺ 
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Table A6.6.1 Covariates analysis of the brain activity during the painful VAS stimulus using 
the post-scanning VAS pain score out of 10 and the actual µ9$6¶ WHPSHUDWXUH ZKLFK ZDV
applied to the left foot (A) or left hand (B). 
(B) Hand stimulus  
   VAS SCORE Temperature (oC) 
 Area Side ADD LSDD HSDD IBS ADD LSDD HSDD IBS 
 S1 L         
SS R         
 S2 L        Ļ 
 
R 
 
Ĺ 
  
Ĺ 
  
Ļ 
SS Post-Ins L  Ļ       
 
R 
 Ĺ Ĺ    Ĺ  
 Mid-Ins L         
  
R  Ĺ Ĺ      
Aff. Ant-Ins L Ĺ    Ĺ Ĺ Ļ  
 
R Ĺ 
 
Ĺ 
     
Aff. ACC L   Ĺ Ļ   Ļ Ĺ 
 
R 
   
Ļ 
  
ĹĻ Ĺ 
Aff. MCC L   Ļ Ļ  Ļ Ĺ  
 
R 
 
Ĺ 
 
Ĺ 
  
Ĺ Ĺ 
 PCC L         
 
R 
        
Aff. Medial PFC L  Ļ  Ļ  Ļ  Ļ 
 
R 
 
ĹĻ 
 
Ļ    Ĺ 
DNIC Lateral PFC L Ĺ  Ļ Ļ  Ĺ Ļ  Ļ 
 
R Ĺ Ĺ Ĺ Ĺ   Ļ Ĺ 
DNIC Orbito-FC L        ĹĻ 
  
R 
 
Ļ 
   
Ĺ 
  
SS Lentiform Nuclei 
and Thalamus 
L Ĺ 
     
Ĺ Ĺ 
 
R ĹĻ 
 
Ĺ Ļ 
   
Ĺ 
Aff. Amygdala 
(Hippocampus) 
L Ļ 
  
Ļ 
  
Ļ 
 
 
R Ļ 
  
Ļ 
    
 Cerebellum L    Ĺ  Ĺ  Ĺ 
 
R ĹĻ 
 
ĹĻ Ļ    Ĺ 
 Inferior Parietal L Ļ  Ļ  Ĺ    
 
R 
        
 Temporal L ĹĻ Ļ Ļ Ļ  ĹĻ Ļ ĹĻ 
 
R Ļ ĹĻ ĹĻ Ļ Ĺ Ļ Ļ ĹĻ 
 Motor L         
  
R 
        
 SMA L Ĺ Ĺ       
  
R 
 
Ĺ Ļ 
    
Ĺ 
SS Post-central 
Gyrus 
L 
 
Ĺ 
 
Ļ Ĺ Ļ 
  
 
R 
 
Ĺ 
 
Ĺ 
  
Ĺ 
 
DNIC Subthalamic/ 
Brainstem 
 
ĹĻ 
  
Ļ 
  Ļ  
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6.6.2 Hospital anxiety and depression score covariate analysis 
%HORZDUHVLPSOLILHGI05,UHVXOWVFRPSDULQJDFWLYDWLRQVĹDQGGHDFWLYDWLRQVĻFRUUHODWLQJ
ZLWKSDUWLFLSDQW¶V+$'DQ[LHW\DQGGHSUHVVLRQVFRUHVXVHGDVWKHVWLPXOXVRn the foot (A) and 
hand (B) during the stimulus (uncorrected p<0.01) (Table A6.5.2). All effects were identified 
using group maps as a mask for the data.  
Table A6.6.2 Covariates analysis of the brain activity during the pain heat VAS stimulus in the 
left foot (A) and left hand (B) using HAD questionnaire scores  
(A) Foot stimulus  
   Anxiety Depression 
 Area Side ADD LSDD HSDD IBS ADD LSDD HSDD IBS 
 S1 L         
SS R         
 S2 L         
 
R 
        
SS Post-Ins L         
 
R 
        
 Mid-Ins L         
  
R 
   
Ĺ 
   
 
Aff. Ant-Ins L        Ĺ 
 
R 
   
Ĺ 
    
Aff. ACC L         
 
R 
   
Ļ 
    
Aff. MCC L  Ĺ  Ļ    Ļ 
 
R Ļ 
 
Ļ 
     
 PCC L         
 
R 
        
Aff. Medial PFC L Ĺ  Ĺ Ļ    Ĺ 
 
R 
  
Ĺ Ĺ   Ĺ  
DNIC Lateral PFC L   Ĺ    Ĺ  
 
R 
   
Ĺ Ĺ Ĺ Ĺ Ĺ 
DNIC Orbito-FC L    Ļ     
  
R Ĺ 
      
Ĺ 
SS Lentiform Nuclei 
and Thalamus 
L 
   
Ĺ 
    
 
R Ĺ 
  
Ĺ 
 
Ĺ 
  
Aff. Amygdala 
(Hippocampus) 
L 
        
 
R 
  
Ļ 
     
 Cerebellum L   Ļ Ĺ   Ļ Ĺ 
 
R Ļ Ļ Ļ ĹĻ   Ļ Ĺ 
 Inferior Parietal L   Ĺ Ĺ    Ĺ 
 
R 
       
Ĺ 
 Temporal L Ļ   Ļ     
 
R 
  
Ĺ ĹĻ 
   
Ĺ 
 Motor L         
  
R 
        
 SMA L         
  
R 
        
SS Post-central 
Gyrus 
L 
 
Ļ 
 
Ļ 
    
 
R 
 
 
 
Ļ Ĺ 
   
DNIC Subthalamic/ 
Brainstem 
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Table A6.6.2 Covariates analysis of the brain activity during the pain heat VAS stimulus in the 
left foot (A) and left hand (B) using HAD questionnaire scores 
(B) Hand stimulus  
   Anxiety Depression 
 Area Side ADD LSDD HSDD IBS ADD LSDD HSDD IBS 
 S1 L         
SS R         
 S2 L         
 
R 
        
SS Post-Ins L  Ĺ       
 
R 
  
Ĺ 
     
 Mid-Ins L   Ĺ Ĺ     
  
R 
   
 
    
Aff. Ant-Ins L         
 
R 
 
Ĺ Ĺ Ĺ 
    
Aff. ACC L         
 
R Ļ Ĺ Ĺ   Ĺ   
Aff. MCC L Ļ Ĺ Ĺ Ļ   Ĺ  
 
R Ĺ Ļ ĹĻ Ļ Ĺ 
   
 PCC L         
 
R Ĺ 
   
Ĺ 
 Ļ  
Aff. Medial PFC L  Ĺ    Ļ Ļ  
 
R 
 
Ļ 
  
    
DNIC Lateral PFC L Ĺ Ļ Ĺ   Ļ   
 
R Ĺ ĹĻ ĹĻ 
 
Ĺ Ĺ Ļ Ĺ 
DNIC Orbito-FC L         
  
R Ĺ 
   
Ĺ ĹĻ 
  
SS Lentiform Nuclei 
and Thalamus 
L 
 
Ĺ Ļ Ĺ 
 
Ĺ Ļ 
 
 
R 
 
Ĺ Ļ Ĺ 
 
Ĺ Ļ 
 
Aff. Amygdala 
(Hippocampus) 
L 
  
Ĺ 
   
Ļ 
 
 
R 
   
Ĺ 
  
Ļ 
 
 Cerebellum L Ĺ Ĺ  Ĺ  Ĺ Ļ Ĺ 
 
R 
 
Ĺ 
  
 Ĺ Ļ Ĺ 
 Inferior Parietal L Ĺ Ļ       
 
R Ĺ Ĺ 
  
Ĺ 
   
 Temporal L   ĹĻ    Ļ  
 
R 
 
Ļ ĹĻ Ļ 
  
ĹĻ 
 
 Motor L         
  
R 
        
 SMA L Ĺ     Ĺ   
  
R 
        
SS Post-central 
Gyrus 
L Ļ ĹĻ Ļ Ļ Ļ Ĺ Ļ Ļ 
 
R 
 
 Ļ Ļ 
    
DNIC Subthalamic/ 
Brainstem 
  
Ĺ 
 
ĹĻ 
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6.6.3 Pain catastrophizing and Physiological health questionnaire 12 score covariate 
analysis 
%HORZDUHVLPSOLILHGI05,UHVXOWVFRPSDULQJDFWLYDWLRQVĹDQGGHDFWLYDWLRQVĻFRUUHODWLQJ
ZLWK SDUWLFLSDQW¶V 3+4 DQG 3& VFRUHV XVHG as the stimulus on the foot (A) and hand (B) 
during the stimulus (uncorrected p<0.01) (Table A6.5.3). All effects were identified using 
overall group maps as a mask for the data.  
Table A6.6.3 Covariates analysis of the brain activity during the pain heat VAS stimulus in the 
left foot (A) and left hand (B) using PCS and PHQ12 questionnaire scores. (A) Foot stimulus  
   PCS PHQ12 
 Area Side ADD LSDD HSDD IBS ADD LSDD HSDD IBS 
 S1 L         
SS R         
 S2 L         
 
R Ĺ 
       
SS Post-Ins L         
 
R 
        
 Mid-Ins L         
  
R 
  
 
   
 
 
Aff. Ant-Ins L   Ĺ      
 
R 
   
Ĺ 
  
Ĺ Ĺ 
Aff. ACC L   Ĺ Ļ   Ĺ  
 
R 
  
Ĺ Ļ 
 
Ĺ Ĺ  
Aff. MCC L      Ĺ Ĺ Ļ 
 
R Ĺ 
 
ĹĻ Ĺ 
 
Ĺ ĹĻ Ļ 
 PCC L       Ĺ  
 
R Ļ 
     
Ĺ 
 
Aff. Medial PFC L Ļ Ĺ ĹĻ Ļ Ļ  Ļ  
 
R 
  
Ĺ 
 
  Ĺ Ĺ 
DNIC Lateral PFC L   ĹĻ  Ļ  ĹĻ  
 
R Ĺ 
   
   Ĺ 
DNIC Orbito-FC L    Ļ  Ļ   
  
R 
  
Ĺ Ļ 
  
Ĺ Ĺ 
SS Lentiform Nuclei 
and Thalamus 
L 
 
Ĺ 
 
Ĺ 
  
Ĺ Ĺ 
 
R Ļ Ĺ Ĺ 
 
Ĺ 
 
Ĺ 
 
Aff. Amygdala 
(Hippocampus) 
L 
 
Ĺ Ĺ 
  
Ļ Ĺ 
 
 
R 
     
Ļ 
 Ĺ 
 Cerebellum L Ļ Ļ Ĺ Ĺ  Ĺ   
 
R Ĺ 
 
Ļ 
 
  Ļ  
 Inferior Parietal L   Ļ    Ļ  
 
R 
        
 Temporal L Ĺ ĹĻ ĹĻ    Ļ  
 
R Ĺ 
 
ĹĻ Ļ Ļ 
 
Ļ Ĺ 
 Motor L         
  
R 
        
 SMA L         
  
R Ĺ 
     
Ĺ 
 
SS Post-central 
Gyrus 
L Ļ  ĹĻ 
  
ĹĻ ĹĻ 
 
 
R 
 
Ļ Ļ Ļ 
  
Ļ Ļ 
DNIC Subthalamic/ 
Brainstem 
 
Ĺ Ĺ Ĺ 
  
Ĺ Ĺ Ļ 
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Table A6.6.3 Covariates analysis of the brain activity during the pain heat VAS stimulus in the 
left foot (A) and left hand (B) using PCS and PHQ12 questionnaire scores. (B) Hand stimulus  
   PCS PHQ12 
 Area Side ADD LSDD HSDD IBS ADD LSDD HSDD IBS 
 S1 L         
SS R         
 S2 L         
 
R 
        
SS Post-Ins L       Ļ  
 
R 
      
Ĺ 
 
 Mid-Ins L   Ĺ    ĹĻ Ĺ 
  
R 
  
Ĺ 
 Ĺ  Ĺ  
Aff. Ant-Ins L   Ĺ  Ĺ  Ĺ  
 
R 
 
Ĺ Ĺ Ĺ Ĺ Ĺ Ĺ Ĺ 
Aff. ACC L    Ļ    ĹĻ  
 
R 
 
Ĺ Ĺ 
   
ĹĻ 
 
Aff. MCC L     Ĺ Ĺ  Ĺ Ļ 
 
R 
 
Ĺ ĹĻ 
 
Ĺ ĹĻ Ĺ 
 
 PCC L         
 
R 
 Ĺ       
Aff. Medial PFC L  Ĺ Ļ Ļ  Ĺ Ļ  
 
R 
  
Ĺ 
 
Ĺ    
DNIC Lateral PFC L   Ĺ   Ļ Ĺ Ļ  
 
R Ļ 
 
ĹĻ Ĺ Ĺ Ĺ Ĺ Ĺ 
DNIC Orbito-FC L     Ĺ    
  
R 
  
Ĺ 
 
Ĺ 
   
SS Lentiform Nuclei 
and Thalamus 
L 
 
Ĺ ĹĻ Ĺ 
 
Ĺ Ļ Ĺ 
 
R 
 
Ĺ Ļ 
 
Ĺ 
 
Ļ Ĺ 
Aff. Amygdala 
(Hippocampus) 
L 
  Ļ    ĹĻ  
 
R 
  
Ĺ 
  Ĺ ĹĻ Ĺ 
 Cerebellum L Ĺ Ĺ Ĺ  Ĺ Ĺ  Ĺ 
 
R 
  
Ļ Ļ  Ĺ Ļ Ļ 
 Inferior Parietal L       Ĺ  
 
R 
  
Ĺ 
   
Ĺ 
 
 Temporal L ĹĻ  Ļ Ĺ  Ļ Ļ Ļ 
 
R ĹĻ ĹĻ Ļ Ļ 
 
ĹĻ Ļ Ļ 
 Motor L         
  
R 
        
 SMA L      Ĺ  Ĺ 
  
R Ĺ 
 
Ļ Ĺ 
 
Ĺ 
  
SS Post-central 
Gyrus 
L 
 
Ļ ĹĻ 
  
Ĺ ĹĻ Ļ 
 
R Ĺ  
 
Ļ Ĺ 
  
Ļ 
DNIC Subthalamic/ 
Brainstem 
  
Ĺ 
 
ĹĻ 
   
Ĺ 
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6.7 Intergroup analysis of the brain activity between the IBS and SDD 
groups during the Cue stimulus 
 
6.7.1 Inter-Group Analysis: Differences between cue stimuli for IBS and SDD groups. 
Table A6.6.1 are VLPSOLILHGVLJQLILFDQWUHVXOWVRIVDPSOHWWHVWFRPSDULQJDFWLYDWLRQVĹDQG
GHDFWLYDWLRQV Ļ EHWZHHQ WKH 6'' JURXSV IRU WKH YLVXDO FXH 8QFRUUHFWHG S YR[HO
threshold 5) (Table R2.15).  The first two columns on the left are areas where there is a 
significant probability that activations and deactivations are greater in the IBS group compared 
to the SDD groups (IBS>SDD). In the two right columns are areas where there is a significant 
probability that activations and deactivations are less in the IBS group compared to the SDD 
groups (SDD>IBS).  
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Table A6.7.1 Inter-Group Analysis: Differences between cue stimuli for IBS and SDD groups. 
 Area Side IBS> 
LSDD 
IBS> 
HSDD 
LSDD> 
IBS 
HSDD> 
IBS 
 S1 L     
SS R     
 S2 L     
 
R 
   Ĺ 
SS Post-Ins L  Ļ   
 
R 
 
Ļ Ļ 
 
 Mid-Ins L     
  
R 
  Ĺ  
Aff. Ant-Ins L     
 
R Ĺ  Ĺ  
Aff. ACC L   Ĺ  
 
R Ĺ ĹĻ   
Aff. MCC L   Ļ  
 
R 
  
ĹĻ Ļ 
 PCC L     
 
R 
    
Aff. Medial PFC L   Ļ Ļ 
 
R 
 
Ļ Ļ Ļ 
DNIC Lateral PFC L   Ĺ Ļ 
 
R Ļ Ļ 
  
DNIC Orbito-FC L     
  
R Ĺ    
SS Lentiform Nuclei and Thalamus L Ĺ Ļ ĹĻ Ĺ 
 
R Ĺ  Ĺ Ĺ 
Aff. Amygdala 
(Hippocampus) 
L 
  
Ļ 
 
 
R 
 
Ļ Ļ 
 
 Cerebellum L  Ĺ Ļ  
 
R 
 Ĺ ĹĻ  
 Inferior Parietal L     
 
R 
    
 Temporal L Ļ Ĺ Ļ  
 
R Ĺ ĹĻ Ļ Ĺ 
 Motor L     
  
R 
    
 SMA L Ĺ Ĺ Ĺ  
  
R 
  Ĺ  
SS Post-central 
Gyrus 
L 
 
 
 Ĺ 
 
R 
 
Ļ 
  
DNIC Subthalamic/ Brainstem     Ļ 
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6.8 Covariate analysis of the brain activity during the Cue stimulus  
6.8.1  Hospital anxiety and depression score covariate analysis 
Below are simplified fMRI UHVXOWVFRPSDULQJDFWLYDWLRQVĹDQGGHDFWLYDWLRQVĻFRUUHODWLQJ
ZLWK SDUWLFLSDQW¶V +$' DQ[LHW\ and depression scores during the cue stimulus (uncorrected 
p<0.01) (Table A6.7.1). All effects were identified using group maps as a mask for the data.  
Table A6.8.1 Cue stimulus: HAD questionnaire scores 
   Anxiety Depression 
 Area Side ADD LSDD HSDD IBS ADD LSDD HSDD IBS 
 S1 L         
SS R         
 S2 L         
 
R 
   
Ļ 
   
Ĺ 
SS Post-Ins L    Ļ     
 
R 
   
Ļ 
  Ĺ  
 Mid-Ins L       Ĺ  
  
R 
  
Ĺ Ļ 
  Ĺ  
Aff. Ant-Ins L        Ĺ 
 
R 
      
Ĺ 
 
Aff. ACC L  Ĺ    Ĺ Ĺ  
 
R 
 
Ĺ 
   Ĺ   
Aff. MCC L       Ĺ Ļ 
 
R 
 Ļ Ĺ    Ĺ  
 PCC L      Ĺ   
 
R 
        
Aff. Medial PFC L  Ĺ Ļ      
 
R 
 
Ļ 
  
  Ļ  
DNIC Lateral PFC L Ĺ Ļ    Ļ   
 
R Ļ 
 
Ļ Ļ   Ĺ  
DNIC Orbito-FC L  Ļ  Ĺ  Ĺ   
  
R 
 
Ĺ 
   
Ĺ 
  
SS Lentiform Nuclei 
and Thalamus 
L 
 
Ļ 
 
ĹĻ 
  
Ĺ 
 
 
R 
   
Ĺ 
  
Ĺ 
 
Aff. Amygdala 
(Hippocampus) 
L 
      Ĺ  
 
R Ļ 
 
Ĺ Ļ 
    
 Cerebellum L    Ļ     
 
R Ĺ 
   
  Ĺ  
 Inferior Parietal L  Ļ Ĺ   Ļ   
 
R 
     
Ļ Ĺ 
 
 Temporal L  Ļ Ĺ Ļ     
 
R 
 
Ļ 
 
ĹĻ 
  
Ĺ Ĺ 
 Motor L         
  
R 
        
 SMA L         
  
R 
        
SS Post-central 
Gyrus 
L Ļ  
  
Ļ 
   
 
R Ļ  
  
Ļ 
  
Ļ 
DNIC Subthalamic/ 
Brainstem 
   
ĹĻ 
   
ĹĻ  
 
  
303 
 
6.8.2 Pain catastrophizing and Physiological health questionnaire 12 score covariate 
analysis 
Below are simplified fMRI UHVXOWVFRPSDULQJDFWLYDWLRQVĹDQGGHDFWLYDWLRQVĻFRUUHODWLQJ
ZLWKSDUWLFLSDQW¶VPCS and PHQ12 scores during the cue stimulus (uncorrected p<0.01) (Table 
A6.7.2). All effects were identified using group maps as a mask for the data.  
Table A6.8.2 Cue stimulus: PCS and PhQ12 scores  
   PCS PHQ12 
 Area Side ADD LSDD HSDD IBS ADD LSDD HSDD IBS 
 S1 L         
SS R         
 S2 L         
 
R 
        
SS Post-Ins L         
 
R 
   
Ļ 
   
Ļ 
 Mid-Ins L         
  
R 
     
 
  
Aff. Ant-Ins L      Ļ   
 
R 
    
Ĺ 
   
Aff. ACC L  Ĺ       
 
R 
 
Ĺ 
      
Aff. MCC L  Ĺ    Ĺ Ĺ  
 
R 
 
Ĺ Ĺ 
   
Ĺ 
 
 PCC L         
 
R 
        
Aff. Medial PFC L  Ļ Ļ   Ļ  Ĺ 
 
R 
 
Ļ Ļ  Ĺ  Ļ  
DNIC Lateral PFC L   Ļ   Ļ Ļ  
 
R 
   
ĹĻ  Ĺ  Ĺ 
DNIC Orbito-FC L  Ĺ   Ĺ   Ĺ 
  
R 
 Ĺ   Ĺ Ĺ   
SS Lentiform N. 
and Thalamus 
L 
 
Ļ Ļ 
 
Ĺ Ļ 
 
Ļ 
 
R Ĺ Ļ Ļ Ĺ Ĺ   Ĺ 
Aff. Amygdala 
(Hippocampus) 
L 
   
Ļ 
   
Ļ 
 
R 
    Ļ Ļ  ĹĻ 
 Cerebellum L    Ļ     
 
R 
   
Ļ   Ĺ  
 Inferior 
Parietal 
L 
    
Ĺ 
   
 
R 
        
 Temporal L   Ļ  Ļ Ļ  ĹĻ 
 
R 
  
Ļ Ĺ Ĺ Ļ Ļ 
 
Ĺ 
 Motor L         
  
R 
        
 SMA L        Ĺ 
  
R 
       Ĺ 
SS Post-central 
Gyrus 
L 
 
 
      
 
R 
 
 Ļ 
   Ļ  
DNIC Subthalamic/ 
Brainstem 
 
Ļ 
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6.9 Patient diary sheets and Bristol Stool Chart  
6.9.1 Front sheet 
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6.9.2 Instructions  
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6.9.3 Bristol Stool Chart  
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6.9.4 Diary Sheet  
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6.9.5 Other symptoms  
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6.10 FRAME Laboratory Standardized protocols 
6.10.1 Method for the simultaneous preparation of RNA from cells and tissues 
Preparation of reagents 
x Bromo-3-Chloropropane (Sigma-Aldrich USA Pcode 1000840974 B9673) 
x Sodium acetate (2M pH4) (Made in house from stocks (Sigma-Aldrich USA Pcode 
1000564120) and treated with DEPC) 
x Isopropanolol (HPLC Grade; Fisher Scientific P/7507/PB17) 
x DEPC- treated water (Diethyl pyrocarbonate Sigma-Aldrich USA D5758) 
 
Preparation of RNA from tissue by phenol-chloroform extraction 
1. 50mg of frozen tissue was transferred to a 5ml polypropylene snap-cap tube (Falcon 
N.J. USA 352063) containing 2ml  of ice-cold TRI reagent®(Sigma Aldrich USA 
Pcode101078497 T9424). 
2. The tissue was homogenised (polytron homogeniser Janke and Kunkel Ultra Turrax 
T25) for 15-30 seconds at room temperature. 
3. The homogenate was incubated for 5 minutes at room temperature to permit complete 
dissociation of nucleoprotein complexes. 
4. 0.4ml of 1-Bromo-3-Chloropropane was added to the lysate and mixed by vigorous 
shaking. 
5. The sample was centrifuged at 10,000g for 15 minutes at 4oC.(Beckman Coulter 
Allegra X-226 centrifuge) 
6. The aqueous phase of the sample was then transferred to two fresh 1.5ml 
polypropylene snap cap eppendorf tubes. 
7. The RNA was precipitated from the aqueous phase by the addition of 0.125ml of 
Sodium acetate (2M pH4) and 0.35ml of isopropanolol. After thorough mixing the 
final solution was stored for at least 30 minutes at -20oC. 
8. The precipitated RNA was collected by centrifugation at maximum speed in an IEC 
(international equipment company) microfuge (model 3593 MA USA) at 4oC. 
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9. The RNA pellet was then washed twice with 70% ethanol, centrifuged as in step 8 
each time. After washing the ethanol was allowed to evaporate, but not to dry 
completely by leaving on the bench uncovered for 5 minutes. 
10. 50µl of DEPC- treated water was added to the washed RNA pellet and the then heated 
to 650C for 5 minutes before being stored at -800C. 
 
6.10.2 RNA cleanup 
Preparation of reagents 
This method was performed using the RNAeasy kit (Qiagen USA Cat No 74106) as per 
manufactures instructions.  All buffers are part of the kit 
Ethanol absolute (Sigma-Aldrich USA UN 1170) 
1. Buffer RLT  
ORIȕ-Mercaptoethanol was added to each 1ml of Buffer RLT required in a fume 
hood. 
2. Buffer RPE 
The supplied concentrate was diluted in 4 volumes of 96-100% of ethanol. 
3. DNAase I 
10µl of DNAase I stock solution was diluted in 70µl of Buffer RDD and mixed gently 
by inverting the tube and briefly centrifuged to collect residual liquid from the sides of 
the tube before storing on ice until use. 
1. 250µl of 100% ethanol was added to the RNA preparation obtained in step 10 of the 
preceding method and mixed thoroughly by pipetting. 
2. The sample was then applied to an RNAeasy mini column contained in a 2ml 
collection tube. The tube was closed gently and centrifuged at 10,000g at 20-35oC for 
15s. The flow through and collection tube were then discarded. 
3. 350µl buffer RW1 was added to the RNA easy spin column and centrifuged as in step 
2. The flow through was discarded. 
4. 80µl of the DNAase I incubation mix was added to the RNAeasy column and 
incubated at room temperature for 15 minutes. 
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5. 350µl of buffer RW1 was then added to the RNAeasy spin column. And centrifuged 
as in step 2.  The flow through was discarded. 
6. The RNAeasy column was transferred to a fresh 2ml collection tube where 500µl of 
buffer RPE was added before centrifuging as in step 2. 
7.  A further 500µl of buffer RPE was added to the RNA easy column and centrifuged 
for 2 minutes at 10,000g. 
8. The RNAeasy column was transferred to a fresh 2ml collection tube and centrifuged 
at 10,000g for 1 minute. 
9. The column was transferred to a 1.5ml collection tube for the final elution step. 30µl 
of RNAse-free water was added to the column and centrifuged for 1 minute at 
10,000g. 
10. The concentration of the RNA was estimated by measuring the absorbance at 260nm 
of an aliquot of the final preparation. 
6.10.3 Quantitative RT-PCR Protocol 
Preliminary Steps 
Primers and probes for the target gene and for a reference gene (usually a housekeeping gene) 
can be ordered as a kit or designed using Primer Express 2. Extensive explanation on how to 
GHVLJQSULPHUVDQGSUREHVLVJLYHQERWKLQ³TaqMan Universal Master Mix´SURWRFROE\$%,
DQGLQ³Primer Express 2´XVHUPDQXDO 
 
The amplicon (PCR product) should span an intron-exon boundary in order to avoid the 
amplification of a false positive product. Primers and probes should be blasted (BLAST N) in 
order to ensure that the chosen sequence is specific for the gene of interest. 
 
'LOXWHSULPHUVDQGSUREHVWR0DQGVWRUHLQVPDOOHUDOLTXRWV:UDSSUREHV¶WXEHVZLWKIRLO
as they are light sensitive. 
 
Always test primers with a DNA template before ordering probes. Primers should be tested 
with PCR reaction, using cycle parameters similar to the ones that will be used in the 
quantitative PCR: 
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x 95°C 10 mins 
x 95°C 15 sec 
x 60°C 1 min  x40 
x 72°C 30 sec 
x 72°C 5 mins 
 
Run a gel with PCR products along with an appropriate DNA ladder to check the DPSOLFRQ¶V 
correct size. 
 
6.10.4 Reverse Transcription PCR 
RNA can be prepared with the Trizol method (Invitrogen), with the solution D method or with 
the mRNA extraction kit (Invitrogen). Always use RNAase free tips while handling RNA. 
 
Purified total/mRNA concentration is detected with the NanoDrop machine. Same amount of 
RNA (usually 1ug total RNA or 100ng mRNA) from different samples will be used as a 
template for RT-PCR synthesis of first strand cDNA.    
Use either M-MLV reverse transcriptase or Superscript: 
 
(a) M-MLV Reaction 
x 1Pg total RNA /100ng mRNA + 1Pl Random Primers (as they come) + DEPC water to 15 
Pl. Incubate at 70qC  for 5 mins then put on ice. 
x Add to the reaction mix:  
RT Buffer 5X 5Pl 
dNTP (10mM)  1.25Pl 
RNAase inhibitor 0.5Pl 
M-MLV   1Pl 
DEPC water   2.25Pl    FINAL REACTION VOL: 25Pl 
Incubate at 37q for 60 mins. 
x Dilute 4X by adding 75Pl HPLC water (This will be the NEAT). 
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(b) Superscript 
Preparation of reagents 
1. Random primers (Promega W.I. USA C118A) 
2. Superscript III Reverse Transcriptase (200 unit/µl) (Invitrogen USA Cat No 18080-093) 
5* First-Strand Buffer 
0.1 M DTT 
51DVH287(Invitrogen USA Cat No 10777-019) 
4. dNTPs  
 
1. 500ng of RNA was added to 1.5ul random primers and 1.5ul of dNTPs in a nuclease-
free 0.5ml eppendorf and made up to a total volume of 19.5µl with DEPC treated 
water. 
2. The tube was vortexed and pulsed in a centrifuge (IEC) for 5 seconds at 4oC to collect 
the contents. 
3. Samples were heated to 65°C for 5 minutes to allow RNA dissociation and binding of 
random primers 
4. 6µl 5X First-Strand Buffer, 1.5µl 0.1 M DTT, 1.5µl 51DVH287 5HFRPELQDQW
RNAse Inhibitor were added to each tube.  
5. 1.5µl of Superscript III RT (200 unit/µl) and the contents mixed by gentle pipetting. 
6. The reaction was then incubated at 25oC for 5 minutes, at 50oC for 60 minutes before 
the reaction was stopped by heating to 70oC for 15 minutes on a Biometra TRIO-
Thermobloc (No 9402208) 
7. cDNA was stored at -20°C  
 
6.10.5 cDNA standards 
Serial dilutions of a standard cDNA are required in order to quantify relative concentrations of 
the target and reference gene in the samples. It is possible to use two different relative 
measurements: the relative standard curve method or the comparative Ct method. As a 
UHIHUHQFHUHDG³Guide to performing relative quantitation of gene expression using real-time 
quantitative PCR´E\$%, 
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A mix of cDNAs from different samples or a cDNA from a sample believed to express the 
gene of interest can be used as a standard. 
 
Dilutions of the standard and the samples need to be determined empirically. As a starting 
point use a 4-fold serial dilution of the NEAT for the standard, and dilute 5 or 10 times the 
NEAT for the samples. 
 
(a) Setting up a TAQMAN 96-well plate 
Serial dilutions of the standard cDNA and a non-template control (NTC) must be run for both 
the reference and the target gene in order to construct two standard curves. Run each standard 
dilution and each dilution of the sample in triplicates. When testing primers and probes for the 
first time, samples can be run in two dilutions in order to have a better possibility of using the 
correct one. This is a typical plate for a TaqMan reaction: 
Neat Neat Neat 1:4 1:4 1:4 1:16 1:16 1:16 1:64 1:64 1:64 
1:256 1:256 1:256 NTC NTC NTC       
Neat Neat Neat 1:4 1:4 1:4 1:16 1:16 1:16 1:64 1:64 1:64 
1:256 1:256 1:256 NTC NTC NTC       
5X 
Sample 1 
5X 
Sample 1 
5X 
Sample 1 
5X 
Sample 2 
5X 
Sample 2 
5X 
Sample 2 
      
10X 
Sample 1 
10X 
Sample 1 
10X 
Sample 1 
10X 
Sample 2 
10X 
Sample 2 
10X 
Sample 2 
      
5X 
Sample 1 
5X 
Sample 1 
5X 
Sample 1 
5X 
Sample 2 
5X 
Sample 2 
5X 
Sample 2 
      
10X 
Sample 1 
10X 
Sample 1 
10X 
Sample 1 
10X 
Sample 2 
10X 
Sample 2 
10X 
Sample 2 
      
 
The reaction mixture for the reference gene is in red, the one for the target gene is in yellow. 
x Prepare one master mix for the reference gene and one for the target gene for the 
numbers of wells required: 
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 TAQMAN Rox-UDG Mix  13 µl    
FW Primer    (10 µM)  0.75 µl 
REV Primer   (10 µM)  0.75 µl 
PROBE        (10 µM)  0.5 µl 
HPLC Water    5 µl 
   Total Volume  20  µl  (per each well) 
 
 
x Add 20 µl of the correct master mix in each well keeping the plate on ice 
x Add 5 µl of the cDNA standards and samples 
x Seal the plate with transparent film and place the rubber cover on the top. Keep the 
plate on ice and put the lid on the box in order to protect from the light 
x Turn the TaqMan machine on and set up the plate document with ABI software. A 
³URXJKJXLGHRQKRZWRXVH7DT0DQ´LVLQ'LQWKH3URWRFROV¶%Rok.  
x The reaction volume is usually set to 50 µl and must be changed to 25 µl 
x The reaction will approximately take between 1 and 2 hours depending on the 
machine  
x 5HIHUWR³Guide to performing relative quantitation of gene expression using real-time 
quantitative PCR´E\$%,LQRUGHUWRDQDO\]HWKHUHVXOWV'DWDFDQEHH[SRUWHGIURP
the ABI software as an excel file 
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6.11 Gene cards 
6.11.1 Genes selected for gene card 
 
IPA = Ingenuity Pathway analysis (Applied Biosystems, California, USA) 
Name Other names Assay ID Pathway Evidence References Notes 
ACTB Beta-Actin Hs99999903_m1 Housekeeper    
ALOX12 12-Lipoxygenase Hs00167524_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Planned LCMS 
  
ALOX15 15-Lipoxygenase Hs00609608_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Planned LCMS 
  
ALOX15B 15-Lipoxygenase B Hs00153988_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Planned LCMS 
  
ALOX5 5-Lipoxygenase Hs01095330_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Literature, 
Planned LCMS 
610
  
ALOX5AP Arachidonate 5-Lipoxygenase 
activating protein 
Hs00233463_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Planned LCMS 
  
BDKRB2 Bradykinin receptor 2 Hs00176121_m1 Neuropeptides: Inflammation IPA linked, 
Literature 
583, 723, 724
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Name Other names Assay ID Pathway Evidence References Notes 
CALCA Calcitonin-related polypeptide alpha Hs01100741_m1 Neuropeptides: Inflammation 
cytokines 
IPA linked   
CALCB  Calcitonin-related polypeptide beta Hs00265194_m1 Neuropeptides: Inflammation 
cytokines 
IPA linked   
CCL13 Chemokine (C-C motif) ligand 13 or 
MCP-4 
Hs00237013_m1 Inflammation: chemokines Literature 725  
CCL11 Chemokine (C-C motif) ligand 13 or 
eotaxin-1 
Hs00234646_m1 Inflammation: chemokines Literature 726  
CCL2 Chemokine (C-C motif) ligand 2 or 
Monocyte Chemotactic protein 1 
(MCP-1) 
Hs00234140_m1 Inflammation: chemokines Literature 727  
CMKLR1 Chemokine-like receptor 1 or 
ChemR23 
Hs01386064_m1 Inflammation: chemokines Literature 728  
CNR2 Cannabinoid receptor 2 Hs00361490_m1 Inflammation: Endocannabinoids Literature 729-731  
CRHR Corticotrophin receptor Hs00366363_m1 Neuropeptides: Inflammation 
cytokines 
Literature 256, 732  
CYP2J2 Cytochrome P450, family 2, 
subfamily J 
Hs00356035_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Literature 
733
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Name Other names Assay ID Pathway Evidence References Notes 
EPHX2 Epoxide hydrolase 2 (SEH) Hs00157403_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked   
F2RL1 Protease activated receptor 2 PAR2 Hs00173741_m1 Inflammation: PAR signaling Literature 665, 734  
F2RL3 Protease activated receptor 4 PAR4 Hs00559732_m1 Inflammation: PAR signaling Literature 665  
FPR2 Formyl peptide receptor 2,  Hs02759175_s1 Inflammation and Arachidonic acid 
signaling 
Literature 735, 736 Primers not 
cross exon 
boundary 
GALR1 Galanin receptor 1 Hs00175668_m1 Neuropeptides: Inflammation Prev. Work 80, 104  
GALR2 Galanin receptor 2 Hs00605839_m1 Neuropeptides: Inflammation IPA linked   
HPRT1 Hypoxanthine 
phosphoribosyltransferase 1 
Hs02800695_m1 Housekeeper    
HTR3A 5HT 3A receptor Hs00356082_m1 Serotonin pathway Prev. Work 605, 606, 608  
HTR3B 5HT 3B receptor Hs00175775_m1 Serotonin pathway Prev. Work 606, 608  
HTR4 5HT 4 receptor Hs00410577_m1 Serotonin pathway Prev. Work 608  
ICAM1 Intercellular adhesion molecule 1 Hs00164932_m1 Cell migration pathway Literature 737  
IFNG Interferon, gamma Hs00989291_m1 Inflammation: Cytokine and 
interferon pathway 
IPA linked   
IL10 Interleukin 10 Hs00961622_m1 Inflammation: Cytokine IPA Linked   
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Name Other names Assay ID Pathway Evidence References Notes 
IL13 Interleukin 13 Hs00174379_m1 Inflammation: Cytokine Literature 738 739 740, 741  
IL17A Interleukin 17A Hs00174383_m1 Inflammation: Cytokine Literature 725, 741, 742  
IL1B Interleukin 1b Hs00174097_m1 Inflammation: Cytokine Literature 543, 743-745  
IL1RN Interleukin 1 receptor antagonist Hs00893625_m1 Inflammation: Cytokine IPA linked   
IL6 Interleukin 6 Hs00174114_m1 Inflammation: Cytokine Prev. Work 104, 740  
IL8 Interleukin 8 Hs00174103_m1 Inflammation: Cytokine Literature 739, 740, 742, 743, 
746
 
 
KITLG KIT ligand Hs00241497_m1 Inflammation: chemokines IPA linked   
LTA4H Leukotriene A4 synthase Hs00168505_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked   
LTB4R Leukotriene B4 receptor Hs00609525_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Literature 
728
  
LTC4S Leukotriene C4 synthase Hs00168529_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked   
MAdCAM1 Mucosal addressin cell adhesion 
marker-1 
Hs00175533_m1 Cell migration pathway Literature 747  
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Name Other names Assay ID Pathway Evidence References Notes 
MCL-1 Myeloid cell leukaemia sequence 1 Hs01050896_m1 Inflammation: chemokines IPA linked   
MGLL Monoglyceride lipase Hs00200752_m1 Inflammation: endocannabinoids IPA linked   
MMP2 Matrix metallopeptidase 2 Hs00968305_m1 Cell migration pathway Literature 748  
MMP9 Matrix metallopeptidase 9 Hs00957562_m1 Cell migration pathway Literature 552, 748  
MUC1 Mucin 1, cell surface associated Hs00159357_m1 Inflammation: barrier function Literature 749, 750  
MUC3A Mucin 3, cell surface associated Hs03649367_mH Inflammation: barrier function Literature 750  
MYD88 Myeloid differentiation primary 
response protein 88 
Hs00182082_m1 Inflammation: Toll receptor 
pathway 
Literature 745, 751, 752 
 
 
NAPEPLD N-acyl phosphatidylethanolamine 
phospholipase D 
Hs00419593_m1 Inflammation: Endocannabinoids Literature 599 
 
 
NGF Nerve growth factor (beta 
polypeptide) 
Hs00171458_m1 Inflammation: multiple Literature 591, 730, 731, 753-
756
 
 
NGFR Nerve growth factor receptor Hs00609976_m1 Inflammation: multiple IPA linked   
NOD2 Nucleotide-binding oligomerization 
domain containing 2 
Hs00223394_m1 Inflammation: Toll receptor 
pathway and PPAR pathway 
Literature 757-760  
NOS2 Nitric oxide synthase 2, inducible Hs01075529_m1 Inflammation: Cytokine Literature 609, 761, 762  
NTRK1 Neurotrophic tyrosine kinase, 
receptor, type 1 
Hs00176787_m1 Inflammation: multiple IPA linked   
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Name Other names Assay ID Pathway Evidence References Notes 
PDE4B Phosphodiesterase 4B, Hs00387320_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked   
PDE4D Phosphodiesterase 4D, Hs00174810_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked   
PLA2 Phosphatidolipase Hs00179898_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked   
PPARG Peroxisome proliferator-activated 
receptor gamma 
Hs01115513_m1 PPAR signaling Literature 749  
PTGER1 Prostaglandin E receptor 1 Hs00168752_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked,  
Planned LCMS 
  
PTGER3 Prostaglandin E receptor 3 Hs00168755_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked,  
Planned LCMS 
  
PTGES Prostaglandin E synthase Hs01115610_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked,  
Planned LCMS 
  
PTGES2 Prostaglandin E synthase 2 Hs00228159_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked,  
Planned LCMS 
  
PTGS1 Prostaglandin-endoperoxide 
synthase 1 
Hs00377726_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked,  
Planned LCMS 
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Name Other names Assay ID Pathway Evidence References Notes 
PTGS2 Prostaglandin-endoperoxide 
synthase 2 
Hs00153133_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked,  
Planned LCMS 
  
RPLPO Ribosomal protein, large, P0,Gene Hs99999902_m1 Housekeeper    
SELE E-selectin Hs00174057_m1 Cell migration pathway Literature 747  763  
SLC6A4 Serotonin transporter Hs00169010_m1 Serotonin signaling Literature 607, 608, 764, 765  
SOD1 Superoxide dismutase 1 Hs00533490_m1 Inflammation: oxidative stress Literature 766, 767  
TACR1 Tachykinin receptor 1 Hs00185530_m1 Neuropeptides: Inflammation Prev. Work, 
Literature 
591
 
575, 768
  
TACR2 Tachykinin receptor 2 Hs00169052_m1 Neuropeptides: Inflammation Prev. Work, 
Literature 
768
  
TBXA2R Thromboxane A2 receptor Hs00169054_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Planned LCMS 
  
TBXAS1 Thromboxane A synthase 1 
(platelet) 
Hs01022706_m1 Arachidonic acid: Eicosanoid 
signaling 
IPA linked, 
Planned LCMS 
  
TGFB1 Transforming growth factor beta Hs00998130_m1 Inflammation: Cytokine - Growth 
factor 
Literature 739  
TGFBR1 Transforming growth factor, beta 
receptor 1 
Hs00610318_m1 Inflammation: Cytokine - Growth 
factor 
IPA linked   
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Name Other names Assay ID Pathway Evidence References Notes 
TGFBR2 Transforming growth factor, beta 
receptor II (70/80kDa) 
Hs00559660_m1 Inflammation: Cytokine - Growth 
factor 
IPA linked   
TJP1 Tight junction protein 1 (zona 
occludens 1) 
Hs01551876_m1 Inflammation: barrier function Literature 629, 769 
 
 
TJP2 Tight junction protein 2 (zona 
occludens 2) 
Hs00910541_m1 Inflammation: barrier function IPA linked   
TLR2 Toll like receptor 2 Hs00152932_m1 Inflammation: Toll receptor 
pathway 
Literature 739, 770 
 
 
TLR4 Toll like receptor 4 Hs00152939_m1 Inflammation: Toll receptor 
pathway 
Literature 739, 745, 751, 752, 
770, 771
 
 
 
TLR5 Toll like receptor 5 Hs00152825_m1 Inflammation: Toll receptor 
pathway 
Literature 739, 745, 771  
TLR7 Toll like receptor 7 Hs00152971_m1 Inflammation: Toll receptor 
pathway 
Literature 739, 745  
TLR8 Toll like receptor 8 Hs00607866_mH Inflammation: Toll receptor 
pathway 
Literature 739  
TLR9 Toll like receptor 9 Hs00152973_m1 Inflammation: Toll receptor 
pathway 
Literature 122, 739  
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Name Other names Assay ID Pathway Evidence References Notes 
TNF Tumor necrosis factor Hs99999043_m1 Inflammation: Cytokine Prev. Work 
Literature 
104
  
TNFSF10A Tumor necrosis factor (ligand) 
superfamily, member 10A 
Hs00269492_m1 Inflammation: Cytokine IPA linked   
TNFSF10 Tumor necrosis factor (ligand) 
superfamily, member 10 
Hs00921974_m1 Inflammation: Cytokine IPA linked   
TNFSF15 Tumor necrosis factor (ligand) 
superfamily, member 15 
Hs00353710_s1 Inflammation: Cytokine Literature 772, 773 No primers 
that cross 
exons 
TOLLIP Toll interacting protein Hs00184085_m1 Inflammation: Toll receptor 
pathway 
IPA linked   
TPH1 Tryptophan hydroxylase 1 Hs00188220_m1 Serotonin pathway Prev. Work 605, 608  
TRPA1 Transient receptor potential ankyrin 
1 
Hs00175798_m1 Inflammation: TRVP pathway Literature 774, 775 
 
 
TRPV1 Transient receptor potential 
vanilloid 1 
Hs00218912_m1 Inflammation: TRVP pathway Literature 590, 591  
TRPV4 Transient receptor potential 
vanilloid 4 
Hs01099348_m1 Inflammation: TRVP pathway Literature 665, 734, 776  
VCAM1 Vascular cell adhesion marker-1 Hs01003372_m1 Cell migration pathway Literature 747  
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6.12 Coefficients of variation for histology assessment 
6.12.1 5HT                           
 SD= standard deviation 
Slide Count Area (mm2) Cells Perimeter (um) Cells/area 
SR67-10-5HT 1.00 0.01 1.00  68.03 
 2.00 0.01 1.00  69.44 
 3.00 0.01 1.00  70.92 
 4.00 0.01 1.00  71.43 
 5.00 0.01 1.00  68.49 
 6.00 0.01 1.00 555.00 72.99 
 7.00 0.01 1.00 564.00 71.94 
 8.00 0.01 1.00 585.00 68.03 
 9.00 0.01 1.00 561.00 70.92 
 10.00 0.01 1.00 560.00 71.94 
 mean 0.01  565.00 70.41 
 SD 0.00  11.64 1.79 
 Coefficient of 
variation 
0.03  0.02 0.03 
 Reproducibility 97.44  97.94 97.46 
SR81-10-5HT 1.00 0.03 2.00  66.89 
 2.00 0.03 2.00  66.45 
 3.00 0.03 2.00  67.34 
 4.00 0.03 2.00  67.57 
 5.00 0.03 2.00  65.36 
 6.00 0.03 2.00 876.00 66.89 
 7.00 0.03 2.00 877.00 66.01 
 8.00 0.03 2.00 879.00 68.73 
 9.00 0.03 2.00 884.00 67.80 
 10.00 0.03 2.00 890.00 66.01 
 mean 0.03  881.20 66.90 
 SD 0.00  5.81 1.00 
 Coefficient of 
variation 
0.01  0.01 0.01 
 Reproducibility 98.51  99.34 98.51 
 
 
  
326 
 
6.12.1 5HT continued 
Slide Count Area (mm2) Cells Perimeter (um) Cells/area 
SR257-10-5HT 1.00 0.01 5.00  357.14 
 2.00 0.01 5.00  344.83 
 3.00 0.01 5.00  349.65 
 4.00 0.01 5.00  375.94 
 5.00 0.01 5.00  354.61 
 6.00 0.01 5.00 604.00 342.47 
 7.00 0.01 5.00 608.00 352.11 
 8.00 0.01 5.00 609.00 354.61 
 9.00 0.01 5.00 609.00 347.22 
 10.00 0.01 5.00 604.00 352.11 
 mean 0.01  606.80 353.07 
 SD 0.00  2.59 9.26 
 Coefficient of 
variation 
0.03  0.00 0.03 
 Reproducibility 97.47  99.57 97.38 
SR173-10-5HT 1.00 0.03 3.00  106.76 
 2.00 0.03 3.00  99.67 
 3.00 0.03 3.00  102.04 
 4.00 0.03 3.00  101.35 
 5.00 0.03 3.00  99.34 
 6.00 0.03 3.00 978.00 103.09 
 7.00 0.03 3.00 986.00 102.39 
 8.00 0.03 3.00 1030.00 102.04 
 9.00 0.03 3.00 982.00 101.35 
 10.00 0.03 3.00 973.00 102.04 
 mean 0.03  989.80 102.01 
 SD 0.00  22.98 2.04 
 Coefficient of 
variation 
0.02  0.02 0.02 
 Reproducibility 98.04  97.68 98.00 
SR201-10-5HT 1.00 0.02 3.00  126.05 
 2.00 0.02 3.00  120.97 
 3.00 0.02 3.00  122.95 
 4.00 0.02 3.00  132.74 
 5.00 0.02 3.00 790.00 125.52 
 6.00 0.02 3.00 781.00 128.21 
 7.00 0.02 3.00 790.00 127.66 
 8.00 0.02 3.00 793.00 125.00 
 9.00 0.02 3.00 776.00 127.12 
 10.00 0.02 3.00 780.00 127.12 
 mean 0.02  785.00 126.33 
 SD 0.00  6.87 3.17 
 Coefficient of 
variation 
0.02  0.01 0.03 
 Reproducibility 97.50  99.12 97.49 
      
Overall coefficient of variance Mean 0.02  0.01 0.02 
Reproducibility 97.79  98.73 97.77 
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6.12.2 CD68 
CD68 Lamina Propria   
Slide Count LP Area (mm2) Cells Perimeter (um) cells/area 
SR162-10-CD3 1.00 0.02 21.00 971.00 1390.73 
 2.00 0.01 18.00 858.00 1267.61 
 3.00 0.01 18.00 873.00 1267.61 
 4.00 0.01 19.00 893.00 1366.91 
 5.00 0.01 20.00 907.00 1398.60 
 6.00 0.02 20.00 892.00 1333.33 
 7.00 0.01 20.00 921.00 1418.44 
 8.00 0.01 21.00 901.00 1438.36 
 9.00 0.02 20.00 962.00 1315.79 
 10.00 0.01 20.00 1000.00 1369.86 
 
mean 0.01 19.70 917.80 1356.72 
 
SD 0.00 1.06 45.72 59.41 
 
Coefficient of 
variation 
0.03 0.05 0.05 0.04 
 
Reproducibility 96.87 94.62 95.02 95.62 
SR198-10-CD3 1.00 0.02 20.00 697.00 1315.79 
 2.00 0.02 19.00 698.00 1158.54 
 3.00 0.02 20.00 694.00 1298.70 
 4.00 0.02 19.00 672.00 1117.65 
 5.00 0.02 21.00 678.00 1320.75 
 6.00 0.02 20.00 690.00 1250.00 
 7.00 0.02 20.00 669.00 1219.51 
 8.00 0.02 21.00 686.00 1272.73 
 9.00 0.02 20.00 676.00 1204.82 
 10.00 0.02 21.00 668.00 1346.15 
 
mean 0.02 20.10 682.80 1250.46 
 
SD 0.00 0.74 11.62 74.77 
 
Coefficient of 
variation 
0.04 0.04 0.02 0.06 
 
Reproducibility 96.41 96.33 98.30 94.02 
SR194-10-CD3 1.00 0.02 29.00 862.00 1502.59 
 2.00 0.02 25.00 729.00 1404.49 
 3.00 0.02 25.00 771.00 1428.57 
 4.00 0.02 28.00 830.00 1609.20 
 5.00 0.02 25.00 861.00 1213.59 
 6.00 0.02 31.00 889.00 1483.25 
 7.00 0.02 29.00 896.00 1450.00 
 8.00 0.02 31.00 861.00 1550.00 
 9.00 0.02 30.00 877.00 1304.35 
 10.00 0.02 31.00 870.00 1527.09 
 
mean 0.02 28.40 844.60 1447.31 
 
SD 0.00 2.55 53.90 117.72 
 
Coefficient of 
variation 
0.09 0.09 0.06 0.08 
 
Reproducibility 91.11 91.03 93.62 91.87 
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6.12.2 CD68 continued 
 
Slide Count LP Area 
(mm2) 
Cells Perimeter 
(mm) 
Cells/area 
SR175-10-CD3 1.00 0.02 31.00 1.12 1371.68 
 2.00 0.02 32.00 1.11 1516.59 
 3.00 0.02 33.00 1.21 1617.65 
 4.00 0.02 38.00 1.28 1759.26 
 5.00 0.02 36.00 1.22 1565.22 
 6.00 0.02 32.00 0.87 1600.00 
 7.00 0.02 36.00 1.27 1531.91 
 8.00 0.02 36.00 1.25 1565.22 
 9.00 0.02 38.00 1.24 1652.17 
 10.00 0.02 37.00 1.20 1644.44 
 mean 0.02 34.90 1.18 1582.41 
 SD 0.00 2.64 0.12 101.88 
 Coefficient of 
variation 
0.06 0.08 0.10 0.06 
 Reproducibility 94.48 92.43 89.71 93.56 
      
Overall coefficient of variance Mean 0.05 0.06 0.06 0.06 
Reproducibility 94.72 93.60 94.16 93.77 
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6.12.3 CD3 
CD3  Epithelium   Lamina Propria   
Slide Count Epi Area (mm2) Cells Perimeter (um) Cells/area LP Area (mm2) Cells Perimeter (um) Cells/area 
SR70-10-CD3 1.00 0.02 12.00 797.00 677.97 0.02 23.00 714.00 1314.29 
 2.00 0.02 12.00 809.00 677.97 0.02 21.00 715.00 1280.49 
 3.00 0.02 12.00 813.00 670.39 0.02 22.00 739.00 1301.78 
 4.00 0.02 12.00 827.00 655.74 0.02 21.00 723.00 1265.06 
 5.00 0.02 12.00 823.00 648.65 0.02 21.00 747.00 1242.60 
 6.00 0.02 12.00 829.00 634.92 0.02 19.00 723.00 1187.50 
 7.00 0.02 12.00 818.00 662.98 0.02 20.00 731.00 1142.86 
 8.00 0.02 12.00 825.00 659.34 0.02 21.00 751.00 1200.00 
 9.00 0.02 12.00 827.00 655.74 0.02 21.00 722.00 1213.87 
 10.00 0.02 12.00 805.00 670.39 0.02 22.00 745.00 1264.37 
 mean 0.02 12.00 817.30 661.41 0.02 21.10 731.00 1241.28 
 SD 0.00 0.00 10.89 13.52 0.00 1.10 13.62 54.43 
 Coefficient of variation 0.02 0.00 0.01 0.02 0.03 0.05 0.02 0.04 
 Reproducibility 97.93 100.00 98.67 97.96 96.88 94.78 98.14 95.62 
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6.12.3 CD3 Continued 
Slide Count Epi Area (mm2) Cells Perimeter (um) Cells/area LP Area (mm2) Cells Perimeter (um) Cells/area 
SR174-10-CD3 1.00 0.02 10.00 752.00 526.32 0.02 17.00 970.00 809.52 
 2.00 0.02 10.00 758.00 523.56 0.02 19.00 928.00 859.73 
 3.00 0.02 10.00 765.00 510.20 0.02 24.00 906.00 1100.92 
 4.00 0.02 10.00 766.00 518.13 0.02 22.00 908.00 973.45 
 5.00 0.02 10.00 766.00 518.13 0.02 22.00 931.00 1013.82 
 6.00 0.02 10.00 762.00 510.20 0.02 22.00 894.00 964.91 
 7.00 0.02 10.00 766.00 520.83 0.02 22.00 898.00 1023.26 
 8.00 0.02 10.00 733.00 526.32 0.02 21.00 925.00 985.92 
 9.00 0.02 10.00 769.00 500.00 0.02 22.00 902.00 995.48 
 10.00 0.02 10.00 759.00 510.20 0.02 22.00 905.00 986.55 
 mean 0.02 10.00 759.60 516.39 0.02 21.30 916.70 971.36 
 SD 0.00 0.00 10.62 8.55 0.00 1.95 22.73 82.33 
 Coefficient of variation 0.02 0.00 0.01 0.02 0.03 0.09 0.02 0.08 
 Reproducibility 98.33 100.00 98.60 98.34 97.40 90.86 97.52 91.52 
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6.12.3 CD3 Continued 
Slide Count Epi Area (mm2) Cells Perimeter (um) Cells/area LP Area (mm2) Cells Perimeter (um) Cells/area 
SR270-10-CD3 1.00 0.02 20.00 882.00 1169.59 0.08 19.00 633.00 246.11 
 2.00 0.02 21.00 844.00 1354.84 0.07 19.00 641.00 255.38 
 3.00 0.02 20.00 857.00 1250.00 0.07 19.00 642.00 260.27 
 4.00 0.02 20.00 851.00 1307.19 0.08 18.00 639.00 237.15 
 5.00 0.02 20.00 860.00 1298.70 0.08 19.00 647.00 250.66 
 6.00 0.02 20.00 853.00 1290.32 0.08 19.00 634.00 250.00 
 7.00 0.02 20.00 839.00 1273.89 0.07 19.00 639.00 258.15 
 8.00 0.02 20.00 846.00 1183.43 0.07 19.00 658.00 256.76 
 9.00 0.02 20.00 836.00 1257.86 0.08 19.00 654.00 243.28 
 10.00 0.02 20.00 847.00 1257.86 0.07 19.00 642.00 254.35 
 mean 0.02 20.10 851.50 1264.37 0.08 18.90 642.90 251.21 
 SD 0.00 0.32 13.07 55.56 0.00 0.32 8.03 7.28 
 Coefficient of variation 0.04 0.02 0.02 0.04 0.02 0.02 0.01 0.03 
 Reproducibility 96.13 98.43 98.46 95.61 97.85 98.33 98.75 97.10 
          
Overall coefficient of variance Mean 0.03 0.01 0.01 0.03 0.03 0.05 0.02 0.05 
Reproducibility 97.47 99.48 98.58 97.30 97.38 94.66 98.14 94.75 
 
  
332 
 
6.12.4 KI67 
Ki67  Epithelium superficial  Epithelium deep   
Slide Count Area 
(mm2) 
Cells Perimeter 
(um) 
cells/area Count Area 
(mm2) 
Cells Perimeter 
(um) 
cells/area 
SR88-10-CD3 1.00 0.01 5.00 531.00 400.00 1.00 0.02 33.00 505.00 2037.04 
 2.00 0.01 5.00 556.00 354.61 2.00 0.02 31.00 506.00 2000.00 
 3.00 0.01 5.00 529.00 378.79 3.00 0.02 34.00 508.00 2098.77 
 4.00 0.01 5.00 578.00 335.57 4.00 0.02 35.00 511.00 2258.06 
 5.00 0.01 5.00  347.22 5.00 0.02 33.00 518.00 2037.04 
 6.00 0.01 5.00 550.00 362.32 6.00 0.02 32.00 522.00 1987.58 
 7.00 0.01 5.00 563.00 335.57 7.00 0.02 32.00 526.00 1963.19 
 8.00 0.01 5.00 557.00 340.14 8.00 0.02 35.00 509.00 2215.19 
 9.00 0.01 5.00 540.00 375.94 9.00 0.02 34.00 521.00 2060.61 
 10.00 0.01 5.00 538.00 364.96 10.00 0.02 34.00 521.00 2060.61 
 mean 0.01 5.00 549.11 359.51 mean 0.02 33.30 514.70 2071.81 
 SD 0.00 0.00 16.11 21.12 SD 0.00 1.34 7.69 95.86 
 Coefficient of 
variation 
0.06 0.00 0.03 0.06 Coefficient of 
variation 
0.02 0.04 0.01 0.05 
 Reproducibility 94.26 100.00 97.07 94.12 Reproducibility 97.73 95.98 98.51 95.37 
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6.12.4 KI57 Continued 
Slide Count Area 
(mm2) 
Cells Perimeter 
(um) 
cells/area Count Area 
(mm2) 
Cells Perimeter 
(um) 
cells/area 
SR196-10-CD3 1.00 0.01 0.00 490.00 0.00 1.00 0.01 22.00 474.00 1560.28 
 2.00 0.01 0.00 484.00 0.00 2.00 0.01 24.00 467.00 1690.14 
 3.00 0.01 0.00 506.00 0.00 3.00 0.01 25.00 466.00 1785.71 
 4.00 0.01 0.00 502.00 0.00 4.00 0.01 25.00 471.00 1851.85 
 5.00 0.01 0.00 506.00 0.00 5.00 0.01 24.00 472.00 1678.32 
 6.00 0.01 0.00 507.00 0.00 6.00 0.01 25.00 472.00 1773.05 
 7.00 0.01 0.00  0.00 7.00 0.01 24.00 471.00 1678.32 
 8.00 0.01 0.00 513.00 0.00 8.00 0.01 26.00 477.00 1805.56 
 9.00 0.01 0.00 507.00 0.00 9.00 0.01 26.00 466.00 1857.14 
 10.00 0.01 0.00 536.00 0.00 10.00 0.01 26.00 479.00 1793.10 
 mean 0.01 0.00 505.67 0.00 mean 0.01 24.70 471.50 1747.35 
 SD 0.00 0.00 14.60 0.00 SD 0.00 1.25 4.40 93.32 
 Coefficient of 
variation 
0.03  0.03  Coefficient of 
variation 
0.02 0.05 0.01 0.05 
 Reproducibility 96.65  97.11  Reproducibility 98.02 94.93 99.07 94.66 
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6.12.4 KI57 Continued 
Slide Count Area 
(um2) 
Cells Perimeter 
(um) 
cells/area Count Area 
(mm2) 
Cells Perimeter 
(um) 
cells/area 
SR391-10-CD3 1.00 0.01 7.00 577.00 800.00 1.00 0.01 29.00 555.00 2843.14 
 2.00 0.01 6.00 606.00 650.05 2.00 0.01 29.00 601.00 2929.29 
 3.00 0.01 6.00 615.00 652.88 3.00 0.01 27.00 593.00 3040.54 
 4.00 0.01 7.00 628.00 760.87 4.00 0.01 29.00 605.00 3251.12 
 5.00 0.01 6.00 600.00 653.59 5.00 0.01 28.00 648.00 3001.07 
 6.00 0.01 5.00 589.00 558.04 6.00 0.01 29.00 618.00 3065.54 
 7.00 0.01 5.00 592.00 568.83 7.00 0.01 26.00 629.00 2699.90 
 8.00 0.01 5.00 604.00 535.91 8.00 0.01 25.00 613.00 2564.10 
 9.00 0.01 4.00  459.77 9.00 0.01 30.00  3141.36 
 10.00 0.01 5.00 605.00 518.67 10.00 0.01 29.00 611.00 3059.07 
 mean 0.01 5.60 601.78 615.86 mean 0.01 28.10 608.11 2959.51 
 SD 0.00 0.97 14.88 107.84 SD 0.00 1.60 25.66 207.03 
 Coefficient of 
variation 
0.03 0.17 0.02 0.18 Coefficient of 
variation 
0.04 0.06 0.04 0.07 
 Reproducibility 96.76 82.75 97.53 82.49 Reproducibility 95.73 94.32 95.78 93.00 
           
Overall coefficient of variance Mean 0.04 0.06 0.03 0.08  0.03 0.05 0.02 0.06 
Reproducibility 95.89 94.25 97.23 92.21  97.16 95.08 97.78 94.35 
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